<HTML xmlns:mso="urn:schemas-microsoft-com:office:office" xmlns:msdt="uuid:C2F41010-65B3-11d1-A29F-00AA00C14882"><head><title>Full Comparison Report</title><style>
                                    br { mso-data-placement: same-cell;}  
                                    .complete {color: green; font-weight: bold;} 
                                    .codedText {font-family: 'Courier New', monospace; font-size: 0.9em;}
                                    table, th, td { border: 1px solid black;  border-collapse: collapse; }                              
                                   </style>
<!--[if gte mso 9]><xml>
<mso:CustomDocumentProperties>
<mso:FHI_TopicTaxHTField msdt:dt="string">Kunnskapsoppsummering|5d5cbb19-68f1-4fe9-a690-87236471a67d;Metodeutvikling|6c50a715-c592-4239-98a4-aee1bc96601c</mso:FHI_TopicTaxHTField>
<mso:TaxCatchAll msdt:dt="string">2;#Metodeutvikling|6c50a715-c592-4239-98a4-aee1bc96601c;#1;#Kunnskapsoppsummering|5d5cbb19-68f1-4fe9-a690-87236471a67d</mso:TaxCatchAll>
<mso:TaxKeywordTaxHTField msdt:dt="string"></mso:TaxKeywordTaxHTField>
<mso:MediaServiceImageTags msdt:dt="string"></mso:MediaServiceImageTags>
<mso:TaxKeyword msdt:dt="string"></mso:TaxKeyword>
<mso:lcf76f155ced4ddcb4097134ff3c332f msdt:dt="string"></mso:lcf76f155ced4ddcb4097134ff3c332f>
</mso:CustomDocumentProperties>
</xml><![endif]-->
</head><body><table><tr><th>ItemId</th><th>ShortTitle</th><th>Title</th><th>I/E/D/S flag</th><th>Eksluder</th><th>Ekskludert, men Relevant litteratur</th><th>Inkluder SR</th><th>Inkluder RCT</th></tr><tr><td colspan='4'><div style='display: flex; justify-content: flex-end; margin-right:0.25em;'>FullPath:</div></td><td>Eksluder</td><td>Ekskludert, men Relevant litteratur</td><td>Inkluder SR</td><td>Inkluder RCT</td></tr><tr><td>59646623</td><td>"Individual placement... (2018)</td><td>"Individual placement and support" provides advantages for early psychosis clients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648755</td><td>145 Incidence and Characteristics... (2020)</td><td>145 Incidence and Characteristics of Akathisia and Restlessness During Cariprazine Treatment for Bipolar I Disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648773</td><td>5th European Conference... (2015)</td><td>5th European Conference on Schizophrenia Research: bridging Gaps Improving Outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634190</td><td>A (1979)</td><td>The effect of fluphenazine upon social and vocational functioning in remitted schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633772</td><td>A (1985)</td><td>A German multicentre study on the long-term treatment of schizophrenic outpatients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634019</td><td>A (2011)</td><td>Early detection and intervention evaluation for people at high-risk of psychosis (EDIE-2): A multisite randomised controlled trial of cognitive therapy for at risk mental states.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647911</td><td>A contingency management... (2019)</td><td>A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646182</td><td>A multicenter study... (2019)</td><td>A multicenter study of ketamine effects on functional connectivity: large scale network relationships, hubs and symptom mechanisms</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644780</td><td>A technology-enhanced... (2018)</td><td>A technology-enhanced intervention to reduce the duration of untreated psychosis through rapid identification & engagement</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645453</td><td>Abayomi (2015)</td><td>Psychosocial interventions for cannabis abuse and/or dependence among persons with co‚Äêoccurring cannabis use and psychotic disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646981</td><td>Abbas (2017)</td><td>Fluphenazine decanoate (timing of administration) for people with schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645745</td><td>Abdel-Baki (2012)</td><td>Pharmacotherapy challenges in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646742</td><td>Abdel-Baki (2020)</td><td>Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645172</td><td>Abram (2020)</td><td>Reward processing electrophysiology in schizophrenia: Effects of age and illness phase</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633707</td><td>Abroms (1973)</td><td>Drug-prescribing and the nonmedical therapist</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633904</td><td>Abse (1960)</td><td>Evaluation of tranquilizing drugs in the management of acute mental disturbance.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648735</td><td>Abstracts of the 46th... (2017)</td><td>Abstracts of the 46th annual meeting of Japanese Society of Clinical Neurophysiology</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647858</td><td>Aceituno (2019)</td><td>Cost-effectiveness of early intervention in psychosis: systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646699</td><td>Aceituno (2020)</td><td>Implementation of early psychosis services in Latin America: A scoping review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644536</td><td>Actrn (2005)</td><td>Vocational rehabilitation in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645400</td><td>Actrn (2007)</td><td>A randomised placebo controlled trial of intensive psychosocial treatment plus or minus anti-psychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES Study: staged Treatment and Acceptability Guidelines in Early Psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59644538</td><td>Actrn (2008)</td><td>Vocational Recovery in Young People With First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647940</td><td>Actrn (2008)</td><td>A comparison study of fish oil capsules and psychological therapy versus placebo capsules and psychological therapy in patients at risk of developing a psychotic disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645934</td><td>Actrn (2010)</td><td>An open randomised clinical trial involving Haloperidol, Olanzapine, Quetiapine, Risperidone, and Ziprasidone in first episode never-treated psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647938</td><td>Actrn (2010)</td><td>A comparison study of quetiapine medication and psychological therapy versus placebo tablets and psychological therapy in patients who are deemed at risk of developing a psychotic disorder</td><td>(E) Excluded</td><td><span >Tiril Borge</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59646732</td><td>Actrn (2012)</td><td>The Impact of Social Cognition Training and Oxytocin on Social Functioning in Early Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646808</td><td>Actrn (2014)</td><td>The Horyzons trial: moderated Online Social Therapy for Maintenance of Treatment Effects from Specialised First Episode Psychosis Services</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644915</td><td>Actrn (2016)</td><td>Staged Treatment in Early Psychosis (STEP): a sequential multistage randomized clinical trial (SMART) of interventions for Ultra High Risk (UHR) of psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647654</td><td>Actrn (2017)</td><td>Does Antipsychotic Dose Reduction in combination with Evidence-Based Intensive Recovery Treatment (EBIRT) Lead to Better Functional Recovery in First Episode Psychosis: a Randomised Controlled Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648636</td><td>Actrn (2017)</td><td>Altitudes East-West: effectiveness of a Moderated Online Social Therapy program for First Episode Psychosis carers</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644751</td><td>Actrn (2018)</td><td>Therapeutic potential for intranasal levodopa in Parkinson‚Äôs Disease ‚Äì Off Reversal (THOR 201)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646147</td><td>Actrn (2018)</td><td>The ‚ÄúNATURE‚Äù Trial: nutritional Adjunctive Treatment Used for Recovery in Early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646680</td><td>Actrn (2020)</td><td>Improving cognition in Early Psychosis using Transcranial Magnetic Stimulation</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648398</td><td>Adachi (2013)</td><td>Basic treatment principles for psychotic disorders in patients with epilepsy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644787</td><td>Adam (2014)</td><td>Tardive dyskinesia in a South Asian population with first episode psychosis treated with antipsychotics</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633520</td><td>Adams (2005)</td><td>Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644646</td><td>Adams (2014)</td><td>Trec-save: a randomised trial comparingmechanical restraints with seclusion for aggressive patients in psychiatric hospitals</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633510</td><td>Adams (2014)</td><td>Chlorpromazine versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646212</td><td>Adams (2018)</td><td>Monitoring oral health of people in Early Intervention for Psychosis (EIP) teams: the extended Three Shires randomised trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647885</td><td>Adanty (2020)</td><td>Copy number variance (CNV) analysis to determine optimal antipsychotic dosage in schizophrenia: A pilot study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645812</td><td>Addington (2003)</td><td>Patterns of premorbid functioning in first-episode psychosis: Initial presentation</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648060</td><td>Addington (2003)</td><td>Cognitive functioning in first episode psychosis: Initial presentation</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645798</td><td>Addington (2005)</td><td>Performance measures for early psychosis treatment services</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645813</td><td>Addington (2005)</td><td>Patterns of premorbid functioning in first episode psychosis: Relationship to 2-year outcome</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648151</td><td>Addington (2005)</td><td>Clinical Trials During the Prodromal Stage of Schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645730</td><td>Addington (2006)</td><td>Phase-specific group treatment for recovery in an early psychosis programme</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646601</td><td>Addington (2006)</td><td>Influence of social perception and social knowledge on cognitive and social functioning in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645533</td><td>Addington (2011)</td><td>The prodrome of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648092</td><td>Addington (2011)</td><td>Cognitive behaviour therapy and early intervention</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645256</td><td>Addington (2013)</td><td>Relationship between relapse and hospitalization in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646767</td><td>Addington (2013)</td><td>Identifying a treatable psychosis-risk cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647046</td><td>Addington (2018)</td><td>Fidelity scales and performance measures to support implementation and quality assurance for first episode psychosis services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644650</td><td>Adelino (2021)</td><td>Treatment-resistant schizophrenia - A RCT on the effectiveness of repeated-dose sodium nitroprusside</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633696</td><td>Adelson (1962)</td><td>A study of phenothiazines with male and female chronically ill schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646607</td><td>Ademola (2007)</td><td>Influence of ethnicity on presentation and outcome of first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647425</td><td>Agahi (2017)</td><td>Effect of melatonin in reducing second-generation antipsychotic metabolic effects: a double blind controlled clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646745</td><td>Agarwal (2016)</td><td>Impact of antipsychotic medication on transcranial direct current stimulation (tDCS) effects in schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644809</td><td>Agarwal (2018)</td><td>A systematic review and metaanalysis of pharmacological interventions for reduction or prevention of weight gain in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644812</td><td>Agarwal (2018)</td><td>A systematic review and meta-analysis of pharmacological interventions for reduction or prevention of weight gain in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645756</td><td>Agarwal (2019)</td><td>Pharmacological interventions for prevention of weight gain in people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644810</td><td>Agarwal (2020)</td><td>A systematic review and metaanalysis of pharmacological interventions for reduction of weight gain in people with schizophrenia: 2019 update</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645822</td><td>Aggarwal (2014)</td><td>A patient with multiple episodes of rhabdomyolysis induced by different neuroleptics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645053</td><td>Aggernaes (2010)</td><td>Sensorimotor gating and habituation in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months' treatment with quetiapine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647498</td><td>Agid (2007)</td><td>Early use of clozapine for poorly responding first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647533</td><td>Agid (2008)</td><td>Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633923</td><td>Agid (2010)</td><td>Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648659</td><td>Agid (2011)</td><td>An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647529</td><td>Agid (2013)</td><td>Early prediction of clinical and functional outcome in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648569</td><td>Agid (2013)</td><td>Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648567</td><td>Agid (2016)</td><td>Antipsychotic treatment algorithm for first episode schizophrenia - A guide for clinicians</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633779</td><td>Agius (2006)</td><td>0081 THREE YEAR OUTCOMES OF MANAGEMENT OF PATIENTS WITH FIRST EPISODE PSYCHOSIS BY AN EARLY INTERVENTION TREATMENT TEAM COMPARED TO TREATMENT AS USUAL</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644740</td><td>Agius (2007)</td><td>Three year outcomes of an early intervention for psychosis service as compared with treatment as usual for first psychotic episodes in a standard community mental health team. Preliminary results</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644508</td><td>Agius (2010)</td><td>What do large scale studies of medication in schizophrenia add to our management strategies?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645121</td><td>Agostoni (2017)</td><td>The Role of Omega-3 Fatty Acids in Developmental Psychopathology: A Systematic Review on Early Psychosis, Autism, and ADHD</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645633</td><td>Aguilar (1994)</td><td>Predictors of acute dystonia in first-episode psychotic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633534</td><td>Aguilar (2007)</td><td>Do antipsychotic drugs influence suicidal behavior in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647200</td><td>Ahmad (2016)</td><td>Endoxifen, a New Treatment Option for Mania: a Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647152</td><td>Ahmad (2020)</td><td>Evaluation on Efficacy of Psychological and Behavioral Intercession and Its Implications on People with Schizophrenia: A Novel Approach</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647231</td><td>Ahmed (1997)</td><td>EffICACY OF RISPERIDONE IN FIRST-EPISODE SCHIZOPHRENIA CONFERENCE ABSTRACTS</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646209</td><td>Ahmed (2011)</td><td>Mood stabilisers for schizoaffective disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647317</td><td>Ahn (2021)</td><td>Effects of comorbid alcohol use disorder on the clinical outcomes of first-episode schizophrenia: a nationwide population-based study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648085</td><td>Ahuir (2021)</td><td>Cognitive biases are associated with clinical and functional variables in psychosis: A comparison across schizophrenia, early psychosis and healthy individuals</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633806</td><td>Ainslie (1966)</td><td>Practical drug evaluation method. II. A drug-drug comparison.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644696</td><td>Airault (2018)</td><td>Travel-related psychosis (TrP): a landscape analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644501</td><td>Aitken (2016)</td><td>What is the relationship between elements of ICU treatment and memories after discharge in adult ICU survivors?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645690</td><td>Ajnakina (2017)</td><td>Polygenic risk score for schizophrenia is associated with treatment resistant schizophrenia during the first five years after first contact with mental health services</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646803</td><td>Ajnakina (2020)</td><td>Hospitalisation and length of hospital stay following first-episode psychosis: systematic review and meta-analysis of longitudinal studies</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647204</td><td>Ajnakina (2021)</td><td>Employment and relationship outcomes in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647578</td><td>Ajnakina (2021)</td><td>Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645701</td><td>Akiyama (1995)</td><td>Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: Comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645250</td><td>Akkaya (2014)</td><td>The relationship between the duration of drug use and the bipolar disorder patients' sociodemographic and clinical characteristics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645518</td><td>Akudjedu (2020)</td><td>Progression of neuroanatomical abnormalities after first-episode of psychosis: A 3-year longitudinal structural mri study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645519</td><td>Akudjedu (2020)</td><td>Progression of neuroanatomical abnormalities after first-episode of psychosis: A 3-year longitudinal sMRI study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647496</td><td>Alabaf (2021)</td><td>Early versus late risk factors for deficit and nondeficit schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648209</td><td>Alameda (2015)</td><td>Childhood sexual and physical abuse: Age at exposure modulates impact on functional outcome in early psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648482</td><td>Alameda (2016)</td><td>Assertive outreach for "difficult to engage" patients: A useful tool for a subgroup of patients in specialized early psychosis intervention programs</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647324</td><td>Al-Amin (2013)</td><td>Effects of antipsychotics on the inflammatory response system of patients with schizophrenia in peripheral blood mononuclear cell cultures</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647914</td><td>Alamiri (2008)</td><td>Considerations regarding the use of metformin with olanzapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645222</td><td>AlAqeel (2012)</td><td>Remission in schizophrenia: Critical and systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59645001</td><td>AlAqeel (2014)</td><td>Should remission in schizophrenia data be combined from different studies?</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647812</td><td>Alatas (2008)</td><td>Death in psychiatry</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647404</td><td>Albacete (2019)</td><td>The effect of second-generation antipsychotics on basal ganglia and thalamus in first-episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645235</td><td>Albayrak (2013)</td><td>Relationships between use of long acting antipsychotics and sociodemographic and clinical characteristics of patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646637</td><td>Albayrak (2014)</td><td>Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645611</td><td>Albert (2011)</td><td>Predictors of recovery from psychosis Analyses of clinical and social factors associated with recovery among patients with first-episode psychosis after 5 years</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646792</td><td>Albert (2016)</td><td>How long should early intervention last? Results from a randomized clinical trial of the effect of five-years versus two years specialized assertive intervention for first episode psychosis - The OPUS-II trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647443</td><td>Albert (2017)</td><td>The effect of duration of untreated psychosis and treatment delay on the outcomes of prolonged early intervention in psychotic disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644498</td><td>Albert (2018)</td><td>When should early intervention start, and for how long should it last?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645901</td><td>Albert (2019)</td><td>The outcome of early intervention in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646860</td><td>Albiston (1998)</td><td>Group programmes for recovery from early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646050</td><td>Albus (1996)</td><td>Neuropsychological impairment in first-episode and chronic schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645502</td><td>Albus (2002)</td><td>A prospective 2-year follow-up study of neurocognitive functioning in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646097</td><td>Albus (2006)</td><td>Neurocognitive functioning in patients with first-episode schizophrenia: Results of a prospective 5-year follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646740</td><td>Alcover (2019)</td><td>Impact of first episode psychosis treatment on heavy cannabis use: secondary analysis on RAISE-ETP study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645159</td><td>Alderson (2017)</td><td>Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: A population-based longitudinal cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648722</td><td>Al-Dhaher (2016)</td><td>Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644707</td><td>Aleman (2010)</td><td>Transcranial magnetic stimulation</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648212</td><td>Alemany (2015)</td><td>Childhood abuse in the etiological continuum underlying psychosis from first-episode psychosis to psychotic experiences</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634089</td><td>Alford (1980)</td><td>The Role and Uses of Psychopharmacological Agents in Behavior Therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645829</td><td>Allan (2020)</td><td>Pathways to care in at-risk mental states: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648693</td><td>Allen (2018)</td><td>Addressing the research to practice gap through co-production & service user leadership in early psychosis intervention research</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645805</td><td>Allison (2013)</td><td>Perception of peer group rank of individuals with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645621</td><td>Allott (2011)</td><td>Predictors of functional outcome following CBT in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645823</td><td>Allott (2011)</td><td>Patient predictors of symptom and functional outcome following cognitive behaviour therapy or befriending in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647646</td><td>Allott (2012)</td><td>Does individual placement and support compensate for neurocognitive deficit in first-episode psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645233</td><td>Allott (2013)</td><td>The relative contribution of neurocognition and social cognition to 6-month vocational outcomes following Individual Placement and Support in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645245</td><td>Allott (2013)</td><td>Relationship between vocational status and perceived stress and daily hassles in first-episode psychosis: An exploratory study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646737</td><td>Allott (2015)</td><td>The impact of neuropsychological functioning and coping style on perceived stress in individuals with first-episode psychosis and healthy controls</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647056</td><td>Allott (2016)</td><td>Feasibility and acceptability of cognitive adaptation training for first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645396</td><td>Allott (2018)</td><td>A randomised, double-blind, placebo-controlled trial of the effects of vitamin B12, B6 and folic acid on cognition and symptoms in first-episode psychosis. the vitamins in psychosis study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645397</td><td>Allott (2018)</td><td>A randomised, double-blind, placebo-controlled trial of the effects of vitamin B12, B6 and folic acid on cognition and symptoms in first-episode psychosis: the vitamins in psychosis study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647584</td><td>Allott (2018)</td><td>Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: a systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644542</td><td>Allott (2019)</td><td>The vitamins in psychosis study: A randomized, double-blind, placebo-controlled trial of the effects of vitamins B12, B6, and folic acid on symptoms and neurocognition in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633953</td><td>Almerie (2007)</td><td>Cessation of medication for people with schizophrenia already stable on chlorpromazine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645938</td><td>Alphs (2011)</td><td>Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633661</td><td>Altamura (1985)</td><td>Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647581</td><td>Altamura (2001)</td><td>Duration of untreated psychosis as a predictor of outcome in first-episode schizophrenia: A retrospective study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648739</td><td>Alvarado-Alanis (2016)</td><td>"Abnormal white matter integrity in antipsychotic-naive first-episode psychosis patients assessed by a DTI principal component analysis": Corrigendum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648429</td><td>Alvarez-Jim√©nez (2006)</td><td>Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646020</td><td>Alvarez-Jimenez (2008)</td><td>Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647193</td><td>Alvarez-Jimenez (2008)</td><td>Enhancing treatment fidelity in psychotherapy research: novel approach to measure the components of cognitive behavioural therapy for relapse prevention in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648546</td><td>Alvarez-Jimenez (2008)</td><td>Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: A systematic critical reappraisal</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645549</td><td>Alvarez-Jimenez (2009)</td><td>Preventing the second episode: a randomized controlled trial of relapse prevention therapy versus specialized treatment for remitted first-episode psychosis patients</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648413</td><td>Alvarez-Jimenez (2009)</td><td>Authors' reply to "One ace and three faults don't win the set."</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645631</td><td>Alvarez-Jim√©nez (2009)</td><td>Predictors of adherence to cognitive-behavioural therapy in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645547</td><td>Alvarez-Jim√©nez (2010)</td><td>Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647709</td><td>Alvarez-Jim√©nez (2010)</td><td>Differential predictors of critical comments and emotional over-involvement in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645548</td><td>Alvarez-Jimenez (2011)</td><td>Preventing the second episode: A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis</td><td>(I) Included</td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td></tr><tr><td>59648377</td><td>Alvarez-Jimenez (2016)</td><td>Beyond clinical remission in first episode psychosis: Thoughts on antipsychotic maintenance vs. guided discontinuation in the functional recovery era</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59646807</td><td>Alvarez-Jimenez (2019)</td><td>HORYZONS trial: protocol for a randomised controlled trial of a moderated online social therapy to maintain treatment effects from first-episode psychosis services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646809</td><td>Alvarez-Jimenez (2021)</td><td>The Horyzons project: a randomized controlled trial of a novel online social therapy to maintain treatment effects from specialist first-episode psychosis services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645995</td><td>Alvir (1999)</td><td>Obstetric complications predict treatment response in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645580</td><td>Amminger (1997)</td><td>Premorbid adjustment and remission of positive symptoms in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646416</td><td>Amminger (2010)</td><td>Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: A randomized, placebo-controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646633</td><td>Amminger (2010)</td><td>Indicated prevention with long-chain omega-3 fatty acids in young people at ultra-high risk for psychosis: a randomized, placebo-controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646122</td><td>Amminger (2018)</td><td>Neurapro revisited: increases in long-chain omega-3 fatty acids improve functional and symptomatic outcomes in ultrahigh risk patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645864</td><td>Amoretti (2020)</td><td>P.548 The effects of clozapine on cognitive functioning in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647497</td><td>Amoretti (2020)</td><td>Early versus delayed prescription of clozapine and the cognitive performance on schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646936</td><td>Amoretti (2021)</td><td>The functioning assessment short test (FAST) applied to first-episode psychosis: Psychometric properties and severity thresholds</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646465</td><td>Amos (2012)</td><td>Letter to the Editor: Early detection of psychosis: Positive effects on 5-year outcome?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647257</td><td>Amr (2013)</td><td>Efficacy and tolerability of quetiapine versus haloperidol in first-episode schizophrenia: a randomized clinical trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>59644619</td><td>An uncontrolled trial... (2018)</td><td>An uncontrolled trial of multi-component care for first-episode psychosis: effects on social cognition</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646454</td><td>Anand (1994)</td><td>Linguistic impairment in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633636</td><td>Ananth (2004)</td><td>Drug Therapy in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634278</td><td>Anda (2021)</td><td>Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648070</td><td>Andersen (2011)</td><td>Cognitive effects of six months of treatment with quetiapine in antipsychotic-naive first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646605</td><td>Andersen (2013)</td><td>The influence of impaired processing speed on cognition in first-episode antipsychotic-naive schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644891</td><td>Andersen (2020)</td><td>Striatal Volume Increase After Six Weeks of Selective Dopamine D<inf>2/3</inf> Receptor Blockade in First-Episode, Antipsychotic-Naive Schizophrenia Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634184</td><td>Anderson (1982)</td><td>Family Treatment of Patients with Chronic Schizophrenia: The Inpatient Phase</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633764</td><td>Anderson (1991)</td><td>Chemical restraint: An idea whose time has gone</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644612</td><td>Anderson (2018)</td><td>Understanding the role of the family physician in early psychosis intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647367</td><td>Anderson (2018)</td><td>Effectiveness of early psychosis intervention: Comparison of service users and nonusers in population-based health administrative data</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647064</td><td>Anderson (2019)</td><td>Family physician access among young people with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633740</td><td>Andersson (1998)</td><td>EMERGING ROLES FOR NOVEL ANTIPSYCHOTIC MEDICATIONS IN THE TREATMENT OF SCHIZOPHRENIA</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647929</td><td>Ando (2014)</td><td>Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): nine-month follow-up of randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646847</td><td>Andrade (2016)</td><td>Hair cortisol in drug-naive first-episode individuals with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647226</td><td>Andrade (2020)</td><td>Efficacy outcomes in the MDD-1 India study: First episode major depressive disorder outcomes in antidepressant-treated real-world patients in India</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646768</td><td>Andrade-Nascimento (2011)</td><td>The identification of unipolar mania subtype based on anxiety comorbidity</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644469</td><td>Andre (2016)</td><td>Working memory circuit as a function of increasing age in healthy adolescence: A systematic review and meta-analyses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646682</td><td>Andreasen (1997)</td><td>Improvement of negative symptoms: Concepts, definition and assessment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646959</td><td>Angst (2012)</td><td>From psychoanalysis to pharmacotherapy: 1951-2011</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648652</td><td>Anhoj (2018)</td><td>Alterations of intrinsic connectivity networks in antipsychotic-naive first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646979</td><td>Anilkumar (2008)</td><td>An fMRI study of face encoding and recognition in first-episode schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633700</td><td>Anisman (1982)</td><td>Anhedonia: Too much, too soon</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633597</td><td>Anker (1979)</td><td>The conquest of "schizophrenia:" Sisyphus revisited.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644988</td><td>Annette (2019)</td><td>Sixth Kraepelin Symposium-Understanding and Treating Cognitive Impairment and Depression in Schizophrenia and Affective Disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647181</td><td>Anonymous (2017)</td><td>Erratum: five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II) (Journal of Mechanical Design, Transactions of the ASME (2017) 356 (i6681) DOI: 10.1136/bmj.i6681)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648087</td><td>Anonymous (2018)</td><td>Cognitive behavioural therapy for psychosis: A health technology assessment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59647668</td><td>Ansell (2015)</td><td>Divergent effects of first-generation and second-generation antipsychotics on cortical thickness in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645047</td><td>Ansermot (2014)</td><td>Serotonin toxicity after addition of mirtazapine to escitalopram</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647873</td><td>Antoniades (2020)</td><td>Cortical neuroanatomical signature of schizotypy in 2,695 individuals assessed in a worldwide enigma study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645782</td><td>Antoniades (2021)</td><td>Personalized Estimates of Brain Structural Variability in Individuals With Early Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646240</td><td>Apiquian (2003)</td><td>Minimum effective doses of haloperidol for the treatment of first psychotic episode: A comparative study with risperidone and olanzapine</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634006</td><td>Appleton (1970)</td><td>Teaching clinical psychopharmacology.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647879</td><td>Arabzadeh (2014)</td><td>Correlation of neurological soft signs and neurocognitive performance in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645504</td><td>Arafat (2018)</td><td>Proportion and reasons for medication non-compliance among schizophrenics: A cross-sectional observation in a tertiary care hospital of Bangladesh</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645987</td><td>Arango (2009)</td><td>Olanzapine compared to quetiapine in adolescents with a first psychotic episode</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645452</td><td>Arango (2015)</td><td>Psychosocial interventions in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59645480</td><td>Arango (2015)</td><td>Psychoeducational group intervention for adolescents with psychosis and their families. A two-year follow-up: the piensa trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646883</td><td>Arango (2015)</td><td>Going beyond "trial-and-error" in psychiatric treatments: OPTiMiSE-ing the treatment of first episode of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647007</td><td>Arango (2015)</td><td>First-episode psychosis research: Time to move forward (by looking backwards)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645920</td><td>Arango (2018)</td><td>Optimise-ing the treatment of firstepisode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645921</td><td>Arango (2019)</td><td>The optimise study: amisulpride and olanzapine followed by openlabel treatment with clozapine in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648764</td><td>Arango (2019)</td><td>17. THE OPTiMISE STUDY: AMISULPRIDE AND OLANZAPINE FOLLOWED BY OPEN-LABEL TREATMENT WITH CLOZAPINE IN FIRST-EPISODE SCHIZOPHRENIA...2019 Congress of the Schizophrenia International Research Society, April 10-14, 2019, Orlando, Florida</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645413</td><td>Aravagiri (1994)</td><td>Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazine</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648608</td><td>Arbus (2010)</td><td>Antidepressant use in Alzheimer's disease patients: Results of the REAL.FR cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634099</td><td>Arbuthnott (1982)</td><td>Support for the hypothesis that the actions of dopamine are ‚Äúnot merely motor.‚Äù</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634040</td><td>Arbuthnott (1993)</td><td>Chapter 22 The thorny problem of what dopamine does in psychiatric disease</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647514</td><td>Arceo (2019)</td><td>Early response in adolescents with schizophrenia is not associated with remission at six months</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646583</td><td>Archie (2006)</td><td>Integrated care improves one year outcomes in first episode psychosis</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>59647033</td><td>Archie (2009)</td><td>First episode psychosis, substance abuse and prognosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645288</td><td>Archie (2013)</td><td>Reflections of young people who have had a first episode of psychosis: What attracted them to use alcohol and illicit drugs?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647023</td><td>Archie (2015)</td><td>First-episode affective psychosis and lipid monitoring: Survival analysis of the first abnormal lipid test</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646373</td><td>Argolo (2020)</td><td>Lowering costs for large-scale screening in psychosis: a systematic review and meta-analysis of performance and value of information for speech-based psychiatric evaluation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646632</td><td>Armando (2016)</td><td>Indicated prevention with long-chain polyunsaturated omega-3 fatty acids in patients with 22q11DS genetically at high risk for psychosis. Protocol of a randomized, double-blind, placebo-controlled treatment trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648437</td><td>Armstrong (2020)</td><td>Associative Inference Deficits in Early Psychosis: A Two-Year Follow-Up Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644580</td><td>Arnaiz (2020)</td><td>The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646106</td><td>Arnold (2015)</td><td>Neurocognitive and social cognitive predictors of cannabis use in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646587</td><td>Arranz (2004)</td><td>Insulin Resistance and Increased Leptin Concentrations in Noncompliant Schizophrenia Patients but Not in Antipsychotic-Naive First-Episode Schizophrenia Patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646374</td><td>Arranz (2007)</td><td>Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644857</td><td>Arranz (2015)</td><td>Substance Use in Patients With First-Episode Psychosis: is Gender Relevant?</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647982</td><td>Arranz (2020)</td><td>Comparison between a morocco and a native-born population, in a sample of first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648119</td><td>Asenjo‚ÄêLobos (2018)</td><td>Clozapine versus olanzapine for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646247</td><td>Ashcroft (2012)</td><td>Mindfulness groups for early psychosis: A qualitative study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648500</td><td>Assalman (2012)</td><td>Aripiprazole for people with schizophrenia whose illness has been partially responsive to clozapine</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646781</td><td>Aston (2010)</td><td>Hyperprolactinaemia in early psychosis-Not only due to antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633858</td><td>Astrachan (1974)</td><td>Symptomatic outcome in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646300</td><td>Atagun (2020)</td><td>Meta-analysis of auditory P50 sensory gating in schizophrenia and bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648265</td><td>Atay (2014)</td><td>A case of risperidone induced stuttering as a paradox</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647596</td><td>Atkinson (2012)</td><td>Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644513</td><td>Attux (2007)</td><td>Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633896</td><td>Auerbach (1964)</td><td>SOME LIMITATIONS OF PSYCHIATRIC RATING SCALES: THE CLINICIAN'S VIEWPOINT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645610</td><td>Austin (2013)</td><td>Predictors of recovery in first episode psychosis: The OPUS cohort at 10 year follow-up</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645093</td><td>Austin (2015)</td><td>Schizophrenia and metacognition: An investigation of course of illness and metacognitive beliefs within a first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645788</td><td>Avery (2020)</td><td>Persistent neural habituation deficits in early psychosis: A 2-year follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647032</td><td>Awad (2006)</td><td>First episode psychosis: olanzapine and haloperidol provide similar improvements in quality of life and social functioning</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645175</td><td>Awad (2019)</td><td>Revisiting the concept of subjective tolerability to antipsychotic medications in schizophrenia and its clinical and research implications: 30 years later</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646481</td><td>Awara (2018)</td><td>Late Onset First Episode Psychosis Emerging as Delusional Misidentification of Familiar Sacred Places During a Holy Pilgrimage: A Case Report and Literature Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633685</td><td>Ayd (1974)</td><td>Side effects of depot fluphenazines.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648336</td><td>Aydin (2020)</td><td>Brain-derived neurotrophic factor levels and psychopathology scores in drug-naive first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646592</td><td>Ayesa-Arriola (2011)</td><td>Insight dimensions in first-episode psychosis patients: Clinical, cognitive, pre-morbid and socio-demographic correlates</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646414</td><td>Ayesa-Arriola (2013)</td><td>Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647478</td><td>Ayesa-Arriola (2021)</td><td>Education and long-term outcomes in first episode psychosis: 10-year follow-up study of the PAFIP cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648223</td><td>Ayora (2020)</td><td>Changes in telomere length in young people with first episode psychosis: A 12-months follow-up study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648079</td><td>Ayres (2007)</td><td>Cognitive deficits in first-episode psychosis: A population-based study in Sao Paulo, Brazil</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633810</td><td>Ayuso-Guti√©rrez (1997)</td><td>Factors influencing relapse in the long-term course of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646850</td><td>Azorin (2013)</td><td>Guidelines on long-acting injectable atypical antipsychotics for first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645591</td><td>Azorin (2015)</td><td>Predominant polarity in bipolar disorders: Further evidence for the role of affective temperaments</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646224</td><td>Azorin (2016)</td><td>A model of care for first-episode psychosis: the RAISE-ETP project</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648573</td><td>Azorin (2020)</td><td>Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634280</td><td>B (1981)</td><td>A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645345</td><td>Baandrup (2020)</td><td>Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647884</td><td>Bachman (2003)</td><td>Corpus callosum in first-episode patients with schizophrenia--a magnetic resonance imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647933</td><td>Bachmann (2007)</td><td>Compliance with medication but not structural MRI measures predict functional outcome in first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646313</td><td>Bachmann (2010)</td><td>MEG does not reveal impaired sensory gating in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646076</td><td>Bachmann (2018)</td><td>Neurological soft signs (NSS) in schizophrenia: An update on the state-versus trait-perspective</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645054</td><td>Badia (2020)</td><td>Sensitivity for motion is weakened in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645702</td><td>Baeza (2009)</td><td>Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648371</td><td>Baeza (2017)</td><td>Biological markers of stress in children and adolescents with firstepisode of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648576</td><td>Baitz (2012)</td><td>Antipsychotic medications: Linking receptor antagonism to neuropsychological functioning in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646213</td><td>Bak (2012)</td><td>Monitoring clozapine adverse effects calls for the integration of protocol and good clinical practice</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646395</td><td>Baker (2012)</td><td>Long-term safety and tolerability of once-monthly aripiprazole intramuscular depot for maintenance treatment in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634124</td><td>Baker (2018)</td><td>What do we really know about PRN use in agitated children with mental health conditions: a clinical review.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645594</td><td>Baksheev (2012)</td><td>Predictors of vocational recovery among young people with first-episode psychosis: findings from a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647731</td><td>Balan (2018)</td><td>Differences in demographic and clinical characteristics between cannabis users and non-drug users: A retrospective study of patients at first hospitalization due to psychotic symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633828</td><td>Baldessarini (1980)</td><td>What Is the Best Maintenance Dose of Neuroleptics in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633612</td><td>Baldessarini (1988)</td><td>Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645590</td><td>Baldessarini (2012)</td><td>Predominant recurrence polarity among 928 adult international bipolar I disorder patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645979</td><td>Bale (2008)</td><td>Olanzapine treatment and weight gain: Considering the lipid side effects of antipsychotics</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648128</td><td>Ballon (2018)</td><td>Clozapine titration for people in early psychosis: A chart review and treatment guideline</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648553</td><td>Bal√µt≈°ev (2019)</td><td>Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: a 7-month follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648434</td><td>Balta (2015)</td><td>Asymmetric dimethylarginine levels in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646769</td><td>Baltzersen (2020)</td><td>Identification of a serotonin 2a receptor subtype of schizophrenia spectrum disorders with pimavanserin: The sub-sero proofof-concept trial protocol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634063</td><td>Ban (1971)</td><td>Drug treatment in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633846</td><td>Ban (1987)</td><td>Prolegomenon to the clinical prerequisite: psychopharmacology and the classification of mental disorders.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633532</td><td>Ban (2004)</td><td>Neuropsychopharmacology and the genetics of schizophrenia: a history of the diagnosis of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647901</td><td>Banaszkiewicz (2020)</td><td>Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644663</td><td>Barateau (2016)</td><td>Treatment options for narcolepsy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646574</td><td>Barbeito (2014)</td><td>Integrated treatment of first episode psychosis with online training (e-learning): study protocol for a randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646227</td><td>Barbeito (2019)</td><td>Mobile App-Based Intervention for Adolescents With First-Episode Psychosis: study Protocol for a Pilot Randomized Controlled Trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644807</td><td>Barbeito (2020)</td><td>A systematic review of online interventions for families of patients with severe mental disorders</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646963</td><td>Barbero (2015)</td><td>Free thyroxine levels are associated with cognitive abilities in subjects with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633749</td><td>Barbui (1996)</td><td>Low-dose neuroleptic therapy and relapse in schizophrenia: meta-analysis of randomized controlled trials</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646843</td><td>Barbui (2007)</td><td>Haloperidol, risperidone and olanzapine are similarly effective for first-episode non-affective psychosis but have differing side effects</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646103</td><td>Barder (2013)</td><td>Neurocognitive development in first episode psychosis 5 years follow-up: Associations between illness severity and cognitive course</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648770</td><td>Barder (2015)</td><td>10 year course of IQ in first-episode psychosis: Relationship between duration of psychosis and long-term intellectual trajectories</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634223</td><td>Barkham (2021)</td><td>Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634258</td><td>Barkham (2021)</td><td>Clinical and cost-effectiveness of person-centred experiential therapy vs. cognitive behavioural therapy for moderate and severe depression delivered in the English Improving Access to Psychological Therapies national programme: a pragmatic randomised non- inferiority trial [PRaCTICED]</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647090</td><td>Barkl (2014)</td><td>Facial emotion identification in early-onset and first-episode psychosis: A systematic review with meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633757</td><td>Barnes (1983)</td><td>Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633594</td><td>Barnes (1991)</td><td>United Kingdom: Neuroleptic Relapse Prevention</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644511</td><td>Barnes (2000)</td><td>West London first-episode study of schizophrenia: Clinical correlates of duration of untreated psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647142</td><td>Barnes (2011)</td><td>Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647141</td><td>Barnes (2020)</td><td>Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644775</td><td>Barrigon (2010)</td><td>Temporal relationship of first-episode non-affective psychosis with cannabis use: A clinical verification of an epidemiological hypothesis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634054</td><td>Barrowclough (2013)</td><td>A phase specific psychological therapy for people with problematic cannabis use following a first episode of psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645729</td><td>Barrowclough (2014)</td><td>A phase-specific psychological therapy for people with problematic cannabis use following a first episode of psychosis: a randomized controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644964</td><td>Bartholomeusz (2012)</td><td>Social cognition training as an intervention for improving functional outcome in first episode psychosis: a pilot study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644963</td><td>Bartholomeusz (2013)</td><td>Social cognition training as an intervention for improving functional outcome in first-episode psychosis: A feasibility study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646439</td><td>Bartzokis (2011)</td><td>Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646726</td><td>Bartzokis (2012)</td><td>Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647950</td><td>Basoglu (2006)</td><td>Comparison of Right Thalamus and Temporal Cortex Metabolite Levels Between Drug-Naive First Episode Psychotic and Chronic Schizophrenic Patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647135</td><td>Bastiampillai (2008)</td><td>Exacerbation of tics secondary to clozapine therapy</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647059</td><td>Bastiampillai (2016)</td><td>FDA changes clozapine monitoring guidelines: Implications for worldwide practice</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644747</td><td>Basu (2014)</td><td>Thin at what cost? Case reports of sibutramine-induced psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645672</td><td>Batalla (2019)</td><td>The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646089</td><td>Batet (2016)</td><td>Neuroimaging of first-episode-psychosis in cannabis users: A review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644655</td><td>Batscha (2010)</td><td>Treatment settings and metabolic monitoring for people experiencing first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633706</td><td>Bauer (1969)</td><td>Effective neuroleptic therapy for hospitalized schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645965</td><td>Baumgart (2005)</td><td>Olanzapine-lnduced Acute Rhabdomyolysis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646255</td><td>Baumgarten (2013)</td><td>Metformin in the treatment of antipsychotic induced amenorrhea</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646948</td><td>Baumgartner (2019)</td><td>Fulminant onset of valproate-associated hyperammonemic encephalopathy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648264</td><td>Bavle (2015)</td><td>Case report of clozapine-induced neutropenia and rechallenge</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645751</td><td>Bayle (2011)</td><td>Pharmacological management of anxiety in patients suffering from schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647532</td><td>Baytunca (2017)</td><td>Early onset schizophrenia associated with obsessive-compulsive disorder: Clinical features and correlates</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648777</td><td>Bazigh (2019)</td><td>4.17 Schizophrenia in Adolescents: Is Schizo-Obsessive a Subtype?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648725</td><td>Bazrafshan (2015)</td><td>Acetophenazine versus chlorpromazine for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648332</td><td>Bazrafshan (2017)</td><td>Brexpiprazole versus placebo for people with schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59647839</td><td>Beary (2012)</td><td>A critical review of major mortality risk factors for all-cause mortality in first-episode schizophrenia: Clinical and research implications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645783</td><td>Beauchamp (2011)</td><td>Personality traits in early psychosis: Relationship with symptom and coping treatment outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647658</td><td>Beauchamp (2013)</td><td>Do personality traits matter when choosing a group therapy for early psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646538</td><td>Bechard-Evans (2010)</td><td>Investigating cognitive deficits and symptomatology across pre-morbid adjustment patterns in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645322</td><td>Bechdolf (2006)</td><td>Recent approaches to psychological interventions for people at risk of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645334</td><td>Bechdolf (2011)</td><td>Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59644907</td><td>Bechdolf (2012)</td><td>State-dependent motivational interviewing for people with schizophrenia and substance use: results of a randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645335</td><td>Bechdolf (2012)</td><td>Rationale and baseline characteristics of prevent: a second generation intervention trial in subjects at-risk (prodromal) of developing first episode psychosis evaluating cognitive behaviour therapy, aripiprazole and placebo for the prevention of psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645551</td><td>Bechdolf (2012)</td><td>Preventing progression to first-episode psychosis in early initial prodromal states</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645555</td><td>Bechdolf (2016)</td><td>PREVENT: a randomized controlled trial comparing cognitive behavioural therapy, clinical management and aripirazole and clinical management and placebo for the prevention of first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645554</td><td>Bechdolf (2017)</td><td>Prevent: a randomized controlled trial for the prevention of first-episode psychosis comparing cognitive-behavior therapy (CBT), clinical management, and aripiprazole combined and clinical management and placebo combined</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61633920</td><td>Beck (2014)</td><td>The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645877</td><td>Beck (2021)</td><td>P.302 N-methyl-D-aspartate receptor availability in first-episode psychosis: a PET-MR brain imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647518</td><td>Beck (2021)</td><td>Early psychosis: Diagnosis and treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648006</td><td>Becker (2016)</td><td>The Common Elements of treatment engagement for clinically high-risk youth and youth with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647966</td><td>Bediou (2012)</td><td>A comparison of facial emotion processing in neurological and psychiatric conditions</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644726</td><td>Begemann (2020)</td><td>To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59644798</td><td>Behan (2017)</td><td>Systematic review of the evidence for service models delivering early intervention in psychosis outside the stand-alone centre</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645891</td><td>Belinskaia (2019)</td><td>Over-expression and pattern disruption of exon II HTR2A spliced transcript isoforms in drug-na√Øve schizophrenic peripheral blood lymphocytes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646952</td><td>Bell (1999)</td><td>Frontal lobe dysfunction in first episode schizophrenia: Redundancy bias in acute and stabilized states</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648025</td><td>Bell (2015)</td><td>Cognitive training to enhance work program outcomes: preliminary findings</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634004</td><td>Bellak (1979)</td><td>A ‚ÄúMini-Max‚Äù: A Research Strategy for Establishing Subgroups of the Schizophrenic Syndrome</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647759</td><td>Belli (2011)</td><td>Determination of schizophrenia patients with increased risk of suicide and treatment with atypical antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633655</td><td>Belmaker (1977)</td><td>Haloperidol in normals.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645445</td><td>Benazzi (2002)</td><td>Psychotic Mania in Bipolar II Depression Related to Sertraline Discontinuation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647845</td><td>Bendall (2006)</td><td>The Credibility and Acceptability of Befriending as a Control Therapy in a Randomized Controlled Trial of Cognitive Behaviour Therapy for Acute First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645065</td><td>Bendall (2014)</td><td>Selective attention to threat is specific to delusions in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648207</td><td>Bendall (2018)</td><td>Childhood trauma is associated with severity of hallucinations and delusions in psychotic disorders: Results of a meta-analysis and implications for early psychosis treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646759</td><td>Ben-David (2019)</td><td>Identity in the context of early psychosis: A review of recent research</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634065</td><td>Beninger (1982)</td><td>The behavioral function of dopamine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644950</td><td>Bennett (2021)</td><td>Socioeconomic status and the effectiveness of treatment for first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644883</td><td>Benoit (2012)</td><td>The structural neural substrates of persistent negative symptoms in first-episode of non-affective psychosis: A voxel-based morphometry study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646901</td><td>Berardicurti (2020)</td><td>Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647848</td><td>Berge (2012)</td><td>Course of negative symptoms in first-episode psychosis on aripiprazole vs. other antipsychotics during a two years follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644764</td><td>Berge (2020)</td><td>Thalamic connectivity in early psychosis during task and at rest</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647216</td><td>Berge (2020)</td><td>Elevated extracellular free-water in a multicentric first-episode psychosis sample, decrease during the first 2 years of illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647174</td><td>Bergemann (2005)</td><td>Estrogen as an adjuvant therapy to antipsychotics does not prevent relapse in women suffering from schizophrenia: results of a placebo-controlled double-blind study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644768</td><td>Bergemann (2008)</td><td>Testosterone and gonadotropins but not estrogen associated with spatial ability in women suffering from schizophrenia: a double-blind, placebo-controlled study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647175</td><td>Bergemann (2008)</td><td>Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633756</td><td>Berger (1978)</td><td>Medical treatment of mental illness</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646453</td><td>Berger (2005)</td><td>Lipid Abnormalities in Schizophrenia and Related Disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647170</td><td>Berger (2007)</td><td>Ethyl-eicosapentaenoic acid in first-episode psychosis: A randomized, placebo-controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647169</td><td>Berger (2008)</td><td>Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647624</td><td>Berger (2008)</td><td>Dosing quetiapine in drug-naive first episode psychosis: A controlled, double-blind, randomized, single-center study investigating efficacy, tolerability, and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647168</td><td>Berger (2009)</td><td>Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Corrigendum</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647869</td><td>Berger (2016)</td><td>Cortisol awakening response in patients with schizophrenia, first-episode psychosis and at-risk mental states: A meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647870</td><td>Berger (2016)</td><td>Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645269</td><td>Berger (2018)</td><td>Relationship between allostatic load and poor functional capacity in youth at ultra-high risk for psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648655</td><td>Berger (2018)</td><td>Allostatic load is associated with psychotic symptoms and decreases with antipsychotic treatment in patients with schizophrenia and first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633682</td><td>Bergiannaki (2001)</td><td>Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634307</td><td>Bergiannaki (2001)</td><td>Prevenci√≥n de reca√≠das en la esquizofrenia: actitudes de los neur√≥logos-psiquiatras</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644664</td><td>Bergink (2015)</td><td>Treatment of psychosis and mania in the postpartum period</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647673</td><td>Bergman (1995)</td><td>Distractibility in schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645095</td><td>Bergman (2015)</td><td>Schedule for Affective Disorders and Schizophrenia for School‚ÄêAge Children (K‚ÄêSADS) for diagnosing schizophrenia in children and adolescents with psychotic symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647061</td><td>Bergstrom (2018)</td><td>The family-oriented open dialogue approach in the treatment of first-episode psychosis: Nineteen-year outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634276</td><td>Bergstr√∂m (2020)</td><td>Five-Year Cumulative Exposure to Antipsychotic Medication After First-Episode Psychosis and its Association With 19-Year Outcomes</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645436</td><td>Berk (2011)</td><td>Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645420</td><td>Berk (2017)</td><td>Quetiapine v. lithium in the maintenance phase following a first episode of mania: randomised controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634136</td><td>Berkhout (2018)</td><td>Paradigm shift? Purity, progress and the origins of first-episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646061</td><td>Bermudez (2008)</td><td>Neuropsychiatric manifestations related to vitamin b12 deficiency</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645824</td><td>Bern (2014)</td><td>Patient outcomes within schizophrenia treatment: A look at the role of long-acting injectable antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645762</td><td>Bernal-Schnatter (1999)</td><td>Pharmacologic treatment of psychosis and pervasive developmental disorders in adolescents</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647757</td><td>Berry (2020)</td><td>Developing a Theory-Informed Smartphone App for Early Psychosis: Learning Points From a Multidisciplinary Collaboration</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646078</td><td>Bersani (2005)</td><td>Neurologic Soft Signs in Schizophrenic Patients Treated With Conventional and Atypical Antipsychotics</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644846</td><td>Bertelsen (2007)</td><td>Suicidal behaviour and mortality in first-episode psychosis: the OPUS trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646987</td><td>Bertelsen (2008)</td><td>Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647041</td><td>Bertelsen (2009)</td><td>First episode of psychosis intensive early intervention programme versus standard treatment--secondary publication</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647849</td><td>Bertelsen (2009)</td><td>Course of illness in a sample of 265 patients with first-episode psychosis--five-year follow-up of the Danish OPUS trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634250</td><td>Berze (2019)</td><td>Implementing the Latvian Early Intervention Program (LAT-EIP) for Patients With Schizophrenia Spectrum First-Episode Psychosis: Study Protocol.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648392</td><td>Best (2018)</td><td>Be outspoken and overcome stigmatizing thoughts (BOOST): A group treatment for internalized stigma in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634210</td><td>Best (2020)</td><td>Relationships between psychiatric symptoms, functioning and personal recovery in psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646638</td><td>Beyazyuz (2014)</td><td>Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647416</td><td>Bharat (2021)</td><td>The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648306</td><td>Bhattacharyya (2018)</td><td>Cannabidiol as a treatment in different stages of psychosis-efficacy and mechanisms</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644929</td><td>Biagianti (2020)</td><td>Specificity and Durability of Changes in Auditory Processing Efficiency After Targeted Cognitive Training in Individuals With Recent-Onset Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634112</td><td>Bighelli (2018)</td><td>Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634239</td><td>Bighelli (2020)</td><td>Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648572</td><td>Bighelli (2021)</td><td>Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645735</td><td>Bioque (2016)</td><td>A pharmacovigilance study in first episode of psychosis: Psychopharmacological interventions and safety profiles in the PEPs project</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647543</td><td>Bird (2010)</td><td>Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: Systematic review</td><td>(I) Included</td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td></tr><tr><td>59647233</td><td>Birules (2016)</td><td>Efficacy of Metacognitive Training (MCT) in recentonset of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648341</td><td>Birur (2017)</td><td>Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder-a systematic review of the magnetic resonance neuroimaging literature</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648342</td><td>Birur (2017)</td><td>Brain structure, function, and neurochemistry across Schizophrenia and bipolar disorder-a sys tematic review of the magnetic resonance neuroima-ging literature</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646072</td><td>Birur (2020)</td><td>Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633774</td><td>Bishop (1965)</td><td>Extrapyramidal Side Effects and Therapeutic Response</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633995</td><td>Bishop (1966)</td><td>Observations of placebo response in chronic schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634076</td><td>Bishop (1977)</td><td>Efficacy of loxapine in the treatment of paranoid schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634202</td><td>Bishop (1980)</td><td>A study of the effectiveness of cognitive therapy and pharmacotherapy, each alone, and in combination, in the treatment of depressed outpatients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645772</td><td>Bishop (2015)</td><td>Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645978</td><td>Bitter (1999)</td><td>Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648561</td><td>Bitter (2005)</td><td>Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648662</td><td>Bjarke (2020)</td><td>Akathisia and atypical antipsychotics: exploring associations to suicidality and agitation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647149</td><td>Bjornestad (2016)</td><td>"Everyone needs a friend sometimes"-Social predictors of long-term remission in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644472</td><td>Bjornestad (2017)</td><td>"With a little help from my friends" social predictors of clinical recovery in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647573</td><td>Black (2001)</td><td>Duration of untreated psychosis predicts treatment outcome in an early psychosis program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633832</td><td>Black (2011)</td><td>Treatment received by persons with BPD participating in a randomized clinical trial of the Systems Training for Emotional Predictability and Problem Solving programme</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646130</td><td>Blackman (2014)</td><td>Neural basis of context processing dysfunction in schizophrenia: A monkey model</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646567</td><td>Blair (2020)</td><td>Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645953</td><td>Blajeski (2018)</td><td>On the cusp: Early psychosis, employment & disability</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633688</td><td>Blashfield (1973)</td><td>An evaluation of the DSM-II classification of schizophrenia as a nomenclature.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644559</td><td>Blessing (2009)</td><td>Vernal fluency tasks in first episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647694</td><td>Bliksted (2016)</td><td>Discriminating autism spectrum disorders from schizophrenia by investigation of mental state attribution on an on-line mentalizing task: A review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646783</td><td>Bliksted (2019)</td><td>Hyper- and hypomentalizing in patients with first-episode schizophrenia: fMRI and behavioral studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633942</td><td>Boardman (2014)</td><td>A peer support programme for enhancing adherence to oral antipsychotic medication in consumers with schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645110</td><td>Bobes (2003)</td><td>Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646753</td><td>Bocchio-Chiavetto (2018)</td><td>Immune and metabolic alterations in first episode psychosis (FEP) patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647221</td><td>Boden (2012)</td><td>Electrocardiographic signs of autonomic imbalance in medicated patients with first-episode schizophrenia spectrum disorders-Relations to first treatment discontinuation and five-year remission status</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644662</td><td>Boden (2019)</td><td>Treatment resistant depression with partial effect of electroconvulsive treatment achieving long lasting remission with dorsomedial prefrontal intermittent theta-burst stimulation ‚Äì a case report</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648046</td><td>Bodnar (2008)</td><td>Cognitive markers of short-term clinical outcome in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646124</td><td>Bodnar (2010)</td><td>Neural markers of remission in first-episode schizophrenia: A volumetric neuroimaging study of the hippocampus and amygdala</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634300</td><td>Bogoviƒá (2012)</td><td>Characteristics of the participants included in the early intervention program for psychotic patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644660</td><td>Bojesen (2020)</td><td>Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naive patients with psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648444</td><td>Bojesen (2020)</td><td>Associations between cognitive function and cortical levels of glutamate and GABA in antipsychotic-naive patients with schizophrenia or psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648442</td><td>Bojesen (2021)</td><td>Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naive Patients With Schizophrenia or Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648781</td><td>Boks (2006)</td><td>The 2-year stability of neurological soft signs after a first episode of non-affective psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633822</td><td>Bola (2002)</td><td>Predicting Drug-Free Treatment Response in Acute Psychosis From the Soteria Project</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634014</td><td>Bola (2003)</td><td>Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project.</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>61633736</td><td>Bola (2006)</td><td>Predicting medication-free treatment response in acute psychosis: cross-validation from the Finnish Need-Adapted Project.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633936</td><td>Bola (2006)</td><td>Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645448</td><td>Bola (2009)</td><td>Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: A review of the literature</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633932</td><td>Bola (2011)</td><td>Antipsychotic Medication for Early-Episode Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645037</td><td>Bolu (2019)</td><td>Serum levels of high sensitivity C-reactive protein in drug-naive first-episode psychosis and acute exacerbation of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645694</td><td>Bolu (2020)</td><td>Plasma prolidase levels are high in schizophrenia but not in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644622</td><td>Bonartsev (2014)</td><td>Ultrastructural changes in platelets and their relationship with serotonin metabolism in patients with schizophrenia treated with olanzapine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647205</td><td>Bond (2015)</td><td>Employment and educational outcomes in early intervention programmes for early psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634230</td><td>Bone (2019)</td><td>Psychosocial Interventions to Reduce Compulsory Psychiatric Admissions: A Rapid Evidence Synthesis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645228</td><td>Bonet (2020)</td><td>ReMindCare App for Early Psychosis: Pragmatic Real World Intervention and Usability Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647254</td><td>Bonet (2020)</td><td>The efficacy of "urgent consultation request"; preliminary analysis of a real-world app (Remidcare) for early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633643</td><td>Bonham (2008)</td><td>Are second generation antipsychotics a distinct class</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645072</td><td>Bonsack (2017)</td><td>Searching a minimal dosage of antipsychotics: A shared decision-making</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648340</td><td>Boonstra (2011)</td><td>Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648570</td><td>Boonstra (2011)</td><td>Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633583</td><td>Boonstra (2011)</td><td>Antipsychotics, brain morphology and duration of untreated illness in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644760</td><td>Bora (2013)</td><td>Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: Systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646298</td><td>Bora (2014)</td><td>Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode Psychosis: Do the cognitive deficits progress over, or after, the onset of psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646291</td><td>Bora (2017)</td><td>Meta-analysis of longitudinal studies of cognition in bipolar disorder: Comparison with healthy controls and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647586</td><td>Bora (2018)</td><td>Duration of untreated psychosis and neurocognition in first-episode psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648394</td><td>Bora (2019)</td><td>BDNF levels and cognitive impairment in schizophrenia: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644801</td><td>Borges (2013)</td><td>A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647330</td><td>Borgwardt (2009)</td><td>The effects of antipsychotics on brain structure: What have we learnt from structural imaging of schizophrenia?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646772</td><td>Borison (1996)</td><td>ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647350</td><td>Bornheimer (2020)</td><td>Effectiveness of Suicide-Focused Psychosocial Interventions in Psychosis: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648542</td><td>Borovcanin (2013)</td><td>Antipsychotics can modulate the cytokine profile in schizophrenia: Attenuation of the type-2 inflammatory response</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646652</td><td>Borovcanin (2015)</td><td>Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644627</td><td>Borovcanin (2020)</td><td>Type 17 immune response facilitates progression of inflammation and correlates with cognition in stable schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644730</td><td>Borriello (2015)</td><td>Timing and effectiveness of Brenner's IPT cognitive training in early psychosis. A pilot study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645044</td><td>Bosc (2020)</td><td>Serum and clinical markers associated with membrane PUFA content in a population of stabilised and treated schizophrenia outpatients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646546</td><td>Bosnjak (2019)</td><td>Interventions for prodromal stage of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59647727</td><td>Bosnjak (2019)</td><td>Differences in facial emotional recognition between patients with the first-episode psychosis, multi-episode schizophrenia, and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634256</td><td>Bossy (2020)</td><td>Feasibility and Efficacy of a Psychological Therapy for Patients With a Schizophrenic Psychosis in an Inpatient Setting: Study Protocol of a Randomized Switch Controlled Trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647373</td><td>Boter (2009)</td><td>Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646913</td><td>Boter (2010)</td><td>Generalizability of the results of efficacy trials in first-episode schizophrenia: Comparisons between subgroups of participants of the European First Episode Schizophrenia Trial (EUFEST)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633573</td><td>Botschev (1992)</td><td>Neue Therapiekonzepte in der Rezidivprophylaxe schizophrener Patienten</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634064</td><td>Bourin (1991)</td><td>[Clinical and neurobiological aspects of long-term administration of psychotropic drugs].</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646910</td><td>Bousman (2018)</td><td>Genetic variation in cytokine genes and risk for transition to psychosis among individuals at ultra-high risk</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647030</td><td>Bowden (2020)</td><td>First episode psychosis: the commensal gut microbiota perspective</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634062</td><td>Bowers (1975)</td><td>Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645443</td><td>Bowers (1990)</td><td>Psychotogenic Drug Use and Neuroleptic Response</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645340</td><td>Bowtell (2018)</td><td>Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648185</td><td>Bowtell (2018)</td><td>Clinical and demographic predictors of continuing remission or relapse following discontinuation of antipsychotic medication after a first episode of psychosis. A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646530</td><td>Bowtell (2019)</td><td>Is a higher dose of antipsychotic medication required to treat a relapse following discontinuation in first episode psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645097</td><td>Boydell (2012)</td><td>Satisfaction with inpatient treatment for first-episode psychosis among different ethnic groups: A report from the UK AESOP study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648274</td><td>Boydell (2014)</td><td>Caregiving in first-episode psychosis: Social characteristics associated with perceived 'burden' and associations with compulsory treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634298</td><td>Boyer (1987)</td><td>Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646690</td><td>Bozikas (2019)</td><td>Improved facial affect recognition in patients with first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645737</td><td>Bozzatello (2017)</td><td>Pharmacotherapy of personality disorders: What we know and what we have to search for</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645646</td><td>Bozzatello (2019)</td><td>Predictive Factors of Treatment Resistance in First Episode of Psychosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645686</td><td>Bozzatello (2019)</td><td>Polyunsaturated Fatty Acids: What is Their Role in Treatment of Psychiatric Disorders?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633622</td><td>Bradford (2003)</td><td>Pharmacological Management of First-Episode Schizophrenia and Related Nonaffective Psychoses</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648208</td><td>Braehler (2013)</td><td>Childhood trauma and dissociation in first-episode psychosis, chronic schizophrenia and community controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633702</td><td>Branchey (1979)</td><td>Effects of Loxapine on the Sleep of Chronic Schizophrenics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633543</td><td>Braslow (1999)</td><td>History and evidence-based medicine: lessons from the history of somatic treatments from the 1900s to the 1950s.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647718</td><td>Braun-Scharm (2006)</td><td>Differential Diagnosis and Pharmacotherapy of Juvenile Mania - A Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647906</td><td>Bredkj√¶r (1999)</td><td>Continuity of care in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647905</td><td>Bredkjaer (2000)</td><td>Continuity of care of severely disturbed first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634020</td><td>Breier (1987)</td><td>Neuroleptic Responsivity of Negative and Positive Symptoms in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647341</td><td>Breier (2017)</td><td>The effects of 12-month, double-blind N-acetyl cysteine treatment on symptoms and brain structures in early phase psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644552</td><td>Breier (2018)</td><td>Viruses and schizophrenia: implications for pathophysiology and treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647342</td><td>Breier (2018)</td><td>Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647616</td><td>Breier (2018)</td><td>A double-blind trial of valacyclovir to improve cognition in early phase schizophrenia: results from the vista study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646838</td><td>Breier (2019)</td><td>Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: results from the VISTA study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633809</td><td>Breitborde (2009)</td><td>Review of the operational definition for first‚Äêepisode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646178</td><td>Breitborde (2011)</td><td>Multifamily group psychoeducation and cognitive remediation for first-episode psychosis: a randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647524</td><td>Breitborde (2015)</td><td>The Early Psychosis Intervention Center (EPICENTER): development and six-month outcomes of an American first-episode psychosis clinical service</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646284</td><td>Breitborde (2017)</td><td>Meta-cognitive skills training enhances computerized cognitive remediation outcomes among individuals with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645990</td><td>Breitborde (2020)</td><td>The Ohio State University Early Psychosis Intervention Center (EPICENTER) step-based care programme for individuals at clinical high risk for psychosis: study protocol for an observational study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644617</td><td>Breitborde (2021)</td><td>Uncontrolled trial of specialized, multi-component care for individuals with first-episode psychosis: Effects on motivation orientations</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634222</td><td>Breitborde (2021)</td><td>Cost Utility of cognition-enhancing interventions for individuals with first-episode psychosis: a naturalistic evaluation.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633877</td><td>Breuning (1982)</td><td>Pharmacotherapy with the mentally retarded: Implications for clinical psychologists</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646308</td><td>Brewer (2005)</td><td>Memory Impairments Identified in People at Ultra-High Risk for Psychosis Who Later Develop First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646641</td><td>Brewer (2007)</td><td>Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645206</td><td>Brewer (2008)</td><td>Response to Degenhardt et al.: 'Depot naltrexone use for opioid dependence in Australia: Large-scale use of an unregistered medication in the absence of data on safety and efficacy.'</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646389</td><td>Briend (2019)</td><td>Longitudinal evaluation of glutamate and n-acetyl-aspartate in antipsychotic-naive first episode psychosis subjects and relationships to duration of untreated psychosis and response to antipsychotic medication</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646907</td><td>Brimicombe (2018)</td><td>Geographical variation in GP drug prescribing for schizophrenia and similar psychosis in England</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633711</td><td>Brissos (2014)</td><td>The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633861</td><td>Bristow (1993)</td><td>Pitfalls and Problems of the Long Term Use of Neuroleptic Drugs in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645873</td><td>Brito (2019)</td><td>P.460 Duration of untreated psychosis and long acting antipsychotics prescription - two-year retrospective analysis of first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645052</td><td>Brockhaus-Dumke (2008)</td><td>Sensory gating in schizophrenia: P50 and N100 gating in antipsychotic-free subjects at risk, first-episode, and chronic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633812</td><td>Brockmeyer (2014)</td><td>Multicomponent reaction for the first synthesis of 2,2-dialkyl- and 2-alkyl-2-aralkyl-5,6-diaryl-2H-1,3-thiazines as scaffolds for various 3,4-dihydro-2H-1,3-thiazine derivatives</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647521</td><td>Brodey (2018)</td><td>The Early Psychosis Screener (EPS): Quantitative validation against the SIPS using machine learning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647713</td><td>Broerse (2002)</td><td>Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634264</td><td>Br√∂ms (2020)</td><td>Psychoeducation and motivational interviewing to reduce relapses and increase patients' involvement in antipsychotic treatment: interventional study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645437</td><td>Brooke (2020)</td><td>Qualitative investigation of perceived barriers to and enablers of sport participation for young people with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647040</td><td>Broussard (2021)</td><td>The first episode of psychosis: A guide for young people and their families: Revised and updated edition</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648692</td><td>Brouwers (2013)</td><td>The adequacy of pharmaceutical treatment of schizophrenia in Quebec varies with age, but is not influenced by sex or neighbourhood deprivation</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647383</td><td>Brown (2013)</td><td>Effectiveness of adherence therapy in patients with early psychosis: A mirror image study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648116</td><td>Brown (2016)</td><td>Clozapine: An effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648308</td><td>Brown (2016)</td><td>Cancer Immune Equilibrium and Schizophrenia Have Similar Interferon-gamma, Tumor Necrosis Factor-alpha, and Interleukin Expression: A Tumor Model of Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644635</td><td>Brown (2019)</td><td>'Twisting the lion's tail': Manipulationist tests of causation for psychological mechanisms in the occurrence of delusions and hallucinations</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645806</td><td>Browne (2017)</td><td>Perceived autonomy support in the NIMH RAISE Early Treatment Program</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644756</td><td>Browne (2019)</td><td>The therapeutic alliance in individual resiliency training for first episode psychosis: relationship with treatment outcomes and therapy participation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645249</td><td>Browne (2019)</td><td>The relationship between the therapeutic alliance and client variables in individual treatment for schizophrenia spectrum disorders and early psychosis: Narrative review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646701</td><td>Browne (2020)</td><td>Implementation case study: Multifamily group intervention in first-episode psychosis programs</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648656</td><td>Browne (2021)</td><td>The alliance-outcome relationship in individual psychosocial treatment for schizophrenia and early psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646223</td><td>Brugnoli (2014)</td><td>Model of Management (Mo.Ma) for the patient with schizophrenia: Crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647087</td><td>Brunette (2015)</td><td>Facilitators and barriers to implementation of coordinated specialty care in u.s. community mental health clinic</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645732</td><td>Brunette (2017)</td><td>A phase II, randomized, double-blind study to evaluate the efficacy, safety and tolerability of ALKS 3831 in subjects with schizophrenia and alcohol use disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644527</td><td>Bruno (2020)</td><td>Vortioxetine on cognition in schizophrenia: A pilot study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633813</td><td>Brunoni (2010)</td><td>Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644597</td><td>Brusov (2011)</td><td>Use of canonical correlation analysis to evaluate the strength of relationships between clinical and biological parameters</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647750</td><td>Bruxner (2010)</td><td>The development of a project designed to test the feasibility and effects of a peer support intervention in young people being discharged from a first episode psychosis treatment centre</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646551</td><td>Bucci (2010)</td><td>Intervention for cannabis use in young people at ultra high risk for psychosis and in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644576</td><td>Bucci (2015)</td><td>Using mobile technology to deliver a cognitive behaviour therapy-informed intervention in early psychosis (Actissist): study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644919</td><td>Bucci (2018)</td><td>Staff and service user perspectives of digital technology for early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645789</td><td>Bucci (2020)</td><td>Persistent negative symptoms in recent-onset psychosis: relationship to treatment response and psychosocial functioning</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648767</td><td>Buchy (2010)</td><td>A 12-month outcome study of insight and symptom change in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646382</td><td>Buchy (2018)</td><td>A longitudinal study of cognitive insight and cortical thickness in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648352</td><td>Buckley (2007)</td><td>Brain derived neurotropic factor in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634023</td><td>Buckley (2007)</td><td>First-episode psychosis: a window of opportunity for best practices.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648335</td><td>Buckley (2011)</td><td>Brain-derived neurotrophic factor: Findings in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644805</td><td>Bucur (2012)</td><td>Systematic review of randomised interventions for patients at high risk of developing psychosis: 2012 update</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646816</td><td>Buehlmann (2010)</td><td>Hippocampus abnormalities in at risk mental states for psychosis? A cross-sectional high resolution region of interest magnetic resonance imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647413</td><td>Bukh (2013)</td><td>The effect of prolonged duration of untreated depression on antidepressant treatment outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645077</td><td>Bumb (2015)</td><td>Schizophreniform psychosis during treatment with alitretinoin</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647068</td><td>Burbach (2012)</td><td>Family interventions: Fundamental considerations when developing routine and formal family interventions services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633760</td><td>Burdock (1960)</td><td>A ward behavior rating scale for mental hospital patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648578</td><td>Burghardt (2020)</td><td>Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633991</td><td>B√ºrki (1983)</td><td>Neuroleptika: Grundlagen und Therapie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646858</td><td>Burlingame (2020)</td><td>Group therapy for schizophrenia: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648402</td><td>Burton (2019)</td><td>Baseline psychopathology and relationship to longitudinal functional outcome in attenuated and early first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647723</td><td>Busquets (2005)</td><td>Differences in the subjective effects of drugs in patients with a first psychotic episode. Preliminary results</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644476</td><td>Bustillo (2017)</td><td>Whole-brain spectroscopic imaging of glutamate in first-episode psychosis before and after antipsychotic therapy</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644806</td><td>Buswell (2021)</td><td>A systematic review of PTSD to the experience of psychosis: prevalence and associated factors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648513</td><td>Butler (2018)</td><td>Are family warmth and positive remarks related to outcomes in psychosis? A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634288</td><td>Byng (2020)</td><td>The PARTNERS2 Study: Trial of Primary Care Based Collaborative Care for People with a Diagnosis of Schizophrenia, Bipolar or other types of Psychosis. Protocol version 7.3 dated 18.08.2020</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644611</td><td>Byrne (2020)</td><td>Understanding young peoples' and family members' views of treatment for first episode psychosis in a randomised controlled trial (MAPS)</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634221</td><td>Byrne (2020)</td><td>Clinicians‚Äô views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647618</td><td>Cacciotti-Saija (2015)</td><td>A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647737</td><td>Cadenhead (2017)</td><td>Dietary omega 3 and erythrocyte omega 3 are associated with symptoms, functioning and psychotic conversion in a clinical high risk population</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645797</td><td>Cadenhead (2020)</td><td>Peripheral and central biomarkers associated with inflammation in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646027</td><td>Cadinu (2018)</td><td>NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648339</td><td>Cahn (2002)</td><td>Brain volume changes in first-episode schizophrenia: A 1-year follow up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648347</td><td>Cahn (2002)</td><td>Brain morphology in antipsychotic-naive schizophrenia: A study of multiple brain structures</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646387</td><td>Cahn (2021)</td><td>Longitudinal grey matter changes following first episode mania in bipolar I disorder: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648744</td><td>Cai (2011)</td><td>Abnormal plasma monoamine metabolism in schizophrenia and its correlation with clinical responses to risperidone treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644648</td><td>Cai (2018)</td><td>Treatment, meta-analysiss247. Therapeutic efficacy of atypical antipsychotic drugs by targeting multiple stress-related metabolic pathways in schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645586</td><td>Cai (2018)</td><td>Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naive patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644995</td><td>Cakici (2019)</td><td>Similarly altered protein markers in drug-naive first-episode patients with schizophrenia or major depressive disorder. A meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644605</td><td>√áakici (2019)</td><td>An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648644</td><td>√áakici (2020)</td><td>Altered Peripheral Blood Compounds in Drug-Na√Øve First-Episode Patients With Either Schizophrenia or Major Depressive Disorder, A Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648226</td><td>√áakici (2021)</td><td>Changes in peripheral blood compounds following psychopharmacological treatment in drug-na√Øve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645503</td><td>Caletti (2018)</td><td>Prosody abilities in a large sample of affective and non-affective first episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645738</td><td>Caley (1996)</td><td>The pharmacotherapy of human aggression: a review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645808</td><td>Calkins (2020)</td><td>Pennsylvania first-episode program evaluation of coordinated specialty care: Six-and 12-month outcomes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634068</td><td>Calvin (2011)</td><td>Factors affecting weight in subjects with an episode of mania in the first month of treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646874</td><td>Calvo (2019)</td><td>Gray matter differences between affective and non-affective first episode psychosis: A review of Magnetic Resonance Imaging studies: Special Section on "Translational and Neuroscience Studies in Affective Disorders" Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645390</td><td>Calvo (2020)</td><td>RANDOMIZED CONTROL TRIAL OF A√Ç MOBILE APP-BASED INTERVENTION FOR ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS: THE THINK APP...Schizophrenia International Research Society (SIRS) 2020 Congress</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644980</td><td>Camacho (2019)</td><td>Smartphone Apps to Support Coordinated Specialty Care for Prodromal and Early Course Schizophrenia Disorders: Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647366</td><td>Camacho-Gomez (2020)</td><td>Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Tiril Borge</span></td><td></td></tr><tr><td>59647952</td><td>Camkurt (2015)</td><td>Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647951</td><td>Camkurt (2016)</td><td>"Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controls": Corrigendum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645138</td><td>Campbell (1999)</td><td>Risperidone-induced tardive dyskinesia in first-episode psychotic patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645268</td><td>Campbell (2013)</td><td>The relationship between childhood trauma and neuropsychological functioning in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645528</td><td>Camporesi (2020)</td><td>Profiling glutamate and d-serine pathways in treatment resistant early psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648032</td><td>Camprodon-Boadas (2020)</td><td>Cognitive reserve in patients with first-episode psychosis as outcome predictor at 5-year follow-up</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646489</td><td>Canal (2003)</td><td>Lack of effect of amisulpride on the pharmacokinetics and safety of lithium</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645120</td><td>Canal-Rivero (2017)</td><td>The role of premorbid personality and social cognition in suicidal behaviour in first-episode psychosis: A one-year follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645593</td><td>Canal-Rivero (2020)</td><td>Predictors of weight acquisition induced by antipsychotic treatment and its relationship with age in a sample of first episode non-affective psychosis patients: A three-year follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644613</td><td>Cancel (2019)</td><td>Understanding the link between childhood trauma and schizophrenia: a systematic review of neuroimaging studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648595</td><td>Cannon (2002)</td><td>Antipsychotic drug treatment in the prodromal phase of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645035</td><td>Cao (2019)</td><td>Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre-post-treatment design</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644657</td><td>Cao (2020)</td><td>Treatment response prediction and individualized identification of first-episode drug-naive schizophrenia using brain functional connectivity</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646280</td><td>Cao (2020)</td><td>The metabolic effects of antipsychotics in the early stage of treatment in first-episode patients with schizophrenia: A real-world study in a naturalistic setting</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647106</td><td>Capdevielle (2013)</td><td>Extended duration of hospitalization in first episode psychosis: An evaluation of its clinical justification</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646747</td><td>Caponnetto (2013)</td><td>Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648704</td><td>Capuzzi (2017)</td><td>Acute variations of cytokine levels after antipsychotic treatment in drug-naive subjects with a first-episode psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647591</td><td>Carbone (1999)</td><td>Duration of untreated psychosis and 12-month outcome in first-episode psychosis: The impact of treatment approach</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645460</td><td>Cardinal (2009)</td><td>Psychosis and catatonia as a first presentation of antiphospholipid syndrome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648202</td><td>Cardoso (2017)</td><td>Chlorpromazine versus thiothixene for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648203</td><td>Cardoso (2017)</td><td>Chlorpromazine versus lithium for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645294</td><td>Carey (2018)</td><td>Reducing weight gain in people with schizophrenia, schizoaffective disorder, and first episode psychosis: describing the process of developing the STructured lifestyle Education for People With SchizophrEnia (STEPWISE) intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646941</td><td>Carhart-Harris (2013)</td><td>Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648607</td><td>Carlson (2007)</td><td>Antidepressant-associated switches from depression to mania in severe bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645890</td><td>Caroff (2019)</td><td>Overcoming barriers to effective management of tardive dyskinesia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647600</td><td>Carpenter (1978)</td><td>A drug-free month for outpatient schizophrenics</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633664</td><td>Carpenter (1981)</td><td>Treatment-relevant subtypes of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633894</td><td>Carpenter (1992)</td><td>Novel neuroleptic dosage reduction strategies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648243</td><td>Carpenter (2007)</td><td>Challenge to atypical antipsychotic drug effect on cognition</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647124</td><td>Carpenter (2015)</td><td>Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647841</td><td>Carpiniello (2016)</td><td>Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646911</td><td>Carr (2007)</td><td>The genetic revolution: When opportunistic hype gets ahead of science</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645486</td><td>Carrillo (2016)</td><td>[Psychiatric manifestations by prions. A narrative review]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646957</td><td>Carrion (2018)</td><td>From the psychosis prodrome to the first-episode of psychosis: no evidence of a cognitive decline</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645266</td><td>Caruana (2015)</td><td>The relationship between cognition, job complexity, and employment duration in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646159</td><td>Carvalho (2013)</td><td>N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647136</td><td>Carvalho (2020)</td><td>Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645655</td><td>Caseiro (2012)</td><td>Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633356</td><td>CASEY (1960)</td><td>Drug Therapy in Schizophrenia: A Controlled Study of the Relative Effectiveness of Chlorpromazine, Promazine, Phenobarbital, and Placebo</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>61633564</td><td>Casey (1960)</td><td>Treatment of schizophrenic reactions with phenothiazine derivatives. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine, and phenobarbital.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633989</td><td>Casey (1961)</td><td>COMBINED DRUG THERAPY OF CHRONIC SCHIZOPHRENICS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645150</td><td>Casquero-Veiga (2019)</td><td>Risperidone administered during adolescence induced metabolic, anatomical and inflammatory/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645962</td><td>Casquero-Veiga (2021)</td><td>Omega-3 fatty acids during adolescence prevent schizophrenia-related behavioural deficits: Neurophysiological evidences from the prenatal viral infection with PolyI:C</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644568</td><td>Cassidy (2008)</td><td>Validation of the alcohol use disorders identification test and the drug abuse screening test in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647939</td><td>Cassidy (2010)</td><td>A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648295</td><td>Cassidy (2012)</td><td>Cannabis use and anticipatory pleasure as reported by subjects with early psychosis and community controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646735</td><td>Castaneda (2016)</td><td>The impact of physical health in young people with psychosis: a chilean sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646621</td><td>Castanheira (2017)</td><td>Inflammation in schizophrenia: Implications for pathophysiology and treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648191</td><td>Castellani (2012)</td><td>Classification of schizophrenia using feature-based morphometry</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648589</td><td>Castellani (2020)</td><td>Antipsychotic drugs impair brain glucose sensing resulting in whole body insulin resistance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644983</td><td>Castelnovo (2018)</td><td>Sleep spindles and slow waves in schizophrenia and related disorders: Main findings, challenges and future perspectives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647854</td><td>Castelnovo (2020)</td><td>Could CBT sustain long-term remission without antipsychotic medication in schizophrenia?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647922</td><td>Castiello-de (2020)</td><td>Computer‚Äêbased Cognitive Remediation Therapy plus standard care versus standard care for people with schizophrenia or related disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647035</td><td>Castro-de-Araujo (2017)</td><td>First episode psychosis moderates the effect of gray matter volume on cognition</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648557</td><td>Castro-Fornieles (2008)</td><td>Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646876</td><td>Castro-Fornieles (2018)</td><td>Gray matter changes and cognitive predictors of 2-year follow-up abnormalities in early-onset first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647728</td><td>Catalan (2016)</td><td>Differences in facial emotion recognition between first episode psychosis, borderline personality disorder and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645248</td><td>Catalan (2018)</td><td>The relationship between theory of mind deficits and neurocognition in first episode-psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647542</td><td>Catalan (2020)</td><td>Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648619</td><td>Catalan (2021)</td><td>Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59646743</td><td>Cather (2018)</td><td>Impact of comprehensive treatment for first episode psychosis on substance use outcomes: a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647735</td><td>Caton (2005)</td><td>Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647291</td><td>Cattarinussi (2020)</td><td>Effects of pharmacological treatments on neuroimaging findings in first episode affective psychosis: A review of longitudinal studies</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645326</td><td>Catts (2008)</td><td>Real-world use of quetiapine in early psychosis: An acute inpatient and community follow-up effectiveness study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648523</td><td>Catts (2010)</td><td>Appraising evidence for intervention effectiveness in early psychosis: Conceptual framework and review of evaluation approaches</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633691</td><td>Cavero (1966)</td><td>EVALUATION OF THIORIDAZINE IN THE AGED</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634205</td><td>Cazzullo (1976)</td><td>The Drug Approach to Therapy. Treatment of Acute Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634098</td><td>Cd (1969)</td><td>A comparative trial of oxypertine and chlorpromazine in chronic schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634027</td><td>Ce (2000)</td><td>Depot fluphenazine for schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644886</td><td>Cea-Canas (2019)</td><td>Structural connectivity in schizophrenia and bipolar disorder: Effects of chronicity and antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647917</td><td>Cea-Canas (2020)</td><td>Connectivity strength of the EEG functional network in schizophrenia and bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645474</td><td>Cebrian (2020)</td><td>Psychological online intervention for psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645704</td><td>Celik (2011)</td><td>Plasma asymmetric dimethylarginine (ADMA) concentrations in patients with first and multiple episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646763</td><td>Cella (2014)</td><td>Identifying cognitive remediation change through computational modelling-Effects on reinforcement learning in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647604</td><td>Centorrino (2003)</td><td>Drug attitudes and treatment adherence in a clinical trial comparing haloperidol and olanzapine in first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645777</td><td>Cervenka (2017)</td><td>Pet studies of TSPO in schizophrenia-understanding initial findings</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646217</td><td>Cervenka (2019)</td><td>Molecular imaging studies of TSPO in schizophrenia-relationship to central and peripheral immune markers and new methods of quantification</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647237</td><td>Cervone (2015)</td><td>Efficacy of LAI in first episode psychosis: An observational study-Clinical reports</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645678</td><td>Ceskova (2000)</td><td>Possibilities of influencing cognitive functions of schizophrenics by risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645511</td><td>Ceskova (2004)</td><td>Prolactin levels in risperidone treatment of first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646073</td><td>Ceskova (2004)</td><td>Neurological Soft Signs in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646920</td><td>Ceskova (2014)</td><td>Gender differences in the pharmacotherapy of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646918</td><td>Ceskova (2015)</td><td>Gender differences in the treatment of first-episode schizophrenia: results from the European First Episode Schizophrenia Trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647479</td><td>Cetin (2015)</td><td>Editorial: Treatment of schizophrenia: Past, present and future</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648432</td><td>Cetin (2015)</td><td>Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: a six-month follow up study for efficacy and adverse effects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646669</td><td>Chakos (1992)</td><td>Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646655</td><td>Chakos (1994)</td><td>Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646668</td><td>Chakos (1996)</td><td>Incidence and correlates of tardive dyskinesia in first episode of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647593</td><td>Chakos (2005)</td><td>Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648427</td><td>Chakraborty (2009)</td><td>Attitudes and beliefs of patients of first episode depression towards antidepressants and their adherence to treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645802</td><td>Chan (2011)</td><td>Perceptions of relapse risks following first-episode psychosis and attitudes towards maintenance medication: A comparison between nursing and social work professionals</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645348</td><td>Chan (2012)</td><td>A randomized, wait-list controlled clinical trial: the effect of life coaching on functioning in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647314</td><td>Chan (2012)</td><td>Effects of extended case management on functioning in people with early psychosis-preliminary findings of the easy3 randomised controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646318</td><td>Chan (2014)</td><td>Medication adherence, knowledge about psychosis, and insight among patients with a schizophrenia-spectrum disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644567</td><td>Chan (2019)</td><td>Validation of the Social Functioning Scale: Comparison and evaluation in early psychosis, autism spectrum disorder and social anxiety disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645281</td><td>Chan (2020)</td><td>Reinforcement learning impairment in patients with early-stage psychotic bipolar disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634123</td><td>Chanen (2019)</td><td>Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: Protocol for the VERBATIM randomized controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648178</td><td>Chang (2012)</td><td>Clinical and social determinants of duration of untreated psychosis: a 4-year randomized controlled-trial of specialized early intervention service for adult-onset first-episode psychosis (JCEP Study)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645384</td><td>Chang (2013)</td><td>Randomized controlled trial evaluating 1-year extended case management for first-episode psychosis patients discharged from EASY program in Hong Kong</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645927</td><td>Chang (2015)</td><td>Optimal duration of an early intervention programme for first-episode psychosis: randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644739</td><td>Chang (2016)</td><td>Three-year clinical and functional outcome comparison between first-episode mania with psychotic features and first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645652</td><td>Chang (2016)</td><td>Prediction of functional remission in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647710</td><td>Chang (2016)</td><td>Differential prediction profiles of amotivation and diminished expression in first-episode psychosis: 12-month follow-up of the randomized-controlled trial on extended early intervention in Hong Kong</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644621</td><td>Chang (2017)</td><td>Unaltered dopamine transporter availability in drug-naive patients with schizophrenia after 6 months of antipsychotics treatment: A naturalistic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644834</td><td>Chang (2017)</td><td>Sustainability of treatment effect of a 3-year early intervention programme for first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645197</td><td>Chang (2017)</td><td>Resting-state functional connectivity in medication-naive schizophrenia patients with and without auditory verbal hallucinations: A preliminary report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645651</td><td>Chang (2017)</td><td>Prediction of motivational impairment: 12-month follow-up of the randomized-controlled trial on extended early intervention for first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646201</td><td>Chang (2018)</td><td>Motivational impairment predicts functional remission in first-episode psychosis: 3-Year follow-up of the randomized controlled trial on extended early intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647475</td><td>Chang (2019)</td><td>EEG-based brain functional connectivity in first-episode schizophrenia patients, ultra-high-risk individuals, and healthy controls during P50 suppression</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648218</td><td>Changes in white matter... (2019)</td><td>Changes in white matter diffusivity in early psychosis: comparison of treatment with long-acting injectable antipsychotic versus usual care</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633723</td><td>Chapman (1978)</td><td>Body-image aberration in Schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644761</td><td>Charach (2008)</td><td>A theoretical approach to medication adherence for children and youth with psychiatric disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646238</td><td>Chaudhry (2012)</td><td>Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645064</td><td>Chaudhry (2016)</td><td>Selective benefit of low dose methotrexate on positive symptoms of schizophrenia in a randomized double-blind placebo-controlled 12-week feasibility trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644900</td><td>Chaumette (2016)</td><td>Stress and psychotic transition: A literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645100</td><td>Chaumette (2016)</td><td>Salivary cortisol in early psychosis: New findings and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647306</td><td>Chaves (2015)</td><td>Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645897</td><td>Chee (2009)</td><td>Outcome study of first-episode schizophrenia in a developing country: Quality of life and antipsychotics</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646346</td><td>Chen (1991)</td><td>Management of first episode psychotic illness in Afro-Caribbean patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644890</td><td>Chen (2001)</td><td>Stroop interference and facilitation effects in first-episode schizophrenic patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645500</td><td>Chen (2005)</td><td>A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648496</td><td>Chen (2008)</td><td>Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646353</td><td>Chen (2010)</td><td>Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: Randomised controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647617</td><td>Chen (2010)</td><td>A double-blind randomized placebo-controlled relapse prevention study in remitted first-episode psychosis patients following one year of maintenance treatment</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59648775</td><td>Chen (2010)</td><td>A 5-year randomized controlled trial of a specialized early intervention service in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633611</td><td>Chen (2010)</td><td>Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59644735</td><td>Chen (2011)</td><td>Three-year outcome of phase-specific early intervention for first-episode psychosis: A cohort study in Hong Kong</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646719</td><td>Chen (2012)</td><td>The impacts of yoga and aerobic exercise on neuro-cognition and brain structure in early psychosis-a preliminary analysis of the randomized controlled clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644894</td><td>Chen (2013)</td><td>Striatal dopamine transporter availability in drug-naive patients with schizophrenia: A case-control SPECT study with</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645166</td><td>Chen (2013)</td><td>Risk factors for medication-induced amenorrhea in first-episode female Chinese patients with schizophrenia treated with risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646723</td><td>Chen (2013)</td><td>The impacts of aerobic exercise and mind-body exercise (Yoga) on cognition in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645846</td><td>Chen (2014)</td><td>P300 waveform and dopamine transporter availability: A controlled EEG and SPECT study in medication-naive patients with schizophrenia and a metaanalysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646706</td><td>Chen (2014)</td><td>Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647102</td><td>Chen (2014)</td><td>Extensive brain structural network abnormality in first-episode treatment-naive patients with schizophrenia: Morphometrical and covariation study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644738</td><td>Chen (2015)</td><td>Three-year community case management for early psychosis: a randomised controlled study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646288</td><td>Chen (2015)</td><td>A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646287</td><td>Chen (2016)</td><td>A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647840</td><td>Chen (2016)</td><td>Critical period in early psychosis intervention: possible dose effect from longitudinal studies from Hong Kong</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646357</td><td>Chen (2017)</td><td>Maintenance discontinuation after first episode psychosis may increase treatment non-responsiveness: 10-year follow-up of an RCT</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647271</td><td>Chen (2017)</td><td>Efficacy and Metabolic Influence on Blood-Glucose and Serum Lipid of Ziprasidone in the Treatment of Elderly Patients with First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645162</td><td>Chen (2018)</td><td>Risk of gastrointestinal hypomotility in schizophrenia and schizoaffective disorder treated with antipsychotics: A retrospective cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647440</td><td>Chen (2018)</td><td>The effect of early medication discontinuation on long-term clinical outcome in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647931</td><td>Chen (2020)</td><td>A comprehensive analysis of GSK3B variation for schizophrenia in Han Chinese individuals</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644749</td><td>Chen (2021)</td><td>Therapeutic Response Is Associated With Antipsychotic-Induced Weight Gain in Drug-Naive First-Episode Patients With Schizophrenia: An 8-Week Prospective Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645114</td><td>Cheng (2014)</td><td>Rural and remote early psychosis intervention services: The Gordian knot of early intervention</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645341</td><td>Cheng (2019)</td><td>Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: results from an open-label, randomized, "real world" clinical trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645933</td><td>Cheng (2019)</td><td>An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: eight-week outcomes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644493</td><td>Cheng (2020)</td><td>Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647088</td><td>Cheng (2020)</td><td>Facilitating pathways to care: A qualitative study of the self-reported needs and coping skills of caregivers of young adults diagnosed with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645204</td><td>Chengappa (2000)</td><td>Response to placebo among bipolar I disorder patients experiencing their first manic episode</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633753</td><td>Cheung (1981)</td><td>Schizophrenics fully remitted on neuroleptics for 3-5 years--to stop or continue drugs?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647702</td><td>Cheung (2008)</td><td>A diffusion tensor imaging study of structural dysconnectivity in never-medicated, first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644881</td><td>Cheung (2009)</td><td>Structural white matter abnormalities in never-medicated patients with first-episode schizophrenia: A diffusion tensor imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646537</td><td>Chhagan (2021)</td><td>Investigating the impact of HIV on patients with first episode psychosis: a study protocol for a longitudinal cohort study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645767</td><td>Chi (2010)</td><td>Pharmacogenomic study of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644870</td><td>Chi (2013)</td><td>A study of the cognitive behavior therapy for first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648612</td><td>Chi (2013)</td><td>Anti-toxoplasma Chinese Medicine as an Adjunct Therapy in Schizophrenia with seropositivity to T. gondii</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645355</td><td>Chi (2014)</td><td>A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648628</td><td>Chi (2015)</td><td>The analysis for the perioperative efficacy of dexmedetomidine on modified electroconvulsive Therapy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645780</td><td>Chi (2016)</td><td>Personalized Strategy for Non-invasive Early Intervention on Clinical High-risk Subjects for Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646183</td><td>Chi (2016)</td><td>Multicenter randomized double-blind controlled clinical research about the effects of Repetitive transcranial magnetic stimulation in first-episode schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646189</td><td>Chi (2016)</td><td>Multi-center clinical research of multidimensional diagnosis and comprehensive intervention in early Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647240</td><td>Chi (2017)</td><td>Efficacy of Electrical Acupuncture on Vascular Cognitive Impairment with No Dementia: study protocol for a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647447</td><td>Chi (2017)</td><td>The effect of dexmedetomidine on prevention electroconvulsive therapy (ECT) postictal delirium</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647551</td><td>Chia (2019)</td><td>Early intervention for bipolar disorder - Do current treatment guidelines provide recommendations for the early stages of the disorder?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644867</td><td>ChiCtr (2018)</td><td>Study on individualized optimal treatment for antipsychotic drugs</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647473</td><td>ChiCtr (2018)</td><td>Effect and mechanism of baicalin on antipsychotic drug-induced obesity</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648623</td><td>ChiCtr (2018)</td><td>An Android Operating System Based mHealth Intervention on Medication Adherence in Patient with Early Psychosis: a Single-Centre Single blinded Randomised Controlled Trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647446</td><td>ChiCtr (2019)</td><td>Effect of different dosage of aripiprazole on preventing risperidone-induced hyperprolactinemia: a 8-week, multicenter, randomized, open-label, controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648381</td><td>ChiCtr (2020)</td><td>Benzhexol prevents extrapyramidal symptoms induced by antipsychotics: a randomized controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633978</td><td>Chien (1967)</td><td>Drug-Induced Extrapyramidal Symptoms and Their Relations to Clinical Efficacy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645377</td><td>Chien (2016)</td><td>A Randomized Controlled Trial of Clinician-Supported Problem-Solving Bibliotherapy for Family Caregivers of People With First-Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648691</td><td>Chien (2016)</td><td>Adherence therapy versus routine psychiatric care for people with schizophrenia spectrum disorders: a randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645360</td><td>Chien (2018)</td><td>A Randomized Controlled Trial on Mutual Support Group Intervention for Families of People With Recent-Onset Psychosis: a Four-Year Follow-Up</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647384</td><td>Chien (2019)</td><td>Effectiveness of a mindfulness-based psychoeducation group programme for early-stage schizophrenia: an 18-month randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645406</td><td>Chien (2020)</td><td>A Randomised Controlled Trial of a Caregiver-Facilitated Problem-Solving Based Self-Learning Program for Family Carers of People with Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645343</td><td>Chiliza (2015)</td><td>Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648234</td><td>Chiliza (2015)</td><td>Changes in body mass and metabolic profiles in patients with first-episode schizophrenia treated for 12 months with a first-generation antipsychotic</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648012</td><td>Chiliza (2016)</td><td>Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647787</td><td>Chin (2019)</td><td>Dementia with Lewy bodies: Challenges in the diagnosis and management</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645429</td><td>Chintoh (2020)</td><td>Quality of life in antipsychoticnaive youth: Exploring the interplay with metabolic side-effects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645042</td><td>Chiou (2017)</td><td>Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naive first-episode schizophrenia: Effects of antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646251</td><td>Cho (2019)</td><td>Microstructural changes in higher-order nuclei of the thalamus in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634235</td><td>Choi (2020)</td><td>Efficacy of targeted education in reducing topical steroid phobia: A randomized clinical trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646473</td><td>Chong (2005)</td><td>Le parkinsonisme spontane chez les patients novices des antipsychotiques au premier episode psychotique</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633946</td><td>Chong (2009)</td><td>An assessment of the understanding and motivations of patients with schizophrenia about participating in a clinical trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646003</td><td>Chopra (2019)</td><td>O5.1. GREY MATTER BRAIN CHANGES IN MEDICATED AND UNMEDICATED FIRST EPISODE PSYCHOSIS: a RANDOMISED PLACEBO-CONTROLLED TRIAL...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646867</td><td>Chopra (2019)</td><td>Grey matter brain changes in medicated and unmedicated first episode psychosis: a randomised placebo-controlled trial</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59646765</td><td>Chopra (2020)</td><td>Identifying changes in whole-brain functional connectivity in complex longitudinal clinical trials</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634243</td><td>Chopra (2020)</td><td>Differentiating the Effect of Medication and Illness on Brain Volume Reductions in First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind, Placebo-controlled MRI study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646393</td><td>Chopra (2021)</td><td>Longitudinal Changes in Functional Connectivity in Antipsychotic-Treated and Antipsychotic-Naive Patients With First Episode Psychosis: A Randomized, Triple-Blind Placebo-Controlled fMRI Study</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647704</td><td>Chopra (2021)</td><td>Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>61633649</td><td>Chou (2007)</td><td>Drug-induced parkinsonism in the elderly</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647092</td><td>Choudhary (2015)</td><td>F-18 fluorodeoxyglucose positron emission tomography study of impaired emotion processing in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633683</td><td>Chouinard (1975)</td><td>Postimperative negative variation (PINV) in ambulatory schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633692</td><td>Chouinard (1975)</td><td>Amitriptyline-Perphenazine Interaction in Ambulatory Schizophrenic Patients: A Controlled Study of Drug Interaction</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633875</td><td>Chouinard (1976)</td><td>Clozapine in the Treatment of Newly Admitted Schizophrenic Patients A Pilot Study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633887</td><td>Chouinard (1977)</td><td>Differences in psychopathology of schizophrenic patients with normal and abnormal postimperative negative variation (PINV).</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634002</td><td>Chouinard (1977)</td><td>Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634028</td><td>Chouinard (1979)</td><td>Factors related to tardive dyskinesia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633670</td><td>Chouinard (1982)</td><td>Pimozide in the treatment of newly admitted schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647531</td><td>Chouinard (1984)</td><td>An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633742</td><td>Chouinard (1990)</td><td>A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633834</td><td>Chouinard (1994)</td><td>Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646709</td><td>Chouinard (2019)</td><td>Impaired insulin signaling in unaffected siblings and patients with first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648036</td><td>Christensen (2014)</td><td>Cognitive remediation combined with an early intervention service in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646026</td><td>Chu (2020)</td><td>No alteration of pitutary volume in patients with firstepisode schizphrenia but a trend of enlargement in non-psychotic firstdegree relatives</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648244</td><td>Chua (2007)</td><td>Cerebral grey, white matter and csf in never-medicated, first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647505</td><td>Chua (2009)</td><td>Early striatal hypertrophy in first-episode psychosis within 3 weeks of initiating antipsychotic drug treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645991</td><td>Chua (2016)</td><td>Oestrogen (adjunct) versus placebo for women with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646431</td><td>Chue (2007)</td><td>Long-acting formulations of atypical antipsychotics: Time to reconsider when to introduce depot antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645875</td><td>Chumakov (2020)</td><td>P.318 Cognitive impairment in patients with first episode of schizophrenia receiving second-generation antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646295</td><td>Chun (2018)</td><td>A meta-analysis of context integration deficits across the schizotypy spectrum using AX-CPT and DPX tasks</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646296</td><td>Chun (2019)</td><td>A meta-analysis of context integration deficits across the schizotypy spectrum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646780</td><td>Chung (1998)</td><td>Hyperprolactinaemia induced by risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647528</td><td>Chung (2016)</td><td>Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648439</td><td>Chung (2017)</td><td>Associations of fatty acids with cognition, psychopathology, and brain-derived neurotrophic factor levels in patients with first-episode schizophrenia and related disorders treated with paliperidone extended release</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647948</td><td>Chvatalova (2018)</td><td>A comparison of the effectiveness of various psychotherapeutic approaches to first-episode psychosis in terms of recovery: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648654</td><td>Ciba (2016)</td><td>Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646263</td><td>Cipriani (2007)</td><td>Metareview on short-term effectiveness and safety of antidepressants for depression: An evidence-based approach to inform clinical practice</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646595</td><td>Citrome (2012)</td><td>Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646424</td><td>Citrome (2017)</td><td>Long-acting injectable antipsychotics update: Lengthening the dosing interval and expanding the diagnostic indications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646670</td><td>Citrome (2020)</td><td>Incidence and characteristics of akathisia and restlessness during cariprazine treatment for bipolar i disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645059</td><td>Ciufolini (2015)</td><td>Self esteem and self agency in first episode psychosis: Ethnic variation and relationship with clinical presentation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634084</td><td>Clark (1970)</td><td>Molindone in chronic schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633698</td><td>Clark (1971)</td><td>Drug treatment in newly admitted schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633971</td><td>Clarke (1997)</td><td>Towards Rational Psychotropic Prescribing for People with Learning Disability</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644986</td><td>Clarke (2020)</td><td>Sleep disturbances and the at risk mental state: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648237</td><td>Clausen (2014)</td><td>Change in cannabis use, clinical symptoms and social functioning among patients with first-episode psychosis: A 5-year follow-up study of patients in the OPUS trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647659</td><td>Claxton (2017)</td><td>Do Family Interventions Improve Outcomes in Early Psychosis? A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647301</td><td>Cleusix (2017)</td><td>Effects of N-acetyl-cysteine as an add-on to standard treatment on neurocognition in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648144</td><td>Clinicians‚Äô views of... (2020)</td><td>Clinicians‚Äô views of treatment types for first episode psychosis delivered in a randomised controlled trial (MAPS)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645523</td><td>Cocchi (2008)</td><td>Programma 2000: Celebrating 10 years of activity of an Italian pilot programme on early intervention in psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645817</td><td>Cocchi (2014)</td><td>Patients with first-episode psychosis are not a homogenous population: Implications for treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647112</td><td>Cochrane (2021)</td><td>Exploring the impacts of a carers' psycho-education group: Personal insights from the family of people with early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645958</td><td>Coentre (2016)</td><td>Omega-3 polyunsaturated fatty acids in first-episode psychosis: a systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647778</td><td>Coentre (2017)</td><td>Depressive symptoms and suicidal behavior after first-episode psychosis: A comprehensive systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647018</td><td>Coentre (2018)</td><td>First-Episode Psychosis and Hypokalemia: A Case Report and Review of the Literature</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645309</td><td>Coffman (2020)</td><td>Reduced Attention-Related Alpha and Gamma Oscillations in First Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648081</td><td>Cognitive deficits in... (2015)</td><td>Cognitive deficits in depression</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645408</td><td>Coid (2009)</td><td>"Raised incidence rates of all psychoses among migrant groups: Findings from the East London first episode psychosis study": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646144</td><td>Colbert (2006)</td><td>Need for closure and anxiety in delusions: A longitudinal investigation in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646501</td><td>Colbert (2010)</td><td>Jumping to conclusions and perceptions in early psychosis: Relationship with delusional beliefs</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645939</td><td>Colbourne (2021)</td><td>Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646319</td><td>Coldham (2002)</td><td>Medication adherence of individuals with a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633878</td><td>Cole (1962)</td><td>Evaluation of drug treatments in psychiatry.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633357</td><td>Cole (1964)</td><td>Phenothiazine treatment in acute schizophrenia</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>61633697</td><td>Cole (1964)</td><td>EMPLOYMENT CHARACTERISTICS OF DISCHARGED SCHIZOPHRENICS.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644856</td><td>Colizzi (2016)</td><td>Substance use, medication adherence and outcome one year following a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646394</td><td>Colizzi (2018)</td><td>Longitudinal assessment of the effect of cannabis use on hospital readmission rates in early psychosis: A 6-year follow-up in an inpatient cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645194</td><td>Colle (2018)</td><td>Restless legs syndrome and schizophrenia: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647973</td><td>Comparison of clinical... (2019)</td><td>Comparison of clinical and sociodemographic characteristics of patients with schizophrenia treated stationary and at day hospital</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647926</td><td>Comprehensive versus... (2016)</td><td>Comprehensive versus usual community care for first-episode psychosis: 2-Year outcomes from the NIMH RAISE early treatment program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648660</td><td>Compton (2007)</td><td>Alcohol and cannabis use in urban, African American, first-episode schizophrenia-spectrum patients: Associations with positive and negative symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645601</td><td>Compton (2011)</td><td>Predictors of the discharge dosage of an atypical antipsychotic agent among hospitalized, treatment-naive, first-episode psychosis patients in naturalistic, public-sector settings</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644494</td><td>Compton (2012)</td><td>Which came first, delusions or hallucinations? An exploration of clinical differences among patients with first-episode psychosis based on patterns of emergence of positive symptoms</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648780</td><td>Condray (2011)</td><td>3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647225</td><td>Congjie (2017)</td><td>The efficacy, acceptability, and safety of five atypical antipsychotics in patients with first-episode drug-na√Øve schizophrenia: a randomized comparative trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647944</td><td>Conley (1999)</td><td>A comparison of the neurocognitive effects of treatment with typical and atypical neuroleptics in first-episode schizoprhenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645177</td><td>Connor (2008)</td><td>Review of The centre cannot hold</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644571</td><td>Conrad (2017)</td><td>Utility of risk-status for predicting psychosis and related outcomes: Evaluation of a 10-year cohort of presenters to a specialised early psychosis community mental health service</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646675</td><td>Contreras (2020)</td><td>Impulse Control Disorders and Other Psychiatric Complications in a Series of Patients Treated Levodopa-Carbidopa Instestinal Gel</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645366</td><td>Conus (2009)</td><td>Randomized controlled trial of olanzapine or chlorpromazine as addition to lithium in the treatment of a first manic episode with psychotic features: an 8-week, flexible dose, single-blind trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645980</td><td>Conus (2015)</td><td>Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646163</td><td>Conus (2016)</td><td>N-Acetyl-Cysteine in a double-blind randomized placebo-controlled trial: towards biomarker guided treatment in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645622</td><td>Conus (2017)</td><td>Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645786</td><td>Conus (2018)</td><td>Personality disorder among youth with first episode psychotic mania: an important target for specific treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646158</td><td>Conus (2018)</td><td>N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: toward Biomarker-Guided Treatment in Early Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648697</td><td>Conus (2018)</td><td>An add-on trial with n-acetyl-cysteine (NAC) in early psychosis patients: towards biomarker guided treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645509</td><td>Cookson (2012)</td><td>Prolactin, hyperprolactinaemia and antipsychotic treatment: A review and lessons for treatment of early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634059</td><td>Cookson (2015)</td><td>Early schizophrenia: skilful management of medication</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634225</td><td>Cooper (2020)</td><td>Psychosocial interventions for people with schizophrenia or psychosis on minimal or no antipsychotic medication: A systematic review</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634284</td><td>Cooper (2021)</td><td>Opinion piece: the case for establishing a minimal medication alternative for psychosis and schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645539</td><td>Corbeil (2019)</td><td>Problem gambling associated with aripiprazole: A nested casecontrol study in a first-episode psychosis cohort using a systematic pharmacovigilance approach</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645561</td><td>Cordes (2017)</td><td>Prevalence of metabolic syndrome in female and male patients at risk of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648732</td><td>Corfdir (2021)</td><td>[Accelerated telomere erosion in schizophrenia: A literature review]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633777</td><td>Cormier (1995)</td><td>Results of a clinical trial of the symptom and medication modules in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648278</td><td>Correll (2009)</td><td>Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645156</td><td>Correll (2010)</td><td>"Risks from antipsychotic medications in children and adolescents": In reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633518</td><td>Correll (2011)</td><td>Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647565</td><td>Correll (2013)</td><td>Early antipsychotic response to aripiprazole in adolescents with schizophrenia: predictive value for clinical outcomes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648541</td><td>Correll (2013)</td><td>Antipsychotics for acute schizophrenia: Making choices</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648279</td><td>Correll (2014)</td><td>Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644593</td><td>Correll (2016)</td><td>The use of long-acting injectable antipsychotics in Schizophrenia: evaluating the evidence</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647969</td><td>Correll (2018)</td><td>Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645879</td><td>Correll (2019)</td><td>P.102 Long-term efficacy of lurasidone in antipsychotic-na√É¬Øve vs. antipsychotic-exposed adolescents with schizophrenia: post-hoc analysis of a two year, open-label study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647234</td><td>Correll (2019)</td><td>Efficacy of lurasidone in antipsychotic-na√É¬Øve adolescents with schizophrenia: post-hoc analysis of a 6-week, randomized, placebocontrolled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648756</td><td>Correll (2020)</td><td>104 Long-term Efficacy of Lurasidone in Antipsychotic-na√É¬Øve vs. Antipsychotic-exposed Adolescents with Schizophrenia: analysis of a Two-Year Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647235</td><td>Correll (2021)</td><td>Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647877</td><td>Corrigendum: a Multicenter... (2020)</td><td>Corrigendum: a Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: a Protocol Design (Frontiers in Psychiatry, (2020), 10, (1023), 10.3389/fpsyt.2019.01023)</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647784</td><td>Corripio (2011)</td><td>Density of striatal D2 receptors in untreated first-episode psychosis: An I123-IBZM SPECT study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647823</td><td>Corsi-Zuelli (2020)</td><td>Cytokine profile in first-episode psychosis, unaffected siblings and community-based controls: the effects of familial liability and childhood maltreatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647788</td><td>Cortes-Briones (2015)</td><td>DELTA9-THC Disrupts Gamma (gamma)-Band Neural Oscillations in Humans</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645241</td><td>Cortese (2005)</td><td>Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647932</td><td>Cortesi (2013)</td><td>Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: Results from the COMETA study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644531</td><td>Coscia (2008)</td><td>Volumetric and shape analysis of the thalamus in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644530</td><td>Coscia (2009)</td><td>Volumetric and shape analysis of the thalamus in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647867</td><td>Cost and health impacts... (2020)</td><td>Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647861</td><td>Cost-effectiveness of... (2016)</td><td>Cost-effectiveness of comprehensive, integrated care for first episode psychosis in the nimh raise early treatment program</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647888</td><td>Cotton (2012)</td><td>Coping strategies in carers of patients with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647889</td><td>Cotton (2012)</td><td>Coping strategies in carers of patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645246</td><td>Cotton (2014)</td><td>The relationship between vocational functioning and quality of life in patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647522</td><td>Cotton (2016)</td><td>Early psychosis research at Orygen, the National Centre of Excellence in Youth Mental Health</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647202</td><td>Cotton (2019)</td><td>ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647637</td><td>Coull (2012)</td><td>Dopamine precursor depletion impairs timing in healthy volunteers by attenuating activity in putamen and supplementary motor area</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648040</td><td>Cowman (2021)</td><td>Cognitive Predictors of Social and Occupational Functioning in Early Psychosis: A Systematic Review and Meta-analysis of Cross-Sectional and Longitudinal Data</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634057</td><td>Cr (1968)</td><td>Predicting response to phenothiazines: the right drug for the right patient.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633531</td><td>Crabb (2009)</td><td>Who should swing the stethoscope? An audit of baseline physical examination and blood monitoring on new patients accepted by an early intervention in psychosis team</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648531</td><td>Crabtree (2020)</td><td>Anxiety and Adverse Life Events in Professional Creative and Early Psychosis Populations</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644944</td><td>Crabtree (2021)</td><td>Spatial working memory, not IQ or executive function, discriminates early psychosis and clinically vulnerable creative individuals</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633577</td><td>Craig (1979)</td><td>Evidence for organicity in concrete vs. overinclusive thought-disordered schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634026</td><td>Craig (1997)</td><td>Diagnosis, treatment, and six-month outcome status in first-admission psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646485</td><td>Craig (2004)</td><td>The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59644537</td><td>Craig (2014)</td><td>Vocational rehabilitation in early psychosis: cluster randomised trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633855</td><td>Crane (1973)</td><td>Clinical Psychopharmacology in Its 20th Year</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633656</td><td>Crawford (1974)</td><td>Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634114</td><td>Crawford (2018)</td><td>Lamotrigine for people with borderline personality disorder: a RCT</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634240</td><td>Crawford (2020)</td><td>Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647003</td><td>Crebbin (2008)</td><td>First-episode psychosis: An epidemiological survey comparing psychotic depression with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647022</td><td>Crebbin (2009)</td><td>First-episode drug-induced psychosis: A medium term follow up study reveals a high-risk group</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645418</td><td>Crepeau-Gendron (2015)</td><td>Quetiapine XR-induced neutropenia: Is a clozapine trial still possible for treatment-resistant schizophrenia? A case report</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646590</td><td>Crespo-Facorro (2000)</td><td>Insular cortex abnormalities in schizophrenia: A structural magnetic resonance imaging study of first-episode patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645667</td><td>Crespo-Facorro (2006)</td><td>A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645632</td><td>Crespo-Facorro (2007)</td><td>Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646560</td><td>Crespo-Facorro (2008)</td><td>Interleukin-12 plasma levels in drug-naive patients with a first episode of psychosis: effects of antipsychotic drugs</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647468</td><td>Crespo-Facorro (2008)</td><td>Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646100</td><td>Crespo-Facorro (2009)</td><td>Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645280</td><td>Crespo-Facorro (2011)</td><td>Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647362</td><td>Crespo-Facorro (2011)</td><td>Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646415</td><td>Crespo-Facorro (2012)</td><td>Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645653</td><td>Crespo-Facorro (2013)</td><td>Prediction of acute clinical response following a first episode of non affective psychosis: results of a cohort of 375 patients from the Spanish PAFIP study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648489</td><td>Crespo-Facorro (2013)</td><td>Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: Result of a 6-week, randomized, flexible-dose, open-label comparison</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648490</td><td>Crespo-Facorro (2013)</td><td>Aripiprazole, Ziprasidone and Quetiapine in the treatment of first-episode nonaffective psychosis: A 12-week randomized, flexible-dose, open-label trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644667</td><td>Crespo-Facorro (2014)</td><td>Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647322</td><td>Crespo-Facorro (2017)</td><td>Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648322</td><td>Crespo-Facorro (2021)</td><td>The burden of disease in early schizophrenia-a systematic literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644544</td><td>Crews (2013)</td><td>Vitamin D deficiency in first episode psychosis: A case-control study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646566</td><td>Crocker (2018)</td><td>The interaction of gender and cannabis in early phase psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645825</td><td>Crocker (2020)</td><td>Patient engagement to early intervention in psychosis services: Retrospective analysis of engagement patterns</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648309</td><td>Crockford (2017)</td><td>Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644838</td><td>Crossley (2009)</td><td>Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647246</td><td>Crossley (2010)</td><td>Efficacy of atypical V. typical antipsychotics in the treatment of early psychosis: Meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633881</td><td>Crow (1976)</td><td>The coincidence of schizophrenia and Parkinsonism: some neurochemical implications.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633752</td><td>Crow (1977)</td><td>The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634201</td><td>Crow (1977)</td><td>The role of dopamine in the antipsychotic effect and the pathogenesis of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633590</td><td>Crow (1978)</td><td>An evaluation of the dopamine hypothesis of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633961</td><td>Crow (1981)</td><td>Positive and negative schizophrenia symptoms and the role of dopamine.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645404</td><td>Crow (1986)</td><td>A randomised controlled trial of prophylactic neuroleptic treatment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646437</td><td>Cruz (2021)</td><td>Long range temporal correlations (LRTCs) in MEG-data during emerging psychosis: Relationship to symptoms, medication-status and clinical trajectory</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648152</td><td>Ctri (2013)</td><td>A clinical trial to study the effects of metformin in prevention of olanzapine induced weight gain, type 2 diabetes mellitus and lipid abnormalities in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647356</td><td>Ctri (2014)</td><td>Effectiveness of ranitidine in weight gain caused by olanzapine in patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645484</td><td>Ctri (2016)</td><td>"Psychiatric Social Work Intervention to Enhance Insight on illness in Persons with Schizophrenia"</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647072</td><td>Ctri (2016)</td><td>Family Centered Psychiatric Social Work Interventions for Persons with First Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647344</td><td>Ctri (2017)</td><td>Effectiveness of vitamin D in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647395</td><td>Ctri (2017)</td><td>Effect of Vitamin D supplementation in treatment of First episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644725</td><td>Ctri (2018)</td><td>to study effect of lurasidone in patients of schizophrenia in comparison with oplanzapine</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647433</td><td>Ctri (2018)</td><td>Effect of High- Definition Transcranial Direct Current Stimulation on Cognitive Deficits in Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644866</td><td>Ctri (2019)</td><td>A study on silymarin (a medicine from plant) on special indicators present in blood (inflammatory cytokines and genetic markers) and in reducing the problems associated with depression in patients suffering from depressive disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645242</td><td>Ctri (2020)</td><td>Relationship of MTHFR gene and schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648153</td><td>Ctri (2020)</td><td>A clinical trial to study effects of oral and long acting injectable antipsychotic in patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647401</td><td>Ctri (2021)</td><td>Effect of SMS reminders on treatment retention rates among patients with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648075</td><td>Cuesta (2009)</td><td>Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59644658</td><td>Cuesta (2012)</td><td>Treatment response of neurological soft signs in drug-naive patients with a first psychotic episode</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647592</td><td>Cuesta (2012)</td><td>Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645581</td><td>Cuesta (2015)</td><td>Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646197</td><td>Cuesta (2018)</td><td>Motor abnormalities in first-episode psychosis patients and long-term psychosocial functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646198</td><td>Cuesta (2018)</td><td>Motor abnormalities and cognitive impairment in first-episode psychosis patients, their unaffected siblings and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644638</td><td>Cui (2005)</td><td>The tumor suppressor adenomatous polyposis coli gene is associated with susceptibility to schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645441</td><td>Cui (2016)</td><td>Putamen-related regional and network functional deficits in first-episode schizophrenia with auditory verbal hallucinations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647916</td><td>Cui (2019)</td><td>Connectome-based patterns of first-episode medication-naive patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646467</td><td>Cui (2020)</td><td>Less reduced gray matter volume in the subregions of superior temporal gyrus predicts better treatment efficacy in drug-naive, first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644545</td><td>Cui (2021)</td><td>Vitamin D and schizophrenia: 20 years on</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645943</td><td>Cullberg (2002)</td><td>One-year outcome in first episode psychosis patients in the Swedish Parachute project</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646575</td><td>Cullberg (2006)</td><td>Integrated treatment and implications for off-medication periods</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646604</td><td>Cullen (2020)</td><td>Influence of methodological and patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-analysis of cross-sectional and case-control studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647712</td><td>Cumbo (2005)</td><td>Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648204</td><td>Curry (1970)</td><td>Chlorpromazine plasma levels and effects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647913</td><td>Curtis (2012)</td><td>Considering metformin in cardiometabolic protection in psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647165</td><td>Curtis (2016)</td><td>Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648417</td><td>Curtis (2021)</td><td>Auditory Cortex Attentional Gain Modulation is Impaired in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634299</td><td>Cuthbert (2021)</td><td>Green care in first-episode psychosis: short report of a mixed-methods evaluation of a 'woodland group' in an early intervention service.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646593</td><td>Czobor (2013)</td><td>Insight and hostility as predictors and correlates of nonadherence in the European First Episode Schizophrenia Trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644689</td><td>Czobor (2015)</td><td>Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644583</td><td>D‚ÄôArcey (2020)</td><td>THE USE OF SHORT MESSAGE SERVICE AS A√Ç MEANS OF CLINICAL ENGAGEMENT IN EARLY PSYCHOSIS...Congress of Schizophrenia International Research Society, April 17-21, 2021, Toronto, Canada</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634154</td><td>Da (1984)</td><td>Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644524</td><td>da Cunha (2012)</td><td>Voxelwise evaluation of white matter volumes in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647634</td><td>da Silva (2013)</td><td>Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646736</td><td>Daglas (2014)</td><td>The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: trauma and early psychotic mania</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646145</td><td>Dal (2019)</td><td>Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647133</td><td>Danaher (2018)</td><td>An examination of sex differences in neurocognition and social cognition in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648383</td><td>Danborg (2019)</td><td>Benefits and harms of antipsychotic drugs in drug-naive patients with psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646323</td><td>Daneault (2019)</td><td>Medication adherence in first episode psychosis: The role of pre-onset subthreshold symptoms</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645338</td><td>Daniel (2020)</td><td>Rates of conversion from substance-associated psychotic disorder to bipolar or schizophrenia spectrum disorder in a community-based teaching hospital</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646458</td><td>Dannaram (2012)</td><td>Levetiracetam-induced acute psychotic episode</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644574</td><td>D'Arcey (2018)</td><td>Using short message service as a means of engagement in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644584</td><td>D'Arcey (2020)</td><td>The use of short message service as a means of clinical engagement in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645363</td><td>D'Arcey (2020)</td><td>A randomized controlled trial of sms text messaging to improve clinical engagement in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644854</td><td>Dardennes (2010)</td><td>Successful augmentation of clozapine-resistant treatment of schizophrenia with clonidine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647089</td><td>Daros (2014)</td><td>Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648632</td><td>Das (2008)</td><td>Amisulpride-induced dystonia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647689</td><td>Das (2018)</td><td>Disorganized gyrification network properties during the transition to psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645955</td><td>Daskalakis (2012)</td><td>On a quest for the elusive schizophrenia biomarker</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646366</td><td>Datka (2016)</td><td>Lurasidone versus typical antipsychotics for schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644624</td><td>Datta (2012)</td><td>Typical antipsychotics for psychosis in adolescents</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59645282</td><td>Datta (2020)</td><td>Reinforcement learning abnormalities in individuals at clinical high risk and in the first episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645132</td><td>Dauvermann (2019)</td><td>The role of childhood trauma in cognitive performance in schizophrenia and bipolar disorder - A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647868</td><td>Dauvermann (2019)</td><td>Cortisol stress response in psychosis from the high-risk to the chronic stage: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634209</td><td>Davey (2019)</td><td>The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633935</td><td>David (2005)</td><td>Depot perphenazine decanoate and enanthate for schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648073</td><td>Davidson (2009)</td><td>"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: A randomized, open-label clinical trial (EUFEST)": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644797</td><td>Davies (2017)</td><td>A systematic review of the nature and correlates of sleep disturbance in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645536</td><td>Davies (2018)</td><td>The process and delivery of cognitive behavioural therapy (CBT) for depression in adults: a network meta‚Äêanalysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646177</td><td>Davies (2018)</td><td>Multimedia‚Äêdelivered cognitive behavioural therapy versus face‚Äêto‚Äêface cognitive behavioural therapy for depression in adults</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644836</td><td>Davies (2019)</td><td>The supportive care needs of individuals recovering from first episode psychosis: A scoping review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645882</td><td>Davies (2019)</td><td>Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647192</td><td>Davies (2019)</td><td>Enteral tube feeding for people with severe dementia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633671</td><td>Davis (1965)</td><td>Efficacy of tranquilizing and antidepressant drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633526</td><td>Davis (1975)</td><td>Overview: maintenance therapy in psychiatry. I. Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633623</td><td>Davis (1976)</td><td>Comparative doses and costs of antipsychotic medication.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634049</td><td>Davis (1976)</td><td>Recent Developments in the Drug Treatment of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633652</td><td>Davis (1977)</td><td>Antipsychotic Drugs: Clinical Pharmacology and Therapeutic Use</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633888</td><td>Davis (1977)</td><td>METHODOLOGICAL ISSUES IN PSYCHOPHARMACOLOGICAL RESEARCH</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634051</td><td>Davis (1978)</td><td>Neuroleptics: Clinical Use in Psychiatry</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633944</td><td>Davis (1980)</td><td>Important Issues in the Drug Treatment of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634094</td><td>Davis (1993)</td><td>Power Analysis for Correlation of Plasma Level and Clinical Data</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633710</td><td>Davis (2004)</td><td>Dose response and dose equivalence of antipsychotics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646046</td><td>Davis (2013)</td><td>Neuropsychological tests for the diagnosis of Alzheimer‚Äôs disease dementia and other dementias: a generic protocol for cross‚Äêsectional and delayed‚Äêverification studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633956</td><td>Dawkins (1999)</td><td>Antipsychotics: Past and Future National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647069</td><td>Day (2017)</td><td>Family interventions in early psychosis service delivery: A systematized review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647070</td><td>Day (2017)</td><td>Family group interventions in an early psychosis program: A re-evaluation of practice after 10 years of service delivery</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634118</td><td>Day (2018)</td><td>A pilot feasibility randomised controlled trial of an adjunct brief social network intervention in opiate substitution treatment services</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633719</td><td>Dayalu (2008)</td><td>Antipsychotic-induced extrapyramidal symptoms and their management</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647722</td><td>Dazzan (2005)</td><td>Different Effects of Typical and Atypical Antipsychotics on Grey Matter in First Episode Psychosis: The AESOP Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644822</td><td>Dazzan (2021)</td><td>Symptom Remission and Brain Cortical Networks at First Clinical Presentation of Psychosis: The OPTiMiSE Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645703</td><td>de Azua (2013)</td><td>Plasma brain-derived neurotrophic factor levels, learning capacity and cognition in patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633593</td><td>de Beaurepaire (1991)</td><td>The Dopamine System and Mental Disorders: Clinical and Psychopharmacological Overview</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644478</td><td>de Boer (2018)</td><td>Who needs assertive outreach in early psychosis interventions?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644888</td><td>de Castro-Manglano (2011)</td><td>Structural brain abnormalities in first-episode psychosis: Differences between affective psychoses and schizophrenia and relationship to clinical outcome</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645167</td><td>de Haan (2007)</td><td>Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; A prospective five year follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647067</td><td>De Haan (2016)</td><td>Family motivational intervention for carers of cannabis using first episode psychosis patients: feasible and effective</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645562</td><td>De Hert (2006)</td><td>Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: A cross-sectional study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644625</td><td>De Hert (2008)</td><td>Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633514</td><td>De Hert (2015)</td><td>The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646830</td><td>de la Fuente-Sandoval (2011)</td><td>Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646894</td><td>de la Fuente-Sandoval (2013)</td><td>Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645589</td><td>de la Fuente-Sandoval (2018)</td><td>Prefrontal and striatal gamma-aminobutyric acid levels and the effect of antipsychotic treatment in first-episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645200</td><td>de Lima (2007)</td><td>Resposta a carta dos Drs. Sa Jr. e Helkis "Comentarios sobre 'Manejo do ganho de peso em pacientes portadores de esquizofrenia durante o tratamento com olanzapina em associacao com nizatidina'."</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645618</td><td>De Luca (2020)</td><td>Predictors of internalized mental health stigma in a help-seeking sample of adolescents and young adults experiencing early psychosis: The roles of psychosis-spectrum symptoms and family functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645181</td><td>De Maio (2015)</td><td>Review of international early psychosis programmes and a model to overcome unique challenges to the treatment of early psychosis in the United States</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634255</td><td>de Pablo (2020)</td><td>Psychosocial Intervention Without Antipsychotic Medication for Brief Psychotic Episodes</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645139</td><td>De Smedt (1999)</td><td>Risperidone vs. Haloperidol in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647827</td><td>de Witte (2014)</td><td>"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment": Corrigendum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647828</td><td>de Witte (2014)</td><td>Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645724</td><td>Deakin (2010)</td><td>The physical health challenges in patients with severe mental illness: cardiovascular and metabolic risks</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648384</td><td>Deakin (2018)</td><td>The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646234</td><td>Dean (2007)</td><td>Minor physical anomalies across ethnic groups in a first episode psychosis sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648665</td><td>Dean (2007)</td><td>Aggressive behaviour at first contact with services: Findings from the AESOP First Episode Psychosis Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644928</td><td>Dean (2013)</td><td>Speed of facial affect intensity recognition as an endophenotype of first-episode psychosis and associated limbic-cortical grey matter systems</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634134</td><td>Deb (2018)</td><td>Aggression Following Traumatic brain injury: Effectiveness of Risperidone (AFTER): study protocol for a feasibility randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634281</td><td>Dehmahdi (2021)</td><td>Estimating the minimum important difference for the questionnaire about the Process of Recovery (QPR): an anchor-based approach</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648307</td><td>Deiana (2018)</td><td>Cannabidiol as a potential novel therapeutic agent for psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646940</td><td>Del Casale (2016)</td><td>Functional Magnetic Resonance Imaging Correlates of First-Episode Psychoses during Attentional and Memory Task Performance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646126</td><td>Del Casale (2018)</td><td>Neural functional correlates of emotional processing in patients with first-episode psychoses: an activation likelihood estimation (ALE) meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644601</td><td>Del-Ben (2019)</td><td>Urbanicity and risk of first-episode psychosis: Incidence study in Brazil</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645695</td><td>Delgado-Alvarado (2019)</td><td>Plasma prolactin levels are associated with the severity of illness in drug-naive first-episode psychosis female patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646364</td><td>Demetriou (2020)</td><td>Machine Learning for Differential Diagnosis Between Clinical Conditions With Social Difficulty: Autism Spectrum Disorder, Early Psychosis, and Social Anxiety Disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646157</td><td>Demiralp (2002)</td><td>N2 and P3 components of event-related potential in first-episode schizophrenic patients: Scalp topography, medication, and latency effects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647500</td><td>Dempster (2020)</td><td>Early treatment response in first episode psychosis: A 7-T magnetic resonance spectroscopic study of glutathione and glutamate</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633686</td><td>Dencker (1981)</td><td>Late (4-8 years) outcome of treatment with megadoses of fluphenazine enanthate in drug-refractory schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633847</td><td>Dencker (1994)</td><td>Does community care reduce the need for psychiatric beds for schizophrenic patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633631</td><td>Dencker (2007)</td><td>Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics: I. A ONE YEAR DOUBLE‚ÄêBLIND STUDY OF CLOPENTHIXOL DECANOATE AND FLUPENTHIXOL PALMITATE</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633845</td><td>Dencker (2007)</td><td>Do schizophrenics well adapted in the community need neuroleptics?: A DEPOT NEUROLEPTIC WITHDRAWAL STUDY</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646905</td><td>Deng (2017)</td><td>Ginkgo biloba versus placebo for schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633897</td><td>Deniker (1960)</td><td>Experimental neurological syndromes and thenew drug therapies in psychiatry</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634232</td><td>Depp (2021)</td><td>A Brief Mobile-Augmented Suicide Prevention Intervention for People With Psychotic Disorders in Transition From Acute to Ongoing Care: Protocol for a Pilot Trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645763</td><td>DeQuardo (1998)</td><td>Pharmacologic treatment of first-episode schizophrenia: Early intervention is key to outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645316</td><td>DeQuardo (1999)</td><td>"Recommended haloperidol and risperidone doses in first-episode psychosis": Commentary reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648596</td><td>Derks (2010)</td><td>Antipsychotic drug treatment in first-episode psychosis: Should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645566</td><td>DeTore (2021)</td><td>Prevalence and correlates of PTSD in first episode psychosis: Findings from the RAISE-ETP study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646045</td><td>Deuschl (2009)</td><td>Neurostimulation for Parkinson disease</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645850</td><td>Devrim-Ucok (2008)</td><td>P50 gating at acute and post-acute phases of first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646233</td><td>Devrim-Ucok (2008)</td><td>Mismatch negativity at acute and post-acute phases of first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644932</td><td>Dewa (2009)</td><td>Specialized home treatment versus hospital-based outpatient treatment for first-episode psychosis: a randomized clinical trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645673</td><td>Dewa (2016)</td><td>Potential Effects of the Choice of Costing Perspective on Cost Estimates: An Example Based on 6 Early Psychosis Intervention Programs</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645071</td><td>Dey (2018)</td><td>Searching for a stratification marker for antioxidant use in schizophrenia and bipolar disorder: A meta-analysis of mrs studies of anterior cingulate glutathione</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647508</td><td>Dey (2019)</td><td>Early stages of conceptual disorganisation and redistribution of cortical hubs in untreated first episode psychosis; a 7T fmri study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647919</td><td>Dey (2021)</td><td>Conceptual disorganization and redistribution of resting-state cortical hubs in untreated first-episode psychosis: A 7T study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633788</td><td>Deykin (1966)</td><td>The relatives of schizophrenic patients: clinical judgments of potential emotional resourcefulness.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646211</td><td>Dezsi (2017)</td><td>Monoamine oxidase B inhibitors in Parkinson's disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646111</td><td>Dhaliwal (2018)</td><td>Neurobiological correlates of soft neurological signs in neuroleptic-naive first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634127</td><td>Di Capite (2018)</td><td>The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647816</td><td>Di Forti (2014)</td><td>Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647666</td><td>Di Forti (2019)</td><td>Dna methylation profiling might shed light on the biology of cannabis associated psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647279</td><td>Di Leone (2015)</td><td>Effects of trazodone on night eating behavior: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647387</td><td>Di Lorenzo (2019)</td><td>Effectiveness of 1-year treatment with longacting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: Retrospective study in a real-world clinical setting</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645043</td><td>Di Nicola (2013)</td><td>Serum and gene expression profile of cytokines in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644573</td><td>Diaz (2011)</td><td>Using structural equations to test for a direct effect of some antipsychotics on triglyceride levels in drug-naive first-episode psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645625</td><td>D√≠az (2013)</td><td>Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644459</td><td>Dickenson (2013)</td><td>Zotepine versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59647562</td><td>Dickerson (2015)</td><td>Early detection and intervention for people with psychosis: Getting to the bottom line</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644977</td><td>Dickerson (2019)</td><td>Smoking and schizophrenia: Still a burning problem</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648272</td><td>Dillinger (2020)</td><td>Caring for caregivers: Understanding and meeting their needs in coping with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648199</td><td>Dilsaver (1984)</td><td>Cholinergic syndrome from psychotropic withdrawal in a marijuana abuser</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634067</td><td>Dimascio (1963)</td><td>The Psychopharmacology Of Phenothiazine Compounds: A Comparative Study Of The Effects Of Chlorpromazine, Promethazine, Trifluoperazine, And Perphenazine In Normal Males. Ii</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647517</td><td>Dimitrakopoulos (2015)</td><td>Early psychotic experiences: Interventions, problems and perspectives</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648721</td><td>Ding (2014)</td><td>Activation of Th17 cells in drug naive, first episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648246</td><td>Ding (2019)</td><td>Cerebellar structural and functional abnormalities in first-episode and drug-naive patients with schizophrenia: A meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646275</td><td>Diurni (2009)</td><td>Metabolic side effects of second generation antipsychotics in drug-naive patients: A preliminary study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647892</td><td>Dixon (1995)</td><td>Conventional antipsychotic medications for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646314</td><td>Dixon (2015)</td><td>Medications for first-episode psychosis: Making a good start</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645884</td><td>Do (2016)</td><td>Oxidative stress as one core mechanism in schizophrenia pathophysiology and impact of antioxidant N-acetyl-cysteine in a clinical trial with early psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647655</td><td>Docosahexaenoic acid... (2018)</td><td>Docosahexaenoic acid in the treatment of rheumatoid arthritis: a double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646150</td><td>Dodd (2010)</td><td>A naturalistic study of treatment outcomes with aripiprazole in young people with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647651</td><td>Does early antipsychotic... (2017)</td><td>Does early antipsychotic response predict long-term treatment outcome?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633637</td><td>Dollfus (2009)</td><td>Les antipsychotiques lors d‚Äôun premier √©pisode psychotique</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644791</td><td>Dolmer (2018)</td><td>Tailor-tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia spectrum disorders in remission of psychotic symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648713</td><td>Dolzan (2008)</td><td>Acute antipyschotic efficacy and side effects in schizophrenia: Association with serotonin transporter promoter genotypes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645858</td><td>Dombi (2020)</td><td>P.573 Efficacy of cariprazine in the early stage of schizophrenia: a pooled, post-hoc analysis of 3 phase II/III double-blind placebo-controlled trials</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648181</td><td>Dominguez-Martinez (2017)</td><td>Clinical and psychosocial characterization of At-Risk Mental State and Recent Onset Psychosis Patients from an Early Psychosis Program in Barcelona (Spain)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634070</td><td>Domino (1962)</td><td>Human pharmacology of tranquilizing drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646367</td><td>Donnelly (2013)</td><td>Lurasidone versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59647635</td><td>Dopaminergic effects... (2018)</td><td>Dopaminergic effects on hierarchical prediction errors and connectivity during social learning</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646645</td><td>Doraiswamy (2006)</td><td>"Increased pituitary volume in ...psychosis study": Comment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644933</td><td>Dor√©-Gauthier (2020)</td><td>Specialized assertive community treatment intervention for homeless youth with first episode psychosis and substance use disorder: a 2-year follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633602</td><td>Dose (2000)</td><td>Psychopharmakologische Langzeittherapie der Schizophrenie: Wie ist der neueste Stand der wissenschaftlichen Erkenntnis?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646083</td><td>Dose (2004)</td><td>Neuroleptic Relapse Prevention in Schizophrenia - The Role of Newly Developed Substances</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648547</td><td>Doufik (2014)</td><td>Antipsychotic-induced priapism and management challenges: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634117</td><td>Dougherty (2019)</td><td>The Psychological Management of the Poor: Prescribing Psychoactive Drugs in the Age of Neoliberalism</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648620</td><td>Downes (2013)</td><td>Animal‚Äêassisted therapy for people with serious mental illness</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646137</td><td>Downs (2019)</td><td>Negative symptoms in early-onset psychosis and their association with antipsychotic treatment failure</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648126</td><td>Doyle (2017)</td><td>Clozapine use in a cohort of first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634188</td><td>Dr (1964)</td><td>EFFECTS OF A PHENOTHIAZINE AND/OR GROUP PSYCHOTHERAPY WITH SCHIZOPHRENICS.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647558</td><td>Drake (2005)</td><td>Early detection of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645501</td><td>Drake (2011)</td><td>A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646149</td><td>Drake (2014)</td><td>A naturalistic, randomized, controlled trial combining cognitive remediation with cognitive-behavioural therapy after first-episode non-affective psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646222</td><td>Drake (2015)</td><td>Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: Implications for intervention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648311</td><td>Drake (2018)</td><td>Can we improve functional outcome and adherence in optimise participants with a psychosocial intervention?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647448</td><td>Drake (2020)</td><td>Effect of delaying treatment of first-episode psychosis on symptoms and social outcomes: A longitudinal analysis and modelling study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59648495</td><td>Dratcu (2007)</td><td>Aripiprazole treatment of Asperger's syndrome in the acute psychiatric setting: Case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646479</td><td>Driscoll (2005)</td><td>Late-onset major depression: clinical and treatment-response variability</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646584</td><td>Drks (2009)</td><td>Integrated Care (IC) with or without Assertive Community Treatment (ACT): a 12- month open randomized single blind trial in patients with early psychosis with 6-month post intervention follow-up (ACCESS study)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648518</td><td>Drks (2015)</td><td>Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies of Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647159</td><td>Drks (2017)</td><td>Evaluation of the ‚Äúspecialist program‚Äù for care in the fields of neurology, psychiatry, psychosomatics and psychotherapy in Baden-Wuerttemberg in accordance with ¬ß73c SGB V</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646679</td><td>Drks (2021)</td><td>Improving functional and clinical recovery by combining Individual Placement and Support (IPS) and Motivational Interviewing-based Adherence Therapy (AT) in patients with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646886</td><td>D'Souza (2012)</td><td>Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645255</td><td>Du (2010)</td><td>Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647502</td><td>Du (2020)</td><td>Early trajectories of positive symptoms remission in first episode-psychosis: A 2-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634257</td><td>Dubreucq (2021)</td><td>Self-stigma in Serious Mental Illness: A Systematic Review of Frequency, Correlates, and Consequences.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645140</td><td>Duggal (2005)</td><td>Risperidone treatment of febrile catatonia in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648708</td><td>Dulude (2010)</td><td>Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647725</td><td>Duran-Cutilla (2020)</td><td>Differences in lifetime patterns of psychostimulants and their impact on the proportion of patients with first-episode psychosis attributable to psychostimulants use across Europe</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647574</td><td>Duration of untreated... (2018)</td><td>Duration of untreated psychosis moderates clinical outcomes and cost-effectiveness in first episode psychosis treatment programs</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646470</td><td>Duricy (2020)</td><td>Left hemisphere MEG deficit in pitch and duration mismatch negativity in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647316</td><td>During (2014)</td><td>Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645014</td><td>During (2019)</td><td>Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade-An exploratory study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633841</td><td>Dysken (1981)</td><td>Fluphenazine pharmacokinetics and therapeutic response.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647734</td><td>Dzikowski (2020)</td><td>The differences between gluten sensitivity, intestinal biomarkers and immune biomarkers in patients with first-episode and chronic schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634198</td><td>E (1973)</td><td>Drug therapy in depressions</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647797</td><td>Earls (2016)</td><td>Deficits in Early Stages of Face Processing in Schizophrenia: A Systematic Review of the P100 Component</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633949</td><td>Earnst (1997)</td><td>Construct validity of negative symptoms: An empirical and conceptual review</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648726</td><td>Ebdrup (2019)</td><td>Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-na√Øve schizophrenia patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633704</td><td>Ebert (1977)</td><td>Changes in primary process expression in hospitalized schizophrenics treated with phenothiazines: two projective tasks compared.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646836</td><td>Ebert (2013)</td><td>High circulatory titer of platelet-associated autoantibodies in childhood onset schizophrenia and its diagnostic implications</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647452</td><td>Ebert (2015)</td><td>Effect of clozapine and other antipsychotics on the level of platelet-associated autoantibodies in children with schizophrenia: A longitudinal follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647480</td><td>Edelsohn (2019)</td><td>Editorial: Making use of what we know: Medical decision-making and antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647199</td><td>Edwards (2003)</td><td>Enduring positive symptoms in first episode psychosis: a randomised controlled trial of clozapine and CBT</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645382</td><td>Edwards (2006)</td><td>Randomized controlled trial of a cannabis-focused intervention for young people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645376</td><td>Edwards (2011)</td><td>Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: a pilot study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647454</td><td>Effect of Citalopram... (2020)</td><td>Effect of Citalopram on Hippocampal Atrophy in First-Episode Psychosis: structural MRI Results From the DECIFER Trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647398</td><td>Effect of switching... (2018)</td><td>Effect of switching to integrase inhibitor on the HIV reservoir in ileum biopsies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647308</td><td>Effects of long-term... (2018)</td><td>Effects of long-term multimodal psychosocial treatment on antipsychotic-induced metabolic changes in patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648617</td><td>Egerton (2012)</td><td>Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645205</td><td>Egerton (2018)</td><td>Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: A multicentre 1H-MRS study (OPTiMiSE)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647156</td><td>Eguiluz (1998)</td><td>Evaluation of the efficacy of psychoeducative groups in schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645319</td><td>Ehrenreich (2010)</td><td>Recombinant human erythropoietin: Novel approach to neuroprotection and neuroregeneration in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646932</td><td>Eichhammer (2004)</td><td>GABA-B-Associated Neuropsychiatric Disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634122</td><td>Einarson (2017)</td><td>Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648376</td><td>Eisenacher (2016)</td><td>Bias against disconfirmatory evidence in the 'at-risk mental state' and during psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647338</td><td>Eker (2009)</td><td>Effects of adding depot antipsychotic medication to oral antipsychotic regimen on treatment compliance in schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645433</td><td>Elahi (2018)</td><td>A qualitative study into using virtual reality to deliver social cognition training to those diagnosed with first episode psychosis (VEEP trial)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646444</td><td>Elaswed (2018)</td><td>A literature review on electrocardiogram (ECG) recording in patients with Huntington's disease on antipsychotic medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633701</td><td>Elkes (1954)</td><td>Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633819</td><td>Ellenbroek (1993)</td><td>Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633559</td><td>Ellenbroek (2000)</td><td>Regional selectivity of antipsychotic drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633724</td><td>Ellenbroek (2012)</td><td>Psychopharmacological treatment of schizophrenia: what do we have, and what could we get?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633907</td><td>Elliott (1973)</td><td>No prescription pads for social workers</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648388</td><td>Elliott (2018)</td><td>Behavioural and cognitive behavioural therapy for obsessive compulsive disorder (OCD) in individuals with autism spectrum disorder (ASD)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646786</td><td>Ellis (2021)</td><td>A human rights-based ethical framework for implementation of 'digital pills'</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647855</td><td>Elowe (2016)</td><td>Could cannabis use moderate the association between insight and depression in psychosis: A prospective study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646190</td><td>Elowe (2017)</td><td>Much ado about everything: A literature review of insight in first episode psychosis and schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646219</td><td>Elowe (2020)</td><td>Moderating role of cannabis use between insight and depression in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647629</td><td>Elzinga (2014)</td><td>Dose reduction/discontinuation for first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634061</td><td>Em (1995)</td><td>The psychobiology of first-episode schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645146</td><td>Emsley (1995)</td><td>Risperidone in the Treatment of First-Episode Patients with Schizophreniform Disorder: a Double-Blind Multicenter Study</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645145</td><td>Emsley (1999)</td><td>Risperidone in the Treatment of First-Episode Psychotic Patients: A Double-Blind Multicenter Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646040</td><td>Emsley (2003)</td><td>The new and evolving pharmacotherapy of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647086</td><td>Emsley (2003)</td><td>The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647139</td><td>Emsley (2004)</td><td>Evidence-based pharmacotherapy of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647138</td><td>Emsley (2005)</td><td>Evidence-based pharmacotherapy of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644733</td><td>Emsley (2006)</td><td>Time course for antipsychotic treatment response in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645224</td><td>Emsley (2006)</td><td>Remission in first-episode psychosis: Predictor variables and symptom improvement patterns</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645225</td><td>Emsley (2007)</td><td>Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645223</td><td>Emsley (2008)</td><td>Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645906</td><td>Emsley (2008)</td><td>Oral versus injectable antipsychotic treatment in early psychosis: Post hoc comparison of two studies</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646041</td><td>Emsley (2009)</td><td>New advances in pharmacotherapy for early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644824</td><td>Emsley (2012)</td><td>Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: A 3-year open-label clinical study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647943</td><td>Emsley (2013)</td><td>Comparison of treatment response in second-episode versus first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633925</td><td>Emsley (2013)</td><td>Long-acting injectable antipsychotics in early psychosis: a literature review</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634008</td><td>Emsley (2013)</td><td>The nature of relapse in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645352</td><td>Emsley (2014)</td><td>A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647632</td><td>Emsley (2015)</td><td>Dorsal striatal volumes in never-treated patients with first-episode schizophrenia before and during acute treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648233</td><td>Emsley (2015)</td><td>Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646428</td><td>Emsley (2016)</td><td>Long-acting injectable antipsychotics in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645949</td><td>Emsley (2017)</td><td>Once-monthly paliperidone palmitate in early stage schizophrenia-A retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646074</td><td>Emsley (2017)</td><td>Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647695</td><td>Emsley (2018)</td><td>Discontinuing antipsychotic treatment after a first-episode of psychosis: Who, when and how?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645612</td><td>Emsley (2020)</td><td>Predictors of psychosis breakthrough during 24 months of long-acting antipsychotic maintenance treatment in first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634302</td><td>Enezes (2006)</td><td>A systematic review of longitudinal outcome studies of first-episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633689</td><td>Engelhardt (1963)</td><td>PHENOTHIAZINES IN PREVENTION OF PSYCHIATRIC HOSPITALIZATION. II. DURATION OF TREATMENT EXPOSURE.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633987</td><td>Engelhardt (1964)</td><td>Phenothiazines in Prevention of Psychiatric Hospitalization: III. Delay or Prevention of Hospitalization</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633801</td><td>Engelhardt (1967)</td><td>Drug treatment of chronic ambulatory patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648058</td><td>Engen (2019)</td><td>Cognitive functioning in patients with first-episode psychosis stratified by level of negative symptoms: A 1-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645455</td><td>Engh (2017)</td><td>Psychosis relapse, medication non-adherence, and cannabis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648017</td><td>England (2009)</td><td>Collaborating to provide early-intervention services to persons in England with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644599</td><td>Englisch (2008)</td><td>Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645034</td><td>Erdem (2012)</td><td>Serum neopterin and haptoglobin concentrations in patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646138</td><td>Ergul (2015)</td><td>Negative symptom subgroups have different effects on the clinical course of schizophrenia after the first episode: A 24-month follow up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645257</td><td>Ergun (2018)</td><td>The relationship between psychopathology and cognitive functions with cytokines in clinically stable patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648024</td><td>Erickson (2010)</td><td>Cognitive-behaviour therapy for medication-resistant positive symptoms in early psychosis: A case series</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646290</td><td>Erickson (2016)</td><td>A meta-analysis of mismatch negativity in schizophrenia: From clinical risk to disease specificity and progression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646622</td><td>Erickson (2020)</td><td>‚ÄúIndividual Placement and Support‚Äù boosts employment for early psychosis clients, even when baseline rates are high</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648741</td><td>Ermakova (2018)</td><td>Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647182</td><td>Erratum: effect of long-acting... (2020)</td><td>Erratum: effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial (JAMA Psychiatry (2020) DOI: 10.1001/jamapsychiatry.2020.2076)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647180</td><td>Erratum: sex-differential... (2019)</td><td>Erratum: sex-differential effects of olanzapine vs. Aripiprazole on glucose and lipid metabolism in first-episode schizophrenia(Arch Clin Psychiatry. 2019;46(2): 33-9)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648588</td><td>Ertugrul (2003)</td><td>Antipsychotic drugs in bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645793</td><td>Esan (2014)</td><td>Persistence in treatment for one year among patients in Nigeria with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647623</td><td>Esmat (2016)</td><td>A doubl e-blind trial of the combination effect of lidocaine, ketamine and verapamil in intravenous regional anesthesia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644935</td><td>Essali (2012)</td><td>Specialist interventions for homeless people with severe mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644610</td><td>Essali (2015)</td><td>Unilateral electroconvulsive therapy versus bilateral electroconvulsive therapy for schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648630</td><td>Essali (2015)</td><td>Amphetamines versus placebo for schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648271</td><td>Essali (2016)</td><td>Cariprazine versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59647611</td><td>Esseveld (2013)</td><td>Drawings during neuropsychiatric recovery from anti-NMDA receptor encephalitis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646964</td><td>Estrada (2020)</td><td>Free Thyroxine Concentrations Moderate the Response to a Cognitive Remediation Therapy in People With Early Psychosis: a Pilot Randomized Clinical Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646965</td><td>Estrada (2020)</td><td>Free thyroxin concentrations moderate the response to a cognitive remediation therapy in people with early psychosis: preliminary findings</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647167</td><td>ETRo: evaluation of... (2020)</td><td>ETRo: evaluation of the treatment approach ‚Äúrobin‚Äù (standardized manual and smartphone app) for adolescents with clinical high risk for developing a psychotic disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633693</td><td>Ettenberg (1982)</td><td>Behavioral effects of neuroleptics: Performance deficits, reward deficits or both?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644528</td><td>Ettinger (2004)</td><td>Volumetric Neural Correlates of Antisaccade Eye Movements in First-Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644990</td><td>Euctr (2006)</td><td>Six week, double-blind, placebo controlled Phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645422</td><td>Euctr (2007)</td><td>Quetiapine induced neuroplasticity in schizophrenic patients: a combined TMS and VBM study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648143</td><td>Euctr (2007)</td><td>CLOZAPINA EN PRIMEROS BROTES DE ESQUIZOFRENIA COMO POSIBLE TRATAMIENTO PREVENTIVO DEL DETERIORO CEREBRAL Y CLINICO</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645349</td><td>Euctr (2009)</td><td>A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648182</td><td>Euctr (2009)</td><td>Clinical and neuropsychological factors associated with second generation antipsychotic response in patients diagnosed with first episode of early onset schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648698</td><td>Euctr (2010)</td><td>Add-on Therapie mit Omega-3 Fetts√§uren bei Jugendlichen mit hohem Risiko f√ºr Schizophrenie und andere psychotische St√∂rungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomatic Patients at Ultra-High Risk for Early Progression to Schizophrenia and Other Psychotic Disorders: a Multicentre Replication Study - Omega-3 fatty acids for indicated prevention of psychotic disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645922</td><td>Euctr (2012)</td><td>Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647122</td><td>Euctr (2012)</td><td>Experimental study in humans to evaluate the efficacy of continual treatment compared to discontinuation based in the presence of early symthoms in a first episode of non-affective psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646969</td><td>Euctr (2013)</td><td>A four-week clinical trial investigating efficacy and safety of cannabidiol as a treatment for acutely ill schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647155</td><td>Euctr (2014)</td><td>Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647345</td><td>Euctr (2014)</td><td>Effectiveness of tolcapone in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647389</td><td>Euctr (2014)</td><td>Effectivenes of second generation antipsychotics in first episode psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647942</td><td>Euctr (2014)</td><td>Comparison of treatment with inhaled loxapine and an injected drug to treat patients with schizophrenia or bipolar disorder and who are seriously agitated</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644744</td><td>Euctr (2017)</td><td>This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646117</td><td>Euctr (2017)</td><td>A neuro-imaging study on the role of fatty acids in cognition</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646842</td><td>Euctr (2017)</td><td>HAMLETT. Handling Antipsychotic Medication: long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuation/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646448</td><td>Euctr (2018)</td><td>Liraglutide and the management of overweight and obesity in people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644640</td><td>Euctr (2020)</td><td>A Trial of Psilocybin in Clinical Depression Resistant to Standard Treatments</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644695</td><td>Euctr (2020)</td><td>Treating Anxiety to PrevEnt Relapse in Psychosis (TAPERS): a feasibility trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648610</td><td>Euctr (2020)</td><td>Antidepressant for the prevention of DEPression following first episode Psychosis trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644872</td><td>eudract_number (2014)</td><td>A study of PQ912 in patients with Alzheimer's Disease</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645731</td><td>eudract_number (2015)</td><td>A phase III safety and efficacy study of ALZT-OP1 in subjects with evidence of early Alzheimer‚Äôs disease</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633680</td><td>Evans (1972)</td><td>Premorbid Adjustment, Phenothiazine Treatment, and Remission in Acute Schizophrenics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633761</td><td>Evans (1973)</td><td>Premorbid Adjustment, Paranoid Diagnosis, and Remission: Acute Schizophrenics Treated in a Community Mental Health Center</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646084</td><td>Evcimen (2007)</td><td>Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647902</td><td>Evensen (2011)</td><td>Contrasting monosymptomatic patients with hallucinations and delusions in first-episode psychosis patients: A five-year longitudinal follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646984</td><td>Evensen (2012)</td><td>Flat affect and social functioning: A 10 year follow-up study of first episode psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647131</td><td>Examining the effect... (2020)</td><td>Examining the effect of a mindfulness based program for the improvement of cognitive function in an early stage of schizophrenia. A random controlled trial</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647125</td><td>Exercise as an intervention... (2018)</td><td>Exercise as an intervention for first-episode psychosis: a feasibility study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646082</td><td>Ey (1975)</td><td>Neuroleptics and hospital psychiatric units</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646801</td><td>Faay (2020)</td><td>Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647310</td><td>Faber (2012)</td><td>The effects of guided discontinuation of antipsychotics on neurocognition in first onset psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647907</td><td>Faber (2012)</td><td>Continued cannabis use and outcome in first-episode psychosis: data from a randomized, open-label, controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647493</td><td>Fachim (2021)</td><td>Early-life stress effects on BDNF DNA methylation in first-episode psychosis and in rats reared in isolation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645229</td><td>Faerden (2018)</td><td>Reliability and validity of the self-report version of the apathy evaluation scale in first-episode psychosis: Concordance with the clinical version at baseline and 12 months follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647288</td><td>Fagerlund (2003)</td><td>Effects of risperidone and zuclopenthixol on cognitive deficits in drug-naive first episode schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647307</td><td>Fagerlund (2004)</td><td>Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646943</td><td>Fahira (2020)</td><td>Functional annotation of regulatory single nucleotide polymorphisms associated with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645954</td><td>Fahndrich (1986)</td><td>On the course of first-time schizophrenic disorders: A five-year catamnestic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648011</td><td>Faiola (2018)</td><td>Combining trait and state model systems of psychosis: The effect of sleep deprivation on cognitive functions in schizotypal individuals</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633913</td><td>Falkai (2005)</td><td>World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: Long-term treatment of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633940</td><td>Falkai (2006)</td><td>Diretrizes da Federa√ß√£o Mundial das Sociedades de Psiquiatria Biol√≥gica para o tratamento biol√≥gico da esquizofrenia. Parte 1: tratamento agudo</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648369</td><td>Falkai (2010)</td><td>Biomarkers, population-based studies and a proof of principle investigation in pharmacotherapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647195</td><td>Falkai (2014)</td><td>Enhancing Schizophrenia prevention and recovery through innovative treatments - a new network approach in Germany</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644462</td><td>Fallu (1998)</td><td>A young man with first-episode psychosis: Case presentation and discussion</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647075</td><td>Family burden in the... (2018)</td><td>Family burden in the us raiseetp program: treatment effects and predictors</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647211</td><td>Fan (2015)</td><td>Elevated serum homocysteine levels in first-episode drug-native patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647406</td><td>Fan (2017)</td><td>Effect of risperidone on serum homocysteine levels in first-episode, drug-na√Øve patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646559</td><td>Fang (2018)</td><td>Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648742</td><td>Fang (2021)</td><td>Abnormal regional homogeneity (ReHo) and fractional amplitude of low frequency fluctuations (fALFF) in first-episode drug-naive schizophrenia patients comorbid with depression</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646861</td><td>Fanning (2012)</td><td>Group cognitive behavioural therapy for first episode psychosis: Who's referred, who attends and who completes it?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647048</td><td>Fannon (2000)</td><td>Features of structural brain abnormality detected in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645063</td><td>Fannon (2003)</td><td>Selective Deficit of Hippocampal N-Acetylaspartate in Antipsychotic-Naive Patients with Schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634170</td><td>Faragher (2011)</td><td>early schizophrenia: acute-phase outcomes Randomised controlled trial of cognitive‚Äîbehavioural therapy in</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633863</td><td>Faraone (1989)</td><td>Neuroleptic nonresponse and affective symptoms: A 2-year prospective study of schizophrenic outpatients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648410</td><td>Farhang (2020)</td><td>Azeri recent onset acute phase psychosis survey (Aras Cohort): Preliminary reports from an observational cohort of first episode psychosis in iran</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646172</td><td>Faria (2021)</td><td>Multimodal MRI assessment for first episode psychosis: A major change in the thalamus and an efficient stratification of a subgroup</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646320</td><td>Faridi (2012)</td><td>Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633763</td><td>Farmer (1993)</td><td>Drug Treatment of Resistant Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648577</td><td>Farmer (2010)</td><td>Antipsychotic medications and their use in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645757</td><td>Farooq (2015)</td><td>Pharmacological interventions for acute and transient psychotic disorder (ATPD)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645009</td><td>Farooq (2019)</td><td>Sharing information about diagnosis and outcome of first-episode psychosis in patients presenting to early intervention services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648196</td><td>Fatemi (2006)</td><td>Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DMA Microarray Technique</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646087</td><td>Favre (1997)</td><td>Neuroleptic compliance in a cohort of first episode schizophrenics: A naturalistic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648216</td><td>Fedyszyn (2011)</td><td>Characteristics of suicide attempts in young people undergoing treatment for first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634301</td><td>Fei (2021)</td><td>Global research on cognitive behavioural therapy for schizophrenia from 2000 to 2019: a bibliometric analysis via CiteSpace</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647904</td><td>Feigenson (2014)</td><td>Contour integration impairment in schizophrenia and first episode psychosis: State or trait?</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648679</td><td>Fekadu (2013)</td><td>Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644985</td><td>Fekih-Romdhane (2020)</td><td>Sleep in first-episode schizophrenia patients, their unaffected siblings and healthy controls: A comparison</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633538</td><td>Fenton (1987)</td><td>Sustained remission in drug-free schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633529</td><td>Fenton (2007)</td><td>Thioridazine for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644651</td><td>Ferentinos (2003)</td><td>Treatment-resistant schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644569</td><td>Ferentinos (2017)</td><td>Validating a two-dimensional bipolar spectrum model integrating DSM-5's mixed features specifier for Major Depressive Disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645485</td><td>Fernanda (2020)</td><td>Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648321</td><td>Fernandes (2016)</td><td>C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: Meta-analysis and implications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644723</td><td>Fernandes (2018)</td><td>Tobacco use decreases visual sensitivity in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646671</td><td>Fern√°ndez-Abascal (2021)</td><td>In- and outpatient lifestyle interventions on diet and exercise and their effect on physical and psychological health: a systematic review and meta-analysis of randomised controlled trials in patients with schizophrenia spectrum disorders and first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647742</td><td>Fernandez-Egea (2013)</td><td>Diabetes or prediabetes in newly diagnosed patients with nonaffective psychosis? A historical and contemporary view</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646038</td><td>Fernandez-Gonzalo (2015)</td><td>A new computerized cognitive and social cognition training specifically designed for patients with schizophrenia/schizoaffective disorder in early stages of illness: a pilot study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644729</td><td>Ferrara (2020)</td><td>The timing of first help-seeking attempt in first episode psychosis can lead to aversive pathways to care. results from the step-ed study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647026</td><td>Ferrara (2021)</td><td>First help-seeking attempt before and after psychosis onset: measures of delay and aversive pathways to care</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645297</td><td>Ferrarelli (2017)</td><td>Reduced sleep spindle activity point to a TRN-MD thalamus-PFC circuit dysfunction in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646923</td><td>Ferrari (2018)</td><td>Gender differences in pathways to care for early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645331</td><td>Ferraro (2020)</td><td>"Real world" clinical effectiveness of paliperidone palmitate 3-monthly injectable in early psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644753</td><td>Ferreira (2007)</td><td>Therapeutic interventions for sleep disorders in Parkinson's disease</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644796</td><td>Ferreira (2020)</td><td>A systematic review of tobacco use in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645529</td><td>Ferrer-Quintero (2020)</td><td>Profiles of social cognition and metacognition in first-episode psychosis: A latent profile analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633929</td><td>Fervaha (2013)</td><td>Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646202</td><td>Fervaha (2015)</td><td>Motivational deficits in early schizophrenia: Prevalent, persistent, and key determinants of functional outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646472</td><td>Fett (2016)</td><td>Learning to trust: Trust and attachment in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646123</td><td>Fett (2019)</td><td>The neural mechanisms of social reward in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648299</td><td>Filippini (2019)</td><td>Cannabis and cannabinoids for people with multiple sclerosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646005</td><td>Firth (2018)</td><td>Nutritional deficiencies and clinical correlates in first-episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646008</td><td>Firth (2018)</td><td>Nutrient deficits and clinical correlates in first episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646009</td><td>Firth (2018)</td><td>Nutrient deficiencies and potential benefits of nutritional interventions in early psychosis: Systematic development of a targeted adjunctive treatment for improving recovery</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648682</td><td>Firth (2018)</td><td>Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647126</td><td>Fisher (2020)</td><td>Exercise as a protective mechanism against the negative effects of oxidative stress in first-episode psychosis: a biomarker-led study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647765</td><td>Fisher (2020)</td><td>Designing a feasible exercise intervention in first-episode psychosis: exercise quality, engagement and effect</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>61634220</td><td>Fishman (2020)</td><td>Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648056</td><td>Fitzgerald (2004)</td><td>Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646990</td><td>Five years of specialised... (2017)</td><td>Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646289</td><td>Flatow (2013)</td><td>Meta-analysis of oxidative stress in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633601</td><td>Fleischhacker (1993)</td><td>Die medikamenteninduzierte Akathisie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633892</td><td>Fleischhacker (1993)</td><td>Classical antipsychotics in the treatment of negative symptoms</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633960</td><td>Fleischhacker (1995)</td><td>New drugs for the treatment of schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647019</td><td>Fleischhacker (2002)</td><td>The first-episode of schizophrenia: A challenge for treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647166</td><td>Fleischhacker (2005)</td><td>The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648160</td><td>Fleischhacker (2010)</td><td>Clinical predictors of response/remission in antipsychotic-naive first episode patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646554</td><td>Fleischhacker (2012)</td><td>Interpreting treatment trials in schizophrenia patients: Lessons learned from EUFEST</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646276</td><td>Fleischhacker (2013)</td><td>Metabolic risk factors in first-episode schizophrenia: Baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646396</td><td>Fleischhacker (2013)</td><td>Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633784</td><td>Flowers (1997)</td><td>Are All Neuroleptics Equal, Or Are Some More Equal Than Others?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646077</td><td>Flyckt (1999)</td><td>Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648751</td><td>Flyckt (2001)</td><td>Aberrant tyrosine transport across the cell membrane in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648004</td><td>Focking (2011)</td><td>Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646509</td><td>Foley (2007)</td><td>Is violence at presentation by patients with first-episode psychosis associated with duration of untreated psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634109</td><td>Fonagy (2018)</td><td>Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645507</td><td>Fond (2015)</td><td>The promise of biological markers for treatment response in first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645668</td><td>Fond (2016)</td><td>Potentially inappropriate psychotropic prescription at discharge is associated with lower functioning in the elderly psychiatric inpatients. A cross-sectional study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645128</td><td>Fond (2020)</td><td>The Role of Inflammation in the Treatment of Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648147</td><td>Forbes (2019)</td><td>The clinical utility of structural neuroimaging in first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648149</td><td>Forbes (2019)</td><td>The clinical utility of brain imaging (computed tomography and magnetic resonance imaging) in first episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645321</td><td>Forester (2004)</td><td>Recognition and Management of Late-Life Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646892</td><td>Fortea (2020)</td><td>Glutamatergic metabolites in the psychosis spectrum: From high risk samples to first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647874</td><td>Fortea (2021)</td><td>Cortical gray matter reduction precedes transition to psychosis in individuals at clinical high-risk for psychosis: A voxel-based meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648067</td><td>Fortgang (2020)</td><td>Cognitive effort and amotivation in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645112</td><td>Forti (2019)</td><td>SA61CAN DNA METHYLATION PROFILING SHED LIGHT ON THE BIOLOGY OF CANNABIS ASSOCIATED PSYCHOSIS? PRELIMINARY DATA ON THE EWAS CANNABIS USE SIGNATURE IN THE EUGEI CASE-CONTROL STUDY</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645723</td><td>Fouhy (2020)</td><td>Physical health interventions for patients who have experienced a first episode of psychosis: a narrative review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646001</td><td>Fountoulakis (2010)</td><td>Obesity and smoking in patients with schizophrenia and normal controls: A case-control study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645215</td><td>Fountoulakis (2020)</td><td>The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645942</td><td>Fountoulakis (2020)</td><td>One-year Outcome of First vs. Later Episode Schizophrenia: A Real-world Naturalistic Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646094</td><td>Fountoulakis (2020)</td><td>Neurocognitive impairment and evidence-based treatment options in Bipolar disorder</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645310</td><td>Fournier (2017)</td><td>Redox dysregulation in schizophrenia pathophysiology: add-on trial with N-acetyl-cysteine (NAC) in early psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644719</td><td>Fournier (2020)</td><td>Topology predicts long-term functional outcome in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648090</td><td>Fowler (2009)</td><td>Cognitive behaviour therapy for improving social recovery in psychosis: A report from the ISREP MRC trial platform study (Improving Social Recovery in Early Psychosis)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>59644956</td><td>Fowler (2018)</td><td>Social recovery therapy in combination with early intervention services for enhancement of social recovery in patients with first-episode psychosis (SUPEREDEN3): a single-blind, randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644955</td><td>Fowler (2019)</td><td>Social Recovery Therapy in improving activity and social outcomes in early psychosis: current evidence and longer term outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646785</td><td>Fowler (2019)</td><td>Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645190</td><td>Fowler (2020)</td><td>Results of the hummingbird study a multicentre, pragmatic trial of a digital medicine system</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645872</td><td>Fowler (2020)</td><td>P.470 A multicentre, pragmatic trial of a digital medicine system: results of the hummingbird study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646784</td><td>Fowler (2021)</td><td>Hummingbird Study: Results from an Exploratory Trial Assessing the Performance and Acceptance of a Digital Medicine System in Adults with Schizophrenia, Schizoaffective Disorder, or First-Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633555</td><td>Fowles (1984)</td><td>Biological Variables in Psychopathology</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633517</td><td>Fowles (2002)</td><td>Biological variables in psychopathology: A psychobiological perspective.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647844</td><td>Fox (2004)</td><td>Cresting</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645855</td><td>Fragoeiro (2020)</td><td>P.774 Olfactory reference syndrome as a prodrome of Alzheimer disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645886</td><td>Fraguas (2017)</td><td>Oxidative Stress and Inflammation in Early Onset First Episode Psychosis: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645885</td><td>Fraguas (2019)</td><td>Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645130</td><td>Fraguas (2021)</td><td>The role of depression in the prediction of a ‚Äúlate‚Äù remission in first-episode psychosis: an analysis of the OPTiMiSE study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646348</td><td>Frajerman (2020)</td><td>Management of cardiovascular co-morbidities in young patients with early onset psychosis: State of the art and therapeutic perspectives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646916</td><td>Frajman (2020)</td><td>Gene expression meta-analysis reveals the down-regulation of three GABA receptor subunits in the superior temporal gyrus of patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644479</td><td>Francey (2010)</td><td>Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>59645004</td><td>Francey (2012)</td><td>Should antipsychotic medication always be given for firstepisode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>59648534</td><td>Francey (2012)</td><td>"Antipsychotics: Is it time to introduce patient choice?": Comment</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645358</td><td>Francey (2016)</td><td>A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first episode psychosis with low-risk of self-harm or aggression. The STAGES study: staged treatment and acceptability guidelines in early psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648580</td><td>Francey (2018)</td><td>Antipsychotic medication in first-episode psychosis: an RCT to assess the risk-benefit ratio</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>61633355</td><td>Francey (2020)</td><td>Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59646834</td><td>Francis (2017)</td><td>High frequency repetitive transcranial magnetic stimulation for cognitive impairment in early-phase psychosis: a pilot study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648071</td><td>Francis (2018)</td><td>Cognitive effects of bilateral high frequency repetitive transcranial magnetic stimulation in early phase psychosis: a pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647312</td><td>Francis (2020)</td><td>Effects of fingolimod, a sphingosine-1-phosphate (S1P) receptor agonist, on white matter microstructure, cognition and symptoms in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633831</td><td>Franck (2005)</td><td>Modalit√©s d'utilisation des neuroleptiques</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644463</td><td>Franco (2020)</td><td>Young Adults With Psychotic Disorders Have Similar Access to Technology and Social Media but May Be Less Active in Posting Than Clinical Risk and Psychosis-Free Peers</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633836</td><td>Frankenburg (1999)</td><td>Choices in antipsychotic therapy in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646678</td><td>Fredrikson (2014)</td><td>Improving metabolic and cardiovascular health at an early psychosis intervention program in Vancouver, Canada</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633999</td><td>Freed (1982)</td><td>Criteria for ruling out sedation as an interpretation of neuroleptic effects</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633850</td><td>Freed (1989)</td><td>An hypothesis regarding the antipsychotic effect of neuroleptic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633829</td><td>Freed (1994)</td><td>Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645489</td><td>Freedman (2012)</td><td>Pseudo-ADHD in a case of first-episode schizophrenia: Diagnostic and treatment challenges</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647173</td><td>Freedman (2019)</td><td>Ethical considerations in prenatal nutritional interventions for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646441</td><td>Freeman (1998)</td><td>The London-East Anglia randomized controlled trial of cognitive-behaviour therapy for psychosis. IV: self-esteem and persecutory delusions</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633975</td><td>Freyhan (1959)</td><td>THERAPEUTIC IMPLICATIONS OF DIFFERENTIAL EFFECTS OF NEW PHENOTHIAZINE COMPOUNDS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634172</td><td>Friedman (2005)</td><td>CHAPTER M1 ‚Äì Drug-Induced Movement Disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648217</td><td>Friedman (2021)</td><td>Characteristics of Hispanics Referred to Coordinated Specialty Care for First-Episode Psychosis and Factors Associated With Enrollment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648174</td><td>Froscher (2020)</td><td>Clinical characteristics of forced normalization and alternative psychosis with special consideration of the new anticonvulsants</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645527</td><td>Frydecka (2018)</td><td>Profiling inflammatory signatures of schizophrenia: A cross-sectional and meta-analysis study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647799</td><td>Fryer (2013)</td><td>Deficient suppression of default mode regions during working memory in individuals with early psychosis and at clinical high-risk for psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648020</td><td>Fu (2019)</td><td>Cognitive, work and social outcomes in fully recovered first-episode schizophrenia: On and off antipsychotic medication</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648015</td><td>Fujiyama (2020)</td><td>Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646114</td><td>Fusar-Poli (2012)</td><td>Neuroanatomical maps of psychosis onset: Voxel-wise meta-analysis of antipsychotic naive VBM studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645524</td><td>Fusar-Poli (2016)</td><td>Prognosis of brief psychotic episodes a meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647739</td><td>Fusar-Poli (2016)</td><td>Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646676</td><td>Fusar-Poli (2017)</td><td>Improving outcomes of first-episode psychosis: An overview</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646580</td><td>Fusar-Poli (2019)</td><td>Integrated Mental Health Services for the Developmental Period (0 to 25 Years): A Critical Review of the Evidence</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645328</td><td>Fusar-Poli (2020)</td><td>Real-World Clinical Outcomes Two Years After Transition to Psychosis in Individuals at Clinical High Risk: Electronic Health Record Cohort Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645304</td><td>Fuste (2013)</td><td>Reduced expression of SP1 and SP4 transcription factors in peripheral blood mononuclear cells in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645602</td><td>Gade (2013)</td><td>Predictors of symptomatic remission in first-episode psychosis outpatients treated with quetiapine: A naturalistic study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634077</td><td>Gaebel (1981)</td><td>[Predictors of the course of schizophrenic diseases under neuroleptic long-term medication (author's transl)].</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633866</td><td>Gaebel (1985)</td><td>Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633605</td><td>Gaebel (1995)</td><td>Grundlagen und Strategien neuroleptischer Rezidivprophylaxe ‚Äî unter besonderer Ber√ºcksichtigung der neuroleptischen Intervallbehandlung</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633603</td><td>Gaebel (1998)</td><td>Stellenwert und Grenzen klassischer Neuroleptika in der Langzeittherapie schizophrener Erkrankungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647024</td><td>Gaebel (2002)</td><td>First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645752</td><td>Gaebel (2004)</td><td>Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633561</td><td>Gaebel (2006)</td><td>Aktuelle Aspekte der Langzeittherapie bei Schizophrenie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645174</td><td>Gaebel (2007)</td><td>Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646352</td><td>Gaebel (2007)</td><td>Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German research network on schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648783</td><td>Gaebel (2009)</td><td>2 year follow-up of withdrawal of antipsychotics in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646558</td><td>Gaebel (2010)</td><td>Intermittent treatment in the second year after a first episode in schizophrenia. Results from the German Research Network on Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647605</td><td>Gaebel (2010)</td><td>Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST)</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645278</td><td>Gaebel (2011)</td><td>Relapse prevention in first-episode schizophrenia--maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645339</td><td>Gaebel (2014)</td><td>Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645636</td><td>Gaebel (2015)</td><td>Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647539</td><td>Gaebel (2016)</td><td>Early medication discontinuation in first episode schizophrenia-Beneficial or risky?</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647179</td><td>Gafoor (2010)</td><td>Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646762</td><td>Gagen (2019)</td><td>Identifying latent groups of individuals with first episode psychosis based on social relationships: A reconsideration of social functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647008</td><td>Gahr (2017)</td><td>First-episode psychosis possibly due to roxithromycin-related inhibition of metabolization of tetrahydrocannabinol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645803</td><td>Gairns (2015)</td><td>Perceptions of clinicians treating young people with first-episode psychosis for post-traumatic stress disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646794</td><td>Gaisler-Salomon (2009)</td><td>How high-resolution basal-state functional imaging can guide the development of new pharmacotherapies for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646729</td><td>Gajsak (2017)</td><td>Impact of stress response in development of first-episode psychosis in schizophrenia: An overview of systematic reviews</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633705</td><td>Galbrecht (1968)</td><td>Pentothal-activated changes in the EEG of schizophrenic patients: response to phenothiazine therapy and relationship to selected patient variables.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647882</td><td>Galderisi (2009)</td><td>Correlates of cognitive impairment in first episode schizophrenia: The EUFEST study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645790</td><td>Galderisi (2013)</td><td>Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61633666</td><td>Galdi (1981)</td><td>Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633797</td><td>Galdi (1981)</td><td>Common genetic mechanisms in alcoholism and psychiatric disorders: negative evidence from a study of ethnic group patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633965</td><td>Galdi (1983)</td><td>The causality of depression in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647146</td><td>Gale (2008)</td><td>Evidence for the effectiveness of therapeutic community treatment of the psychoses</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644555</td><td>Galeazzi (2006)</td><td>Views on psychosis and judgment of appropriateness of early interventions in pre-psychotic phase: A survey of members of the International Early Psychosis Association</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645493</td><td>Galinska-Skok (2019)</td><td>Proton magnetic resonance spectroscopy changes in a longitudinal schizophrenia study: A pilot study in eleven patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646406</td><td>Gallardo-Ruiz (2019)</td><td>Long-Term Grey Matter Changes in First Episode Psychosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644732</td><td>Gallego (2011)</td><td>Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645832</td><td>Gallego (2012)</td><td>Partial adherence to antipsychotic treatment and return of positive symptoms in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646317</td><td>Galletly (2018)</td><td>Medication discontinuation in first episode psychosis: Thinking about the offset of psychotic disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647368</td><td>Galling (2018)</td><td>Effectiveness of coordinated specialty care for early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647369</td><td>Galling (2018)</td><td>Effectiveness of coordinated specialty care for early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Tiril Borge</span></td><td></td></tr><tr><td>59645676</td><td>Galliot (2019)</td><td>[Post-traumatic stress disorder in reaction to psychotic experience: A systematic revue]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647210</td><td>Gama (2006)</td><td>Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: A study of patients treated with haloperidol or clozapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647897</td><td>Gan (1999)</td><td>A control study of risperidone and clozapine in the treatment of first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648422</td><td>Gan (2014)</td><td>Atypical antipsychotic drug treatment for 6 months restores N-acetylaspartate in left prefrontal cortex and left thalamus of first-episode patients with early onset schizophrenia: A magnetic resonance spectroscopy study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646833</td><td>Gan (2021)</td><td>High frequency repetitive transcranial magnetic stimulation of dorsomedial prefrontal cortex for negative symptoms in patients with schizophrenia: a double-blind, randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645230</td><td>Gangdev (2004)</td><td>Relevance of sleep paralysis and hypnic hallucinations to psychiatry</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645543</td><td>Ganguli (2014)</td><td>Prevention of weight gain in early psychosis: a randomized controlled clinical trial of a stepped behavioral intervention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647274</td><td>Gao (2020)</td><td>Effects on social functioning and metabolism in the patients with first-episode schizophrenia: Aipiprazole vs risperidone</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634041</td><td>Garbutt (1983)</td><td>The Interaction Between GABA and Dopamine: Implications for Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645867</td><td>Garcia (2020)</td><td>P.510 First episode psychosis and migration: an observational study in a portuguese acute patient unit</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648705</td><td>Garcia-Andrade (2015)</td><td>Acute treatment of Cycloid Psychosis: Study on a sample of naive hospitalized patients with First-Episode Psychosis (FEP)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647049</td><td>Garcia-Jimenez (2020)</td><td>Features Associated With Depressive Predominant Polarity and Early Illness Onset in Patients With Bipolar Disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645852</td><td>Garcia-Portilla (2020)</td><td>P.848Functionality in patients with newly diagnosed schizophrenia treated with paliperidone palmitate 3-month formulation in real-world clinical practice study (TIME study)</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644789</td><td>Garcia-Ribera (2010)</td><td>Tardive dyskinesia and other movement disorders in first episode schizophrenic patients treated with second generation antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644790</td><td>Garcia-Ribera (2010)</td><td>Tardive dyskinesia among patients being treated for a first episode of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648367</td><td>Garcia-Rizo (2020)</td><td>Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647998</td><td>Gardizi (2019)</td><td>Comparability of the WCST and WCST-64 in the assessment of first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646660</td><td>Gardner (2015)</td><td>Incidence of oculogyric crisis and long-term outcomes with second-generation antipsychotics in a first-episode psychosis program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633874</td><td>Gardos (1973)</td><td>The importance of dosage in antipsychotic drug administration--a review of dose-response studies.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647525</td><td>Garety (2001)</td><td>Early psychosis in the inner city: A survey to inform service planning</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644939</td><td>Garety (2006)</td><td>"Specialised care for early psychosis: Symptoms, social functioning and patient satisfaction: Randomised controlled trial": Corrigenda</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646494</td><td>Garip (2019)</td><td>l-arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645853</td><td>Garip (2020)</td><td>P.841QTc changes in the management of SARS-CoV-2 infection in patents schizophrenia spectrum disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647025</td><td>Garlow (2010)</td><td>The first time is best: highest remission rate to SSRI antidepressant in first episode of treatment for depression</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645710</td><td>Garner (2009)</td><td>Pituitary volume and early treatment response in drug-naive first-episode psychosis patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648605</td><td>Garner (2016)</td><td>Antiglucocorticoid and related treatments for psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648447</td><td>Gasso (2020)</td><td>Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646405</td><td>Gastal (2010)</td><td>Long-term impact of the diagnostic announcement on the insight of patients suffering from schizophrenic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647836</td><td>Gattaz (1988)</td><td>CT scans and neuroleptic response in schizophrenia: A multidimensional approach</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645775</td><td>Gau (2008)</td><td>A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633522</td><td>Gaudiano (2015)</td><td>Acceptance-based Behavior Therapy for Depression With Psychosis: Results From a Pilot Feasibility Randomized Controlled Trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634236</td><td>Gaudiano (2020)</td><td>Feasibility and Preliminary Effects of Implementing Acceptance and Commitment Therapy for Inpatients With Psychotic-Spectrum Disorders in a Clinical Psychiatric Intensive Care Setting.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645692</td><td>Gaugain (2020)</td><td>PND34 Comparison of Antipsychotic Treatment Sequences for the Management of Schizophrenia in France: A Cost-Effectiveness Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647431</td><td>Gaughran (2019)</td><td>Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: Prospective cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644543</td><td>Gaughran (2020)</td><td>Vitamin D supplementation compared to placebo in people with First Episode psychosis - Neuroprotection Design (DFEND): a protocol for a randomised, double-blind, placebo-controlled, parallel-group trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648378</td><td>Gauthier (2008)</td><td>Between narratives: Investigate the clinical encounter in the early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646717</td><td>Gaweda (2018)</td><td>Impaired action self-monitoring and cognitive confidence among ultra-high risk for psychosis and first-episode psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646173</td><td>Gawne (2020)</td><td>A multimodal magnetoencephalography 7 T fMRI and 7 T proton MR spectroscopy study in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644957</td><td>Gayer-Anderson (2013)</td><td>Social networks, support and early psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647980</td><td>Gayer-Anderson (2020)</td><td>A comparison between self-report and interviewer-rated retrospective reports of childhood abuse among individuals with first-episode psychosis and population-based controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646862</td><td>Gaynor (2011)</td><td>Group cognitive behavioural therapy as a treatment for negative symptoms in first-episode psychosis</td><td>(I) Included</td><td></td><td><span >Tiril Borge</span></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>61633540</td><td>Ge (1976)</td><td>Drug discontinuation among long term, successfully maintained schizophrenic outpatients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633535</td><td>Ge (1984)</td><td>Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646324</td><td>Gearing (2009)</td><td>Medication adherence for children and adolescents with first-episode psychosis following hospitalization</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645650</td><td>Geddes (1994)</td><td>Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634141</td><td>Geddes (2005)</td><td>Large simple trials in psychiatry: providing reliable answers to important clinical questions.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646897</td><td>Geddes (2014)</td><td>GluN2B protein deficits in the left, but not the right, hippocampus in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648425</td><td>Geerts (2013)</td><td>Attitudes towards the administration of long-acting antipsychotics: A survey of physicians and nurses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645039</td><td>Gehrmann (2019)</td><td>Serum level measurements optimize aripriprazole treatment in adolescent patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633677</td><td>Gelder (1979)</td><td>Variability of response to neuroleptics in schizophrenia: clinical, pharmacologic, and neuroendocrine correlates.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645759</td><td>Geller (2010)</td><td>Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648505</td><td>Geng (2017)</td><td>Arginine vasopressin improves the memory deficits in Han Chinese patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645106</td><td>Gentile (2017)</td><td>Safety concerns associated with second-generation antipsychotic long-acting injection treatment. A systematic update</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647747</td><td>Geoffroy (2016)</td><td>The developmental course of suicidal ideation in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645948</td><td>George (2009)</td><td>One ace and three faults don't win the set</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648228</td><td>Gergerlioglu (2007)</td><td>Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644859</td><td>Gerlach (1999)</td><td>Subjective experience and mental side-effects of antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634093</td><td>German (1982)</td><td>Dopamine neurons, reward and behavior</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634242</td><td>Germeys (2021)</td><td>Efficacy of Acceptance and Commitment Therapy in Daily Life (Act-Dl) in Early Psychosis: Results from the Multi-Centre Interact Randomized Controlled Trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644899</td><td>Gerritsen (2019)</td><td>Stress precedes negative symptom exacerbations in clinical high risk and early psychosis: A time-lagged experience sampling study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633959</td><td>Gervasoni (2010)</td><td>Early telephone intervention for psychiatric outpatients starting antidepressant treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646032</td><td>Gharabawi (2006)</td><td>New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol...Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G, Early Psychosis Global Working Group: risperidone and haloperidol in first-episode psychosis: a long-term randomized trial Am J Psychiatry 2005; 162: 947-953</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646033</td><td>Gharabawi (2006)</td><td>New-Onset Tardive Dyskinesia in Patients With First-Episode Psychosis Receiving Risperidone or Haloperidol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645535</td><td>Ghio (2012)</td><td>Process of implementation and development of early psychosis clinical services in Italy: A survey</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646599</td><td>Ghosh (2018)</td><td>The influence of unmeasured confounding effects in a study of antipsychotic discontinuation in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634138</td><td>Gianfrancesco (2019)</td><td>Treating the ‚ÄúE‚Äù in ‚ÄúG √ó E‚Äù: Trauma-Informed Approaches and Psychological Therapy Interventions in Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633731</td><td>Gibb (1986)</td><td>The clinical phenomenon of akathisia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633958</td><td>Gibbons (1985)</td><td>An Empirical Test of a Kraepelinian vs. a Bleulerian View of Negative Symptoms</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645010</td><td>Gibbs (2008)</td><td>Sexually dimorphic changes in the amygdala in relation to delusional beliefs in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648758</td><td>Gibbs (2018)</td><td>42.4 Interventions to Engage and Support the Family System</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645454</td><td>Giblin (2004)</td><td>Psychosocial correlates of late-onset psychosis: Life experiences, cognitive schemas, and attitudes to ageing</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646565</td><td>Giegling (2010)</td><td>Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644954</td><td>Giegling (2011)</td><td>Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648261</td><td>Giggie (2021)</td><td>Catatonia in a 10-year-old boy with early childhood neglect and disruptive behaviours in psychiatric residential treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644554</td><td>Gil (2018)</td><td>Violence in first-episode psychosis patients: What do we know?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633610</td><td>Gilbert (1995)</td><td>Neuroleptic withdrawal in schizophrenic patients. A review of the literature.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646397</td><td>Gilden (2020)</td><td>Long-Term Outcomes of Postpartum Psychosis: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647284</td><td>Gilleen (2021)</td><td>The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645029</td><td>Gilmer (2020)</td><td>Service use following first-episode schizophrenia among commercially insured youth</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648419</td><td>Ginsberg (2003)</td><td>Atypical neuroleptics enhance nerve growth factor</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644783</td><td>Giongo (2020)</td><td>Taurine does not prevent social deficits induced by MK-801 in adult zebrafish</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634174</td><td>Girardi (2014)</td><td>Assessment of self-disturances in high risk adolescents and clinical controls: preliminary findings from a multicentre psychosis prevention programme.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645148</td><td>Girgis (2006)</td><td>Risperidone in first-episode psychosis: A longitudinal, exploratory voxel-based morphometric study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648122</td><td>Girgis (2011)</td><td>Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648493</td><td>Girgis (2011)</td><td>Aripiprazole versus haloperidol treatment in early-stage schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648123</td><td>Girgis (2012)</td><td>"Clozapine v. chlorpromazine in treatment-naive first-episode schizophrenia": Reply</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645350</td><td>Girgis (2018)</td><td>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, An Interleukin-6 Receptor Antibody, For Residual Symptoms in Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647670</td><td>Girshkin (2016)</td><td>Diurnal cortisol variation and cortisol response to an MRI stressor in schizophrenia and bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633541</td><td>Gitlin (1988)</td><td>Persistence of fluphenazine in plasma after decanoate withdrawal.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633916</td><td>Gitlin (2001)</td><td>Clinical Outcome Following Neuroleptic Discontinuation in Patients With Remitted Recent-Onset Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646653</td><td>Gjerde (2018)</td><td>Increase in serum HDL level is associated with less negative symptoms after one year of antipsychotic treatment in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646686</td><td>Gjerde (2020)</td><td>Improvement in verbal learning over the first year of antipsychotic treatment is associated with serum HDL levels in a cohort of first episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647185</td><td>Gleeson (2008)</td><td>The EPISODE II trial of cognitive and family therapy for relapse prevention in early psychosis: rationale and sample characteristics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>61633941</td><td>Gleeson (2008)</td><td>The EPISODE II trial of cognitive and family therapy for relapse prevention in early psychosis: Rationale and sample characteristics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645365</td><td>Gleeson (2009)</td><td>A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>61634178</td><td>Gleeson (2009)</td><td>The Recognition and Management of Early Psychosis: Relapse prevention in early psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644803</td><td>Gleeson (2010)</td><td>A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59647066</td><td>Gleeson (2010)</td><td>Family outcomes from a randomized control trial of relapse prevention therapy in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644693</td><td>Gleeson (2012)</td><td>Treating co-occurring first-episode psychosis and borderline personality: a pilot randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647065</td><td>Gleeson (2012)</td><td>Family outcomes from an RCT of relapse prevention therapy in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645364</td><td>Gleeson (2013)</td><td>A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Tiril Borge</span></td></tr><tr><td>59645108</td><td>Gleeson (2014)</td><td>Safety and privacy outcomes from a moderated online social therapy for young people with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645405</td><td>Gleeson (2014)</td><td>A randomised controlled trial of moderated online social therapy for carers of first-episode psychosis clients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646221</td><td>Gleeson (2017)</td><td>Moderated online social therapy for carers of young people recovering from first-episode psychosis: study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645683</td><td>Gleeson (2020)</td><td>Positive and meaningful lives: Systematic review and meta-analysis of eudaimonic well-being in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647328</td><td>Glenthoj (2000)</td><td>Effects of antipsychotics on information-processing and extrastriatal dopamine d2/d3 receptors in first-episode drug-naive schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648406</td><td>Glenthoj (2007)</td><td>Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646170</td><td>Glentworth (2009)</td><td>Multiple family groups in early psychosis: A brief psychoeducational and therapeutic intervention</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634036</td><td>Glick (1976)</td><td>Short versus long hospitalization: a prospective controlled study. V. One-year follow-up results for nonschizophrenie patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645577</td><td>Glick (1993)</td><td>Premorbid social competence and the effectiveness of early neuroleptic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644653</td><td>Glick (2001)</td><td>Treatment with atypical antipsychotics: New indications and new populations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646250</td><td>Glick (2011)</td><td>Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: A data-driven, personalized clinical approach</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646888</td><td>Glyceryl trinitrate... (2020)</td><td>Glyceryl trinitrate in first episode psychosis unmedicated with antipsychotics: a randomised controlled feasibility study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645129</td><td>Glynn (2015)</td><td>The role of family intervention in coordinated specialty care for first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644477</td><td>Glynn (2018)</td><td>Who participated in family work in the us raise-ETP first episode sample?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645153</td><td>Goff (2004)</td><td>Risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648370</td><td>Goff (2016)</td><td>Biomarkers for drug development in early psychosis: Current issues and promising directions</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648193</td><td>Goff (2018)</td><td>Citalopram in first episode psychosis: the DECIFER trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648454</td><td>Goff (2018)</td><td>Association of hippocampal atrophy with duration of untreated psychosis and molecular biomarkers during initial antipsychotic treatment of first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648192</td><td>Goff (2019)</td><td>Citalopram in first episode schizophrenia: the DECIFER trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634042</td><td>Goghari (2012)</td><td>14:30 EFFECTS OF EIGHT WEEKS OF ATYPICAL ANTI-PSYCHOTIC MEDICATION TREATMENT ON MIDDLE FRONTAL THICKNESS IN DRUG-NA√èVE FIRST EPISODE PSYCHOSIS PATIENTS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647315</td><td>Goghari (2013)</td><td>Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naive first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647572</td><td>Golay (2016)</td><td>Duration of untreated psychosis: Impact of the definition of treatment onset on its predictive value over three years of treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645819</td><td>Golay (2018)</td><td>Patients participating to neurobiological research in early psychosis: A selected subgroup?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634101</td><td>Gold (1984)</td><td>The TRH Test in the Diagnosis of Affective Disorders and Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633868</td><td>Goldberg (1965)</td><td>CHANGES IN SCHIZOPHRENIC PSYCHOPATHOLOGY AND WARD BEHAVIOUR AS A FUNCTION OF PHENOTHIAZINE TREATMENT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633769</td><td>Goldberg (1966)</td><td>Sex and race differences in response to drug treatment among schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633857</td><td>Goldberg (1967)</td><td>Prediction of improvement in schizophrenia under four phenothiazines.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633981</td><td>Goldberg (1972)</td><td>Prediction of response to phenothiazines in schizophrenia. A crossvalidation study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633947</td><td>Goldberg (1985)</td><td>Negative and Deficit Symptoms in Schizophrenia Do Respond to Neuroleptics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648047</td><td>Goldberg (2007)</td><td>Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646493</td><td>Goldberg (2009)</td><td>Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647044</td><td>Goldman (2013)</td><td>Financing first-episode psychosis services in the United States</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645470</td><td>Goldsmith (2015)</td><td>Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variables analysis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645471</td><td>Goldsmith (2015)</td><td>Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: An instrumental variable analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633790</td><td>Goldstein (1966)</td><td>Psychophysiological reactions to films by chronic schizophrenics. I. Effects of drug status.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633804</td><td>Goldstein (1969)</td><td>The differential prediction of response to two anti-psychotic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633977</td><td>Goldstein (1969)</td><td>Psychophysiological and behavioral effects of phenothiazine administration in acute schizophrenics as a function of premorbid status</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634044</td><td>Goldstein (1970)</td><td>Premorbid Adjustment, Paranoid Status, and Patterns of Response to Phenothiazine in Acute Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633893</td><td>Goldstein (1972)</td><td>The stability and sensitivity of measures of thought, perception and emotional arousal</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645021</td><td>Goldstein (2002)</td><td>Sex differences in clinical response to olanzapine compared with haloperidol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633570</td><td>Golier (1996)</td><td>Patterns of Clinical Efficacy for Antipsychotic Drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645122</td><td>Golubchik (2008)</td><td>The role of neurosteroids in development of pediatric psychopathology</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646413</td><td>G√≥mez-Revuelta (2018)</td><td>Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: a 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648559</td><td>Gomez-Revuelta (2020)</td><td>Antipsychotic Treatment effectiveness in First Episode of Psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine and ziprasidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648491</td><td>Gomez-Revuelta (2021)</td><td>Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647641</td><td>Gomis (2017)</td><td>Domiciliary intervention in psychosis: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646113</td><td>Gong (2015)</td><td>A neuroanatomical signature for schizophrenia across different ethnic groups</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645061</td><td>Gong (2016)</td><td>A selective review of cerebral abnormalities in patients with first-episode schizophrenia before and after treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645202</td><td>Gong (2016)</td><td>Response to Sarpal et al.: Importance of neuroimaging biomarkers for treatment development and clinical practice</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646131</td><td>Gong (2017)</td><td>Network-Level Dysconnectivity in Drug-Na√Øve First-Episode Psychosis: dissociating Transdiagnostic and Diagnosis-Specific Alterations</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648736</td><td>Gong (2020)</td><td>Abnormalities of intrinsic regional brain activity in first-episode and chronic schizophrenia: a meta-analysis of resting-state functional MRI</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648324</td><td>Gonul (2004)</td><td>The Broken P300 in Schizophrenia: Can It Be Fixed?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644795</td><td>Gonzalez (2017)</td><td>Systematic review on the efficacy of mushroom preparations as an adjuvant treatment of non-small cell lung cancer. [Spanish]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644509</td><td>Gonzalez (2018)</td><td>What are the main brain changes in fmri after treatment in first episode psychosis? A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646491</td><td>Gonz√°lez-Blanch (2008)</td><td>Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647313</td><td>Gonzalez-Blanch (2010)</td><td>Effects of family psychoeducation on expressed emotion and burden of care in first-episode psychosis: A prospective observational study</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59644959</td><td>Gonzalez-Blanch (2015)</td><td>Social functioning trajectories of young first-episode psychosis patients with and without cannabis misuse: a 30-month follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645870</td><td>Gonzalez-Blanco (2020)</td><td>P.502 Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644861</td><td>Gonzalez-Ortega (2015)</td><td>Subclinical depressive symptoms and continued cannabis use: Predictors of negative outcomes in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648095</td><td>Gonzalez-Ortega (2016)</td><td>Cognitive behavioral therapy program for cannabis use cessation in first-episode psychosis patients: study protocol for a randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645851</td><td>Gonzalez-Ortega (2020)</td><td>P.856Evidence-based psychoeducational program in first psychotic episode patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>61634308</td><td>Gonz√°lez-Ortega (2021)</td><td>A Multicentre, Randomised, Controlled Trial of a Combined Clinical Treatment for First-Episode Psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646656</td><td>Gonzalez-Pinto (2010)</td><td>Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648298</td><td>Gonzalez-Pinto (2011)</td><td>Cannabis and first-episode psychosis: Different long-term outcomes depending on continued or discontinued use</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647590</td><td>Gonzalez-Valderrama (2017)</td><td>Duration of untreated psychosis and acute remission of negative symptoms in a South American first-episode psychosis cohort</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646384</td><td>Gonzalez-Vivas (2019)</td><td>Longitudinal studies of functional magnetic resonance imaging in first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646687</td><td>Good (2002)</td><td>Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: An interim analysis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645240</td><td>Good (2004)</td><td>The relationship of neuropsychological test performance with the PANSS in antipsychotic na√Øve, first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646934</td><td>Goodby (2016)</td><td>Future-directed thinking in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634130</td><td>Goodyer (2016)</td><td>Effectiveness and cost-effectiveness of cognitive behavioural therapy and short-term psychoanalytic psychotherapy compared with brief psychological intervention in maintaining reduced depressive symptoms 12 months after end of treatment in adolescents with unipolar major depression (IMPACT): A pragmatic superiority randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644820</td><td>Gopal (2005)</td><td>Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634207</td><td>Gordon (1967)</td><td>Appendix A ‚Äì Phenothiazine Bibliographies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647664</td><td>Gordon (2011)</td><td>Do all relapses in schizophrenia warrant resumption of medication?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644905</td><td>Gossage-Worrall (2016)</td><td>STEPWISE - STructured lifestyle Education for People WIth SchizophrEnia: a study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644923</td><td>Gotfredsen (2017)</td><td>Stability and development of psychotic symptoms and the use of antipsychotic medication-Long-term follow-up</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646025</td><td>Goto (2010)</td><td>No alterations of brain GABA after 6 months of treatment with atypical antipsychotic drugs in early-stage first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644989</td><td>Goto (2012)</td><td>Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634135</td><td>G√∏tzsche (2016)</td><td>Tvangsmedisinering m√• forbys</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634119</td><td>G√∏tzsche (2017)</td><td>Psychopharmacology Is Not Evidence-Based Medicine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647017</td><td>Goutte (2019)</td><td>[First-episode psychosis as primary manifestation of medical disease: An update]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647770</td><td>Grabb (2016)</td><td>Derisking psychiatric drug development: The NIMH's fast fail program, a novel precompetitive model</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646029</td><td>Grabb (2020)</td><td>The NIMH 'Fast-Fail Trials' (FAST) Initiative: Rationale, Promise, and Progress</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645984</td><td>Graham (1998)</td><td>Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647421</td><td>Graham (2005)</td><td>Effect of Olanzapine on Body Composition and Energy Expenditure in Adults With First-Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647606</td><td>Graham (2005)</td><td>Drs. Graham and Perkins Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647499</td><td>Graham (2008)</td><td>Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634271</td><td>Grahame (1986)</td><td>The Northwick Park Study of First Episodes of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646476</td><td>Granger (2020)</td><td>Latent inhibition and its potential as a biomarker for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647577</td><td>Grano (2010)</td><td>Duration of untreated psychosis is associated with more negative schizophrenia symptoms after acute treatment for first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645193</td><td>Grawe (1998)</td><td>Result of two years optimal out-patient treatment of first episode schizophrenia: a controlled study</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>59646049</td><td>Grawe (2001)</td><td>Neuropsychological impairments in patients with schizophrenia: Stability and prediction of outcome</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633537</td><td>Gray (2001)</td><td>A randomised controlled trial of medication management training for CPNs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634016</td><td>Gray (2001)</td><td>The use of outcome measures to evaluate the efficacy and tolerability of antipsychotic medication: a comparison of Thorn graduate and CPN practice.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633560</td><td>Gray (2013)</td><td>Bayesean Analysis as a Predictor of outcome rate.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644503</td><td>Gray (2016)</td><td>What is it like to take antipsychotic medication? A qualitative study of patients with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648001</td><td>Green (2001)</td><td>Comorbid substance use disorder and first episode schizophrenia: acute effects of olanzapine versus haloperidol</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647027</td><td>Green (2004)</td><td>First episode schizophrenia-related psychosis and substance use disorders: Acute response to olanzapine and haloperidol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645989</td><td>Green (2006)</td><td>Olanzapine and haloperidol in first episode psychosis: Two-year data</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648106</td><td>Green (2007)</td><td>Cognition, drug treatment, and functional outcome in schizophrenia: A tale of two transitions</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646942</td><td>Green (2008)</td><td>Functional co-primary measures for clinical trials in schizophrenia: Results from the MATRICS Psychometric and Standardization Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634197</td><td>Greenblatt (1961)</td><td>Mental patients in transition</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633566</td><td>Greenblatt (1975)</td><td>Drugs in combination with other therapies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647036</td><td>Greenfield (2018)</td><td>First episode psychosis in the over 35s: Is there a role for early intervention?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633966</td><td>Greenhouse (2003)</td><td>On psychiatry, epidemiology, and statistics: a view from the 1950s and 1960s.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647184</td><td>Greenland-White (2017)</td><td>Episodic memory functions in first episode psychosis and clinical high risk individuals</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634244</td><td>Greenway (2020)</td><td>Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647311</td><td>Greenwood (2018)</td><td>The effects of glycine on auditory mismatch negativity in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647494</td><td>Greenwood (2021)</td><td>The Early Youth Engagement in first episode psychosis (EYE-2) study: pragmatic cluster randomised controlled trial of implementation, effectiveness and cost-effectiveness of a team-based motivational engagement intervention to improve engagement</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633658</td><td>Gregory (1994)</td><td>Pharmacological Management of Schizophrenia in Older Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648710</td><td>Grent-'t-Jong (2018)</td><td>Acute ketamine dysregulates task-related gamma-band oscillations in thalamo-cortical circuits in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634294</td><td>Griboura (2021)</td><td>Still Relevant Today: The Asinger Multicomponent Reaction.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645267</td><td>Griffiths (2018)</td><td>The relationship between cognition and functional improvement in the context of a psychosocial intervention targeting social disability in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646254</td><td>Griffiths (2018)</td><td>Method of levels therapy for first-episode psychosis: rationale, design and baseline data for the feasibility randomised controlled Next Level study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>59644947</td><td>Griffiths (2019)</td><td>Sources of Distress in First-Episode Psychosis: A Systematic Review and Qualitative Metasynthesis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646253</td><td>Griffiths (2019)</td><td>Method of levels therapy for first-episode psychosis: the feasibility randomized controlled Next Level trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646507</td><td>Griffiths (2019)</td><td>'It was me answering my own questions': experiences of method of levels therapy amongst people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644816</td><td>Griffiths (2020)</td><td>A Synthetic Literature Review on the Management of Emerging Treatment Resistance in First Episode Psychosis: Can We Move towards Precision Intervention and Individualised Care?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647622</td><td>Grijalva (2020)</td><td>Double Jeopardy: Untangling Depression, Parkinson's Disease & Frontotemporal Dementia in Clinical Practice with Bedside Cognitive Testing</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633835</td><td>Grisso (1993)</td><td>Structuring the debate about ethical predictions of future violence.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633737</td><td>Grob (1998)</td><td>Psychiatry's Holy Grail: The Search for the Mechanisms of Mental Diseases</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645573</td><td>Grolleau (2007)</td><td>Prescription practices of antipsychotic medication in early psychosis: A two-year follow-up survey of subjects admitted in two psychiatric hospitals of South-Western France</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646303</td><td>Gronholm (2017)</td><td>Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646788</td><td>Groot (2020)</td><td>How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647275</td><td>Grootens (2010)</td><td>Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647460</td><td>Grosic (2014)</td><td>The effect of atypical antipsychotics on brain N-acetylaspartate levels in antipsychotic-naive first-episode patients with schizophrenia: A preliminary study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634180</td><td>Gross (1970)</td><td>Das Neuroleptikum 100-129/HF-1854 (Clozapin) in der Psychiatrie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646600</td><td>Gross (1980)</td><td>The influence of somatotherapeutic measures on the long-term outcome of schizophrenic illnesses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644973</td><td>Grossman (2017)</td><td>Smoking status and its relationship to demographic and clinical characteristics in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646214</td><td>Grossman (2018)</td><td>Money talks: the influence of monetary reinforcement on social cognitive performance in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646499</td><td>Grossman (2020)</td><td>Jumping to social conclusions?: The implications of early and uninformed social judgements in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646857</td><td>'Group therapy for schizophrenia:... (2020)</td><td>'Group therapy for schizophrenia: A meta-analysis': Correction to Burlingame et al. (2020)</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647484</td><td>Grover (2019)</td><td>ECT in schizophrenia: a review of the evidence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633673</td><td>Groves (1975)</td><td>The Long-Acting Phenothiazines</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648517</td><td>Grunder (2015)</td><td>Are antipsychotics neurotoxic or neuroprotective? a long-term comparison of two treatment strategies: study design of the multicenter APIC trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645871</td><td>Grunina (2019)</td><td>P.499 Expression of serotonin receptor 2A alternative isoforms in peripheral blood lymphocytes during olanzapine therapy is modulated by gene polymorphisms rs6311/rs6313</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644772</td><td>Gry (2015)</td><td>Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647042</td><td>Gschwandtner (2006)</td><td>Fine motor function and neuropsychological deficits in individuals at risk for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648093</td><td>Guaiana (2012)</td><td>Cognitive behaviour therapy (group) for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59647864</td><td>Guan (2017)</td><td>Cost-effectiveness analysis of five clinical commonly used atypical antipsychotics as the first-line treatment of first-episode schizophrenia in China based on a decision tree model. [Chinese]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647510</td><td>Guccione (2019)</td><td>Early signs of schizophrenia and autonomic nervous system dysregulation: A literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645048</td><td>Gudlowski (2009)</td><td>Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647011</td><td>Guerrero-Pedraza (2012)</td><td>First-episode psychosis is characterized by failure of deactivation but not by hypo- or hyperfrontality</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645320</td><td>Guimond (2016)</td><td>Recollection rejection of new items in individuals with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647786</td><td>Gultekin (2008)</td><td>Demographic and clinical variables among mood disorders inpatients: A preliminary report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647714</td><td>Gultekin (2017)</td><td>Differential effects of clozapine and risperidone on facial emotion recognition ability in patients with treatment-resistant schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648405</td><td>Gunduz (2002)</td><td>Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjects</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647582</td><td>Gunduz-Bruce (2005)</td><td>Duration of untreated psychosis and time to treatment response for delusions and hallucinations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647467</td><td>Guo (2010)</td><td>Effect of antipsychotic medication alone vs combined with psychosocial intervention on outcomes of early-stage schizophrenia: a randomized, 1-year study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647358</td><td>Guo (2011)</td><td>Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647334</td><td>Guo (2012)</td><td>Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648445</td><td>Guo (2012)</td><td>Association study of reticulon 4 receptor gene polymorphism with schizophrenia in Han Chinese population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647806</td><td>Guo (2014)</td><td>Decreased gray matter volume in the left middle temporal gyrus as a candidate biomarker for schizophrenia: A study of drug naive, first-episode schizophrenia patients and unaffected siblings</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646635</td><td>Guo (2015)</td><td>Increased short-range and long-range functional connectivity in first-episode, medication-naive schizophrenia at rest</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647679</td><td>Guo (2015)</td><td>Dissociation of anatomical and functional alterations of the default-mode network in first-episode, drug-naive schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648748</td><td>Guo (2015)</td><td>Abnormal causal connectivity by structural deficits in first-episode, drug-naive schizophrenia at rest</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634171</td><td>Guo (2016)</td><td>A randomised controlled trial of brief cognitive‚Äìbehavioural therapy for community patients with schizophrenia in Beijing, China</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646870</td><td>Guo (2019)</td><td>Gray matter volume changes following antipsychotic therapy in first-episode schizophrenia patients: A longitudinal voxel-based morphometric study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645833</td><td>Guo (2020)</td><td>Parietal memory network and default mode network in first-episode drug-naive schizophrenia: Associations with auditory hallucination</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645199</td><td>Gur (1995)</td><td>Resting cerebral glucose metabolism in first-episode and previously treated patients with schizophrenia relates to clinical features</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646977</td><td>Gur (1998)</td><td>A follow-up magnetic resonance imaging study of schizophrenia: Relationship of neuroanatomical changes to clinical and neurobehavioral measures</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647708</td><td>Gurrera (2018)</td><td>Differentiating anti-NMDA receptor encephalitis from psychiatric disorders and neuroleptic malignant syndrome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645135</td><td>Gutierrez-Esteinou (1997)</td><td>Risperidone: An analysis of the first three years in general use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648220</td><td>Gutierrez-Galve (2010)</td><td>Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646542</td><td>Gutman (2012)</td><td>Intolerable fever: A previously unreported side-effect of quetiapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634029</td><td>Guttmacher (1964)</td><td>PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634001</td><td>Guy (1970)</td><td>A data processing system for psychotropic drug evaluation.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634168</td><td>Ha (2017)</td><td>Promoting medication adherence among patientswith bipolar disorder: a multicenter randomizedcontrolled trial of a multifaceted intervention</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633934</td><td>Haahr (2012)</td><td>Patient satisfaction with treatment in first-episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646187</td><td>Haahr (2020)</td><td>Multi-family group and single-family intervention in first-episode psychosis: a prospective, quasi-experimental cohort study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634021</td><td>Haandel (2001)</td><td>Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645665</td><td>Haarsma (2020)</td><td>Precision weighting of cortical unsigned prediction error signals benefits learning, is mediated by dopamine, and is impaired in psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646602</td><td>Haarsma (2020)</td><td>Influence of prior beliefs on perception in early psychosis: Effects of illness stage and hierarchical level of belief</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644921</td><td>Haatveit (2015)</td><td>Stability of executive functions in first episode psychosis: One year follow up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644788</td><td>Haberfellner (1997)</td><td>Tardive dyskinesia during treatment with risperidone</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633600</td><td>Haddad (1984)</td><td>Clinical Use of Lithium with Geriatric Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644522</td><td>Haddad (2005)</td><td>Weight change with atypical antipsychotics in the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648593</td><td>Haddad (2012)</td><td>Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: A systematic review of head-head comparisons</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648711</td><td>Haddad (2018)</td><td>The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td></tr><tr><td>61634270</td><td>Haddad (2020)</td><td>A Brief History of Psychopharmacology</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645716</td><td>Haddock (1999)</td><td>A pilot study evaluating the effectiveness of individual inpatient cognitive-behavioural therapy in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646613</td><td>Haddock (2006)</td><td>Influence of age on outcome of psychological treatments in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>59648718</td><td>Haddock (2016)</td><td>Active Assistance for Psychological Therapy (ACTISSIST): a cognitive behavioural therapy informed smartphone intervention for early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648634</td><td>Hadrys (2020)</td><td>Amisulpride - is it as all other medicines or is it different? An update</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646756</td><td>Hafizi (2017)</td><td>Imaging microglial activation in untreated first-episode psychosis: A pet study with</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648451</td><td>Hafizi (2020)</td><td>Association of psychiatric disorders and psychotropic medications with bone quality as measured with trabecular bone score</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647561</td><td>Hafner (2004)</td><td>Early detection and secondary prevention of psychosis: Facts and visions</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645569</td><td>Hagen (2013)</td><td>Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645997</td><td>Hagen (2014)</td><td>Obsessive-compulsive disorder (OCD) in patients with first-episode psychosis (FEP): A prospective study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645755</td><td>Hahn (2014)</td><td>Pharmacological interventions for reducing weight gain in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645671</td><td>Hahn (2018)</td><td>The potential of cannabidiol treatment for cannabis users with recent-onset psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645754</td><td>Hahn (2019)</td><td>Pharmacological interventions for reduction of weight gain in people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648587</td><td>Hahn (2020)</td><td>Antipsychotic drugs inhibit central glucose sensing to result in whole-body insulin resistance</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646231</td><td>Haigh (2017)</td><td>Mismatch Negativity in First-Episode Schizophrenia: A Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648044</td><td>Hajkova (2021)</td><td>Cognitive performance and lifetime cannabis use in patients with first-episode schizophrenia spectrum disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648452</td><td>Hakiri (2018)</td><td>Association of multiple sclerosis and bipolar disorder: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634150</td><td>Hall (2018)</td><td>Protocol investigating the clinical utility of an objective measure of attention, impulsivity and activity (QbTest) for optimising medication management in children and young people with ADHD ‚ÄòQbTest Utility for Optimising Treatment in ADHD‚Äô (QUOTA): a feasibility randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648013</td><td>Haller (2013)</td><td>Combined grey matter VBM and white matter TBSS analysis in young first episode psychosis patients with and without cannabis consumption</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645828</td><td>Halverson (2019)</td><td>Pathways to Functional Outcomes in Schizophrenia Spectrum Disorders: Meta-Analysis of Social Cognitive and Neurocognitive Predictors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633591</td><td>Hambrecht (1998)</td><td>Fr√ºherkennung und Fr√ºhintervention bei schizophrenen Rezidiven</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646766</td><td>Hamilton (2017)</td><td>Identifying attributes of care that may improve cost-effectiveness in the youth mental health service system</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644887</td><td>Hammer (2013)</td><td>Structural brain correlates of sensorimotor gating in antipsychotic-naive men with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648205</td><td>Han (2014)</td><td>The Chinese First-Episode Schizophrenia Trial: Background and study design</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647676</td><td>Han (2020)</td><td>Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646846</td><td>Hanafi (2017)</td><td>Haloperidol (route of administration) for people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634194</td><td>Handley (2014)</td><td>A randomised controlled trial of group cognitive behavioural therapy for clinical perfectionism</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633690</td><td>Hanlon (1965)</td><td>The comparative effectiveness of eight phenothiazines.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633789</td><td>Hanlon (1966)</td><td>Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648757</td><td>Hannon (2019)</td><td>57methylomic Biomarkers of Schizophrenia and Antipsychotic Medication Exposure</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634015</td><td>Hansen (2012)</td><td>Cognitive adaptation training combined with assertive community treatment: A randomised longitudinal trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646795</td><td>Hansen (2018)</td><td>How Do People Experience Early Intervention Services for Psychosis? A Meta-Synthesis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634274</td><td>Hansen (2021)</td><td>Lessons from an aborted controlled trial on the impact of befriending in an early intervention in psychosis population.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647083</td><td>Harber (2017)</td><td>Factors associated with drug attitude in patients with schizophrenia spectrum disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648326</td><td>Hardy (2021)</td><td>Brief report describing the integration of two psychotherapy evidence-based practices within coordinated specialty care services for early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647085</td><td>Haring (2015)</td><td>Factorial validity, measurement equivalence and cognitive performance of the Cambridge Neuropsychological Test Automated Battery (CANTAB) between patients with first-episode psychosis and healthy volunteers</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648552</td><td>Haring (2015)</td><td>Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647967</td><td>Harneet (2019)</td><td>Comparison of efficacy and tolerability of Escitaloparm and Venlafaxine in Treatment na√Øve patients with unipolar non psychotic depression: is there a need to revisit the the prescription patterns?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633885</td><td>Harris (1983)</td><td>Effects of chlorpromazine and promazine on the visual aftereffects of tilt and movement.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648159</td><td>Harris (2005)</td><td>Clinical profiles, scope and general findings of the Western Sydney First Episode Psychosis Project</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645207</td><td>Harris (2009)</td><td>Response suppression deficits in treatment-naive first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648320</td><td>Harris (2012)</td><td>Cabergoline associated with first episode mania</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633512</td><td>Harrow (2007)</td><td>Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: a 15-year multifollow-up study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648458</td><td>Hart (2021)</td><td>Association of Aripiprazole with Reduced Hippocampal Atrophy during Maintenance Treatment of First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633556</td><td>Hartman (1996)</td><td>Interaction of Antipsychotic Drugs with Dopamine Receptor Subtypes</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633838</td><td>Hartman (1996)</td><td>Molecular attributes of dopamine receptors: new potential for antipsychotic drug development.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633955</td><td>Hartman (1997)</td><td>Dopamine receptor diversity: Molecular and pharmacological perspectives</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633856</td><td>Harvey (1982)</td><td>Speech competence of children vulnerable to psychopathology.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633859</td><td>Harvey (1986)</td><td>Speech performance in mania and schizophrenia: the association of positive and negative thought disorders and reference failures.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647837</td><td>Harvey (2003)</td><td>Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644671</td><td>Harvey (2005)</td><td>Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648051</td><td>Harvey (2005)</td><td>Cognitive Impairment in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645096</td><td>Harvey (2006)</td><td>Scaling Mount Rushmore: Cartography of a manic episode</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647800</td><td>Hasan (2012)</td><td>Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: A cross-sectional study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633911</td><td>Hasan (2013)</td><td>World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647215</td><td>Hashimoto (2005)</td><td>Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647859</td><td>Hastrup (2013)</td><td>Cost-effectiveness of early intervention in first-episode psychosis: economic evaluation of a randomised controlled trial (the OPUS study)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647649</td><td>Hastrup (2019)</td><td>Does future resource input reflect need in first-episode psychosis: Examining the association between individual characteristics and 5-year costs</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647850</td><td>Hasty (2010)</td><td>Course of illness and predictors of relapse following a first episode of psychotic mania</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644474</td><td>Hasty (2018)</td><td>Will it happen again? Course of illness and predictors of relapse in first episode mania</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645785</td><td>Hasty (2021)</td><td>Personality disorder among youth with first episode psychotic mania: an important target for specific treatment?</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648701</td><td>Hatta (2003)</td><td>Acute-phase treatment in general hospitals: Clinical psychopharmacologic evaluation in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646047</td><td>Hauser (2017)</td><td>Neuropsychological test performance to enhance identification of subjects at clinical high risk for psychosis and to be most promising for predictive algorithms for conversion to psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646055</td><td>Hawkins (2008)</td><td>Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646615</td><td>Hayes (2014)</td><td>Inflammatory molecular signature associated with infectious agents in psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645487</td><td>Hayes (2019)</td><td>Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633523</td><td>Hayhurst (2015)</td><td>Patients' subjective rating of mental health improvement in a randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633827</td><td>Hayward (2009)</td><td>Promoting Therapeutic Alliance in Clozapine Users: An Exploratory Randomized Controlled Trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645030</td><td>Hazell (2020)</td><td>Service evaluation of a sole-session psychoeducational intervention to improve caregivers' key illness beliefs after first episode psychosis (FEP)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645540</td><td>Hazlett (2008)</td><td>Probing attentional dysfunctions in schizophrenia: Startle modification during a Continuous Performance Test</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633542</td><td>He (2007)</td><td>Oral fluphenazine versus placebo for schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644497</td><td>He (2012)</td><td>When to hold that thought: An experimental study showing reduced inhibition of pre-trained associations in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644600</td><td>He (2020)</td><td>Uric acid levels in subjects with schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645856</td><td>Heald (2019)</td><td>P.700 Using SWATH mass spectrometry to identify possible circulating proteins that predict future weight gain in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648526</td><td>Heald (2020)</td><td>Application of SWATH mass spectrometry in the identification of circulating proteins does not predict future weight gain in early psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634305</td><td>Healey (1998)</td><td>Cost-effectiveness evaluation of compliance therapy for people with psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647838</td><td>Healey (2006)</td><td>Cross-Cultural Validation of Expressed Emotion in Caregivers of Chinese Patients with First Episode Psychosis in Singapore: A Qualitative Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647796</td><td>Healey (2016)</td><td>Deficits in social cognition in first episode psychosis: A review of the literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648696</td><td>Hegde (2012)</td><td>Addition of home-based cognitive retraining to treatment as usual in first episode schizophrenia patients: a randomized controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633924</td><td>Heinssen (2015)</td><td>Preventing the Onset of Psychosis: Not Quite There Yet</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645706</td><td>Heitz (2019)</td><td>Plasma and serum brain-derived neurotrophic factor (BDNF) levels and their association with neurocognition in at-risk mental state, first episode psychosis and chronic schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646926</td><td>Heitz (2019)</td><td>Gender differences in first self-perceived signs and symptoms in patients with an at-risk mental state and first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644830</td><td>Helfer (2015)</td><td>Switching antipsychotic for non response in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634241</td><td>Henckes (2019)</td><td>Schizophrenia Infrastructures: Local and Global Dynamics of Transformation in Psychiatric Diagnosis-Making in the Twentieth and Twenty-First Centuries.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645674</td><td>Heo (2021)</td><td>Potential compensatory effects of uric acid on white matter connectivity and treatment response in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648210</td><td>Hepgul (2012)</td><td>Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647333</td><td>Herbener (2005)</td><td>Effects of Antipsychotic Treatment on Emotion Perception Deficits in First-Episode Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645482</td><td>Heres (2011)</td><td>Psychiatrists' attitude to antipsychotic depot treatment in patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645816</td><td>Heres (2012)</td><td>Patients' acceptance of the deltoid application of risperidone long-acting injection</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644669</td><td>Heres (2014)</td><td>Treatment of early episode in patients with schizophrenia: The role of long acting antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647203</td><td>Hergenrather (2018)</td><td>Employment as a Social Determinant of Health: Exploring the Relationship Between Neurocognitive Function and Employment Status</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648551</td><td>Heriot-Maitland (2018)</td><td>Antipsychotic treatments: Who is really failing here?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634199</td><td>Herman (1963)</td><td>Clinical evaluation of thioridazine and chlorpromazine in chronic schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648023</td><td>Herman (2018)</td><td>Cognitive-behavioural social skills training for first-episode psychosis: A feasibility study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645073</td><td>Herman (2020)</td><td>Screening for anti-NMDAR antibodies amongst patients with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645074</td><td>Herman (2020)</td><td>Screening for Anti-NMDA Receptor Antibodies Among Patients With First Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633645</td><td>Hernandez (1989)</td><td>Haloperidol given chronically decreases basal dopamine in the prefrontal cortex more than the striatum or nucleus accumbens as simultaneously measured by microdialysis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633674</td><td>Hernandez (1990)</td><td>Neurochemical effects of chronic haloperidol and lithium assessed by brain microdialysis in rats.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633840</td><td>Hernandez (1995)</td><td>Chronic clozapine selectively decreases prefrontal cortex dopamine as shown by simultaneous cortical, accumbens, and striatal microdialysis in freely moving rats.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646466</td><td>Hernandez (2019)</td><td>Lessons learned in clinical research recruitment of immigrants and minority group members with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647451</td><td>Herniman (2017)</td><td>The effect of comorbid depression on facial and prosody emotion recognition in first-episode schizophrenia spectrum</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648110</td><td>Herniman (2018)</td><td>Co-morbid depressive disorder is associated with better neurocognitive performance in first episode schizophrenia spectrum</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647779</td><td>Herniman (2019)</td><td>Depressive psychopathology in first-episode schizophrenia spectrum disorders: a systematic review, meta-analysis and meta-regression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647829</td><td>Herrera-Huerta (2020)</td><td>Cycloid psychosis and its longitudinal diagnosis: Case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645067</td><td>Herrington (1965)</td><td>Sedation threshold and Archimedes' spiral after-effect in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645458</td><td>Herrmann (2020)</td><td>Psychosis associated to CASPR2 autoantibodies and ovarian teratoma: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647486</td><td>Heslin (2011)</td><td>The economic cost of pathways to care in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647883</td><td>Heydebrand (2004)</td><td>Correlates of cognitive deficits in first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646023</td><td>Hickling (2018)</td><td>Non-adherence to antipsychotic medication in first-episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634195</td><td>Higgins (2004)</td><td>Preliminary communication Concordance therapy: an intervention to help older people take antidepressants</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645794</td><td>Higuchi (2013)</td><td>Perospirone normalized P300 and cognitive function in a case of early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646053</td><td>Hill (2004)</td><td>Neuropsychological Dysfunction in Antipsychotic-Naive First-Episode Unipolar Psychotic Depression</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647224</td><td>Hill (2008)</td><td>Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645993</td><td>Hill (2009)</td><td>Oculomotor and neuropsychological effects of antipsychotic treatment for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647955</td><td>Hill (2009)</td><td>A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646018</td><td>Hill (2010)</td><td>Nonadherence to medication four years after a first episode of psychosis and associated risk factors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644833</td><td>Hilti (2010)</td><td>Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naive first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647665</td><td>Hindocha (2020)</td><td>Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647488</td><td>Hinojosa-Marques (2019)</td><td>Ecological validity of expressed emotion in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647896</td><td>Hinze-Selch (2007)</td><td>A controlled prospective study of Toxoplasma gondii infection in individuals with schizophrenia: Beyond seroprevalence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647703</td><td>Hirschfeld (2020)</td><td>Differentiation of the first psychotic episode and autoimmune encephalitis with anti-NMDA receptor antibodies, using the EEG findings - Case report and literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634081</td><td>Hj (1961)</td><td>Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634105</td><td>Hj (1977)</td><td>[Legasthenia. Diagnosis, therapy--experiences in a child and adolescent psychiatric ambulatory].</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647767</td><td>Hjorthoj (2008)</td><td>Design paper: the CapOpus trial: a randomized, parallel-group, observer-blinded clinical trial of specialized addiction treatment versus treatment as usual for young patients with cannabis abuse and psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634032</td><td>Hjorth√∏j (2012)</td><td>14:15 SPECIALIZED ADDICTION TREATMENT VERSUS TREATMENT AS USUAL FOR PATIENTS WITH CANNABIS USE DISORDER AND PSYCHOSIS -RESULTS FROM THE CAPOPUS RANDOMIZED, PARALLEL-GROUP, OBSERVER-BLINDED CLINICAL TRIAL</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646815</td><td>Ho (2005)</td><td>Hippocampus Volume and Treatment Delays in First-Episode Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645648</td><td>Ho (2018)</td><td>Prediction of self-stigma in early psychosis: 3-year follow-up of the randomized-controlled trial on extended early intervention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648450</td><td>Hochstrasser (2018)</td><td>The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646039</td><td>Hodgins (2017)</td><td>New Clinically Relevant Findings about Violence by People with Schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647164</td><td>Hodgson (2014)</td><td>Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645105</td><td>Hofer (2003)</td><td>The safety of clozapine in the treatment of first- and multiple-episode patients with treatment-resistant schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647613</td><td>Hofer (2004)</td><td>Dr. Hofer and Colleagues Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633550</td><td>Hofer (2014)</td><td>Pharmacological Strategies to Enhance Adherence in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646490</td><td>Hoff (2000)</td><td>Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633786</td><td>Hogarty (1966)</td><td>Preadmission symptom differences between first-admitted schizophrenics in the predrug and postdrug era</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633816</td><td>Hogarty (1973)</td><td>Drug and Sociotherapy in the Aftercare of Schizophrenic Patients: II. Two-Year Relapse Rates</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633620</td><td>Hogarty (1998)</td><td>The limited effects of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644556</td><td>Hoivik (2015)</td><td>Video feedback compared to treatment as usual in families with parent-child interactions problems: a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644909</td><td>Hojlund (2021)</td><td>Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634251</td><td>Holding (2020)</td><td>Young people's beliefs about psychological therapy for psychosis: a Q-Methodological study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633547</td><td>Holland (2005)</td><td>The HOMER trial: an RCT of medication review in older people. A detailed description of the intervention, and an analysis of whether results differed by pharmacist characteristics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633805</td><td>Hollister (1967)</td><td>REPORTS OF CLINICAL STUDIES OF PSYCHIATRIC DRUGS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634192</td><td>Hollister (1967)</td><td>Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633584</td><td>Hollister (1971)</td><td>Chemotherapy of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633884</td><td>Hollister (1972)</td><td>Clinical use of psychotherapeutic drugs. I. Antipsychotic and antimanic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633679</td><td>Hollister (1974)</td><td>Specific Indications for Different Classes of Phenothiazines</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633596</td><td>Hollister (1984)</td><td>Sedatives in the Management of Psychiatric Emergencies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633906</td><td>Holmberg (1966)</td><td>Tioridazin och flufenazin</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644878</td><td>Holt (2018)</td><td>Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634152</td><td>Holt (2018)</td><td>Stepwise: structured lifestyle education for people with schizophrenia, schizoaffective disorder and first episode psychosis: randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644879</td><td>Holt (2019)</td><td>Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): Randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645837</td><td>Homan (2018)</td><td>Parahippocampal thickness predicts treatment improvement in early and chronic schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645838</td><td>Homan (2018)</td><td>Parahippocampal thickness predicts treatment improvement in early and chronic schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648137</td><td>Homan (2018)</td><td>Clozapine as an early-stage treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644882</td><td>Homan (2019)</td><td>Structural similarity networks predict clinical outcome in early-phase psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646030</td><td>Homan (2020)</td><td>Nigrostriatal connectivity and the prediction of thought disturbance in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647113</td><td>Homberger (2021)</td><td>Exploring the experiences and understandings of psychosis through relationships with family members, mental health services, and society</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647079</td><td>Hon (2012)</td><td>Factors influencing the adherence of antipsychotic medication (Aripiprazole) in first-episode psychosis: Findings from a grounded theory study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647097</td><td>Honer (2005)</td><td>Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647920</td><td>Honer (2007)</td><td>Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647286</td><td>Hong (2002)</td><td>Effects of risperidone on information processing and attention in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646086</td><td>Hong (2009)</td><td>Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633794</td><td>Honigfeld (1965)</td><td>BEHAVIORAL IMPROVEMENT IN THE OLDER SCHIZOPHRENIC PATIENT: DRUG AND SOCIAL THERAPIES.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647642</td><td>Horikoshi (2020)</td><td>Does Treatment Response With Antidementia Drugs After 6 Months in Alzheimer's Disease Predict Long-term Treatment Outcome?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644691</td><td>Horisberger (2020)</td><td>Treating negative symptoms of schizophrenia with a motive-specific intervention: a randomized brief intervention trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634214</td><td>Horowitz (2021)</td><td>A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633883</td><td>Horton (2012)</td><td>P-926 - Borderline personality disorder: pharmacotherapy and psychological interventions in inpatient services after introduction of the nice guideline in the UK</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644994</td><td>Horvitz-Lennon (2019)</td><td>Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645734</td><td>Hosford (2014)</td><td>Phase 2 clinical trial of TC-5619, an alpha 7 nicotinic receptor agonist in the treatment of negative and cognitive symptoms in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646099</td><td>Hou (2020)</td><td>Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646761</td><td>Hovington (2012)</td><td>Identifying persistent negative symptoms in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646703</td><td>Hovington (2013)</td><td>Impairment in verbal memory observed in first episode psychosis patients with persistent negative symptoms</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634115</td><td>Howard (2018)</td><td>Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648345</td><td>Howes (2018)</td><td>Brain structural and neurochemical heterogeneity and homogeneity in psychotic disorders: Transdiagnostic pet and mri imaging findings in schizophrenia and bipolar affective disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648361</td><td>Howes (2018)</td><td>Body and mind: Cardio-metabolic and immune function in first episode psychosis and comparison with central neurofunctional measures</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648157</td><td>Howes (2021)</td><td>The clinical significance of duration of untreated psychosis: an umbrella review and random-effects meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647076</td><td>Hoyer (2010)</td><td>Familial differential treatment response in schizophrenia - lessons from a case of three affected siblings</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646000</td><td>Hsiao (2004)</td><td>Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648416</td><td>Hsieh (2012)</td><td>Auditory event-related potential of subjects with suspected pre-psychotic state and first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647962</td><td>Hsu (2010)</td><td>Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647805</td><td>Hu (2013)</td><td>Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645137</td><td>Hu (2016)</td><td>Risperidone-induced topological alterations of anatomical brain network in first-episode drug-naive schizophrenia patients: A longitudinal diffusion tensor imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645800</td><td>Hu (2016)</td><td>Percutaneous radiological gastrostomies versus nasogastric tube feeding for people with swallowing disturbances</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647372</td><td>Huang (2013)</td><td>Effectiveness of aripiprazole in adolescents and young adults with schizophrenia spectrum disorders: Comparison of first-episode to recurrent psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645356</td><td>Huang (2018)</td><td>A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648538</td><td>Huang (2018)</td><td>Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647652</td><td>Huang (2019)</td><td>Does depressive-type schizophrenia exist? How do we prove it?: An updated review and overview</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646651</td><td>Huang (2020)</td><td>Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647961</td><td>Huang (2021)</td><td>Comparison of Long-Acting Injectable Antipsychotics with Oral Antipsychotics and Suicide and All-Cause Mortality in Patients with Newly Diagnosed Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646299</td><td>Hubbard (2019)</td><td>Meta-analysis of blood cortisol levels in individuals with first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648327</td><td>Huber (2012)</td><td>Brief Psychiatric Rating Scale-Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634289</td><td>Huber (2021)</td><td>Delusion and Dopamine: Neuronal Insights in Psychotropic Drug Therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648480</td><td>Huffman (2010)</td><td>Assessing clinicians' management of first episode schizophrenia using clinical case vignettes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647711</td><td>Hughes (2021)</td><td>Differential Macrophage Responses in Affective Versus Non-Affective First-Episode Psychosis Patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647960</td><td>Huh (2019)</td><td>Comparison of long-term efficacy and safety of blonanserin treatment in individuals with first-episode and relapsed schizophrenia: A 3-year retrospective study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647991</td><td>Huhn (2019)</td><td>"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis": Correction</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647992</td><td>Huhn (2020)</td><td>Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648539</td><td>Huhn (2020)</td><td>"Antipsychotics for schizophrenia and substance misuse": Authors' reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634292</td><td>Huhn (2021)</td><td>Antipsychotika in der Akuttherapie der Schizophrenie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647764</td><td>Hui (2006)</td><td>Detection of non-adherent behaviour in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633644</td><td>Hui (2008)</td><td>A double-blind randomized placebo-controlled study of relapse predictors in remitted first-episode psychosis patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633741</td><td>Hui (2008)</td><td>Predictors for relapse in a double-blind randomized placebo-controlled discontinuation study of remitted first-episode psychosis patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634025</td><td>Hui (2011)</td><td>Relapse in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645661</td><td>Hui (2013)</td><td>Predicting 1-year risk for relapse in patients who have discontinued or continued quetiapine after remission from first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648778</td><td>Hui (2013)</td><td>A 3-year retrospective cohort study of predictors of relapse in first-episode psychosis in Hong Kong</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645312</td><td>Hui (2014)</td><td>"Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial": Comment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645564</td><td>Hui (2015)</td><td>Prevalence and predictors of medication non-adherence among Chinese patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647417</td><td>Hui (2015)</td><td>The effect of paternal age on relapse in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644548</td><td>Hui (2016)</td><td>Visual working memory deterioration preceding relapse in psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644549</td><td>Hui (2016)</td><td>Visual working memory deterioration preceding relapse in psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645168</td><td>Hui (2016)</td><td>Risk factors for antipsychotic medication non-adherence behaviors and attitudes in adult-onset psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645657</td><td>Hui (2018)</td><td>Predicting first-episode psychosis patients who will never relapse over 10 years</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645804</td><td>Hui (2018)</td><td>Perception towards relapse and its predictors in psychosis patients: A qualitative study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646411</td><td>Hui (2018)</td><td>Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: A 10 year follow-up of a randomised, double-blind trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648769</td><td>Hui (2018)</td><td>The 10-year clinical outcome of early medication discontinuation in remitted first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645481</td><td>Hui (2019)</td><td>Psychiatrists' opinion towards medication discontinuation in remitted first-episode psychosis: A multi-site study of the Asian Network for Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647080</td><td>Hui (2019)</td><td>Factors associated with successful medication discontinuation after a randomized clinical trial of relapse prevention in first-episode psychosis: A 10-year follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645778</td><td>Hui (2020)</td><td>Perspective on medication decisions following remission from first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647526</td><td>Humphries (2017)</td><td>Early psychosis in central Vietnam: A longitudinal study of short-term functional outcomes and their predictors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646480</td><td>Hung (2009)</td><td>Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645131</td><td>Hung (2017)</td><td>Role of cytokine changes in clozapine-induced fever: A cohort prospective study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644842</td><td>Hunt (2003)</td><td>Suicides in ethnic minorities within 12 months of contact with mental health services: National clinical survey</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645563</td><td>Hunt (2018)</td><td>Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644641</td><td>Huq (2004)</td><td>A Trial of Low Doses of Risperidone in the Treatment of Patients With First-Episode Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634139</td><td>Husain (2017)</td><td>Pilot randomised controlled trial of culturally adapted cognitive behavior therapy for psychosis (CaCBTp) in Pakistan</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644972</td><td>Hutton (1998)</td><td>Smooth pursuit and saccadic abnormalities in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645008</td><td>Hutton (2001)</td><td>Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645111</td><td>Hutton (2001)</td><td>Saccadic hypometria in drug naive and drug-treated schizophrenic patients: A working memory deficit?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647809</td><td>Hutton (2002)</td><td>Decision making deficits in patients with first-episode and chronic schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633818</td><td>Huttunen (1995)</td><td>Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645090</td><td>Huxley (2021)</td><td>Schizophrenia outcomes in the 21st century: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647219</td><td>Iacono (1993)</td><td>Electrodermal nonresponding in first-episode psychosis as a function of stimulus significance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645236</td><td>Iasevoli (2020)</td><td>Relationships between age at onset of psychotic symptoms and poor response to antipsychotics in a sample of TRS/non-TRS patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646845</td><td>Ibragimov (2019)</td><td>Haloperidol versus olanzapine for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633554</td><td>Id (1975)</td><td>Short versus long hospitalization: a prospective controlled study. II. Results for schizophrenic inpatients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634048</td><td>Id (1981)</td><td>Outcome of irregularly discharged psychiatric patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647388</td><td>Ifteni (2014)</td><td>Effectiveness and safety of rapid clozapine titration in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646425</td><td>Ifteni (2020)</td><td>Long-acting injectable antipsychotics treatment during COVID-19 pandemic-A new challenge</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645558</td><td>Ihara (2009)</td><td>The prevalence, diagnostic significance and demographic characteristics of Schneiderian first-rank symptoms in an epidemiological sample of first-episode psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644860</td><td>Ikuta (2014)</td><td>Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646361</td><td>Iliuta (2021)</td><td>Magnetic resonance imaging in schizophrenia: Luxury or necessity? (Review)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646702</td><td>Implementation and fidelity... (2018)</td><td>Implementation and fidelity assessment of the NAVIGATE treatment program for first episode psychosis in a multi-site study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646689</td><td>Improved social functioning... (2021)</td><td>Improved social functioning following social recovery therapy in first episode psychosis: do social cognition and neurocognition change following therapy, and do they predict treatment response?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634175</td><td>Inman (2015)</td><td>Occupational therapy for people with a diagnosis of psychosis; intervention specification</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645410</td><td>Insel (2016)</td><td>RAISE-ing our expectations for first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645426</td><td>Iqbal (2019)</td><td>Quetiapine dose for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647432</td><td>Irct138804222046N (2009)</td><td>Effect of ice massage on nausea and vomiting of cancer patients under chemotherapy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648155</td><td>Irct20120603009934N (2019)</td><td>Clinical trial of investigation of add-on of Probiotics to standard treatment on symptoms of patients with first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647428</td><td>Irct2012100611019N (2013)</td><td>The effect of low dose intravenouse ketamine on post operative pain after cesarean section with spinal anesthesia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645930</td><td>Irct2012122511885N (2013)</td><td>Opium tincture and methadone syrup effectiveness for management of opium withdrawal</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644869</td><td>Irct201302174438N (2013)</td><td>The Study of the Effect of Face-to-Face Education and Educational Booklet on Heart Health Indexes of the Hospitalized Patients with Myocardial Infarction</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647409</td><td>Irct201306086280N (2013)</td><td>The effect of remifentanil - thiopental sodium on cognitive impairment after electroconvulsive therapy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646853</td><td>Irct2014031016919N (2014)</td><td>Guided Imagery for Anxiety Reduction in Cardiac Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647979</td><td>Irct201404122898N (2014)</td><td>Comparison effect of religious cognitive- behavioral therapy, classic cognitive behavioral therapy and Sertraline on anxiety, depression, related bio markers and quality of life in post coronary artery bypass surgery Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647236</td><td>Irct2015021721121N (2015)</td><td>Efficacy of laser therapy on the cholecystectomy wound pain</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647227</td><td>Irct2015041720178N (2015)</td><td>Efficacy of vitB12 plus standard chronic HCV treatment versus standard chronic HCV treatment on sustained virologic response rate</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648247</td><td>Irct2015080423478N (2016)</td><td>Celecoxib versus placebo as an adjunct in the treatment of Adolescents with bipolar mood disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647974</td><td>Irct2015123025768N (2016)</td><td>Comparison of Aripiprazole and Risperidone on ADHD</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647947</td><td>Irct201604116480N (2016)</td><td>Comparison of the effects of lavender and venlafaxine in the treatment of depression</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647936</td><td>Irct20180528039882N (2018)</td><td>Comparison the effect of Benson Relaxation and Foot Reflexology on the Quality of Sleep in Patients with Heart Failure</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647151</td><td>Irct20180716040485N (2019)</td><td>Evaluation the effect of supportive-expressive dynamic psychotherapy in Bipolar Spectrum patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647405</td><td>Irct20201016049041N (2020)</td><td>The Effect of rTMS on stroke</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646903</td><td>Iruretagoyena (2018)</td><td>Global recovery in a first episode psychosis program in south america</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646528</td><td>Is autonomous motivation... (2018)</td><td>Is autonomous motivation the key to maintaining an active lifestyle in first-episode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645988</td><td>Isaac (2005)</td><td>Olanzapine and Weight Gain</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646882</td><td>Isbister (2016)</td><td>Good clinical guidelines must define the setting, patients and evidence: Benzodiazepines versus droperidol for acute behavioural disturbance in the emergency department</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647857</td><td>Ising (2015)</td><td>Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: Multi-centre randomized controlled trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646967</td><td>Ising (2017)</td><td>Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633524</td><td>Ismail (2007)</td><td>National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimers Disease (CATIE-AD): Baseline Characteristics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645969</td><td>Ispir (2017)</td><td>Olanzapine-induced delayed-onset oculogyric crisis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645081</td><td>Isrctn (2005)</td><td>Schizophrenia Termination Of Pharmacotherapy: sTOP-trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648113</td><td>Isrctn (2005)</td><td>Cluster randomised trial comparing outcomes of early psychosis care by a specialist team and augmented community mental health teams (CMHTs)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648035</td><td>Isrctn (2006)</td><td>Cognitive remediation for young people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647981</td><td>Isrctn (2009)</td><td>Comparison between extension of specialised early intervention for first episode psychosis and regular care: a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644968</td><td>Isrctn (2010)</td><td>Social Anxiety Research Clinic: an exploratory randomised controlled trial of standard versus enhanced cognitive behavioural therapy for social anxiety in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648088</td><td>Isrctn (2010)</td><td>Cognitive behavioural therapy (CBT) for people with psychosis not taking antipsychotic medication: a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644643</td><td>Isrctn (2014)</td><td>A trial of antipsychotic medication in comparison to cognitive behaviour therapy or a combination of both in adults with psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td></tr><tr><td>59644880</td><td>Isrctn (2014)</td><td>Structured lifestyle education for people wIth schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648348</td><td>Isrctn (2014)</td><td>Brain imaging of the adenosine A2A receptor in schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644962</td><td>Isrctn (2017)</td><td>Social cognitive therapy in virtual reality for early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646345</td><td>Isrctn (2017)</td><td>Managing adolescent first episode psychosis: a feasibility study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646505</td><td>Isrctn (2017)</td><td>IVIG and rituximab in antibody-associated psychosis - SINAPPS2</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647243</td><td>Isrctn (2017)</td><td>The efficacy of cognitive remediation on processing speed in patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648504</td><td>Isrctn (2018)</td><td>ARIES: app to support Recovery in Early Intervention Services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646447</td><td>Isrctn (2019)</td><td>Liraglutide and the management of overweight and obesity in people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647094</td><td>Isrctn (2019)</td><td>Eye movement desensitization and reprocessing therapy in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647495</td><td>Isrctn (2019)</td><td>Early Youth Engagement in First Episode Psychosis (EYE-2) Randomised Controlled Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648609</td><td>Isrctn (2020)</td><td>Antidepressant for the prevention of depression following first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645020</td><td>Ittig (2015)</td><td>Sex differences in cognitive functioning in at-risk mental state for psychosis, first episode psychosis and healthy control subjects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646071</td><td>Iwata (2016)</td><td>Neurometabolite levels in antipsychotic naive/free patients with schizophrenia: A meta-analysis of 1H-MRS studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646070</td><td>Iwata (2018)</td><td>Neurometabolite levels in antipsychotic-naive/free patients with schizophrenia: A systematic review and meta-analysis of <sup>1</sup>H-MRS studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645372</td><td>Iyer (2016)</td><td>A randomized controlled trial of extended specialized early intervention verses specialized early intervention followed by regular care for treatment of early psychosis over the five year critical period</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646378</td><td>Iyer (2020)</td><td>Look before you leap: Representativeness of those completing self-reports in early psychosis research</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634033</td><td>Ja (1984)</td><td>Methylphenidate challenge as a predictor of relapse in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644563</td><td>Jaakkola (2017)</td><td>Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646665</td><td>Jack (2020)</td><td>Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: A population-based cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646568</td><td>Jackson (1996)</td><td>The inter-rater and test-retest reliabilities of prodromal symptoms in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648018</td><td>Jackson (1998)</td><td>Cognitively-oriented psychotherapy for early psychosis (COPE): Preliminary results</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648019</td><td>Jackson (2001)</td><td>Cognitively oriented psychotherapy for early psychosis (COPE): A 1-year follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647894</td><td>Jackson (2005)</td><td>A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646533</td><td>Jackson (2008)</td><td>The investigation of neuroactive steroids, kynurenine metabolites and glutamate in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648702</td><td>Jackson (2008)</td><td>Acute-phase and 1-year follow-up results of a randomized controlled trial of CBT versus Befriending for first-episode psychosis: the ACE project</td><td>(I) Included</td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59646286</td><td>Jackson (2019)</td><td>Meta-Analysis of Total and Differential White Blood Cell Counts in Schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634272</td><td>Jacobsen (2019)</td><td>Mindfulness-Based Crisis Interventions (MBCI) for psychosis within acute inpatient psychiatric settings; A feasibility randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634133</td><td>Jacobsen (2020)</td><td>Mindfulness-based crisis interventions (MBCI) for psychosis within acute inpatient psychiatric settings; a feasibility randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645760</td><td>Jager (2006)</td><td>Pharmacological acute treatment in first episode schizophrenic disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648772</td><td>J√§ger (2009)</td><td>8-week results of the efficacy and extrapyramidal tolerability of risperidone or haloperidol in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634143</td><td>Jahoda (2015)</td><td>A randomised controlled trial comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: summary of study protocol</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647707</td><td>Jalbrzikowski (2018)</td><td>Differentiating between clinical and behavioral phenotypes in first-episode psychosis during maintenance of visuospatial working memory</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648537</td><td>James (2017)</td><td>Antipsychotics in adolescent-onset psychosis: A work in progress</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634306</td><td>Janakiramaiah (1982)</td><td>Early Placebo Responders in Hospitalized Depressed Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644685</td><td>Janet (2002)</td><td>Treatment emergent psychosis associated with mirtazapine and tianeptine: Commentary</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648709</td><td>Janicak (2014)</td><td>Acute management of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644718</td><td>Jansen (2015)</td><td>Towards a better understanding of caregiver distress in early psychosis: A systematic review of the psychological factors involved</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645028</td><td>Jansen (2015)</td><td>Service user perspectives on the experience of illness and pathway to care in first-episode psychosis: A qualitative study within the TOP project</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645285</td><td>Janssen (2008)</td><td>Regional gray matter volume deficits in adolescents with first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648536</td><td>Jarema (2008)</td><td>Antipsychotics in clinical practice. Treatment of the first schizophrenic episode</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644771</td><td>Jauhar (2017)</td><td>A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647129</td><td>Jauhar (2018)</td><td>Examining the presynaptic dopamine system and antipsychotic response in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648086</td><td>Jauhar (2018)</td><td>Cognitive behavioural therapy-A valid alternative to antipsychotics for psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647332</td><td>Jauhar (2019)</td><td>The effects of antipsychotic treatment on presynaptic dopamine synthesis capacity in first-episode psychosis: A positron emission tomography study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647760</td><td>Jauhar (2019)</td><td>Determinants of treatment response in first-episode psychosis: an 18F-DOPA PET study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647893</td><td>Jauhar (2019)</td><td>Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634211</td><td>Jauhar (2019)</td><td>The case for improved care and provision of treatment for people with first-episode mania.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634246</td><td>Jauhar (2020)</td><td>Psychosocial interventions versus antipsychotics for early-onset psychosis: can we fill the evidence gap?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634237</td><td>Jauhar (2021)</td><td>Mindfulness-based cognitive therapy and depression relapse-evaluating evidence through a meta-analytic lens may indicate myopia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646817</td><td>Javadapour (2010)</td><td>Hippocampal volumes in adults with bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646691</td><td>Javed (2018)</td><td>The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646181</td><td>Javitt (2017)</td><td>Multicenter validation study of biomarkers for glutamate-targeted drug development in psychotic disorders: a randomized clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644572</td><td>Javitt (2018)</td><td>Utility of imaging-based biomarkers for glutamate-targeted drug development in psychotic disorders: A randomized clinical trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644848</td><td>Jayaram (2011)</td><td>Successful use of aripiprazole for delusional disorder with comorbid pituitary microadenoma: A case report</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646402</td><td>Jazi (2020)</td><td>Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance Metabolique a Long Terme des Jeunes Traites par Antipsychotiques de Deuxieme Generation, Cinq ans Apres la publication des Lignes Directrices Camesa: Faisons-Nous des Progres?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634007</td><td>Jenkins (1961)</td><td>Quantitative aspects of sentence completion in the study of the improvement of schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634189</td><td>Jenner (1982)</td><td>Chapter 5 ‚Äì Antiparkinsonian and antidyskinetic drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648706</td><td>Jensen (2016)</td><td>Acute tranquilisation in young people with first-episode psychosis: Let's start low, go slow</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645570</td><td>Jensen (2017)</td><td>Pretreatment cardiometabolic status in youth with early-onset psychosis: baseline results from the TEA trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648238</td><td>Jensen (2018)</td><td>Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: Results from the TEA trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648283</td><td>Jensen (2019)</td><td>Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the tolerance and effect of antipsychotics in children and adolescents with psychosis (tea) trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648285</td><td>Jensen (2019)</td><td>Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-er versus aripiprazole: 12-week results: from the tea trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646427</td><td>Jeong (2013)</td><td>Long-acting injectable antipsychotics in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646573</td><td>Jeppesen (2005)</td><td>Integrated treatment of first-episode psychosis: Effect of treatment on family burden: OPUS trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648468</td><td>Jeppesen (2008)</td><td>The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648750</td><td>Ji (2013)</td><td>Abnormal auditory sensory gating-out in first-episode and never-medicated paranoid schizophrenia patients: An fMRI study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644637</td><td>Jimenez (2014)</td><td>Twelve-week treatment of tardive dyskinesia with NBI-98854</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647866</td><td>Jin (2021)</td><td>Cost and health impacts of adherence to the National Institute for Health and Care Excellence schizophrenia guideline recommendations</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634034</td><td>Jm (1985)</td><td>Compliance in the long-term treatment of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645238</td><td>Jo (2020)</td><td>The relationship of treatment delay with personality trait and family cohesion in patients with first-episode schizophrenia spectrum disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647292</td><td>Jo (2020)</td><td>The effects of patient personality traits and family cohesion on the treatment delay for patients with first-episode schizophrenia spectrum disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645698</td><td>Joaquim (2020)</td><td>Plasma Metabolite Profiles in First Episode Psychosis: Exploring Symptoms Heterogeneity/Severity in Schizophrenia and Bipolar Disorder Cohorts</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648389</td><td>Jody (1990)</td><td>Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647557</td><td>Johannessen (2001)</td><td>Early detection strategies for untreated first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647009</td><td>Johannessen (2007)</td><td>First-episode psychosis patients recruited into treatment via early detection teams versus ordinary pathways: Course, outcome and health service use during first 2 years</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647010</td><td>Johannessen (2011)</td><td>First-episode psychosis patients recruited into treatment via early detection teams versus ordinary pathways: Course and health service use during 5 years</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647352</td><td>Johnsen (2008)</td><td>Effectiveness of second generation antipsychotics: A systematic review of randomized trials</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648548</td><td>Johnsen (2008)</td><td>Antipsychotic-induced hyperprolactinemia: A cross-sectional survey</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647374</td><td>Johnsen (2018)</td><td>Effectiveness of antipsychotic treatments in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td></tr><tr><td>61633902</td><td>Johnson (1971)</td><td>Differential response to psychotropic drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634043</td><td>Johnson (1976)</td><td>The duration of maintenance therapy in chronic schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633848</td><td>Johnson (1979)</td><td>Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633638</td><td>Johnson (1983)</td><td>The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633735</td><td>Johnson (1987)</td><td>Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633585</td><td>Johnson (1988)</td><td>Observations on the use of depot neuroleptics in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633662</td><td>Johnson (1990)</td><td>Long-Term Drug Treatment of Psychosis: Observations on some Current Issues</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633886</td><td>Johnson (1990)</td><td>Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633549</td><td>Johnson (1991)</td><td>Who Should Be Treated</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633921</td><td>Johnson (2009)</td><td>Historical perspective on antipsychotic long-acting injections</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645402</td><td>Johnson (2016)</td><td>A randomised controlled trial of the clinical and cost-effectiveness of a contingency management intervention compared to treatment as usual for reduction of cannabis use and of relapse in early psychosis (CIRCLE): a study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634233</td><td>Johnson (2019)</td><td>A contingency management intervention to reduce cannabis use and time to relapse in early psychosis: the CIRCLE RCT.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633945</td><td>Johnstone (1983)</td><td>Adverse effects of anticholinergic medication on positive schizophrenic symptoms</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633821</td><td>Johnstone (1988)</td><td>The Northwick Park "functional" psychosis study: diagnosis and treatment response.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633762</td><td>Johnstone (1993)</td><td>Schizophrenia: problems in clinical practice</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634038</td><td>Johnstone (1996)</td><td>The nature of 'transient' and 'partial' psychoses: findings from the Northwick Park 'Functional' Psychosis Study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645645</td><td>Johnstone (1998)</td><td>Predictive symptomatology, course, and outcome in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648028</td><td>Jolley (2003)</td><td>Cognitive therapy in early psychosis: a pilot randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644586</td><td>Jones (1999)</td><td>The use of quetiapine in first-episode schizophrenia: A case study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646180</td><td>Jones (1999)</td><td>A multicentre comparison of olanzapine, risperidone, and haloperidol on working memory, new learning, and delayed recall of verbal and nonverbal materials in early-phase schizophrenia over a 12-month prospective double-blind clinical trial conference abstract</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647876</td><td>Jones (2004)</td><td>Cortical Effects of Quetiapine in First-Episode Schizophrenia: A Preliminary Functional Magnetic Resonance Imaging Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648089</td><td>Jones (2009)</td><td>Cognitive behaviour therapy versus specific pharmacological treatments for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59645465</td><td>Jones (2011)</td><td>Psychopharmacology: Acute phase</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634166</td><td>Jones (2018)</td><td>Improving access to psychological therapies (IAPT) for people with bipolar disorder: Summary of outcomes from the IAPT demonstration site</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644960</td><td>Jongsma (2020)</td><td>Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case-control study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646088</td><td>Jonker (2016)</td><td>Neuroinflammation in patients with psychosis: first results of a placebo controlled study with 8 gram valaciclovir daily</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648562</td><td>Joo (2021)</td><td>Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646522</td><td>Joober (2006)</td><td>Is Olanzapine a Brain-Sparing Medication?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645234</td><td>Jordan (2014)</td><td>The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645682</td><td>Jordan (2018)</td><td>Positive Changes Experienced After a First Episode of Psychosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647299</td><td>Joshi (2017)</td><td>Effects of nmda receptor antagonism in patients with schizophrenia: improvement in markers of cortical oscillatory dynamics</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648524</td><td>Joshi (2019)</td><td>Applications of neurophysiological biomarkers in CNS drug development: Focus on psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647541</td><td>Josiassen (2010)</td><td>Early intervention with second-generation antipsychotics in first-episode psychosis: Results of an 8-week naturalistic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648497</td><td>Jprn (2009)</td><td>Aripiprazole research over schizophrenia patients (both on first episode and recurrence) about its efficacy and influence on cognitive function</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646184</td><td>Jprn (2011)</td><td>A multicenter randomized control trial in Japan of comprehensive early intervention in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646549</td><td>Jprn (2011)</td><td>An intervention study of optimizing algorism-based pharmacological treatment for schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647996</td><td>Jprn (2013)</td><td>Comparative effect of second-generation antipsychotic blonanserin and aripiprazole on cognitive impairment in first-episode schizophrenia: an open-label trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646972</td><td>Jprn (2015)</td><td>A follow-up study of patients at early stage of psychotic disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647751</td><td>Jprn (2018)</td><td>Development of a comprehensive treatment based on psychosocial approach for support for the individuals with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633684</td><td>Judd (1973)</td><td>Phenothiazine effects in good premorbid schizophrenics divided into paranoid-nonparanoid status.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647492</td><td>Julayanont (2020)</td><td>Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646664</td><td>Juncal-Ruiz (2017)</td><td>Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647949</td><td>Juncal-Ruiz (2018)</td><td>Comparison of the anti-inflammatory effect of aripiprazole and risperidone in 75 drug-na√Øve first episode psychosis individuals: a 3‚ÄØmonths randomized study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647108</td><td>Juncal-Ruiz (2020)</td><td>Expression and functionality study of 9 toll-like receptors in 33 drug-naive non-affective first episode psychosis individuals: A 3-month study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634208</td><td>Juul (2021)</td><td>Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648360</td><td>Juutinen (2008)</td><td>Body mass index (BMI) of drug-naive psychotic adolescents based on a population of adolescent psychiatric inpatients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644690</td><td>Kader (2010)</td><td>Treatment adherence in first episode mania</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645367</td><td>Kader (2010)</td><td>Randomized controlled trial of olanzapine or chlorpromazine as addition to lithium in the treatment of a first manic episode with psychotic features: an 8 weeks, flexible dose, single blind trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633898</td><td>Kadota (1992)</td><td>A study of clinical response to different kinds of neuroleptics in first time medicated schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648688</td><td>Kafantaris (2001)</td><td>Adjunctive antipsychotic treatment of adolescents with bipolar psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633891</td><td>Kagan (1981)</td><td>Matched Tasks for Measuring Single-Word, Referent Communication: The Performance of Patients With Schizophrenic and Affective Disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648362</td><td>Kagan (2020)</td><td>Blunted affect early progression in drug-naive first episode schizophrenia patients: 10-week follow up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646034</td><td>Kahn (2002)</td><td>New study designs for new antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647377</td><td>Kahn (2008)</td><td>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648520</td><td>Kahn (2008)</td><td>"Are all antipsychotics equal?": Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647351</td><td>Kahn (2009)</td><td>Effectiveness of second-generation antipsychotics in first episode schizophrenia: the eufest study</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647376</td><td>Kahn (2009)</td><td>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial A second generation of antipsychotics (SGAs) was introduced over a decade ago for the treatment of schizophrenia. However, despite a multitude of studies, their purported clinical superiority is still a matter of debate. This open study, with 50 sites in 14 countries, included498 first-episode schizophrenia patients with minimal prior antipsychotic treatment. Follow-up was one year with treatment discontinuation as primary outcome. Secondary outcomes were (re)hospitalization rates, psychopathology, severity of illness, and measures of safety and tolerability. Patients were randomized to haloperidol (1-4mg/day; n=103), amisulpride (200-800 mg/day; n=104), olanzapine(5-20 mg/day; n=105), quetiapine (200-750 mg/day; n=104), or ziprasidone (40-160 mg/day; n=82). Analysis was by intention-to treat. The proportions of patients who discontinued treatment within12 months were 72% for haloperidol, 40% for amisulpride, 33% for olanzapine, 53% for quetiapine, and 45% for ziprasidone. Comparisons with haloperidol showed lower risks for discontinuation for amisulpride (hazard ratio, HR 0.36; 95% CI 0.23-0.55), olanzapine(HR 0.27; 95% CI 0.17-0.42), quetiapine (HR 0.49; 95% CI 0.33-0.73), and ziprasidone (HR 0.47; 95% CI 0.29-0.76). Patients on haloperidol showed similar improvements in psychopathology and in hospitalization rates, but displayed more signs of parkinsonism and used more anticholinergics than patients treated with the other antipsychotics. This pragmatic trial suggests that clinically meaning fullong-term antipsychotic treatment is achievable in the first episode of schizophrenia. However, due to the discrepancy in discontinuation rates and symptomatic improvement between haloperidol and the SGAs it cannot be concluded that SGAs are more efficacious than haloperidol in the treatment of these patients</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645919</td><td>Kahn (2018)</td><td>Optimising the treatment and management of first-episode schizophrenia: the optimise clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648550</td><td>Kahn (2018)</td><td>"Antipsychotic treatments: Who is really failing here?" Authors' reply</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648633</td><td>Kahn (2018)</td><td>Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): A three-phase switching study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648219</td><td>Kaiser (2005)</td><td>Changes in the pattern of substance abuse after the onset of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645929</td><td>Kale (2008)</td><td>Opposite changes in predominantly docosahexaenoic acid (DHA) in cerebrospinal fluid and red blood cells from never-medicated first-episode psychotic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645308</td><td>Kale (2009)</td><td>Reduced cerebrospinal fluid and plasma nerve growth factor in drug-naive psychotic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647587</td><td>Kalla (2002)</td><td>Duration of untreated psychosis and its correlates in first-episode psychosis in Finland and Spain</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648078</td><td>Kalla (2002)</td><td>Cognitive deficits in patients with first-episode psychosis as identified by Exner's Schizophrenia Index in Finland and Spain</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648768</td><td>Kalla (2011)</td><td>12-month follow-up of first-episode psychosis in Finland and Spain-Differential significance of social adjustment-related variables</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645815</td><td>Kam (2021)</td><td>Patterns and predictors of trajectories for subjective quality of life in patients with early psychosis: Three-year follow-up of the randomized controlled trial on extended early intervention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644755</td><td>Kamakura (2004)</td><td>Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645498</td><td>Kamali (2006)</td><td>A prospective evaluation of adherence to medication in first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646629</td><td>Kampman (2002)</td><td>Indicators of medication compliance in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647013</td><td>Kanahara (2018)</td><td>First-episode psychosis in treatment-resistant schizophrenia: A cross-sectional study of a long-term follow-up cohort</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646856</td><td>Kanas (2006)</td><td>Group therapy with schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633852</td><td>Kane (1979)</td><td>Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646980</td><td>Kane (1982)</td><td>Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td></tr><tr><td>61633726</td><td>Kane (1983)</td><td>Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633973</td><td>Kane (1983)</td><td>Low Dose Medication Strategies in the Maintenance Treatment of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633928</td><td>Kane (1987)</td><td>Treatment of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633558</td><td>Kane (1989)</td><td>Innovations in the Psychopharmacologic Treatment of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633648</td><td>Kane (1990)</td><td>Treatment programme and long‚Äêterm outcome in chronic schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634056</td><td>Kane (1991)</td><td>Dosage and Route of Administration of Neuroleptic Drugs During Different Phases of a Schizophrenic Illness</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634200</td><td>Kane (1993)</td><td>Treatment duration of psychiatric disorders: long-term treatment of resistant schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633970</td><td>Kane (1997)</td><td>Update on treatment strategies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634160</td><td>Kane (1999)</td><td>Olanzapine in the long-term treatment of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633937</td><td>Kane (2007)</td><td>Unanswered Questions in Schizophrenia Clinical Trials</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647986</td><td>Kane (2009)</td><td>Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633915</td><td>Kane (2009)</td><td>Clinical guideline recommendations for antipsychotic long-acting injections.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633609</td><td>Kane (2010)</td><td>Past and present progress in the pharmacologic treatment of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645411</td><td>Kane (2015)</td><td>The RAISE early treatment program for first-episode psychosis: background, rationale, and study design</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647925</td><td>Kane (2016)</td><td>Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645546</td><td>Kane (2019)</td><td>The prevention of relapse and hospitalization in first episode and early phase schizophrenia: results from the prelapse trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645818</td><td>Kane (2019)</td><td>Patients With Early-Phase Schizophrenia Will Accept Treatment With Sustained-Release Medication (Long-Acting Injectable Antipsychotics): results From the Recruitment Phase of the PRELAPSE Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645545</td><td>Kane (2020)</td><td>The prevention of relapse and hospitalization in first episode and early phase schizophrenia: results from the prelapse trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647430</td><td>Kane (2020)</td><td>Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: a Randomized Clinical Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647258</td><td>Kang (2016)</td><td>Efficacy and tolerability of paliperidone extended-release in the treatment of first-episode psychosis: An eight-week, open-label, multicenter trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647820</td><td>Kantrowitz (2016)</td><td>"D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: A pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial": Correction</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646344</td><td>Kantrowitz (2017)</td><td>Managing Negative Symptoms of Schizophrenia: How Far Have We Come?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645026</td><td>Kaplan (2020)</td><td>Severe Hypothyroidism Manifested as Acute Mania With Psychotic Features: A Case Report and Review of the Literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645265</td><td>Kapur (2000)</td><td>Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633808</td><td>Kapur (2005)</td><td>From dopamine to salience to psychosis‚Äîlinking biology, pharmacology and phenomenology of psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633918</td><td>Kapur (2005)</td><td>Evidence for Onset of Antipsychotic Effects Within the First 24 Hours of Treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633716</td><td>Kapur (2006)</td><td>How antipsychotics work-from receptors to reality.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645033</td><td>Karadeniz (2020)</td><td>Serum nesfatin-1, ghrelin, and lipid levels in adolescents with first episode drug naive unipolar depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646042</td><td>Karageorgiou (2019)</td><td>Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645835</td><td>Karakula-Juchnowicz (2018)</td><td>Paranoid Syndrome as the First Sign of Central Neurocytoma: A Case Report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647900</td><td>Karambelas (2018)</td><td>The contribution of employment duration to 18-month neurocognitive outcomes in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647898</td><td>Karambelas (2019)</td><td>Contribution of neurocognition to 18-month employment outcomes in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647147</td><td>Karanikas (2016)</td><td>Evidence for increased immune mobilization in First Episode Psychosis compared with the prodromal stage in males</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647822</td><td>Karanikas (2017)</td><td>Cytokines, cortisol and IGF-1 in first episode psychosis and ultra high risk males. Evidence for TNF-alpha, IFN-gamma, TNF-beta, IL-4 deviation</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647872</td><td>Karanikas (2019)</td><td>Cortisol and cytokines in early psychosis, do they correlate? A scoping review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647323</td><td>Karlovic (2021)</td><td>Effects of aripiprazole long-acting injectable antipsychotic on hospitalization in recent-onset schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646939</td><td>Karlsgodt (2008)</td><td>Functional magnetic resonance imaging of verbal working memory in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633659</td><td>Karson (1985)</td><td>Tardive dyskinesia and psychopathology in chronic schizophrenia: a cross-sectional study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646398</td><td>Karson (2016)</td><td>Long-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59646002</td><td>Karsten (2019)</td><td>O12.1. CARDIOMETABOLIC ADVERSE EFFECTS AND ITS PREDICTORS IN CHILDREN AND ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS DURING TREATMENT WITH QUETIAPINE-ER VERSUS ARIPIPRAZOLE: 12-WEEK RESULTS: FROM THE TEA TRIAL...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646497</td><td>Karwautz (2017)</td><td>[Key-topics in Austrian Child and Adolescent Psychiatry 2007-2017]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644720</td><td>Kaskie (2019)</td><td>Topographic deficits in sleep spindle density and duration point to frontal thalamo-cortical dysfunctions in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645303</td><td>Kaskie (2019)</td><td>Reduced frontal slow wave density during sleep in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646994</td><td>Kasper (1999)</td><td>First-episode schizophrenia: The importance of early intervention and subjective tolerability</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634010</td><td>Kasper (2003)</td><td>Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646335</td><td>Kastelic (2010)</td><td>MDR1 gene polymorphisms and response to acute risperidone treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644551</td><td>Katsanis (1996)</td><td>Visual event-related potentials in first-episode psychotic patients and their relatives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646152</td><td>Katsura (2014)</td><td>A naturalistic longitudinal study of at-risk mental state with a 2.4 year follow-up at a specialized clinic setting in Japan</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633780</td><td>Katz (1964)</td><td>Nonspecificity of Diagnosis of Paranoid Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633830</td><td>Katz (1974)</td><td>Video Methodology for Research in Psychopathology and Psychopharmacology: Rationale and Application</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633984</td><td>Katz (1982)</td><td>Dopamine and the limits of behavioral reduction ‚Äì or why aren't all schizophrenics fat and happy?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634071</td><td>Katz (1982)</td><td>Hedonic arousal, memory, and motivation</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633974</td><td>Katz (2003)</td><td>The contributions of Sam Greenhouse to research on psychiatric diagnosis and psychopharmacology.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644683</td><td>Kaur (2010)</td><td>Treatment implications of the schizophrenia prodrome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646067</td><td>Kaur (2012)</td><td>Neurophysiological biomarkers support bipolar-spectrum disorders within psychosis cluster</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648328</td><td>Kavanagh (2004)</td><td>A brief motivational intervention for substance misuse in recent-onset psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646541</td><td>Kavzoglu (2013)</td><td>Intracellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1) and E-selectin levels in first episode schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645346</td><td>Kazmierski (2020)</td><td>A Rare Trigger of Asthma Exacerbation: The Scotch Marigold</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648294</td><td>Kazour (2011)</td><td>Cannabis use and bipolar disorder: Search for association through a review of literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645758</td><td>Keating (2017)</td><td>Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646978</td><td>Keedy (2009)</td><td>An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647692</td><td>Keedy (2014)</td><td>Disease and drug effects on internally-generated and externally-elicited responses in first episode schizophrenia and psychotic bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646744</td><td>Keedy (2015)</td><td>Impact of antipsychotic treatment on attention and motor learning systems in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644665</td><td>Keefe (2001)</td><td>Treatment of neurocognitive deficits with olanzapine or low-dose haloperidol in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647997</td><td>Keefe (2004)</td><td>Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646093</td><td>Keefe (2006)</td><td>Neurocognitive Impairments</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646401</td><td>Keefe (2006)</td><td>Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647296</td><td>Keefe (2007)</td><td>Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647612</td><td>Keefe (2007)</td><td>Dr. Keefe and colleagues reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646855</td><td>Keefe (2012)</td><td>Guide to assessment scales in schizophrenia., 3rd ed</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648050</td><td>Keefe (2012)</td><td>Cognitive impairment in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648150</td><td>Keefe (2013)</td><td>Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648477</td><td>Keefe (2013)</td><td>Assessment of cognition in schizophrenia treatment studies</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647547</td><td>Keefe (2017)</td><td>Early intervention in attenuated psychosis syndrome: a phase II study evaluating efficacy, safety, and tolerability of oral BI 409306</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645359</td><td>Keefe (2020)</td><td>A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: design and rationale</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647554</td><td>Keinanen (2015)</td><td>Early insulin resistance predicts weight gain and waist circumference increase in first-episode psychosis - a one year follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644591</td><td>Keith (2005)</td><td>Use of Long-Acting Risperidone: Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634173</td><td>Kellam (1982)</td><td>The Prevention of Teenage Substance Use: Longitudinal Research and Strategy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633588</td><td>Kellner (1971)</td><td>Outlines of the Management of Common Psychiatric Crises and Emergencies in the Community</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648683</td><td>Kelly (2014)</td><td>Adjunctive minocycline in clozapine treated schizophrenia patients with persistent symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634252</td><td>Kelly (2021)</td><td>Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646752</td><td>Kelsven (2020)</td><td>Immuno-inflammatory changes across phases of early psychosis: The impact of antipsychotic medication and stage of illness</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645171</td><td>Kendall (2011)</td><td>The rise and fall of the atypical antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647461</td><td>Kenny (1992)</td><td>Effect of atypical and typical antipsychotic drugs on neuropsychological functions in early-stage schizophrenic patients conference abstract</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644499</td><td>Kerwin (2007)</td><td>When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633939</td><td>Keshavan (1992)</td><td>First-episode studies in schizophrenia : criteria and characterization</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645212</td><td>Keshavan (1998)</td><td>Research and treatment strategies in first episode psychoses: the Pittsburgh experience</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647740</td><td>Keshavan (2003)</td><td>Diagnostic Specificity and Neuroanatomical Validity of Neurological Abnormalities in First-Episode Psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644984</td><td>Keshavan (2007)</td><td>Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648356</td><td>Keshavan (2019)</td><td>Brain changes in the early course of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633798</td><td>Keskiner (1968)</td><td>Maintenance Treatment of Schizophrenic Outpatients With a Depot Phenothiazine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645344</td><td>Kessing (2017)</td><td>Rate and predictors of conversion from unipolar to bipolar disorder: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648431</td><td>Kettle (2019)</td><td>Attentional processing of facial expressions and gaze direction in depression and first-episode psychosis as reflected by LPP modulation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646877</td><td>Keymer-Gausset (2018)</td><td>Gray and white matter changes and their relation to illness trajectory in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644844</td><td>Khalsa (2008)</td><td>Suicidal events and accidents in 216 first-episode bipolar I disorder patients: Predictive factors</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645305</td><td>Khan (2002)</td><td>Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647783</td><td>Khan (2016)</td><td>Depot antipsychotics: Where do we stand?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634296</td><td>Khan (2019)</td><td>A Preliminary Study of the Nociceptin Receptor System in Individuals with Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648054</td><td>Khawar (2014)</td><td>Cognitive impairment and duration of untreated first episode psychoses in Pakistan</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646504</td><td>Khizar (2017)</td><td>Jerking movements: An adolescent with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644745</td><td>Khoury (2015)</td><td>Third-wave strategies for emotion regulation in early psychosis: A pilot study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646970</td><td>Khoyratty (2015)</td><td>Forming implementation intentions improves prospective memory in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647970</td><td>Kidd (2020)</td><td>A comparison of compensatory and restorative cognitive interventions in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646215</td><td>Kiejna (2014)</td><td>Money matters: Does the reimbursement policy for second-generation antipsychotics influence the number of recorded schizophrenia patients and the burden of stigmatization?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648616</td><td>Kikinis (2015)</td><td>Anterior commissural white matter fiber abnormalities in first-episode psychosis: A tractography study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646153</td><td>Kikuchi (2007)</td><td>Native EEG and treatment effects in neuroleptic-naive schizophrenic patients: Time and frequency domain approaches</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644561</td><td>Kilciksiz (2020)</td><td>Verbal memory measurement towards digital perspectives in first-episode psychosis: A review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648473</td><td>Kilian (2020)</td><td>The association between childhood trauma and treatment outcomes in schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644535</td><td>Killackey (2006)</td><td>Vocational rehabilitation in first-episode psychosis: results of the first Australian randomized controlled trial of individual placement and support</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644541</td><td>Killackey (2008)</td><td>Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646543</td><td>Killackey (2008)</td><td>Interventions in the early stages of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646626</td><td>Killackey (2010)</td><td>Individual placement and support in early psychosis: evidence of benefit and future directions</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644539</td><td>Killackey (2012)</td><td>Vocational recovery in first-episode psychosis: first results from a large randomized controlled trial of IPS</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646625</td><td>Killackey (2012)</td><td>Individual placement and support research and development in early psychosis in Australia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645123</td><td>Killackey (2013)</td><td>The role of neurocognition within a randomised controlled trial of Individual Placement and Support for first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645361</td><td>Killackey (2013)</td><td>A randomized controlled trial of vocational intervention for young people with first-episode psychosis: Method</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644540</td><td>Killackey (2014)</td><td>Vocational recovery in first episode psychosis: preliminary results from a large randomised controlled trial of individual placement and support</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648399</td><td>Killackey (2014)</td><td>Baseline to 18 months: main results from a randomized controlled trial of individual placement and support for young people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646627</td><td>Killackey (2019)</td><td>Individual placement and support for vocational recovery in first-episode psychosis: Randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646204</td><td>Kim (2003)</td><td>Morphology of the lateral superior temporal gyrus in neuroleptic naive patients with schizophrenia: Relationship to symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647355</td><td>Kim (2008)</td><td>Effectiveness of risperidone long-acting injection in first-episode schizophrenia: In naturalistic setting</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644853</td><td>Kim (2013)</td><td>Successful early clozapine trial in the treatment of first-episode schizophrenia: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644484</td><td>Kim (2016)</td><td>White-matter connectivity related to paliperidone treatment response in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646797</td><td>Kim (2016)</td><td>How close are we to individualized medicine for Parkinson's disease?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648602</td><td>Kim (2018)</td><td>Antipsychotic discontinuation in first episode psychosis: [18F]DOPA and [11C]raclopride PET study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648600</td><td>Kim (2019)</td><td>Antipsychotic discontinuation in first-episode psychosis: A prospective study with [<sup>18</sup>F]DOPA and [<sup>11</sup>C]raclopride PET</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648601</td><td>Kim (2019)</td><td>Antipsychotic discontinuation in first episode psychosis: a prospective study using [18F]DOPA and [11C]raclopride PET</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646707</td><td>Kim (2020)</td><td>Impaired Performance on the Reading the Mind in the Eyes Test in First-Episode Psychosis and Clinical High Risk for Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647261</td><td>Kim (2020)</td><td>Efficacy and Tolerability of Dopamine D2 Receptor Partial Agonists Versus D2 Receptor Antagonists in Early Psychosis: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648179</td><td>Kim (2020)</td><td>Clinical and psychosocial factors associated with depression in patients with psychosis according to stage of illness</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648438</td><td>Kim (2020)</td><td>Associations of food craving with psychological and physical characteristics in patients with first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646066</td><td>Kim (2021)</td><td>Neurophysiological Correlate of Emotion Regulation by Cognitive Reappraisal and Its Association With Psychotic Symptoms in Early Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646391</td><td>Kim (2021)</td><td>The longitudinal effect of amisulpride on striatal dopamine synthesis capacity in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647262</td><td>Kim (2021)</td><td>Efficacy and tolerability of aripiprazole versus D<inf>2</inf> antagonists in the early course of schizophrenia: a systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647309</td><td>Kim (2021)</td><td>Effects of Long-Acting Injectable Paliperidone Palmitate on Clinical and Functional Outcomes in Patients With Schizophrenia Based on Illness Duration</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647429</td><td>Kim (2021)</td><td>Effect of long-acting injections of paliperidone palmitate on clinical and functional outcomes in patients with schizophrenia based on illness duration</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645669</td><td>Kimura (2013)</td><td>Potential treatment strategy of risperidone in long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634053</td><td>Kinderman (1998)</td><td>The Clinical Implications of a Psychological Model of Paranoia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646944</td><td>Kindler (2019)</td><td>Functional and structural correlates of abnormal involuntary movements in psychosis risk and first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645211</td><td>Kirch (1992)</td><td>Research on First-Episode Psychosis: Report on a National Institute of Mental Health Workshop</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647909</td><td>Kirenskaya (2011)</td><td>The contingent negative variation laterality and dynamics in antisaccade task in normal and unmedicated schizophrenic subjects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647189</td><td>Kirkbride (2017)</td><td>The epidemiology of first-episode psychosis in early intervention in psychosis services: Findings from the social epidemiology of psychoses in East Anglia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645656</td><td>Kirkbride (2018)</td><td>Predicting population-level need for early treatment programmes in first episode psychosis: The advanced psychiatric MAPping translated into innovations for care [PsyMaptic-A] study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644562</td><td>Kirschner (2018)</td><td>Ventral striatal dysfunction and symptom expression in individuals with schizotypal personality traits and early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647798</td><td>Kirschner (2018)</td><td>Deficits in context-dependent adaptive coding in early psychosis and healthy individuals with schizotypal personality traits</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645904</td><td>Kirschner (2021)</td><td>Orbitofrontal-Striatal Structural Alterations Linked to Negative Symptoms at Different Stages of the Schizophrenia Spectrum</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647530</td><td>Kishi (2014)</td><td>Early prediction of blonanserin response in Japanese patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647444</td><td>Kishi (2019)</td><td>Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645861</td><td>Kishimoto (2020)</td><td>P.556 Long-acting injectable vs. oral antipsychotics for preventing rehospitalisation in schizophrenia: a meta-analysis of randomised, mirror-image, and cohort studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647394</td><td>Kishore (2020)</td><td>Effect of vitamin D supplementation in treatment of first episode psychosis: A randomized double blind, placebo controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644500</td><td>Kiss (2010)</td><td>When doors of perception open: Visual contrast sensitivity in never-medicated, first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633873</td><td>Kissling (1985)</td><td>Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633580</td><td>Kissling (1990)</td><td>Fluanxol Depot 10% versus Haloperidoldecanoat ‚Äî Dosierung und Applikationsintervalle</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633544</td><td>Kissling (1991)</td><td>Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633578</td><td>Kissling (1991)</td><td>Duration of Neuroleptic Maintenance Treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634144</td><td>Kissling (1991)</td><td>Guidelines for Neuroleptic Relapse Prevention in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634018</td><td>Kissling (1992)</td><td>Ideal and reality of neuroleptic relapse prevention.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648543</td><td>Kiviniemi (2013)</td><td>Antipsychotics and mortality in first-onset schizophrenia: Prospective Finnish register study with 5-year follow-up</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646487</td><td>Klauser (2015)</td><td>Lack of evidence for regional brain volume or cortical thickness abnormalities in youths at clinical high risk for psychosis: Findings from the Longitudinal Youth at Risk Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646160</td><td>Klauser (2018)</td><td>N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634125</td><td>Klein (1969)</td><td>Diagnosis and Drug Treatment of Psychiatric Disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633851</td><td>Klein (1973)</td><td>Premorbid Asocial Adjustment and Response to Phenothiazine Treatment Among Schizophrenic Inpatients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645799</td><td>Klein (2004)</td><td>A perfect checklist</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634087</td><td>Klemm (1982)</td><td>Time for a new synthesis of hedonia mechanisms: Interaction of multiple and interdependent reinforcer systems</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633802</td><td>Klerman (1965)</td><td>The teaching of psychopharmacology in the psychiatric residency</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633869</td><td>Klett (1965)</td><td>The right drug for the right patient.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647956</td><td>Kline (2019)</td><td>A comparison of neurocognition and functioning in first episode psychosis populations: Do research samples reflect the real world?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646199</td><td>Kline (2021)</td><td>Motivational Interviewing for Loved Ones in Early Psychosis: Development and Pilot Feasibility Trial of a Brief Psychoeducational Intervention for Caregivers</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634248</td><td>Klingberg (2018)</td><td>Cognitive Behavioral Therapy for Psychosis (CBTp): Multicenter Randomized Clinical Trial on Specific Efficacy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648639</td><td>Knolle (2020)</td><td>Altered subcortical emotional salience processing differentiates Parkinson's patients with and without psychotic symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648640</td><td>Knolle (2020)</td><td>Altered subcortical emotional salience processing and a 'jumping to conclusions' bias in Parkinson's patients with psychotic symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647745</td><td>Koenig (1999)</td><td>A deviant EEG brain microstate in acute, neuroleptic-naive schizophrenics at rest</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647671</td><td>Koethe (2006)</td><td>Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648372</td><td>Koethe (2009)</td><td>Binocular depth inversion as a paradigm of reduced visual information processing in prodromal state, antipsychotic-naive and treated schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646935</td><td>Kohler (2020)</td><td>Further evidence supporting coordinated specialty care for early psychosis: Findings from the samhsa supported penn psychosis evaluation and recovery center (PERC)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647928</td><td>Koike (2011)</td><td>Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645880</td><td>Kolenic (2019)</td><td>P.4.10 Obesity, first-episode psychosis and lower brain gray matter volumes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646831</td><td>Kolenic (2020)</td><td>Higher Body-Mass Index and Lower Gray Matter Volumes in First Episode of Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648134</td><td>Kolivakis (2002)</td><td>Clozapine for first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648501</td><td>Kolli (2013)</td><td>Aripiprazole for neuroleptic induced hyperprolactinaemia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648215</td><td>Kolyaskina (2015)</td><td>Characteristics of the immune system and the risk of developing endogenous psychosis at juvenile age</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647360</td><td>Komatsu (2013)</td><td>Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647881</td><td>Kondratova (2019)</td><td>Correlates of negative attitudes towards medication in people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646904</td><td>Kondziella (2006)</td><td>Glial-Neuronal Interactions are Impaired in the Schizophrenia Model of Repeated MK801 Exposure</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645923</td><td>Kontaxakis (2000)</td><td>Optimal risperidone dose in drug-naive, first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644752</td><td>Kontaxakis (2005)</td><td>Therapeutic interventions in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633862</td><td>Koob (1982)</td><td>The dopamine anhedonia hypothesis: A pharmacological phrenology</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648313</td><td>Koola (2019)</td><td>Can N-acetylcysteine, varenicline, or the combination prevent psychosis by enhancing mismatch negativity?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644819</td><td>Kopala (1996)</td><td>Symptoms in neuroleptic-naive, first-episode schizophrenia: Response to risperidone</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647098</td><td>Kopala (1997)</td><td>Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: Response to low-dose risperidone</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648165</td><td>Kopala (1997)</td><td>Clinical experience in developing treatment regimens with the novel antipsychotic risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645147</td><td>Kopala (1998)</td><td>Risperidone in first-episode schizophrenia: Improvement in symptoms and pre-existing extrapyramidal signs</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648714</td><td>Kopala (1998)</td><td>Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646338</td><td>Kopala (2004)</td><td>Maximizing function after first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644680</td><td>Kopala (2006)</td><td>Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647935</td><td>Kopczynska (2019)</td><td>Complement system biomarkers in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646585</td><td>Kopf (2012)</td><td>Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647602</td><td>Korczyn (2007)</td><td>Drug trials in dementia: Challenging ethical dilemmas</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645270</td><td>Koreen (1994)</td><td>Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645700</td><td>Koreen (1994)</td><td>Plasma homovanillic acid levels in first-episode schizophrenia: Psychopathology and treatment response</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648390</td><td>Koreen (1997)</td><td>The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647411</td><td>Korostenskaja (2009)</td><td>The effect of quetiapine on auditory P300 response in patients with schizoaffective disorder: Preliminary study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645941</td><td>Kostev (2019)</td><td>One-year persistence with donepezil, memantine, and rivastigmine in more than 66,000 elderly patients followed in Poland</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648249</td><td>Kotecha (2018)</td><td>Celecoxib plus standard care for people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644911</td><td>Koulenti (2012)</td><td>Stages, course and prognosis of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646309</td><td>Kour (2013)</td><td>Memantine for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646167</td><td>Koutsouleris (2017)</td><td>"Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: A machine learning approach": Correction</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647523</td><td>Kozloff (2020)</td><td>Early Psychosis Intervention-Spreading Evidence-based Treatment (EPI-SET): protocol for an effectiveness-implementation study of a structured model of care for psychosis in youth and emerging adults</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644486</td><td>Kraguljac (2020)</td><td>White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naive first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644487</td><td>Kraguljac (2020)</td><td>White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naive first episode psychosis patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633595</td><td>Kramer (1970)</td><td>Problems in psychiatric epidemiology.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633853</td><td>Kramer (1976)</td><td>Issues in the development of statistical and epidemiological data for mental health services research.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645412</td><td>Kreyenbuhl (2016)</td><td>The RAISE connection program: Psychopharmacological treatment of people with a first episode of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648030</td><td>Krieger (2001)</td><td>Cognitive subprocesses and schizophrenia: B. Maze tasks</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648031</td><td>Krieger (2001)</td><td>Cognitive subprocesses and schizophrenia: A. Reaction-time decomposition</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645091</td><td>Krishan (1977)</td><td>Schizophrenia in a 46,XY male with the Noonan syndrome</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646614</td><td>Kroken (2017)</td><td>The influence of 3 weeks of antipsychotic treatment on cell adhesion molecules in drug naive patients with schizophrenia spectrum disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647545</td><td>Krstev (2004)</td><td>Early intervention in first-episode psychosis--the impact of a community development campaign</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645195</td><td>Krukow (2020)</td><td>Resting-state hyperconnectivity within the default mode network impedes the ability to initiate cognitive performance in first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645670</td><td>Krystal (2010)</td><td>Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645714</td><td>Kuang (2017)</td><td>A pilot study of cognitive insight and structural covariance in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645277</td><td>Kucukalic (2007)</td><td>Relapse prevention in schizophrenia--New therapeutic challenges</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646898</td><td>Kucukgoncu (2019)</td><td>Glucose metabolism dysregulation at the onset of mental illness is not limited to first episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644849</td><td>Kudla (2004)</td><td>Successful treatment of schizophrenia is more than a reduction of symptoms. A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645424</td><td>Kulaksizoglu (2003)</td><td>Quetiapine for Mania With Wilson's Disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645584</td><td>Kulkarni (2008)</td><td>Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646810</td><td>Kulkarni (2017)</td><td>Hormone modulation: a novel approach to managing psychosis in women</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648414</td><td>Kumar (2011)</td><td>The authors respond</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648486</td><td>Kumar (2012)</td><td>Asenapine versus typical antipsychotics for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634145</td><td>Kumar (2017)</td><td>Antipsychotic treatment, psychoeducation & regular follow up as a public health strategy for schizophrenia: Results from a prospective study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647073</td><td>Kumar (2019)</td><td>Family caregivers' needs of young patients with first episode psychosis: A qualitative study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646954</td><td>Kumar (2020)</td><td>Frontal GABA in schizophrenia: a meta-analysis of 1H-MRS studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647277</td><td>Kumari (2002)</td><td>Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: A critical evaluation of current evidence and directions for future research</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647339</td><td>Kumari (2003)</td><td>Effects of acute procyclidine administration on prepulse inhibition of the startle response in schizophrenia: a double-blind, placebo-controlled study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645576</td><td>Kumari (2005)</td><td>Prepulse Inhibition Deficits in Schizophrenia: Static or Amenable to Treatment? [References]</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644908</td><td>Kumari (2007)</td><td>Startle gating in antipsychotic-naive first episode schizophrenia patients: One ear is better than two</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645951</td><td>Kuo (2019)</td><td>On understanding variability in brain structure volumes in schizophrenia: A reply to De Peri and Vita</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633572</td><td>Kupfer (1971)</td><td>Chlorpromazine and Sleep in Psychiatric Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633871</td><td>Kurlakd (1961)</td><td>The Comparative Effectiveness Of Six Phenothiazine Compounds, Phenobarbetal And Inert Placebo In The Treatment Of Acutely Ill Patlents: Global Measures Of Severity Of Illness</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633792</td><td>Kurland (1962)</td><td>The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: personality dimensions.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648499</td><td>Kuzmanovic (2015)</td><td>Aripiprazole in treatment of first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646410</td><td>Kwon (2009)</td><td>Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647761</td><td>Kwong (2016)</td><td>Determinants of subjective quality of life in first-episode psychosis patients receiving specialized early intervention service in Hong Kong</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648176</td><td>Kwong (2017)</td><td>Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634072</td><td>L (1976)</td><td>Postpsychotic state, convalescent environment, and therapeutic relationship in schizophrenic outcome.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634212</td><td>L‚ÄôInsalata (2020)</td><td>Confirming the Efficacy of an Adaptive Component to Family-Based Treatment for Adolescent Anorexia Nervosa: Study Protocol for a Randomized Controlled Trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647260</td><td>La Pia (2001)</td><td>Efficacy and tolerability of olanzapine in the early phase of schizophrenia: Evidences from a naturalistic study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648171</td><td>Labad (2018)</td><td>Clinical correlates of hypothalamic-pituitary-adrenal axis measures in individuals at risk for psychosis and with first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633903</td><td>Lader (1971)</td><td>Clinical psychopharmacology: some current problems.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633598</td><td>Lader (1977)</td><td>The clinical actions of major tranquillizers.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633992</td><td>Lader (1989)</td><td>Clinical pharmacology of antipsychotic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647116</td><td>Lago (2021)</td><td>Exploring cellular markers of metabolic syndrome in peripheral blood mononuclear cells across the neuropsychiatric spectrum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646511</td><td>Lahti (2011)</td><td>Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647579</td><td>Lahti (2019)</td><td>Duration of untreated psychosis correlates with resting state functional connectivity and cortical morphology in antipsychotic-naive first episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645888</td><td>Lai (2012)</td><td>An overview of a specialized intervention service for adult onset first-episode psychosis - The Jockey Club Early Psychosis (JCEP) Project</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647422</td><td>Lajoie (2020)</td><td>Effect of non-pharmacological interventions on source memory processes in the early course of psychosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645490</td><td>Lakusta (2013)</td><td>A Proton-MRS and neurocognitive analysis of psychotic symptoms in stimulant dependence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644468</td><td>Lal (2019)</td><td>"Worried about relapse": Family members' experiences and perspectives of relapse in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648700</td><td>Lal (2020)</td><td>Adaptation of a Digital Health Innovation to Prevent Relapse and Support Recovery in Youth Receiving Services for First-Episode Psychosis: Results From the Horyzons-Canada Phase 1 Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644634</td><td>Lally (2016)</td><td>Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648135</td><td>Lally (2016)</td><td>Clozapine augmentation for treatment‚Äêresistant schizoaffective disorder</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645226</td><td>Lally (2017)</td><td>Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645214</td><td>Lally (2018)</td><td>The Representativeness of Participants With Severe Mental Illness in a Psychosocial Clinical Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644546</td><td>Lally (2019)</td><td>Vitamin D and clinical symptoms in First Episode Psychosis (FEP): A prospective cohort study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644661</td><td>Lally (2019)</td><td>Treatment resistant schizophrenia - review and a call to action</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644877</td><td>Lambden (2018)</td><td>Structured physical exercise and recovery from first episode psychosis in young adults, the FitForLife study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645985</td><td>Lambert (2005)</td><td>Olanzapine in subjects with a first-episode psychosis non-responsive, intolerant or non-compliant to a first-line trial of risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647954</td><td>Lambert (2005)</td><td>Comparison of Olanzapine and Risperidone in 367 First-Episode Patients with Non-Affective or Affective Psychosis: Results of an Open Retrospective Medical Record Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645982</td><td>Lambert (2006)</td><td>Olanzapine is associated with more rapid weight gain than haloperidol in people with first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645557</td><td>Lambert (2010)</td><td>Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633747</td><td>Lambert (2010)</td><td>ASSERTIVE COMMUNITY TREATMENT (ACT) AS PART OF INTEGRATED CARE VERSUS STANDARD CARE: A 12-MONTH TRIAL IN PATIENTS WITH FIRST- AND MULTIPLE-EPISODE SCHIZOPHRENIA-SPECTRUM DISORDERS TREATED WITH QUETIAPINE IR (ACCESS TRIAL)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634279</td><td>Lambert (2010)</td><td>Assertive community Treatment (ACT) as part of integrated care versus standard care: a 12-month trial in patients with first- and negatively selected multiple-episode schizophrenia spectrum-disorders treated with quetiapine IR.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647968</td><td>Lambert (2016)</td><td>Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647564</td><td>Lambert (2017)</td><td>Early detection and integrated care for adolescents and young adults with psychotic disorders: the ACCESS III study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647563</td><td>Lambert (2018)</td><td>Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644609</td><td>Landolt (2012)</td><td>Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646553</td><td>Landolt (2012)</td><td>The interrelation of needs and quality of life in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645623</td><td>Landolt (2016)</td><td>Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645721</td><td>Lane (2001)</td><td>A pilot double-blind, dose-comparison study of risperidone in drug-naive, first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646755</td><td>Lane (2004)</td><td>Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648424</td><td>Langdon (2013)</td><td>Attributional biases, paranoia, and depression in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646500</td><td>Langdon (2014)</td><td>Jumping to delusions in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647121</td><td>Lange (2017)</td><td>Experimentally induced psychosocial stress in schizophrenia spectrum disorders: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645419</td><td>Lankappa (2012)</td><td>Quetiapine versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59648373</td><td>Lappin (2014)</td><td>Bilateral hippocampal increase following first-episode psychosis is associated with good clinical, functional and cognitive outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645896</td><td>Lappin (2016)</td><td>Outcomes following first-episode psychosis-Why we should intervene early in all ages, not only in youth</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647503</td><td>Lappin (2018)</td><td>Early sustained recovery following first episode psychosis: Evidence from the AESOP10 follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645169</td><td>Large (2014)</td><td>Risk assessment for violence and self-harm in first episode psychosis and the need for early psychosis intervention services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647337</td><td>Larrison (2011)</td><td>Effects of adjunct valproic acid on clinical symptoms and saccadic eye movements in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647560</td><td>Larsen (2006)</td><td>Early Detection of First-Episode Psychosis: The Effect on 1-Year Outcome</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644615</td><td>Larsen (2007)</td><td>Understanding a complex intervention: Person-centered ethnography in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644826</td><td>Larsen (2007)</td><td>Symbolic healing of early psychosis: psychoeducation and sociocultural processes of recovery</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646741</td><td>Larsen (2019)</td><td>The impact of exercise training complementary to early intervention in patients with first-episode psychosis: A qualitative sub-study from a randomized controlled feasibility trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634275</td><td>Larsen-Barr (2021)</td><td>Service-user efforts to maintain their wellbeing during and after successful withdrawal from antipsychotic medication.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645638</td><td>Lasalvia (2017)</td><td>Predictors and moderators of treatment outcome in patients receiving multi-element psychosocial intervention for early psychosis: Results from the GET UP pragmatic cluster randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645983</td><td>Lasic (2016)</td><td>Olanzapine induced stuttering: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645741</td><td>Lass (2008)</td><td>Pharmacotherapy of first episode psychosis in Estonia: Comparison with national and international treatment guidelines</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634005</td><td>Lassen (1975)</td><td>Inhibition of 4,alpha-dimethyl-m-tyramine (H 77/77)-induced hypermotility in rats by single and repeated administration of chloropromazine, haloperidol, clozapine and thioridazine.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633879</td><td>Lassen (1976)</td><td>Inhibition and potentiation of apomorphine-induced hypermotility in rats by neuroleptics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633993</td><td>Lassen (2009)</td><td>Inhibition of apomorphine-induced climbing in mice by cholinergic drugs and neuroleptics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633994</td><td>Lassen (2009)</td><td>Inhibition of Apomorphine-induced Hypermotility in Rats by Chlorpromazinc, Perphenazine, Thioridazine and Melperone</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646417</td><td>Lasser (2007)</td><td>Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646301</td><td>Latham (2018)</td><td>Meta-analysis of adult height and birth length in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645986</td><td>Latifeh (2019)</td><td>Olanzapine dose for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633694</td><td>Latz (1965)</td><td>The effects of chlorpromazine and secobarbital under two conditions of reinforcement on the performance of chronic schizophrenic subjects.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645342</td><td>Lau (2019)</td><td>Rates and predictors of disengagement of patients with first-episode psychosis from the early intervention service for sychosis service (EASY) covering 15 to 64 years of age in Hong Kong</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646377</td><td>Lauretti (1999)</td><td>Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645862</td><td>Laurin (2020)</td><td>P.551 Effects of the transcranial magnetic stimulation on the sense of agency and body ownership impairments in schizophrenia with first-rank symptoms</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648222</td><td>Lavagnino (2015)</td><td>Changes in the corpus callosum in women with late-stage bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647639</td><td>Lavalaye (1999)</td><td>Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645719</td><td>Law (2017)</td><td>A pilot randomised controlled trial comparing antipsychotic medication, to cognitive behavioural therapy to a combination of both in people with psychosis: Rationale, study design and baseline data of the COMPARE trial</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Tiril Borge</span></td></tr><tr><td>61634231</td><td>Law (2021)</td><td>Combined individual and family therapy in comparison to treatment as usual for people at‚Äêrisk of psychosis: A feasibility study (IF CBT): Trial rationale, methodology and baseline characteristics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647171</td><td>Lawrence (2021)</td><td>Ethnicity and power in the mental health system: experiences of white British and black Caribbean people with psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634216</td><td>Lawrence (2021)</td><td>A historical review of placebo-controlled, relapse prevention trials in schizophrenia: The loss of clinical equipoise</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634169</td><td>Lawrie (2010)</td><td>15 ‚Äì Schizophrenia and related disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645659</td><td>Lawrie (2012)</td><td>Predicting first episode psychosis in those at high risk for genetic or cognitive reasons</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634110</td><td>Laws (2018)</td><td>Cognitive Behavioural Therapy for schizophrenia - outcomes for functioning, distress and quality of life: a meta-analysis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634158</td><td>Laws (2018)</td><td>Why cognitive behavioural therapy should stop being offered to people with schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634206</td><td>Le (1960)</td><td>Trifluoperazine in chronic psychiatric patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645750</td><td>Le Fauve (2004)</td><td>Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645613</td><td>Le Quach (2009)</td><td>Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634283</td><td>Leach (2021)</td><td>Essential oils for agitation in dementia [rELOAD]: A pragmatic, cluster-randomized, placebo-controlled, pilot feasibility trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645383</td><td>Leavey (2004)</td><td>A randomized controlled trial of a brief intervention for families of patients with a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648101</td><td>Lecardeur (2013)</td><td>Cognitive behavior therapy after first-episodes psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>59645766</td><td>Leckband (2007)</td><td>Pharmacogenomics in psychiatry</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646174</td><td>Leclerc (2015)</td><td>Multimodal group intervention in first-episode psychosis: a randomized clinical trial of effectiveness</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647763</td><td>Leclerc (2015)</td><td>Determinants of adherence to treatment in first-episode psychosis: A comprehensive review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648213</td><td>Leclerc (2021)</td><td>A Chart Audit Study of Clozapine Utilization in Early Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633854</td><td>Lecomte (2006)</td><td>WC12C GROUP CBT VS SKILLS TRAINING FOR FIRST EPISODES OF PSYCHOSIS ‚Äì RESULTS OF A RCT</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645637</td><td>Lecomte (2008)</td><td>Predictors and profiles of treatment non-adherence and engagement in services problems in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646865</td><td>Lecomte (2010)</td><td>Group CBT for early psychosis - Are there still benefits 1 year later?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646864</td><td>Lecomte (2012)</td><td>Group CBT for early psychosis--are there still benefits one year later?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648765</td><td>Lee (1998)</td><td>The 15-year outcome of Chinese patients with schizophrenia in Hong Kong</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644925</td><td>Lee (2008)</td><td>Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644642</td><td>Lee (2010)</td><td>Trial of aripiprazole in the treatment of first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644485</td><td>Lee (2012)</td><td>White matter tract abnormalities in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646154</td><td>Lee (2012)</td><td>"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia": Correction</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648034</td><td>Lee (2013)</td><td>Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645431</td><td>Lee (2016)</td><td>Quality of life and functioning in first-episode psychosis Chinese patients with different antipsychotic medications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648211</td><td>Lee (2017)</td><td>Childhood adversity and schizophrenia: The protective role of resilience in mental and physical health, and metabolic markers</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645253</td><td>Lee (2020)</td><td>Relationship between resting-state theta phase-gamma amplitude coupling and neurocognitive functioning in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647325</td><td>Lee (2020)</td><td>Effects of antipsychotics on rumination in patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646225</td><td>Lees (2017)</td><td>Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: The effects of test battery in a randomised controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647677</td><td>Leeson (2009)</td><td>Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647693</td><td>Leeson (2009)</td><td>Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: Stability over six years and specific associations with medication type and disorganization syndrome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647930</td><td>Lefaucheur (2016)</td><td>A comprehensive database of published tDCS clinical trials (2005-2016)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633824</td><td>Leff (1971)</td><td>Trial of Maintenance Therapy in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634179</td><td>Leff (2011)</td><td>schizophrenic patients: two year follow-up A controlled trial of social intervention in the families of</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648672</td><td>Leguay (2016)</td><td>[Advocacy for the establishment of a comprehensive strategy to reduce the "burden" of schizophrenic disorders]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644699</td><td>Lehman (1998)</td><td>Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) Treatment Recommendations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633672</td><td>Lehmann (1975)</td><td>Psychopharmacological treatment of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634106</td><td>Lehmann (1975)</td><td>psychopharmacological treatment of schizophrenia9</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633964</td><td>Lehmann (1983)</td><td>Minimal maintenance medication: Effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633527</td><td>Lehmann (1997)</td><td>The history of the psychopharmacology of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646937</td><td>Lehmann (2014)</td><td>Functionally aberrant electrophysiological cortical connectivities in first episode medication-naive schizophrenics from three psychiatry centers</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644630</td><td>Lehtinen (2000)</td><td>Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646871</td><td>Lei (2015)</td><td>Gray matter volume alterations in first-episode drug-naive patients with deficit and nondeficit schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644958</td><td>Lemmers-Jansen (2019)</td><td>Social mindfulness and psychosis: Neural response to socially mindful behavior in first-episode psychosis and patients at clinical high-risk</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648415</td><td>Lemvigh (2020)</td><td>Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648638</td><td>Lencer (2011)</td><td>Altered transfer of visual motion information to parietal association cortex in untreated first-episode psychosis: Implications for pursuit eye tracking</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647610</td><td>Lencz (2006)</td><td>DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647609</td><td>Lencz (2010)</td><td>DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646332</td><td>Lencz (2020)</td><td>Measurement of falff from resting-state fmri at baseline predicts acute treatment response in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648403</td><td>Lencz (2021)</td><td>Baseline FALFF Derived From Resting-State fMRI Predicts Acute Treatment Response in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645640</td><td>Lenior (2003)</td><td>Predictors and five-year outcome in early-onset schizophrenia. A path analysis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645567</td><td>Lennox (2017)</td><td>"Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: A case-control study": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646547</td><td>Lenora (2019)</td><td>Interventions for helping people recognise early signs of recurrence in depression</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634265</td><td>Leong (2021)</td><td>Psychiatric care for a person with MELAS syndrome: A case report</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647242</td><td>Leopold (2020)</td><td>Efficacy of cognitive-behavioral group therapy in patients at risk for serious mental illness presenting with subthreshold bipolar symptoms: results from a prespecified interim analysis of a multicenter, randomized, controlled study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646513</td><td>Lepage (2010)</td><td>Is there an association between neurocognitive performance and medication adherence in first episode psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646095</td><td>Lepage (2021)</td><td>Neurocognitive functions in persistent negative symptoms following a first episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645526</td><td>Leppik (2018)</td><td>Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645525</td><td>Leppik (2020)</td><td>Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633837</td><td>Lerner (1977)</td><td>Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648673</td><td>Lertxundi (2015)</td><td>Adverse reactions to antipsychotics in Parkinson disease: An analysis of the Spanish Pharmacovigilance Database</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646176</td><td>Lesh (2015)</td><td>A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647099</td><td>Lesh (2021)</td><td>Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647755</td><td>Lester (2005)</td><td>The development and implementation of an educational intervention on first episode psychosis for primary care</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645311</td><td>Lester (2009)</td><td>REDIRECT: cluster randomised controlled trial of GP training in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633910</td><td>Leucht (1999)</td><td>Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633608</td><td>Leucht (2005)</td><td>What does the PANSS mean</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633709</td><td>Leucht (2005)</td><td>Clinical implications of Brief Psychiatric Rating Scale scores.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645069</td><td>Leucht (2009)</td><td>Second-generation antipsychotics for schizophrenia: Can we resolve the conflict?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633708</td><td>Leucht (2009)</td><td>How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634155</td><td>Leucht (2009)</td><td>Kapitel 10 ‚Äì Schizophrenien und andere psychotische St√∂rungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648522</td><td>Leucht (2011)</td><td>Are all antipsychotic drugs the same?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633530</td><td>Leucht (2011)</td><td>√úberlegungen zur Wirksamkeit von Psychopharmaka</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633533</td><td>Leucht (2011)</td><td>Evidenzbasierung und leitliniengest√ºtzte Therapie in der Psychiatrie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634011</td><td>Leucht (2011)</td><td>Evidence-based pharmacotherapy of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644675</td><td>Leucht (2012)</td><td>Treatment of affective or negative symptoms of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>61633509</td><td>Leucht (2012)</td><td>Maintenance treatment with antipsychotic drugs for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633548</td><td>Leucht (2012)</td><td>Essential Evidence-Based Psychopharmacology: Evidence-based pharmacotherapy of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633908</td><td>Leucht (2012)</td><td>Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647631</td><td>Leucht (2014)</td><td>Dose equivalents for second-generation antipsychotics: The minimum effective dose method</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645917</td><td>Leucht (2015)</td><td>The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) trial: Rationale for its methodology and a review of the effectiveness of switching antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634108</td><td>Leucht (2016)</td><td>Dose Equivalents for Antipsychotic Drugs: The DDD Method</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647663</td><td>Leucht (2017)</td><td>Do antipsychotic drugs lose their efficacy for relapse prevention over time?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646512</td><td>Leucht (2018)</td><td>Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646873</td><td>Leung (2011)</td><td>Gray matter in first-episode schizophrenia before and after antipsychotic drug treatment. Anatomical likelihood estimation meta-analyses with sample size weighting</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646713</td><td>Leung (2014)</td><td>Impaired facilitation of self-control cognition by glucose in patients with schizophrenia: a randomized controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648108</td><td>Leung (2018)</td><td>Coaching intervention for psychosis: A lifestyle redesigning approach</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645809</td><td>Levasseur (2019)</td><td>Peer-driven family support services in the context of first-episode psychosis: Participant perceptions from a Canadian early intervention programme</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633890</td><td>Levene (1970)</td><td>The aftercare of schizophrenics: an evaluation of group and individual approaches.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646812</td><td>Levesque (2020)</td><td>Homeless youth with first-episode psychosis: A 2-year outcome study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647583</td><td>Levi (2020)</td><td>Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633732</td><td>Levinson (1990)</td><td>Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634080</td><td>Levinson (1991)</td><td>Genetic Linkage Studies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646191</td><td>Levitt (2002)</td><td>MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645060</td><td>Levitt (2010)</td><td>A selective review of volumetric and morphometric imaging in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647615</td><td>Levkovitz (2010)</td><td>A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646316</td><td>Levy (2012)</td><td>Medication-adherent first-episode psychosis patients also relapse: Why?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646112</td><td>Lewandowski (2020)</td><td>Neurobiological and Functional Trajectories in Distinct Cognitive Subtypes: Predicting Neuroprogression in First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648625</td><td>Leweke (2007)</td><td>Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647198</td><td>Leweke (2014)</td><td>Enhancing recovery in early schizophrenia - A controlled clinical trial investigating cannabidiol CR vs. placebo as an add-on to antipsychotic treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647197</td><td>Leweke (2018)</td><td>Enhancing recovery in early schizophrenia by randomized controlled add-on of cannabidiol to an individualized antipsychotic treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634177</td><td>Lewine (1991)</td><td>9 ‚Äì Ontogenetic Implications of Sex Differences in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647045</td><td>Lewis (2003)</td><td>Filicidal Mothers and the Impact of Psychosis on Maternal Filicide</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645401</td><td>Lewis (2006)</td><td>Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645469</td><td>Lewis (2015)</td><td>Psychological treatments for early psychosis can be beneficial or harmful, depending on the therapeutic alliance: an instrumental variables analysis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59644978</td><td>Lewis (2018)</td><td>Smartphone-enhanced symptom management and relapse prevention: a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645403</td><td>Lewis (2018)</td><td>A randomised controlled trial of smartphone active symptom monitoring in psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647340</td><td>Lewis (2018)</td><td>Effects of a nicotinic agonist on the Brief Psychiatric Rating Scale five-factor subscale model in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645032</td><td>Leypoldt (2017)</td><td>Serum neuronal cell-surface antibodies in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645515</td><td>Lho (2020)</td><td>Progressive Impairment of Mismatch Negativity Is Reflective of Underlying Pathophysiological Changes in Patients With First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646230</td><td>Lho (2020)</td><td>Mismatch negativity is reflective of disease progression rather than symptomatic recovery in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645945</td><td>Li (2004)</td><td>One-year follow-up study of systematic early intervention to first episode schizophrene</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646606</td><td>Li (2004)</td><td>Influence of family mental intervention on social function, family environment and relapse rate in first-episode schizophrenics</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647441</td><td>Li (2004)</td><td>Effect of early intervention on quality of life in patients with first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646379</td><td>Li (2011)</td><td>Longitudinal treatment outcome of African American and Caucasian patients with first episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644533</td><td>Li (2012)</td><td>Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647256</td><td>Li (2012)</td><td>Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: A 6-week, randomized, open-label, flexible-dose study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647773</td><td>Li (2012)</td><td>Depressive symptoms in first-episode schizophrenia: A 9-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647987</td><td>Li (2013)</td><td>A comparative study of the effects of paliperidone and risperidone on the glucose and lipid metabolism in first-episode male schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647910</td><td>Li (2015)</td><td>Contingent negative variation in patients with deficit schizophrenia or bipolar I disorder with psychotic features: Measurement and correlation with clinical characteristics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644974</td><td>Li (2016)</td><td>Smoking in male patients with schizophrenia in China: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646611</td><td>Li (2016)</td><td>Influence of drug compliance treatment on prognosis of first episode schizophrenic patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646639</td><td>Li (2016)</td><td>Increased serum brain-derived neurotrophic factor levels following electroconvulsive therapy or antipsychotic treatment in patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647283</td><td>Li (2017)</td><td>Effects of second-generation antipsychotic medications treatment: cognitive improvement in Chinese patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648334</td><td>Li (2017)</td><td>Brain-Wide Analysis of Functional Connectivity in First-Episode and Chronic Stages of Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647921</td><td>Li (2018)</td><td>COMT, 5-HTR2A, and SLC6A4 mRNA expressions in first-episode antipsychotic-naive schizophrenia and association with treatment outcomes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648637</td><td>Li (2018)</td><td>Altered white matter connectivity within and between networks in antipsychotic-naive first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645972</td><td>Li (2019)</td><td>Olanzapine versus placebo for people with schizophrenia</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59644793</td><td>Li (2020)</td><td>Tai Chi plus standard care versus other exercise plus standard care for people with schizophrenia or related disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645049</td><td>Li (2020)</td><td>Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: rationale and trial design</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645307</td><td>Li (2020)</td><td>Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645575</td><td>Li (2020)</td><td>Prepulse inhibition in first-degree relatives of schizophrenia patients: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647051</td><td>Li (2020)</td><td>Feasibility, acceptability, and preliminary effectiveness of mindfulness-based interventions for people with recent-onset psychosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648650</td><td>Li (2021)</td><td>Altered Antioxidant Defenses in Drug-Naive First Episode Patients with Schizophrenia Are Associated with Poor Treatment Response to Risperidone: 12-Week Results from a Prospective Longitudinal Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648197</td><td>Lian (2015)</td><td>Chronic betahistine co-treatment reverses olanzapine's effects on dopamine D2 but not 5-HT2A/2C bindings in rat brains</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647946</td><td>Liang (2010)</td><td>Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: A randomized, double-blind, crossover study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633592</td><td>Libiger (2001)</td><td>Treatment in The Early Stages of Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645347</td><td>Librenza-Garcia (2018)</td><td>Rapid cycling prediction in bipolar disorder using clinical variables: A machine learning, proof-of-concept study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646754</td><td>Liddle (2000)</td><td>Immediate effects of risperidone on cortico-striato-thalamic loops and the hippocampus</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633733</td><td>Lieberman (1987)</td><td>Prediction of Relapse in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644734</td><td>Lieberman (1993)</td><td>Time course and biologic correlates of treatment response in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634017</td><td>Lieberman (1993)</td><td>Understanding the Mechanism of Action of Atypical Antipsychotic Drugs: A Review of Compounds in Use and Development</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645743</td><td>Lieberman (1996)</td><td>Pharmacotherapy for patients with first-episode, acute, and refractory schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647270</td><td>Lieberman (2000)</td><td>Efficacy and safety of clozapine versus chlorpromazaine in first-episode psychosis: results of a 52 week randomized double blind trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647269</td><td>Lieberman (2001)</td><td>Efficacy and safety of clozapine versus chlorpromazine in first episode psychosis: results of a 52-week randomized double-blind trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647506</td><td>Lieberman (2002)</td><td>"The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647420</td><td>Lieberman (2003)</td><td>Effect of olanzapine versus haloperidol on brain pathomorphology in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647994</td><td>Lieberman (2003)</td><td>Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648423</td><td>Lieberman (2003)</td><td>Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648635</td><td>Lieberman (2003)</td><td>American Journal of Psychiatry: Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648599</td><td>Lieberman (2005)</td><td>Antipsychotic drug effects on brain morphology in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646368</td><td>Lieberman (2013)</td><td>Lurasidone in the treatment of early-stage schizophrenia: a post-HOC analysis of three pooled acute treatment studies</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646369</td><td>Lieberman (2013)</td><td>Lurasidone in the treatment of early-stage schizophrenia: a post-HOC analysis of three pooled acute treatment studies</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61634088</td><td>Liebman (1982)</td><td>Understanding neuroleptics: From ‚Äúanhedonia‚Äù to ‚Äúneuroleptothesia‚Äù</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647509</td><td>Liem-Moolenaar (2013)</td><td>Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647985</td><td>Liew (2010)</td><td>Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644991</td><td>Light (2016)</td><td>Single-dose memantine normalizes evoked gamma power and phase synchronization deficits in patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644992</td><td>Light (2017)</td><td>Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646498</td><td>Lim (2018)</td><td>Key worker mediated enhancement of physical health in first episode psychosis: A scoping review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645494</td><td>Lim (2019)</td><td>Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648239</td><td>Lim (2019)</td><td>Challenges of managing a first episode of pediatric catatonia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645126</td><td>Lim (2021)</td><td>The role of key workers in improving physical health in first episode psychosis: A scoping review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645572</td><td>Limosin (2008)</td><td>Present data and treatment schedule of aripiprazole in the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646722</td><td>Lin (2014)</td><td>The impacts of aerobic exercise and mind-body exercise (yoga) on neuro-cognition and clinical symptoms in early psychosis a single-blind radomized controlled clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646718</td><td>Lin (2015)</td><td>The impacts of yoga on cortical thickness, neural connectivity and cognitive function in early psychosis: preliminary results from a randomized controlled clinical trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648670</td><td>Lin (2015)</td><td>Aerobic exercise and yoga improve neurocognitive function in women with early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648671</td><td>Lin (2015)</td><td>Aerobic exercise and yoga hold promises for improving neuro-cognition and symptom in early psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61633619</td><td>Lin (2015)</td><td>Comparing Antipsychotic Treatments for Schizophrenia: A Health State Approach</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644465</td><td>Lin (2017)</td><td>Yoga reduces the brain's amplitude of low-frequency fluctuations in patients with early psychosis results of a randomized controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644466</td><td>Lin (2018)</td><td>Yoga reduces the brain's amplitude of low-frequency fluctuations in patients with early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645041</td><td>Lin (2018)</td><td>Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646720</td><td>Lin (2018)</td><td>Impacts of electroconvulsive therapy on 1-year outcomes in patients with schizophrenia: A controlled, population-based mirror-image study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647556</td><td>Lin (2019)</td><td>Early identification and intervention of schizophrenia: Insight from hypotheses of glutamate dysfunction and oxidative stress</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645680</td><td>Lin (2021)</td><td>Positive symptoms in antipsychotic-naive schizophrenia are associated with increased body mass index after treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633895</td><td>Linden (1982)</td><td>High vs. Low Dose Treatment with Antipsychotic Agents</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645892</td><td>Lindgren (2006)</td><td>Outpatient vs. comprehensive first-episode psychosis services, a 5-year follow-up of Soteria Nacka</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644759</td><td>Lindgren (2016)</td><td>Theory of mind in a first-episode psychosis population using the Hinting Task</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644757</td><td>Lindgren (2018)</td><td>Theory of mind in a first-episode psychosis population using the Hinting Task</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644758</td><td>Lindgren (2018)</td><td>Theory of mind in a first-episode psychosis population using the hinting task</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634107</td><td>Lingj√¶rde (1966)</td><td>Kliniske psykofarmakologiske unders√∂kelser i fremtiden Behov og forskningsoppgaver</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633843</td><td>Linkowski (1984)</td><td>Haloperidol plasma levels and clinical response in paranoid schizophrenics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645795</td><td>Linnaranta (2021)</td><td>Peripheral metabolic state and immune system in first-episode psychosis - A gene expression study with a prospective one-year follow-up</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647546</td><td>Linszen (2001)</td><td>Early intervention in first episode psychoses and the critical period</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647553</td><td>Linszen (2001)</td><td>Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647519</td><td>Linszen (2002)</td><td>Early psychosis, schizophrenia and the family</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633767</td><td>Linszen (2008)</td><td>CONTINUITY OF CARE AND PARENT GROUPS IN EARLY SCHIZOPHRENIA: A 5 YEAR RANDOMIZED CONTROLLED TRIAL</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646710</td><td>Lis (2020)</td><td>Impaired hormonal regulation of appetite in schizophrenia: A narrative review dissecting intrinsic mechanisms and the effects of antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648386</td><td>Lisiecka (2015)</td><td>The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645624</td><td>Listunova (2020)</td><td>Predictors of cognitive remediation therapy improvement in (partially) remitted unipolar depression</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647208</td><td>Littrell (1998)</td><td>Emerging applications of newer antipsychotic agents in specific patient populations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646492</td><td>Liu (2009)</td><td>Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647801</td><td>Liu (2010)</td><td>Deficient inhibition of return in chronic but not first-episode patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646973</td><td>Liu (2011)</td><td>Follow-up of subjects with suspected pre-psychotic state in Taiwan</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647293</td><td>Liu (2012)</td><td>Effects of paliperidone extended-release tablets and risperidone on cognitive function in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648502</td><td>Liu (2013)</td><td>Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: An open-label study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645385</td><td>Liu (2014)</td><td>Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646235</td><td>Liu (2014)</td><td>Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644794</td><td>Liu (2015)</td><td>Tai chi for schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646096</td><td>Liu (2015)</td><td>Neurocognitive functioning of subjects with putative pre-psychotic states and early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648256</td><td>Liu (2017)</td><td>Cavum septum pellucidum and first-episode psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645333</td><td>Liu (2018)</td><td>Rationale of an observational clinical trial focused on guided dose reduction of antipsychotic treatment for patients with remitted state of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647675</td><td>Liu (2018)</td><td>Distinguishable brain networks relate disease susceptibility to symptom expression in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644714</td><td>Liu (2019)</td><td>Trajectories after first-episode psychosis: Complement to ambiguous outcomes of long-term antipsychotic treatment by exploring a few hidden cases</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644784</td><td>Liu (2019)</td><td>Targeting relapse prevention and positive symptom in first-episode schizophrenia using brief cognitive behavioral therapy: a pilot randomized controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647678</td><td>Liu (2019)</td><td>Dissociation of fractional anisotropy and resting-state functional connectivity alterations in antipsychotic-naive first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648404</td><td>Liu (2019)</td><td>Basal ganglia volumetric changes in psychotic spectrum disorders</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644773</td><td>Liu (2020)</td><td>Ten-year follow-up after first episode psychosis: Focused on low dose antipsychotic maintenance and functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646268</td><td>Liu (2021)</td><td>Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naive patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648235</td><td>Liu-Seifert (2011)</td><td>Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648622</td><td>Lizano (2016)</td><td>Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644709</td><td>Lizano (2020)</td><td>Trajectory of neurological examination abnormalities in antipsychotic-naive first-episode psychosis population: a 1 year follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633743</td><td>Llorca (2008)</td><td>Indications des NAP : pr√©coces ou tardives ?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646851</td><td>Llorca (2013)</td><td>Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645318</td><td>Lo (2016)</td><td>Recommendations for the optimal care of patients with recent-onset psychosis in the Asia-Pacific region</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648329</td><td>Lo (2019)</td><td>A Brief Mindfulness-Based Family Psychoeducation Intervention for Chinese Young Adults With First Episode Psychosis: a Study Protocol</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634213</td><td>Loeb (2020)</td><td>Family-Based Treatment for Anorexia Nervosa Symptoms in High-Risk Youth: A Partially-Randomized Preference-Design Study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648129</td><td>Loffler (2010)</td><td>Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648132</td><td>Loffler (2010)</td><td>Clozapine mobilizes CD34+ hematopoietic stem and progenitor cells and increases plasma concentration of interleukin 6 in patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644895</td><td>Lomena (2004)</td><td>Striatal dopamine D2 receptor density in neuroleptic-naive and in neuroleptic-free schizophrenic patients: An 123I-IBZM-SPECT study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648441</td><td>Longden (2016)</td><td>Associations between nonauditory hallucinations, dissociation, and childhood adversity in first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634260</td><td>Longden (2021)</td><td>Engaging dialogically with auditory hallucinations: design, rationale and baseline sample characteristics of the Talking With Voices pilot trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648510</td><td>Lopez-Diaz (2017)</td><td>Are there differences in the antipsychotic load between deficit and non-deficit syndrome in first-episode schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647706</td><td>Lopez-Diaz (2020)</td><td>Differentiating non-affective acute remitting psychosis (NARP) from schizophrenia in first-episode psychosis: Findings from a 3-year longitudinal study in the PAFIP cohort</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633917</td><td>L√≥pez-Mu√±oz (2005)</td><td>History of the discovery and clinical introduction of chlorpromazine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645098</td><td>Lorenzo-Villalba (2020)</td><td>SARS-CoV-2 infection and psychiatric manifestations in a previous healthy patient</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648357</td><td>Louhija (2017)</td><td>Brain atrophy is a frequent finding in elderly patients with first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645094</td><td>Lovelace (2015)</td><td>Schizophrenia and endocannabinoid signaling in the prefrontal cortex</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646331</td><td>Lowen (2020)</td><td>Measuring adherence in social recovery therapy with people with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633951</td><td>Loy (2014)</td><td>Protocol for REducing Anti-Psychotic use in residential care-Huntington Disease (REAP-HD): a pilot cluster randomised controlled trial of a multifaceted intervention for health professionals.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646043</td><td>Lu (2005)</td><td>Neurotrophic Effects of Psychotropic Drugs: Significance for Schizophrenia and Other Neurodevelopmental Disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648076</td><td>Lublin (2001)</td><td>Cognitive dysfunction in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645744</td><td>Lubman (2010)</td><td>Pharmacotherapy for co-occurring alcohol and drug disorders in schizophrenia and bipolar disorder: Where is the evidence?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646056</td><td>Lucas (2004)</td><td>Neuropsychological correlates of symptom profiles in first episode schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644517</td><td>Luckhoff (2019)</td><td>Weight gain and metabolic change as predictors of symptom improvement in first-episode schizophrenia spectrum disorder patients treated over 12 months</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646805</td><td>Ludwig (2021)</td><td>Horyzons USA: A moderated online social intervention for first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645007</td><td>Lui (2010)</td><td>Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647720</td><td>Lui (2021)</td><td>Different trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648643</td><td>Luk (2021)</td><td>Altered risky decision making in patients with early non-affective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646307</td><td>Lundy (2013)</td><td>Memory profiles in schizophrenia: A neuropsychological comparison with temporal lobe epilepsy</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647047</td><td>Lustenberger (2015)</td><td>Feedback-controlled sleep spindle transcranial alternating current stimulation reveals the functional role of sleep spindles in motor memory consolidation</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646986</td><td>Lutgens (2015)</td><td>A five-year randomized parallel and blinded clinical trial of an extended specialized early intervention vs. regular care in the early phase of psychotic disorders: study protocol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645477</td><td>Lutgens (2017)</td><td>Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Tiril Borge</span></td><td></td></tr><tr><td>59645520</td><td>Lutgens (2018)</td><td>"Progress of negative symptoms over the initial 5 years of a first episode of psychosis": Corrigendum</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645522</td><td>Lutgens (2019)</td><td>Progress of negative symptoms over the initial 5 years of a first episode of psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646868</td><td>Lyall (2018)</td><td>Greater extracellular free-water in first-episode psychosis predicts better neurocognitive functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647336</td><td>Lyall (2019)</td><td>Effects of adjuvant omega-3 polyunsaturated fatty acids on white matter in individuals with recent-onset psychosis treated concurrently with risperidone</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647595</td><td>Lyne (2017)</td><td>Duration of active psychosis and first-episode psychosis negative symptoms</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634102</td><td>Lyness (1982)</td><td>Dopaminergic and serotonergic influence on d-amphetamine self-administration: Alterations of reward perception</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647915</td><td>Lyngstad (2018)</td><td>Consequences of persistent depression and apathy in first-episode psychosis-A one-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634103</td><td>Lyons (1982)</td><td>The anhedonia vs the eclectic hypothesis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647903</td><td>Lysaker (2020)</td><td>Contrasting metacognitive profiles and their association with negative symptoms in groups with schizophrenia, early psychosis and depression in a Russian sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646429</td><td>Lytle (2017)</td><td>Long-Acting Injectable Antipsychotics in Children and Adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646104</td><td>Ma (2007)</td><td>Neurocognitive deficits in first-episode schizophrenic patients and their first-degree relatives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646349</td><td>Maayan (2010)</td><td>Management of antipsychotic-related weight gain</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633516</td><td>Maayan (2015)</td><td>Fluphenazine decanoate (depot) and enanthate for schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645315</td><td>MacCabe (2018)</td><td>Reconsidering the evidence for clozapine for treatment refractory schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645428</td><td>Macdonald (2000)</td><td>The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645827</td><td>MacDonald (2018)</td><td>Pathways to mental health services for young people: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644460</td><td>MacDougall (2019)</td><td>Youth-focused group mindfulness-based intervention in individuals with early psychosis: A randomized pilot feasibility study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645831</td><td>MacDougall (2020)</td><td>Participatory video as a novel recovery-oriented intervention in early psychosis: A pilot study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646878</td><td>Macedo (2013)</td><td>Graves' hyperthyroidism-induced psychosis treated with aripiprazole-A case report</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634304</td><td>Mackay (1982)</td><td>Chapter 4 ‚Äì Antischizophrenic drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647326</td><td>Mackeprang (2002)</td><td>Effects of antipsychotics on prepulse inhibition of the startle response in drug-na√Øve schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645080</td><td>Mackintosh (2018)</td><td>Schizophrenia, dopamine and eeg resting-state functional connectivity: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647476</td><td>Mackintosh (2020)</td><td>EEG Microstate Differences in Medicated vs. Medication-Naive First-Episode Psychosis Patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647464</td><td>MacMaster (2007)</td><td>Effect of antipsychotics on pituitary gland volume in treatment-naive first-episode schizophrenia: A pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645006</td><td>MacMillan (1986)</td><td>Short-term outcome in trial entrants and trial eligible patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646015</td><td>MacMillan (1986)</td><td>The Northwick Park study of first episodes of schizophrenia: III. Short-term outcome in trial entrants and trial eligible patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61633938</td><td>MacMillan (1986)</td><td>Expressed emotion and relapse.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648318</td><td>Macneil (2012)</td><td>Can a targeted psychological intervention be effective for young people following a first manic episode? Results from an 18-month pilot study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644845</td><td>Madsen (2012)</td><td>Suicidal changes in patients with first episode psychosis: clinical predictors of increasing suicidal tendency in the early treatment phase</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644712</td><td>Madsen (2016)</td><td>Trajectories of suicidal ideation in patients with first-episode psychosis: Secondary analysis of data from the OPUS trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648448</td><td>Maffioletti (2020)</td><td>Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648776</td><td>Maguire (2019)</td><td>4.55 Trauma History and Cannabis Use Are Associated with Positive Symptomatology in an Early Psychosis Population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645895</td><td>Maguire (2020)</td><td>Outcomes for migrants with a first episode of psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646518</td><td>Mahadik (2003)</td><td>Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633626</td><td>Mahmoud (2004)</td><td>Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646028</td><td>Maia-de-Oliveira (2015)</td><td>Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647471</td><td>Majercikova (2014)</td><td>Effect of acute asenapine treatment on Fos expression in the forebrain structures under normal conditions and mild stress preconditioning in the rat</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645691</td><td>Mak (2019)</td><td>Polish version of the Structured Interview For Psychosis-Risk Syndromes (SIPS)-Description of the tool</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645231</td><td>Malhotra (2003)</td><td>The relevance of pharmacogenetics to schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646909</td><td>Malhotra (2007)</td><td>Genomics and the future of pharmacotherapy in psychiatry</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647681</td><td>Malhotra (2015)</td><td>Dissecting the Heterogeneity of Treatment Response in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648565</td><td>Malhotra (2015)</td><td>Antipsychotic treatment and functional connectivity of the striatum: a prospective controlled study in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644858</td><td>Malik (2000)</td><td>Substance misuse in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647206</td><td>Malik (2010)</td><td>Emotion recognition and duration of untreated first-episode psychosis among patients in Pakistan</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645013</td><td>Malik (2011)</td><td>Sexual dysfunction in first-episode schizophrenia patients: Results from European first episode schizophrenia trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634277</td><td>Malik (2020)</td><td>Cognitive-behavioural therapy combined with music therapy for chronic fatigue following Epstein-Barr virus infection in adolescents: a randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647959</td><td>Malla (2001)</td><td>A comparison of long-term outcome in first-episode schizophrenia following treatment with risperidone or a typical antipsychotic</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644818</td><td>Malla (2002)</td><td>Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647941</td><td>Malla (2004)</td><td>A comparison of two novel antipsychotics in first episode non-affective psychosis: One-year outcome on symptoms, motor side effects and cognition</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647005</td><td>Malla (2005)</td><td>First-Episode Psychosis, Early Intervention, and Outcome: What Have We Learned?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647004</td><td>Malla (2006)</td><td>"First-Episode Psychosis, Early Intervention, and Outcome: What Have We Learned?": Erratum</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645718</td><td>Malla (2009)</td><td>A pilot randomized controlled evaluation of ‚Äúextended specialized early intervention service‚Äù vs. ‚Äúregular care‚Äù for longterm management of early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645387</td><td>Malla (2010)</td><td>A randomized controlled evaluation of ‚Äúextended specialized early intervention service‚Äù vs. ‚Äúregular care‚Äù for long-term management of early psychosis: a pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646510</td><td>Malla (2010)</td><td>Is treating patients with first-episode psychosis cost-effective?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647576</td><td>Malla (2011)</td><td>Duration of untreated psychosis is associated with orbital-frontal grey matter volume reductions in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645932</td><td>Malla (2012)</td><td>An open-label randomized trial comparing risperidone long acting injectable (RLAI) with oral antipsychotic medication in the treatment of early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645926</td><td>Malla (2015)</td><td>The optimal duration of early intervention services for psychosis: two Canadian studies</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647117</td><td>Malla (2016)</td><td>An exploratory, open-label, randomized Tria comparing Risperidone long-Acting Injectabl with oral antipsychotic medication in the treatment of early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647456</td><td>Malla (2016)</td><td>The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: An exploratory study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647983</td><td>Malla (2017)</td><td>Comparing three-year extension of early intervention service to regular care following two years of early intervention service in first-episode psychosis: A randomized single blind clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645902</td><td>Malla (2018)</td><td>Outcome in patients converting to psychosis following a treated clinical high risk state</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647111</td><td>Mallawaarachchi (2019)</td><td>Exploring the use of the Hinting Task in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633796</td><td>Malmo (1982)</td><td>Wise's neural model implicating the reticular formation: Some queries</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646822</td><td>Mamah (2012)</td><td>Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648049</td><td>Man (2018)</td><td>Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633632</td><td>Mancevski (2007)</td><td>Lifelong Course of Positive and Negative Symptoms in Chronically Institutionalized Patients with Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644566</td><td>Manchanda (2004)</td><td>Value of early intervention in psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645787</td><td>Manchanda (2005)</td><td>Persistent psychoses in first episode patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647477</td><td>Manchanda (2005)</td><td>EEG abnormalities and two year outcome in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648549</td><td>Manchanda (2007)</td><td>Antipsychotic use in a first episode psychosis program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646423</td><td>Manchanda (2013)</td><td>Long-acting injectable antipsychotics: Evidence of effectiveness and use</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645157</td><td>Mangurian (2010)</td><td>Risks from antipsychotic medications in children and adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646996</td><td>Mangurian (2017)</td><td>First-episode schizophrenia and diabetes risk: Comment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646502</td><td>Maniam (2016)</td><td>The journey of young people in an early psychosis program involved in participatory photography</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645354</td><td>Manli (2015)</td><td>A randomized, 13-week study assessing the efficacy and safety of paliperidone palmitate and olanzapine in first-episode schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647716</td><td>Mann (2008)</td><td>Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and P50 suppression measures of sensorimotor and sensory gating in humans</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648753</td><td>Mantyla (2018)</td><td>Aberrant cortical integration in first-episode psychosis during natural audiovisual processing</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648594</td><td>Mao (2007)</td><td>Antipsychotic drug use in 503 Chinese inpatients with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644825</td><td>Maraj (2017)</td><td>Symptom profiles and explanatory models of first-episode psychosis in African-, Caribbean- and European-origin groups in Ontario</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647690</td><td>Maraj (2018)</td><td>Disengagement in immigrant groups receiving services for a first episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647386</td><td>Marchira (2018)</td><td>The effectiveness of a brief interactive psychoeducational intervention for persons living with first episode psychosis and family caregivers in Yogyakarta, Indonesia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648330</td><td>Marchira (2019)</td><td>Brief interactive psychoeducation for caregivers of patients with early phase psychosis in Yogyakarta, Indonesia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646347</td><td>Marcinkowska (2020)</td><td>Management of dementia-related psychosis, agitation and aggression: A review of the pharmacology and clinical effects of potential drug candidates</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633787</td><td>Marder (1983)</td><td>Approaches to Maintenance Therapy in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633729</td><td>Marder (1984)</td><td>Costs and Benefits of Two Doses of Fluphenazine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633725</td><td>Marder (1987)</td><td>Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633576</td><td>Marder (1991)</td><td>Predictors of Risk of Relapse in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633739</td><td>Marder (1991)</td><td>Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633627</td><td>Marder (1999)</td><td>Antipsychotic drugs and relapse prevention</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645152</td><td>Marder (2001)</td><td>Risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645654</td><td>Marenco (2014)</td><td>Predicting response to antipsychotics with proton magnetic resonance spectroscopy (MRS)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647833</td><td>Maric (2005)</td><td>Cumulative exposure to estrogen and psychosis: A peak bone mass, case-control study in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647037</td><td>Marinelli (2016)</td><td>First episode psychosis in an adult patient with tuberous sclerosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645461</td><td>Marinho (2016)</td><td>Psychosis among HIV-infected patients -a serious and complex association</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648250</td><td>Marini (2016)</td><td>Celecoxib adjunctive treatment to risperidone in schizophrenia: A review of randomized clinical add-on trials</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648251</td><td>Marini (2016)</td><td>Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645791</td><td>Marino (2020)</td><td>Persistent cannabis use among young adults with early psychosis receiving coordinated specialty care in the united states</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647157</td><td>Markiewicz (2019)</td><td>Evaluation of the effectiveness of rehabilitation of people diagnosed with schizophrenia using clinical tools, psychological tests, QEEG, and the brain-derived neurotrophic factor (BDNF)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648690</td><td>Markkula (2011)</td><td>Adherence to guidelines and treatment compliance in the Chilean national program for first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634092</td><td>Markowitz (2008)</td><td>Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644607</td><td>Maroney (2020)</td><td>An update on current treatment strategies and emerging agents for the management of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645012</td><td>Marques (2012)</td><td>Sexual dysfunction in people with prodromal or first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644489</td><td>Marques (2014)</td><td>White matter integrity as a predictor of response to treatment in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646799</td><td>Marques (2014)</td><td>How antipsychotics impact the different dimensions of schizophrenia: A test of competing hypotheses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633755</td><td>Marrazzi (2006)</td><td>SYNAPTIC AND BEHAVIORAL CORRELATES OF PSYCHOTHERAPEUTIC and RELATED DRUG ACTIONS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633931</td><td>Marsden (1980)</td><td>The pathophysiology of extrapyramidal side-effects of neuroleptic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634132</td><td>Marsden (2018)</td><td>Memory-Focused Cognitive Therapy for Cocaine Use Disorder: Theory, Procedures and Preliminary Evidence From an External Pilot Randomised Controlled Trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633629</td><td>Marshall (2015)</td><td>The HELPER programme: Healthy Living and Prevention of Early Relapse ‚Äì three exploratory randomised controlled trials of phase-specific interventions in first-episode psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646525</td><td>Martin (2019)</td><td>Is early management of psychosis designed for migrants? Improving transcultural variable collection when measuring duration of untreated psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647789</td><td>Martin (2020)</td><td>Delirium, Encephalopathy, and COVID-19: An Update From the Field</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646141</td><td>Martinez (2011)</td><td>The need-adapted integrated treatment in Sant Pere Claver-Early Psychosis Program (SPC-EPP) in Barcelona, Spain</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648396</td><td>Martinez-Cengotitabengoa (2016)</td><td>BDNF and NGF signalling in early phases of psychosis: Relationship with inflammation and response to antipsychotics after 1 year</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648395</td><td>Martinho (2012)</td><td>BDNF gene polymorphism, cognition and symptom severity in a Brazilian population-based sample of first-episode psychosis subjects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644602</td><td>Martini (2006)</td><td>Upregulation of A2AA adenosine receptors in platelets from patients affected by bipolar disorders under treatment with typical antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644902</td><td>Martinuzzi (2019)</td><td>Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645842</td><td>Martos (2021)</td><td>Paliperidone induced neutropenia in first episode psychosis: A case report</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633926</td><td>Marvin (2016)</td><td>Family-focused therapy for individuals at clinical high risk for psychosis: treatment fidelity within a multisite randomized trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645771</td><td>Mas (2015)</td><td>Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645781</td><td>Mas (2020)</td><td>Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647691</td><td>Mascayano (2021)</td><td>Disengagement From Early Intervention Services for Psychosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645769</td><td>Masellis (2000)</td><td>Pharmacogenetics of antipsychotic treatment: Lessons learned from clozapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648268</td><td>Mashiko (2004)</td><td>Case of bipolar disorder successfully stabilized with clonazepam, valproate and lithium after numerous relapses for 47 years</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644534</td><td>Massana (2005)</td><td>Volume Changes in Gray Matter in First-Episode Neuroleptic-Naive Schizophrenic Patients Treated With Risperidone</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633980</td><td>Massie (1999)</td><td>Duration of treatment in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645865</td><td>Masvidal (2020)</td><td>P.526 Structural covariance networks predict clinical outcome in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648465</td><td>Mata (2006)</td><td>Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646486</td><td>Mata (2008)</td><td>Lack of influence of COMT Val158Met genotype on cognition in first-episode non-affective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646118</td><td>Mata (2009)</td><td>A neuregulin 1 variant is associated with increased lateral ventricle volume in patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646982</td><td>Matar (2013)</td><td>Fluphenazine (oral) versus placebo for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644521</td><td>Matei (2015)</td><td>Weight gain and antipsychotics, data from EUFEST study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644520</td><td>Matei (2016)</td><td>WEIGHT GAIN AND ANTIPSYCHOTICS. DATA FROM EUFEST STUDY</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648146</td><td>Matei (2020)</td><td>Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients : An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647804</td><td>Mateos (2005)</td><td>Decreased striatal dopamine transporter binding assessed with</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646376</td><td>Mateos (2007)</td><td>Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645432</td><td>Matheson (2010)</td><td>Quality assessment and comparison of evidence for electroconvulsive therapy and repetitive transcranial magnetic stimulation for schizophrenia: A systematic meta-review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647357</td><td>Matoba (2016)</td><td>The effectiveness of psychoeducation programs following first episode psychosis: a systematic review protocol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647188</td><td>Matrisciano (2018)</td><td>Epigenetic Alterations in Prenatal Stress Mice as an Endophenotype Model for Schizophrenia: Role of Metabotropic Glutamate 2/3 Receptors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647054</td><td>Matsuda (2018)</td><td>Feasibility and effectiveness of a cognitive remediation programme with original computerised cognitive training and group intervention for schizophrenia: a multicentre randomised trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648164</td><td>Matsumoto (2000)</td><td>Clinical Features of Adolescent Methamphetamine Abusers: Current Patterns of Methamphetamine Use</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644668</td><td>Matsumoto (2004)</td><td>The Treatment of First Episode Schizophrenia with Olanzapine: The study with the Scale for Insight</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646085</td><td>Matsumoto (2004)</td><td>Neuroleptic malignant syndrome induced by donepezil</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633826</td><td>Mattes (1997)</td><td>Risperidone: How Good Is the Evidence for Efficacy?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633663</td><td>Matthews (1979)</td><td>A Non-neuroleptic Treatment for Schizophrenia: Analysis of the Two-year Postdischarge Risk of Relapse</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647570</td><td>Mattinson (2015)</td><td>Dynamic l-glutamate signaling in the prefrontal cortex and the effects of methylphenidate treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645841</td><td>Mauri (2017)</td><td>Paliperidone long-acting plasma level monitoring and a new method of evaluation of clinical stability</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646563</td><td>Mavrogiorgou (2012)</td><td>Interferon-induced obsessive-compulsive symptoms in malignant melanoma</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647580</td><td>Maximo (2020)</td><td>Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naive Patients With First-Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633546</td><td>May (1968)</td><td>Treatment of schizophrenia : a comparative study of five treatment methods</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633770</td><td>May (1978)</td><td>Test Dose Response in Schizophrenia: Chlorpromazine Blood and Saliva Levels</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645444</td><td>Mayenberger (2006)</td><td>Psychotic therapeutical aspects in the prodromal phase of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648162</td><td>Mayoral-Van (2016)</td><td>Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644510</td><td>Mazza (2021)</td><td>What about heart and mind in the Covid-19 era?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646506</td><td>McBride (2018)</td><td>It's Worth It: The Use of Long-Acting Injectable Antipsychotics in Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634012</td><td>McCabe (2016)</td><td>Training to enhance psychiatrist communication with patients with psychosis (TEMPO): cluster randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648131</td><td>McCaffrey (2019)</td><td>Clozapine rechallenge following neuroleptic malignant syndrome-a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648375</td><td>McCann (2012)</td><td>Bibliotherapy for first-time primary caregivers of family members with first-episode psychosis: a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645378</td><td>McCann (2013)</td><td>A randomized controlled trial of bibliotherapy for carers of young people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645435</td><td>McCann (2014)</td><td>Qualitative process evaluation of a problem-solving guided self-help manual for family carers of young people with first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647890</td><td>McClellan (2018)</td><td>Coordinated Specialty Care for First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644516</td><td>McCloughen (2011)</td><td>Weight gain associated with taking psychotropic medication: An integrative review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633768</td><td>McCreadie (1980)</td><td>Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633771</td><td>McCreadie (1982)</td><td>Once weekly pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645076</td><td>McCreadie (1987)</td><td>The Scottish first episode schizophrenia study: II. Treatment: Pimozide versus flupenthixol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634163</td><td>McCreadie (1988)</td><td>The Scottish First Episode Schizophrenia Study V. One-year Follow-up: The Scottish Schizophrenia Research Group</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645075</td><td>McCreadie (1989)</td><td>The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59644647</td><td>McDonagh (2017)</td><td>Treatments for Schizophrenia in Adults: A Systematic Review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648785</td><td>McDonagh (2017)</td><td>Agency for Healthcare Research and Quality</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644942</td><td>McDonald (2019)</td><td>Special Issue: Psychosis from early intervention to treatment resistance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647830</td><td>McDonnell (2021)</td><td>Cushing's disease presenting with severe weight loss, anorexia and refractory psychotic depression</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646081</td><td>McEvoy (1986)</td><td>"Neuroleptics and sexual functioning": Commentary</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647620</td><td>McEvoy (1987)</td><td>A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633613</td><td>McEvoy (1991)</td><td>Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644975</td><td>McEvoy (1999)</td><td>Smoking in first-episode patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646400</td><td>McEvoy (2003)</td><td>Long-Term Olanzapine Treatment Versus Haloperidol in First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646409</td><td>McEvoy (2003)</td><td>Long-term efficacy and safety of atypical and conventional antipsychotic drugs in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646591</td><td>McEvoy (2006)</td><td>Insight in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647259</td><td>McEvoy (2007)</td><td>Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646449</td><td>McEvoy (2013)</td><td>Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647063</td><td>McFarlane (2012)</td><td>Family psychoeducation in clinical high risk and first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647781</td><td>McGinty (2018)</td><td>Depression during first episode psychosis and subsequent suicide risk: A systematic review and meta-analysis of longitudinal studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647774</td><td>McGinty (2020)</td><td>Depressive symptoms during first episode psychosis and functional outcome: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644616</td><td>McGlashan (2004)</td><td>Under surveillance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646956</td><td>McGlashan (2015)</td><td>From treating to preventing psychosis: Personal perspectives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644557</td><td>McGorry (1997)</td><td>Very low dose neuroleptic-treatment of first episode psychosis - is it feasible in routine clinical care?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645370</td><td>McGorry (2002)</td><td>Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644839</td><td>McGorry (2003)</td><td>Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia (2003)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645116</td><td>McGorry (2005)</td><td>Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633508</td><td>McGorry (2008)</td><td>Early intervention in psychosis: concepts, evidence and future directions.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634187</td><td>McGorry (2008)</td><td>FORUM: EaRly INTERVENTION IN psychOsIs: clINIcal aNd EThIcal challENgEs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633528</td><td>McGorry (2011)</td><td>Early Recognition and Prevention of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648581</td><td>McGorry (2013)</td><td>Antipsychotic medication during the critical period following remission from first-episode psychosis: less is more</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td><span >Trine Bjerke Johansen</span></td></tr><tr><td>61634009</td><td>McGorry (2015)</td><td>Early intervention in psychosis: obvious, effective, overdue.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646013</td><td>McGorry (2016)</td><td>Novel and established therapies in early psychosis and their transdiagnostic potential</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634022</td><td>McGorry (2016)</td><td>Early Intervention in Emerging Psychosis: State of the Art and Future Perspectives</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647393</td><td>McGorry (2017)</td><td>Effect of œâ-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: the NEURAPRO Randomized Clinical Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647418</td><td>McGorry (2017)</td><td>Effect of omega-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648312</td><td>McGorry (2018)</td><td>Can some young people recover from first-episode psychosis with integrated psychosocial treatment without antipsychotic medications? An rct to assess risks, benefits, and range of outcomes</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646550</td><td>McGorry (2021)</td><td>Intervention strategies for ultra-high risk for psychosis: Progress in delaying the onset and reducing the impact of first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633635</td><td>McGrath (1999)</td><td>Treatment of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647856</td><td>McGreal (2021)</td><td>Cotard Syndrome in an Adolescent With a First Episode of Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646218</td><td>McGregor (2018)</td><td>Modification of the association between antipsychotic treatment response and childhood adversity by MMP9 gene variants in a first-episode schizophrenia cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648287</td><td>McGregor (2021)</td><td>Cannabis-based medicines as novel interventions for psychiatric disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646793</td><td>McGuckin (2020)</td><td>How High? Trends in Cannabis Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada, between 2007 and 2017: A quelle hauteur? Les tendances de l'usage du cannabis avant la premiere hospitalisation en psychiatrie en Ontario, Canada entre 2007 et 2017</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648009</td><td>McGuire (2018)</td><td>Commentary on "The potential of cannabidiol treatment for cannabis users with recent-onset psychosis"</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634086</td><td>McIntyre (1995)</td><td>How Much Neuroleptic is Enough</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646938</td><td>McNabb (2018)</td><td>Functional network dysconnectivity as a biomarker of treatment resistance in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644706</td><td>McNamara (2001)</td><td>Transcranial magnetic stimulation for depression and other psychiatric disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646532</td><td>McNamara (2011)</td><td>Investigation of postmortem brain polyunsaturated fatty acid composition in psychiatric disorders: Limitations, challenges, and future directions</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634116</td><td>McNamara (2017)</td><td>A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647402</td><td>McQueen (2020)</td><td>Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648275</td><td>McWilliams (2010)</td><td>Caregiver psychoeducation for first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645221</td><td>Mechri (2005)</td><td>Repeat suicide attempts: characteristics of repeaters versus first-time attempters admitted in the emergency of a tunisian general hospital</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646241</td><td>Mediavilla (2019)</td><td>Mindfulness-based social cognition training (SocialMIND) versus psychoeducational multicomponent intervention for people with a first episode of psychosis: a study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633985</td><td>Mehl (1977)</td><td>Endogenous ligands of a putative LSD-serotonin receptor in the cerebrospinal fluid: higher level of LSD-displacing factors (LDF) in unmedicated psychotic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634151</td><td>Mehl (2018)</td><td>Does CBT for Psychosis Have an Impact on Delusions by Improving Reasoning Biases and Negative Self-Schemas?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647232</td><td>Mehta (2016)</td><td>Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647536</td><td>Mehta (2019)</td><td>Early motor resonance differentiates schizophrenia patients from healthy subjects and predicts social cognition performance</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634224</td><td>Mei (2021)</td><td>Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647424</td><td>Meijer (2014)</td><td>The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients withmulti-episode schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633979</td><td>Meise (1994)</td><td>Outpatient Care in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634095</td><td>Meise (1994)</td><td>Schizophrenia Patients: Is There a Consensus?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647436</td><td>Melau (2011)</td><td>The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647650</td><td>Melau (2011)</td><td>Does extended specialized intervention for patients with first episode psychosis improve outcome in the critical period? The OPUS II trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648463</td><td>Melau (2012)</td><td>The association between working alliance, compliance, self-efficacy, and social function in a cohort of 397 patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648464</td><td>Melau (2015)</td><td>The association between working alliance and clinical and functional outcome in a cohort of 400 patients with first-episode psychosis: a cross-sectional study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648224</td><td>Melau (2018)</td><td>Changes in psychopathology predict changes in working alliance in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644491</td><td>Melicher (2015)</td><td>White matter changes in first episode psychosis and their relation to the size of sample studied: A DTI study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645295</td><td>Melle (2004)</td><td>Reducing the duration of untreated first-episode psychosis: effects on clinical presentation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645296</td><td>Melle (2005)</td><td>Reducing the duration of untreated first-episode psychosis--Effects on baseline social functioning and quality of life</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646327</td><td>Melle (2005)</td><td>Measuring quality of life in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647852</td><td>Melle (2010)</td><td>Course and predictors of suicidality over the first two years of treatment in first-episode schizophrenia spectrum psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634096</td><td>Mellgren (1982)</td><td>The anhedonia hypothesis: Termites in the basement</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633579</td><td>Meltzer (1987)</td><td>Effect of neuroleptics on the schizophrenic syndrome.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633825</td><td>Meltzer (1995)</td><td>Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647501</td><td>Mena (2018)</td><td>Early treatment resistance in a Latin-American cohort of patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645585</td><td>Menard (2014)</td><td>Preliminary and ongoing French multicenter prospective naturalistic study of adverse events of antipsychotic treatment in naive children and adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633712</td><td>Menezes (2006)</td><td>A systematic review of longitudinal outcome studies of first-episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644475</td><td>Meng (2019)</td><td>Widespread white-matter microstructure integrity reduction in first-episode schizophrenia patients after acute antipsychotic treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644629</td><td>Merlo (1995)</td><td>Two-years effects of low-dose neuroleptisation during initial acute state in first-episode psychosis conference abstract</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634000</td><td>Merlo (1995)</td><td>Two-years effects of low-dose neuroleptisation during initial acute state in first-episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647729</td><td>Merlo (1998)</td><td>Differences in EEG profiles of early and late responders to antipsychotic treatment in first-episode, drug-naive psychotic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645464</td><td>Merlo (2001)</td><td>Psychopharmacotherapy in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645136</td><td>Merlo (2002)</td><td>Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646148</td><td>Merritt (2016)</td><td>Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646887</td><td>Merritt (2020)</td><td>Glyceryl trinitrate in first-episode psychosis unmedicated with antipsychotics: A randomised controlled pilot study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647638</td><td>Mesa (2013)</td><td>Dopamine partial agonism in antipsychotic-induced sexual dysfunction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646259</td><td>Metformin for Early... (2020)</td><td>Metformin for Early Onset Comorbid Type 2 Diabetes or Prediabetes in Schizophrenia Spectrum Disorders: a Double-Blind Randomized Pilot Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648615</td><td>Meyer (2011)</td><td>Anti-inflammatory signaling in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645446</td><td>Meyer (2014)</td><td>The psychotic face of the immune system: Inflammation and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647891</td><td>Meyer (2017)</td><td>Converting oral to long-acting injectable antipsychotics: a guide for the perplexed</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647194</td><td>Meyer-Kalos (2019)</td><td>Enhancing stress reactivity and wellbeing in first episode psychosis with individual coping awareness therapy (I-CAT): pilot data and efficacy study design</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648761</td><td>Meyer-Kalos (2019)</td><td>31.4 ENHANCING STRESS REACTIVITY AND WELLBEING IN FIRST EPISODE PSYCHOSIS WITH INDIVIDUAL COPING AWARENESS THERAPY (I-CAT): PILOT DATA AND EFFICACY STUDY DESIGN...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646683</td><td>Meyer-Lindenberg (1997)</td><td>Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648010</td><td>Meyh√∂fer (2017)</td><td>Combining two model systems of psychosis: the effects of schizotypy and sleep deprivation on oculomotor control and psychotomimetic states</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647290</td><td>Meyhofer (2019)</td><td>The effects of positive schizotypy and sleep deprivation on prepulse inhibition</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647626</td><td>Mezaki (1995)</td><td>Dose-response relationship in the treatment of cervical dystonia with botulinum toxin type A (AGN 191622)--a phase II study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645859</td><td>Mezquida (2020)</td><td>P.567 What happens in naive first-episode of psychosis patients initiating olanzapine treatment? Body mass index gain and improvement in negative symptomatology</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645863</td><td>Mezquida (2020)</td><td>P.549 Thresholds to establish functional impairment according to severity using the functioning assessment short test (FAST) in non-affective psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645765</td><td>Miceli (2005)</td><td>Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644969</td><td>Michail (2009)</td><td>Social anxiety disorder in first-episode psychosis: Incidence, phenomenology and relationship with paranoia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644504</td><td>Michie (2001)</td><td>What has MMN revealed about the auditory system in schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633633</td><td>Miklowitz (1989)</td><td>Is expressed emotion an index of a transactional process? I. Parents' affective style.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646776</td><td>Milano (2017)</td><td>Hyperprolactinemia Induced by Antipsychotics: From Diagnosis to Treatment Approach</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648391</td><td>Milanovic (2018)</td><td>Be outspoken and overcome stigmatizing thoughts (BOOST): a group treatment for internalized stigma in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648026</td><td>Miley (2020)</td><td>Cognitive Training and Remediation in First-Episode Psychosis: A Literature Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634074</td><td>Milgram (1982)</td><td>On the generality of the anhedonia hypothesis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648469</td><td>Miljevic (2018)</td><td>Association between neurological soft signs and antioxidant enzyme activity in schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633967</td><td>Miller (1984)</td><td>Major psychosis and dopamine: controversial features and some suggestions.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633660</td><td>Miller (1987)</td><td>The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633867</td><td>Miller (1989)</td><td>Hyperactivity of Associations in Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633545</td><td>Miller (1993)</td><td>Striatal dopamine in reward and attention: a system for understanding the symptomatology of acute schizophrenia and mania.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633650</td><td>Miller (1997)</td><td>Risk factors for the development of neuroleptic induced akathisia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633668</td><td>Miller (1997)</td><td>Dose-response relationships for the antipsychotic effects and Parkinsonian side-effects of typical neuroleptic drugs: practical and theoretical implications.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633815</td><td>Miller (2000)</td><td>Managing antipsychotic-induced acute and chronic akathisia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645541</td><td>Miller (2003)</td><td>The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644673</td><td>Miller (2006)</td><td>Treatment of Chronic Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648286</td><td>Miller (2007)</td><td>Cannabis: A vulnerability-stress factor in the treatment of recent onset of schizophrenia, schizoaffective disorder, and schizophreniform disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645178</td><td>Miller (2008)</td><td>A review of second-generation antipsychotic discontinuation in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645070</td><td>Miller (2011)</td><td>Second-generation antipsychotic discontinuation in first episode psychosis: An updated review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644672</td><td>Miller (2012)</td><td>Treatment of chronic schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647627</td><td>Miller (2014)</td><td>A dose reduction/discontinuation strategy improves long-term recovery in people with remitted first-episode psychosis compared to maintenance therapy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646064</td><td>Miller (2019)</td><td>Neuroprotective Effects of Antidepressants in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646294</td><td>Miller (2019)</td><td>Meta-analysis of cytokine levels and psychopathology in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648077</td><td>Millgate (2020)</td><td>Cognitive deficits in treatment resistant schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645776</td><td>Milovan (2009)</td><td>Pharmacodynamic response patterns to ketamine, Zolpidem, and diazepam in abuse liability studies</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648664</td><td>Milton (2001)</td><td>Aggressive incidents in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647515</td><td>Min (2001)</td><td>Early rehabilitation of schizophrenics</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646536</td><td>Minichino (2017)</td><td>Investigating the link between drug-naive first episode psychoses (FEPs), weight gain abnormalities and brain structural damages: Relevance and implications for therapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646535</td><td>Minichino (2020)</td><td>Investigating the link between the peripheral endocannabinoid system and central glutamatergic neurotransmission in early psychosis: A 7T-MRS study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646328</td><td>Minichino (2021)</td><td>"Measuring disturbance of the endocannabinoid system in psychosis: A systematic review and meta-analysis": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646929</td><td>Minzenberg (2010)</td><td>Gamma oscillatory power is impaired during cognitive control independent of medication status in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647686</td><td>Minzenberg (2014)</td><td>Disrupted action monitoring in recent-onset psychosis patients with schizophrenia and bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646127</td><td>Mirzakhanian (2011)</td><td>Neural correlates of cognitive and emotional processing in individuals at-risk for schizophrenia and first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646663</td><td>Misawa (2004)</td><td>The Incidence of Hyperglycemia in Patients Treated With Olanzapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634295</td><td>Misciagna (2020)</td><td>Introductory Chapter: Definition of Cognitive Behavioral Therapy and Its Principal Applications</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647282</td><td>Misiak (2014)</td><td>Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645946</td><td>Misiak (2016)</td><td>One-carbon metabolism in schizophrenia: Lessons from genetic and epigenetic studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646814</td><td>Misiak (2016)</td><td>A history of childhood trauma and response to treatment with antipsychotics in first-episode schizophrenia patients: Preliminary results</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647327</td><td>Misiak (2016)</td><td>Effects of antipsychotics on insight in schizophrenia: Results from independent samples of first-episode and acutely relapsed patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646451</td><td>Misiak (2017)</td><td>Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644564</td><td>Misiak (2018)</td><td>Vascular endothelial growth factor in patients with schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644767</td><td>Misiak (2018)</td><td>Testosterone, DHEA and DHEA-S in patients with schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646450</td><td>Misiak (2018)</td><td>Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: Authors' reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648528</td><td>Misiak (2019)</td><td>Appetite regulating hormones in first-episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633750</td><td>Mitchell (1993)</td><td>Chlorpromazine Turns Forty</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646515</td><td>Mitchell (2013)</td><td>Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634269</td><td>Mitsunaga-Ohmuro (2021)</td><td>Longitudinal changes in personal recovery in individuals with psychotic disorders through hospitalisation in a psychiatric ward: preliminary findings.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633820</td><td>Mittal (2009)</td><td>Antipsychotic Adherence Intervention for Veterans over Forty with Schizophrenia: Results of a Pilot Study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646196</td><td>Mittal (2010)</td><td>Movement abnormalities and schizophrenia in DSM-V</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648525</td><td>Miyakoshi (2009)</td><td>Application of the Comprehensive Assessment of At-Risk Mental States (CAARMS) to the Japanese population: Reliability and validity of the Japanese version of the CAARMS</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644850</td><td>Miyamoto (2007)</td><td>Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633624</td><td>Mizrahi (2005)</td><td>How antipsychotics work: the patients' perspective.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647329</td><td>Mizrahi (2011)</td><td>Effects of antipsychotics on D3 receptors: A clinical PET study in first episode antipsychotic naive patients with schizophrenia using</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646837</td><td>Mizuno (2019)</td><td>Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633899</td><td>Ml (1961)</td><td>Chlorpromazine in chronic schizophrenic women: I. Experimental design and effects at maximum point of treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646312</td><td>Modabbernia (2014)</td><td>Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646128</td><td>Modinos (2015)</td><td>Neural correlates of aberrant emotional salience predict psychotic symptoms and global functioning in high-risk and first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648618</td><td>Moe (2016)</td><td>Anomalies of self in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648003</td><td>Mohan (2013)</td><td>Comorbid situs inversus totalis and schizophrenia in a young male</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648080</td><td>Mohr (2015)</td><td>Cognitive deficits in depression</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634261</td><td>Moitra (2021)</td><td>Development and Initial Testing of an mHealth Transitions of Care Intervention for Adults with Schizophrenia-Spectrum Disorders Immediately Following a Psychiatric Hospitalization.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646775</td><td>Molina (2005)</td><td>Hypofrontality in men with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646869</td><td>Molina (2014)</td><td>Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647794</td><td>Molina (2020)</td><td>Deficits of entropy modulation of the EEG: A biomarker for altered function in schizophrenia and bipolar disorder?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633563</td><td>M√∂ller (1981)</td><td>Psychopathometrische Verlaufsuntersuchungen an Patienten mit Schizophrenien und verwandten Psychosen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633582</td><td>M√∂ller (1987)</td><td>Indikation und Differentialindikation der neuroleptischen Langzeitmedikation</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633568</td><td>M√∂ller (1990)</td><td>Neuroleptische Langzeittherapie schizophrener Erkrankungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633562</td><td>M√∂ller (1991)</td><td>Typical Neuroleptics in the Treatment of Positive and Negative Symptoms</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633581</td><td>M√∂ller (2003)</td><td>Schizophrenie√§hnliche St√∂rungen und nichtorganische Wahnerkrankungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645005</td><td>Moller (2008)</td><td>Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647039</td><td>Moloney (2020)</td><td>First episode psychosis (FEP) and substance use: Impact of early intervention service (EIS)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648611</td><td>Momcilovic (2014)</td><td>Anticholinergics for neuroleptic‚Äêinduced parkinsonism and tardive dyskinesia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647826</td><td>Momtazmanesh (2019)</td><td>Cytokine Alterations in Schizophrenia: An Updated Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633811</td><td>Moncrieff (2005)</td><td>Rethinking models of psychotropic drug action.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633817</td><td>Moncrieff (2008)</td><td>The creation of the concept of an antidepressant: an historical analysis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633615</td><td>Moncrieff (2009)</td><td>A critique of the dopamine hypothesis of schizophrenia and psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634060</td><td>Moncrieff (2009)</td><td>Deconstructing psychiatric drug treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633986</td><td>Moncrieff (2010)</td><td>Challenging conventional models of psychiatric drug therapy: an alternative patient-centered approach</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645427</td><td>Moncrieff (2011)</td><td>Questioning the 'neuroprotective' hypothesis: Does drug treatment prevent brain damage in early psychosis or schizophrenia?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633713</td><td>Moncrieff (2013)</td><td>The psychoactive effects of psychiatric medication: the elephant in the room.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634128</td><td>Moncrieff (2016)</td><td>Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647842</td><td>Moncrieff (2019)</td><td>A critical analysis of recent data on the long-term outcome of antipsychotic treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634137</td><td>Moncrieff (2019)</td><td>An Alternative Approach to Drug Treatment in Psychiatry</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648747</td><td>Mondelli (2010)</td><td>Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: The role of stress and of antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646616</td><td>Mondelli (2014)</td><td>Inflammation: Its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647871</td><td>Mondelli (2015)</td><td>Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645299</td><td>Mondragon-Maya (2013)</td><td>Reduced P3a amplitudes in antipsychotic naive first-episode psychosis patients and individuals at clinical high-risk for psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647807</td><td>Monsonet (2020)</td><td>Deconstructing the relationships between self-esteem and paranoia in early psychosis: an experience sampling study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646640</td><td>Montalvo (2014)</td><td>Increased prolactin levels are associated with impaired processing speed in subjects with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646889</td><td>Montalvo (2020)</td><td>Glycated Haemoglobin Is Associated With Poorer Cognitive Performance in Patients With Recent-Onset Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645068</td><td>Montemagni (2016)</td><td>Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646482</td><td>Montero-Olvera (2017)</td><td>Late diagnosis of systemic lupus erythematosus and antiphospholipid syndrome in an older woman with psychosis: a case report and review of the literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645103</td><td>Montes (2003)</td><td>Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648269</td><td>Montreuil (2012)</td><td>Case manager- and patient-rated alliance as a predictor of medication adherence in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648530</td><td>Montreuil (2013)</td><td>Anxiety symptoms severity and short-term clinical outcome in first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646342</td><td>Montreuil (2016)</td><td>Manualized group cognitive-behavioral therapy for social anxiety in at-risk mental state and first episode psychosis: A pilot study of feasibility and outcomes</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645550</td><td>Moon (2010)</td><td>Preventing psychotic disorders in high-risk patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644766</td><td>Moore (2007)</td><td>The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648300</td><td>Morales-Munoz (2015)</td><td>Cannabis abuse effects on prepulse inhibition in patients with first episode psychosis in schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648344</td><td>Morch-Johnsen (2015)</td><td>Brain structure abnormalities in first-episode psychosis patients with persistent apathy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647724</td><td>Moreno (2019)</td><td>Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634191</td><td>Morgan (2005)</td><td>Drug- and Toxin-Induced Tremor</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647832</td><td>Morgan (2008)</td><td>Cumulative social disadvantage, ethnicity and first-episode psychosis: A case-control study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646521</td><td>Morgan (2009)</td><td>Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645284</td><td>Morin (2017)</td><td>Rehabilitation Interventions to Promote Recovery from Schizophrenia: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646661</td><td>Morl√°n-Coarasa (2016)</td><td>Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647619</td><td>Morozova (2012)</td><td>Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633653</td><td>Morrison (1973)</td><td>Catatonia. Retarded and excited types.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648029</td><td>Morrison (2004)</td><td>Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644737</td><td>Morrison (2007)</td><td>Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648091</td><td>Morrison (2009)</td><td>Cognitive behaviour therapy for first episode psychosis: Good for nothing or fit for purpose?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648535</td><td>Morrison (2012)</td><td>"Antipsychotics: Is it time to introduce patient choice?": Author's reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633616</td><td>Morrison (2013)</td><td>Assessing Cognitive Therapy Instead Of Neuroleptics: Rationale, study design and sample characteristics of the ACTION trial</td><td>(I) Included</td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>61633909</td><td>Morrison (2014)</td><td>Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633354</td><td>Morrison (2018)</td><td>Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>61634111</td><td>Morrison (2018)</td><td>Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634161</td><td>Morrison (2018)</td><td>Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment - Author's reply.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648585</td><td>Morrison (2019)</td><td>"Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: A randomised controlled pilot and feasibility study": Correction</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>61634126</td><td>Morrison (2019)</td><td>Should people with psychosis be supported in choosing cognitive therapy as an alternative to antipsychotic medication: A commentary on current evidence.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634245</td><td>Morrison (2019)</td><td>Cognitive‚Äìbehavioural therapy for clozapine-resistant schizophrenia: the FOCUS RCT</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648579</td><td>Morrison (2020)</td><td>Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645476</td><td>Morrison (2021)</td><td>Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645176</td><td>Morse (2011)</td><td>Review: Exploring the role of mental health nurse-practitioner in the treatment of early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646840</td><td>Mortier (2019)</td><td>Hepatic encephalopathy resulting in mania, a possible role of bilirubin and glutamate?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644604</td><td>Mortimer (2009)</td><td>Update on the management of symptoms in schizophrenia: Focus on amisulpride</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634083</td><td>Mosher (1983)</td><td>Scientific Evidence and System Change: The Soteria Experience</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634091</td><td>Mosher (1985)</td><td>Wissenschaftliche Erkenntnisse und Systemver√§nderungen Erfahrungen im Soteria-Projekt</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646022</td><td>Mosher (2013)</td><td>Non-hospital, non-medication interventions in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59647814</td><td>Mossner (2010)</td><td>DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648411</td><td>Mota (2018)</td><td>Automated speech analysis to predict development of psychosis: a novel endpoint in a randomized, phase II trial of BI 409306 in attenuated psychosis syndrome</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633778</td><td>Mott (1965)</td><td>COMPARATIVE STUDY OF HALLUCINATIONS.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647273</td><td>Mottaghipour (2000)</td><td>Efficacy and effectiveness in early psychosis family education group program</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644553</td><td>Moulin (2019)</td><td>Violent behaviour in early psychosis patients: Can we identify clinical risk profiles?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644742</td><td>Moulin (2019)</td><td>Three clinical risk profiles of violent behavior in a cohort of early psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647015</td><td>Moura (2016)</td><td>First-episode psychosis in a 15 year-old female with clinical presentation of anti-NMDA receptor encephalitis: a case report and review of the literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633738</td><td>Mowbray (2002)</td><td>Mental Health and Mental Illness: Out of the Closet?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648021</td><td>Mucci (2008)</td><td>Cognitive-enhancing effects of aripiprazole: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634226</td><td>Mueller (2021)</td><td>Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646146</td><td>Mueser (2015)</td><td>The NAVIGATE Program for First-Episode Psychosis: rationale, Overview, and Description of Psychosocial Components</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647769</td><td>Mueser (2015)</td><td>Description and implementation of the raise-etp study psychosocial treatment model: the navigate program</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648540</td><td>M√ºhlbauer (2019)</td><td>Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644814</td><td>Mui (2019)</td><td>Systematic review (meta-aggregation) of qualitative studies on the experiences of family members caring for individuals with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646142</td><td>Mulder (2016)</td><td>The need to do and imbibe as well as debate and discuss</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646171</td><td>Mullen (2002)</td><td>Multiple family group interventions in first episode psychosis: Enhancing knowledge and understanding</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648248</td><td>Muller (2010)</td><td>Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646544</td><td>Muller (2012)</td><td>Interventions in people at risk of developing first episode psychosis: A survey of current randomised controlled studies</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646751</td><td>Muller (2014)</td><td>Immunological treatment options for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646750</td><td>Muller (2015)</td><td>Immunomodulation as therapeutic approach in schizophrenia and depression: State of the art</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633575</td><td>M√ºller-Spahn (1990)</td><td>Neue Aspekte in der Langzeitbehandlung schizophrener Patienten mit Neuroleptika</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646162</td><td>Mullier (2018)</td><td>N-acetyl-cysteine supplementation improves functional connectivity in the cingulate cortex in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646161</td><td>Mullier (2019)</td><td>N-acetyl-cysteine supplementation improves functional connectivity within the cingulate cortex in early psychosis: A pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647648</td><td>Mullin (2012)</td><td>Does giving up substance use work for patients with psychosis? A systematic meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645473</td><td>Murawiec (2008)</td><td>Psychological phenomena in the first two weeks of pharmacotherapy of schizophrenic patients in the framework of Shitij Kapur's theory of psychosis as a state of aberrant salience: A preliminary report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645217</td><td>Murdie (2016)</td><td>Reply to: The importance of keeping in mind the diagnosis of N-methyl-D-aspartate receptor encephalitis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647251</td><td>Murphy (2006)</td><td>Efficacy of amisulpride in treating primary negative symptoms in first-episode psychosis: A pilot study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647485</td><td>Murphy (2018)</td><td>An economic evaluation of Coordinated Specialty Care (CSC) services for first-episode psychosis in the U.S. public sector</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633800</td><td>Murray (1989)</td><td>Neuroleptic-resistant schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647643</td><td>Murray (2019)</td><td>Does tobacco smoking cause psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646116</td><td>Murri (2016)</td><td>Neuroactive Steroids in First-Episode Psychosis: a Role for Progesterone?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644703</td><td>Murrie (2020)</td><td>Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634066</td><td>Muser (2015)</td><td>Original research Cost effectiveness of paliperidone palmitate versus oral antipsychotics in patients with schizophrenia and a history of criminal justice involvement</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646060</td><td>Mushet (2020)</td><td>Neuropsychiatric presentations of sydenham's chorea in the UK</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645634</td><td>Mustafa (2018)</td><td>Predictors of 'all-cause discontinuation' of initial oral antipsychotic medication in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634164</td><td>Mustafa (2018)</td><td>Stand-alone cognitive behavioural therapy is not in clinical equipoise with antipsychotic treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645329</td><td>Mustafa (2019)</td><td>Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: A Canadian naturalistic non-interventional prospective cohort study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648172</td><td>Mutsatsa (2003)</td><td>Clinical correlates of early medication adherence: West London first episode schizophrenia study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647977</td><td>Mwesiga (2021)</td><td>Comparison of antipsychotic naive first-episode psychosis patients and healthy controls in Uganda</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634285</td><td>Mwesiga (2021)</td><td>Quality of individual and group level interventions for first-episode psychosis at the tertiary psychiatric hospital in Uganda</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647810</td><td>Myers (2019)</td><td>Decision making about pathways through care for racially and ethnically diverse young adults with early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644724</td><td>Myles (2012)</td><td>Tobacco use before, at, and after first-episode psychosis: A systematic meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648288</td><td>Myles (2016)</td><td>Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645844</td><td>Myles-Worsley (2007)</td><td>The Palau early psychosis study: Distribution of cases by level of genetic risk</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647318</td><td>Na (2016)</td><td>Effects of community mental health service in subjects with early psychosis: One-year prospective follow up</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645055</td><td>Naeem (2015)</td><td>Self‚Äêhelp and guided self‚Äêhelp interventions for schizophrenia and related disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648731</td><td>Naeem (2015)</td><td>Acceptance and Commitment Therapy for schizophrenia and related disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647021</td><td>Nagaoka (1997)</td><td>First-episode neuroleptic-free schizophrenics: Concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647217</td><td>Nagase (1996)</td><td>Electroencephalography in schizophrenic patients: Comparison between neuroleptic-naive state and after treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646820</td><td>Nakahara (2018)</td><td>Hippocampal subregion abnormalities in schizophrenia: A systematic review of structural and physiological imaging studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634147</td><td>Nakao (2018)</td><td>Web-Based Cognitive Behavioral Therapy Blended With Face-to-Face Sessions for Major Depression: Randomized Controlled Trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647186</td><td>Nakhli (2016)</td><td>Epileptic seizures and clozapine titration</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644874</td><td>Nani (2020)</td><td>A study in first-episode psychosis patients: Does angiotensin I-converting enzyme activity associated with genotype predict symptom severity reductions after treatment with atypical antipsychotic risperidone?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647364</td><td>Napa (2017)</td><td>Effectiveness of family interventions on psychological distress and expressed emotion in family members of individuals diagnosed with first-episode psychosis: a systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645104</td><td>Narayan (2018)</td><td>Safety profile of superior petrosal vein (the vein of Dandy) sacrifice in neurosurgical procedures: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644721</td><td>Narula (2010)</td><td>Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646129</td><td>Nawani (2014)</td><td>neural basis of tDCS effects on auditory verbal hallucinations in schizophrenia: A case report evidence for cortical neuroplasticity modulation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634287</td><td>Nawaz (2020)</td><td>Overview of schizophrenia research and treatment in Pakistan.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644684</td><td>Nct (1999)</td><td>Treatment for First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648319</td><td>Nct (2002)</td><td>CAFE Comparison of Atypicals in First Episode of Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644570</td><td>Nct (2005)</td><td>V3: vancouver-Victoria Valacyclovir Trial for Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644645</td><td>Nct (2005)</td><td>A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644676</td><td>Nct (2005)</td><td>Treatment of Acute Schizophrenia With Vitamin Therapy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644863</td><td>Nct (2005)</td><td>Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645109</td><td>Nct (2005)</td><td>Safety and Efficacy of Seroquel in First Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645532</td><td>Nct (2005)</td><td>Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645556</td><td>Nct (2005)</td><td>PREvent First Episode Relapse (PREFER)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645918</td><td>Nct (2005)</td><td>Optimization of Acute Treatment in First Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645947</td><td>Nct (2005)</td><td>One Year Drug Treatment in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646355</td><td>Nct (2005)</td><td>Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647228</td><td>Nct (2005)</td><td>Efficacy of Treating First Episode Psychosis With Folic Acid,B12 and B6 in Addition to Antipsychotic Medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647633</td><td>Nct (2005)</td><td>Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647972</td><td>Nct (2005)</td><td>Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648066</td><td>Nct (2005)</td><td>Cognitive Enhancement Therapy for Early-Stage Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648120</td><td>Nct (2005)</td><td>Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648156</td><td>Nct (2005)</td><td>Clinical Trial of Integrated Treatment Versus Standard Treatment in First Episode Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648695</td><td>Nct (2005)</td><td>The ADDITION Study. Intensive Treatment in People With Screen Detected Diabetes in Primary Care</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644873</td><td>Nct (2006)</td><td>Study of Amantadine for Weight Stabilization During Olanzapine Treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644931</td><td>Nct (2006)</td><td>Specialized Treatment Early in Psychosis (STEP)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645099</td><td>Nct (2006)</td><td>Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645450</td><td>Nct (2006)</td><td>Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645905</td><td>Nct (2006)</td><td>Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646035</td><td>Nct (2006)</td><td>The New Strategy for Pharmacological Treatment in People With Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646631</td><td>Nct (2006)</td><td>Indicated Prevention With Omega-3 Fatty Acids in Adolescents With 'At-Risk-Mental-State' for Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646880</td><td>Nct (2006)</td><td>Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646971</td><td>Nct (2006)</td><td>A Follow-Up Study of Schizophrenic Participants Following Treatment Discontinuation After Remission From a First Psychotic Episode</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647397</td><td>Nct (2006)</td><td>Effect of the 'Mother and Baby' Program on Well-Being</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647621</td><td>Nct (2006)</td><td>A Double-blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-naive First-episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647975</td><td>Nct (2006)</td><td>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648568</td><td>Nct (2006)</td><td>Antipsychotic Therapy and First Episode</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644871</td><td>Nct (2007)</td><td>A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644934</td><td>Nct (2007)</td><td>Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645210</td><td>Nct (2007)</td><td>Research Study of Bipolar Mood Symptoms and Cognitive Problems</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646092</td><td>Nct (2007)</td><td>Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646274</td><td>Nct (2007)</td><td>Metabolic Signatures and Biomarkers in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646279</td><td>Nct (2007)</td><td>Metabolic Profile and Anthropometric Changes in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647029</td><td>Nct (2007)</td><td>First Episode Schizophrenia and Cannabis-Related Disorder Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647630</td><td>Nct (2007)</td><td>Dose Finding of Quetiapine Fumarate 200mg vs 400mg in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645371</td><td>Nct (2008)</td><td>A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645845</td><td>Nct (2008)</td><td>Pain Medicine for Wound Care Procedures</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646236</td><td>Nct (2008)</td><td>Minocycline for the Treatment of Early-Phase Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644918</td><td>Nct (2009)</td><td>Stage-specific Case Management for Early Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645124</td><td>Nct (2009)</td><td>Role of Minocycline in First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646321</td><td>Nct (2009)</td><td>Medication Adherence in Schizophrenia: development of a CBT-Based Intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647105</td><td>Nct (2009)</td><td>Extended Specialized Assertive Intervention for First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647470</td><td>Nct (2009)</td><td>Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647811</td><td>Nct (2009)</td><td>DECIFER: depression and Citalopram In First Episode Recovery</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648479</td><td>Nct (2009)</td><td>Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644467</td><td>Nct (2010)</td><td>Yoga and Aerobic Exercise in Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644910</td><td>Nct (2010)</td><td>Standard Comprehensive Intervention to Treat First-episode Schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645544</td><td>Nct (2010)</td><td>Prevention of Weight Gain in Early Psychoses</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648484</td><td>Nct (2010)</td><td>Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645219</td><td>Nct (2011)</td><td>Repetitive Transcranial Magnetic Stimulation for First-episode Schizophrenia Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645907</td><td>Nct (2011)</td><td>Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646156</td><td>Nct (2011)</td><td>NAPLS Omega-3 Fatty Acid Versus Placebo Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646165</td><td>Nct (2011)</td><td>N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646483</td><td>Nct (2011)</td><td>A Large Pragmatic Cluster Randomized Controlled Trial of a Multi-element Psychosocial Intervention for Early Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646578</td><td>Nct (2011)</td><td>An Integrated Program for the Treatment of First Episode of Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646835</td><td>Nct (2011)</td><td>High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647423</td><td>Nct (2011)</td><td>The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648097</td><td>Nct (2011)</td><td>Cognitive Behavioral Therapy for Patients With an Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59648121</td><td>Nct (2011)</td><td>Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648488</td><td>Nct (2011)</td><td>Artemisinin With Risperidone for First-Episode and Drug-Naive Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648613</td><td>Nct (2011)</td><td>Anti-psychotic Medication (New Use) Weight Loss Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645332</td><td>Nct (2012)</td><td>A RCT Study in Schizophrenia Relapse Prevention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646031</td><td>Nct (2012)</td><td>Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646524</td><td>Nct (2012)</td><td>Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646906</td><td>Nct (2012)</td><td>Ginkgo Biloba Extract for Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645381</td><td>Nct (2013)</td><td>Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645542</td><td>Nct (2013)</td><td>Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646210</td><td>Nct (2013)</td><td>Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646237</td><td>Nct (2013)</td><td>Minocycline for Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646311</td><td>Nct (2013)</td><td>Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646582</td><td>Nct (2013)</td><td>Integrated Care in Psychotic Disorders With Severe Mental Illness</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647567</td><td>Nct (2013)</td><td>e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648109</td><td>Nct (2013)</td><td>Coaching Intervention for Patients With Early Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648154</td><td>Nct (2013)</td><td>Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645115</td><td>Nct (2014)</td><td>rTMS in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646244</td><td>Nct (2014)</td><td>Mindfulness RCT for Early Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646341</td><td>Nct (2014)</td><td>Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646579</td><td>Nct (2014)</td><td>Integrated Metacognitive Therapy in First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646581</td><td>Nct (2014)</td><td>Integrated Care Including Assertive Community Treatment in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646968</td><td>Nct (2014)</td><td>A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647154</td><td>Nct (2014)</td><td>Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648094</td><td>Nct (2014)</td><td>COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644631</td><td>Nct (2015)</td><td>The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645496</td><td>Nct (2015)</td><td>Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645713</td><td>Nct (2015)</td><td>A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645830</td><td>Nct (2015)</td><td>Participatory Video as a Recovery-Oriented Intervention in Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646248</td><td>Nct (2015)</td><td>Mindfulness Group-based Intervention for Early Psychosis: a Pilot Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647978</td><td>Nct (2015)</td><td>Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647989</td><td>Nct (2015)</td><td>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648117</td><td>Nct (2015)</td><td>Clozapine-induced Hypersalivation - Feasibility Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648301</td><td>Nct (2015)</td><td>Cannabidiol Treatment in Patients With Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648349</td><td>Nct (2015)</td><td>Brain Effects of Memory Training in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644674</td><td>Nct (2016)</td><td>Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644708</td><td>Nct (2016)</td><td>Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644722</td><td>Nct (2016)</td><td>Tocilizumab in Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644914</td><td>Nct (2016)</td><td>The Staged Treatment in Early Psychosis Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644997</td><td>Nct (2016)</td><td>Siltuximab in Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645102</td><td>Nct (2016)</td><td>Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645592</td><td>Nct (2016)</td><td>Prednisolone Addition for Patients With Recent-onset Psychotic Disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646418</td><td>Nct (2016)</td><td>Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646556</td><td>Nct (2016)</td><td>Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647160</td><td>Nct (2016)</td><td>Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647238</td><td>Nct (2016)</td><td>Efficacy of ISST in Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648252</td><td>Nct (2016)</td><td>CBT-I as Early Intervention of Mood Disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648255</td><td>Nct (2016)</td><td>Cbt for Psychosis and Affect on Psychosis Symptoms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648385</td><td>Nct (2016)</td><td>The Benefit of Minocycline on Negative Symptoms in Schizophrenia: extent and Mechanisms</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648485</td><td>Nct (2016)</td><td>Aspirin in Young Psychotic Patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645117</td><td>Nct (2017)</td><td>Role of Vitamin D Supplementation in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645479</td><td>Nct (2017)</td><td>Psychoeducative Treatment of FEP With Mobile Training</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645994</td><td>Nct (2017)</td><td>Occupational Recovery After First Episode Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646014</td><td>Nct (2017)</td><td>The Norwegian Prednisolone in Early Psychosis Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646239</td><td>Nct (2017)</td><td>Minnesota Community-Based Cognitive Training in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646249</td><td>Nct (2017)</td><td>Mindfulness Group-based Intervention for Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646459</td><td>Nct (2017)</td><td>Levetiracetam in Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646527</td><td>Nct (2017)</td><td>Is Cognitive Training Neuroprotective in Early Psychosis?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647353</td><td>Nct (2017)</td><td>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647385</td><td>Nct (2017)</td><td>Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647426</td><td>Nct (2017)</td><td>Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648716</td><td>Nct (2017)</td><td>An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648771</td><td>Nct (2017)</td><td>A 8-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644769</td><td>Nct (2018)</td><td>Testing the Effectiveness of an Evening Blue-depleted Light Environment in an Acute Psychiatric Ward</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644868</td><td>Nct (2018)</td><td>A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645937</td><td>Nct (2018)</td><td>OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646010</td><td>Nct (2018)</td><td>A Novel Treatment Approach for Self-Stigma in First Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646242</td><td>Nct (2018)</td><td>Mindfulness-Based Family Psychoeducation Intervention for Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646243</td><td>Nct (2018)</td><td>Mindfulness Therapy for Chronic Migraine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647052</td><td>Nct (2018)</td><td>Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648100</td><td>Nct (2018)</td><td>Cognitive Behavior Therapy for Patients With Psychoses</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648206</td><td>Nct (2018)</td><td>Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59648359</td><td>Nct (2018)</td><td>Body-Mind-Spirit Intervention for Women With Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644589</td><td>Nct (2019)</td><td>Use of Parent Connectors in First Episode Psychosis (FEP)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644728</td><td>Nct (2019)</td><td>Title: safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645220</td><td>Nct (2019)</td><td>Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645227</td><td>Nct (2019)</td><td>ReMindCare App for Patients From First Episode of Psychosis Unit</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646101</td><td>Nct (2019)</td><td>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 3-years Follow-up</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646246</td><td>Nct (2019)</td><td>Mindfulness Intervention and Relapse in Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646264</td><td>Nct (2019)</td><td>Metacognitive Training and Insight in Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646330</td><td>Nct (2019)</td><td>Measuring and Improving Medication Adherence by Early Phase Participants</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646564</td><td>Nct (2019)</td><td>Interactive Obesity Treatment Approach (iOTA) for Obesity Prevention in Adults With Early Serious Mental Illness: iOTA-SMI</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647335</td><td>Nct (2019)</td><td>Effects of an Integrative Psychological Program in Bipolar Disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648253</td><td>Nct (2019)</td><td>CBT to Reduce Insomnia and Improve Social Recovery in Early Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648304</td><td>Nct (2019)</td><td>Cannabidiol for Treatment of Recent-onset Psychosis With Comorbid Cannabis Use</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648723</td><td>Nct (2019)</td><td>Action-based Cognitive Remediation for First Episode Psychosis</td><td>(I) Included</td><td><span class='complete'>Trine Bjerke Johansen</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59644575</td><td>Nct (2020)</td><td>Using Short Message Service as a Means of Clinical Engagement in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644577</td><td>Nct (2020)</td><td>Using mHealth to Optimize Pharmacotherapy Regimens</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645416</td><td>Nct (2020)</td><td>R33: levetiracetam in Early Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645447</td><td>Nct (2020)</td><td>Psychotherapy for Psychosis, Adverse Events, and Substance Misuse</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645952</td><td>Nct (2020)</td><td>On Track Chile For First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646017</td><td>Nct (2020)</td><td>Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646226</td><td>Nct (2020)</td><td>A Mobile Application to Improve Case-management and Patient's Functioning in First Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646539</td><td>Nct (2020)</td><td>Invest in My Recovery Bank: a Pilot Study of a Peer-Led Intervention for Co-Occurring Early Psychosis and Substance Use</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647118</td><td>Nct (2020)</td><td>Exploratory Intervention Study of HD-tDCS on Impaired Insight in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647295</td><td>Nct (2020)</td><td>Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647320</td><td>Nct (2020)</td><td>Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647412</td><td>Nct (2020)</td><td>The Effect of Psycho-education on Clinical Outcomes Among Patients With a First Episode Psychosis in Central Uganda</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647482</td><td>Nct (2020)</td><td>ED to EPI: using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647808</td><td>Nct (2020)</td><td>Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648038</td><td>Nct (2020)</td><td>Cognitive Remediation and Social Recovery in Early Psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648242</td><td>Nct (2020)</td><td>CHALLENGE. A Randomised Clinical Trial Examining Virtual Reality Avatar Therapy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648420</td><td>Nct (2020)</td><td>Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648684</td><td>Nct (2020)</td><td>Adjunctive Celecoxib in Childhood-onset OCD Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645218</td><td>Nct (2021)</td><td>Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645717</td><td>Nct (2021)</td><td>Pilot RCT of Self-stigma Treatment for First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646826</td><td>Nct (2021)</td><td>HIIT in Patients With a First-episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648699</td><td>Nct (2021)</td><td>Add-on MEmaNtine to Dopamine Antagonism to Improve Negative Symptoms at First Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633996</td><td>nd (1976)</td><td>Methodological issues in psychopharmacological research: chlorpromazine--a case in point.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648124</td><td>Nebhinani (2012)</td><td>Clozapine v. chlorpromazine in treatment-naive first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633640</td><td>Neborsky (1981)</td><td>Rapid Treatment of Acute Psychotic Symptoms With High- and Low-Dose Haloperidol: Behavioral Considerations</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646760</td><td>Negatsch (2019)</td><td>Identifying violent behavior using the Oxford Mental Illness and Violence Tool in a psychiatric ward of a German prison hospital</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633983</td><td>Neill (1982)</td><td>Problems of concept and vocabulary in the anhedonia hypothesis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646704</td><td>Nejad (2011)</td><td>Impaired temporoparietal deactivation with working memory load in antipsychotic-naive patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646125</td><td>Nejad (2013)</td><td>Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646143</td><td>Nelson (2011)</td><td>The need for drug-naive research in first-episode psychosis: A response to Moncrieff & Leo (2010)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646120</td><td>Nelson (2017)</td><td>Neurapro: a multi-center rct of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders: medium-term outcome</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644913</td><td>Nelson (2018)</td><td>Staged treatment in early psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646119</td><td>Nelson (2018)</td><td>NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders - Medium-term follow-up and clinical course</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648387</td><td>Nelson (2018)</td><td>Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646824</td><td>Nelson (2020)</td><td>Hippocampal connectivity and volume as predictors of treatment response-a replication study in two psychosis cohorts</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646110</td><td>Nelson (2021)</td><td>Neurobiological signatures of treatment response - a multi-modal study in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633783</td><td>Nemeroff (1982)</td><td>The anhedonia hypothesis of neuroleptic drug action: Basic and clinical considerations</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648161</td><td>Nemoto (2012)</td><td>Clinical practice at a multi-dimensional treatment centre for individuals with early psychosis in Japan</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648343</td><td>Nenadic (2015)</td><td>Brain structure in people at ultra-high risk of psychosis, patients with first-episode schizophrenia, and healthy controls: A VBM study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646658</td><td>Nesvag (2018)</td><td>The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646107</td><td>Neurochemical effects... (2019)</td><td>Neurochemical effects of oxytocin in people at clinical high risk for psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646057</td><td>NEUROPSYCHOLOGICAL CHANGE... (1998)</td><td>NEUROPSYCHOLOGICAL CHANGE IN EARLY PHASE SCHIZOPHRENIA OVER TWELVE MONTHS OF TREATMENT WITH OLANZAPINE, RISPERIDONE, OR HALOPERIDOLl. CONFERENCE PRESENTATION</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647667</td><td>Newton (2018)</td><td>Diverse definitions of the early course of schizophrenia-a targeted literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645154</td><td>Ng (2020)</td><td>Risky decision-making impairment in early-stage psychotic bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646445</td><td>Nguyen (2018)</td><td>A literature review of the effectiveness of community treatment order with first episode psychosis population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645291</td><td>Nguyen (2020)</td><td>Reduction in the prescription of olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646685</td><td>Nielsen (2012)</td><td>Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647818</td><td>Nielsen (2012)</td><td>DAI-10 is as good as DAI-30 in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644608</td><td>Nielssen (2009)</td><td>Untreated psychotic illness in the survivors of violent suicide attempts</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644779</td><td>Niendam (2018)</td><td>A technology-enhanced intervention to reduce the duration of untreated psychosis through rapid identification & engagement</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645263</td><td>Nikisch (2012)</td><td>"Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine": Retraction notice</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633982</td><td>Ninan (1989)</td><td>Pharmacological Management of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646408</td><td>Ninomiya (2014)</td><td>Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: A 1-year open-label trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646407</td><td>Ninomiya (2017)</td><td>"Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: A 1-year open-label trial": Retraction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647927</td><td>Nishida (2012)</td><td>Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645373</td><td>Nishida (2018)</td><td>A randomized controlled trial of comprehensive early intervention care in patients with first-episode psychosis in Japan: 1.5-year outcomes from the J-CAP study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>61633872</td><td>Nishikawa (1982)</td><td>Prophylactic effect of neuroleptics in symptom-free schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648267</td><td>Nishikawa (1998)</td><td>A case of meige and neck dystonia appearing following very low dose sulpiride</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647280</td><td>Nishikawa (2017)</td><td>Effects of the concurrent use of a reduced dose of propofol with divided supplemental remifentanil and moderate hyperventilation on duration and morphology of electroconvulsive therapy-induced electroencephalographic seizure activity: a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648680</td><td>Nitta (2013)</td><td>Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: A meta-analytic investigation of randomized controlled trials</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647552</td><td>No (2005)</td><td>Early Intervention Beneficial for Persons with Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647378</td><td>No (2009)</td><td>Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644636</td><td>Noguera (2013)</td><td>Twenty-four months of antipsychotic treatment in children and adolescents with first psychotic episode: Discontinuation and tolerability</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646443</td><td>Noiriel (2020)</td><td>The Lived Experience of First-Episode Psychosis: A Systematic Review and Metasynthesis of Qualitative Studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634162</td><td>Noordraven (2017)</td><td>Ethical acceptability of offering financial incentives for taking antipsychotic depot medication: patients‚Äô and clinicians‚Äô perspectives after a 12-month randomized controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648118</td><td>Noordsy (2010)</td><td>Clozapine vs. risperidone for people with first episode schizophrenia and co-occurring cannabis use disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644750</td><td>Noordsy (2018)</td><td>Therapeutic potential of physical exercise in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646955</td><td>Norbak-Emig (2016)</td><td>Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: relation to Cognitive Functions and Psychopathology</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647095</td><td>Norbak-Emig (2017)</td><td>Extrastriatal dopamine D2/3 receptors and cortical grey matter volumes in antipsychotic-naive schizophrenia patients before and after initial antipsychotic treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645913</td><td>Nordentoft (2002)</td><td>OPUS study: Suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: One-year follow-up of a randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645914</td><td>Nordentoft (2003)</td><td>OPUS project: a randomised controlled trial of integrated psychiatric treatment in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645910</td><td>Nordentoft (2006)</td><td>OPUS: a randomized, multicenter clinical trial of integrated treatment compared with standard treament before the first episode psychosis - Secondary publication</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59645911</td><td>Nordentoft (2006)</td><td>OPUS: a randomised multicenter trial of integrated versus standard treatment for patients with a first-episode psychosis--secondary publication</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59647791</td><td>Nordentoft (2010)</td><td>Deinstitutionalization revisited: a 5-year follow-up of a randomized clinical trial of hospital-based rehabilitation versus specialized assertive intervention (OPUS) versus standard treatment for patients with first-episode schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647143</td><td>Nordentoft (2011)</td><td>Evidence-based approach to suicide risk in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644523</td><td>Nordentoft (2014)</td><td>Was risk of suicide underestimated?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633948</td><td>Nordentoft (2014)</td><td>EPA-1816 - Intervention in First Episode Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644941</td><td>Nordentoft (2015)</td><td>Specialised assertive intervention in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647000</td><td>Nordentoft (2021)</td><td>First-episode psychosis: Phenomenology, onset, course, and early intervention (OPUS)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645711</td><td>Nordholm (2013)</td><td>Pituitary gland volume in patients with schizophrenia, subjects at ultra high-risk of developing psychosis and healthy controls: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646169</td><td>Nordholm (2018)</td><td>Multiple measures of HPA axis function in ultra high risk and first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644713</td><td>Nordon (2014)</td><td>Trajectories of antipsychotic response in drug-naive schizophrenia patients: Results from the 6-month ESPASS follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647766</td><td>North (2019)</td><td>Design, Implementation, and Assessment of a Public Comprehensive Specialty Care Program for Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645192</td><td>Nossel (2018)</td><td>Results of a coordinated specialty care program for early psychosis and predictors of outcomes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645883</td><td>Noto (2015)</td><td>Oxidative stress in drug naive first episode psychosis and antioxidant effects of risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648720</td><td>Noto (2019)</td><td>Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644688</td><td>Novak-Grubic (1999)</td><td>Treatment compliance in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648575</td><td>Novick (2012)</td><td>Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European schizophrenia outpatient health outcomes study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634303</td><td>Nr (1979)</td><td>Depot fluphenazine in the prevention of relapse in schizophrenia: evaluation of a treatment regimen [proceedings].</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647370</td><td>Ntr (2014)</td><td>Effectiveness of Cognitive Remediation Training (CRT) embedded in vocational rehabilitation (IPS) for persons with Early Psychosis Effectiviteit van Cognitieve Remediatie Training (CRT) ge√Øntegreerd in arbeidsrehabilitatie (IPS) voor mensen met een vroege psychose</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647746</td><td>Nuechterlein (1992)</td><td>Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633957</td><td>Nuechterlein (1995)</td><td>The Early Course of Schizophrenia and Long-term Maintenance Neuroleptic Therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633720</td><td>Nuechterlein (2006)</td><td>Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646430</td><td>Nuechterlein (2012)</td><td>Long-acting injectable antipsychotic medication after a first episode of schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646738</td><td>Nuechterlein (2012)</td><td>The impact of long-acting injectable versus oral risperidone on cognition and work functioning after an initial psychotic episode: the critical role of early medication adherence</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646421</td><td>Nuechterlein (2013)</td><td>Long-acting injectable risperidone and medication adherence enhance cognition and work functioning after a first psychotic episode</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647241</td><td>Nuechterlein (2013)</td><td>Efficacy of depot antipsychotics beyond mere relapse prevention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648325</td><td>Nuechterlein (2013)</td><td>Broad-spectrum cognitive remediation after a first episode of schizophrenia: impact on cognition and work/school functioning</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645375</td><td>Nuechterlein (2014)</td><td>A randomized controlled trial of cognitive remediation after a first episode of schizophrenia: improving cognition and work/school functioning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647540</td><td>Nuechterlein (2014)</td><td>The early longitudinal course of cognitive deficits in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648669</td><td>Nuechterlein (2018)</td><td>Aerobic exercise training for individuals with schizophrenia: the broad benefits across physical health, cognition, and everyday functioning and promising mechanisms of action</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645374</td><td>Nuechterlein (2020)</td><td>A randomized controlled trial of cognitive remediation and long-acting injectable risperidone after a first episode of schizophrenia: improving cognition and work/school functioning</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646953</td><td>Nuechterlein (2020)</td><td>Frontal intracortical myelin volume is related to speed of processing in patients with first-episode schizophrenia assessed with the matrics consensus cognitive battery (MCCB)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647196</td><td>Nuechterlein (2020)</td><td>Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645165</td><td>Nugent (2012)</td><td>Risk factors for schizophrenia subtypes: An investigation utilizing Danish registries and latent variable modeling</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647239</td><td>Nunes (2018)</td><td>Efficacy of esketamine in the treatment of negative symptoms in schizophrenia-A case series</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648293</td><td>Nunez (2016)</td><td>Cannabis use and cognitive function in first episode psychosis: Differential effect of heavy use</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646021</td><td>Nyboe (2019)</td><td>Non-pharmacological interventions for preventing weight gain in patients with first episode schizophrenia or bipolar disorder: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646790</td><td>Obermeier (2009)</td><td>How to handle the PANSS in statistical analyses</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646496</td><td>O'Brien (2014)</td><td>Kinect 2: nBI-98854 treatment of moderate to severe tardive dyskinesia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647028</td><td>O'Callaghan (2006)</td><td>First episode schizophrenia in general practice: A national survey</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648039</td><td>Ochoa (2013)</td><td>Cognitive profiles of three clusters of patients with a first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647347</td><td>Ochoa (2018)</td><td>Effectiveness of the meta-cognitive training in people with first-episode psychosis: does gender matter?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647361</td><td>Ochoa (2020)</td><td>Effectiveness of individual metacognitive training (MCT+) in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647128</td><td>O'Connell (2017)</td><td>Examining variation in the dopamine receptor genes (DRD1-5) with regards to antipsychotic treatment response in a South African first episode schizophrenia cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646526</td><td>O'Connor (2012)</td><td>Is deterioration of IQ a feature of first episode psychosis and how can we measure it?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648314</td><td>O'Connor (2017)</td><td>Can cognitive insight predict symptom remission in a first episode psychosis cohort?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648631</td><td>O'Daly (2014)</td><td>Amphetamine sensitization alters reward processing in the human striatum and amygdala</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646523</td><td>Odejayi (2018)</td><td>Is maintenance treatment needed when the first episode of psychosis is not due to schizophrenia?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633565</td><td>Odejide (1982)</td><td>Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648195</td><td>O'Doherty (2020)</td><td>Chronic paroxysmal hemicrania presenting as facial pain in a child with autism and bipolar disorder: Diagnostic challenges</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648115</td><td>O'Donaghue (2018)</td><td>Clozapine: When to start, how to augment and guidelines for management</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646372</td><td>O'Donnell (2007)</td><td>Lowering homocysteine with adjuvant folic acid, B12 & B6 in patients with first episode psychosis to protect/enhance cognition and symptomatology. The vitamins in psychosis (vip) randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646371</td><td>O'Donnell (2008)</td><td>Lowering homocysteine with adjuvant folic acid, b12 and b6 in patients with first episode psychosis to protect/enhance cognition and symptomatology. The vitamins in psychosis (vip) randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645733</td><td>O'Donnell (2016)</td><td>Phase II, double-blind, randomised, placebocontrolled study of adjunctive taurine in firstepisode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648681</td><td>O'Donnell (2016)</td><td>Adjunctive Taurine in First-Episode Psychosis: a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646283</td><td>O'Donoghue (2014)</td><td>Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646134</td><td>O'Donoghue (2016)</td><td>Neighbourhood level social deprivation and the risk of psychotic disorders: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645615</td><td>O'Donoghue (2018)</td><td>Predictors of outcomes following discontinuation of antipsychotic medication after a first episode of psychosis - Findings from a systematic review and cohort study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644916</td><td>O'Donoghue (2019)</td><td>Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645725</td><td>O'Donoghue (2020)</td><td>Physical health assistance in early recovery of psychosis: study protocol for a randomized controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645163</td><td>O'Donoghue (2021)</td><td>Risk of first-episode psychosis in migrants to the Republic of Ireland</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645722</td><td>O'Donoghue (2021)</td><td>Physical health trajectories of young people commenced on clozapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634227</td><td>O'Donoghue (2021)</td><td>Response to 'Diagnostic uncertainty, antipsychotic dosing, and optimal psychosocial interventions: Unanswered questions in first-episode psychosis'.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647923</td><td>Oduola (2019)</td><td>Compulsory admission at first presentation to services for psychosis: Does ethnicity still matter? Findings from two population-based studies of first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648514</td><td>Oduola (2019)</td><td>Are ethnic differences in pathways to care for psychosis in England reducing? Analysis of two population-based studies of first-episode psychosis in South London</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648236</td><td>Oduola (2021)</td><td>Change in incidence rates for psychosis in different ethnic groups in south London: Findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648382</td><td>Ogino (2014)</td><td>Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646461</td><td>Ohara (2006)</td><td>Letters: Interictal Psychosis After Stroke with Forced Normalization</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646569</td><td>Ohlenschlaeger (2007)</td><td>Intensive treatment models and coercion</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648168</td><td>Ohlsen (2004)</td><td>Clinical effectiveness in first-episode patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633646</td><td>Ohmori (1999)</td><td>Psychotic relapse and maintenance therapy in paranoid schizophrenia: a 15 year follow up.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648472</td><td>Ohmuro (2015)</td><td>The association between cognitive deficits and depressive symptoms in at-risk mental state: A comparison with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647795</td><td>Ohmuro (2016)</td><td>Deficits of cognitive theory of mind and its relationship with functioning in individuals with an at-risk mental state and first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648440</td><td>Ohmuro (2017)</td><td>The associations between quality of life and clinical symptoms in individuals with an at-risk mental state and first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648053</td><td>Ohrmann (2007)</td><td>Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: A proton magnetic resonance spectroscopy study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647107</td><td>Ojagbemi (2018)</td><td>The expression of neurological soft signs in two African populations with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644927</td><td>Ojagbemi (2021)</td><td>Spontaneous and emergent extrapyramidal syndromes in Black Africans with first-episode schizophrenia and first exposure to antipsychotics</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645434</td><td>O'Keeffe (2021)</td><td>A qualitative study exploring personal recovery meaning and the potential influence of clinical recovery status on this meaning 20 years after a first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648138</td><td>Okhuijsen-Pfeifer (2018)</td><td>Clozapine as a first- or second-line treatment in schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644852</td><td>Okumura (2005)</td><td>Successful risperidone therapy for a first episode of musical auditory hallucinations in elderly patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646304</td><td>Olagunju (2018)</td><td>Mental health services in Nigerian prisons: Lessons from a four-year review and the literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645981</td><td>Olanzapine or chlorpromazine... (2015)</td><td>Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645964</td><td>Olanzapine, quetiapine... (2007)</td><td>Olanzapine, quetiapine and risperidone effects similar for early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648262</td><td>Olfson (2008)</td><td>A case-control study of antidepressants and attempted suicide during early phase treatment of major depressive episodes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648310</td><td>Oliver (2018)</td><td>Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648042</td><td>Olivier (2015)</td><td>Cognitive performance during the first year of treatment in first-episode schizophrenia: A case-control study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645414</td><td>Oluwoye (2018)</td><td>Racial-Ethnic Disparities in First-Episode Psychosis Treatment Outcomes From the RAISE-ETP Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648784</td><td>Oluwoye (2018)</td><td>1.2 Racial Differences in First-Episode Psychosis Treatment Outcomes: data From the National RA1SE Early Treatment Program (ETP) Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646727</td><td>Oluwoye (2019)</td><td>Impact of tobacco, alcohol and cannabis use on treatment outcomes among patients experiencing first episode psychosis: data from the national RAISE-ETP study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647687</td><td>Oluwoye (2019)</td><td>Disparities in service utilization among youth experiencing first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648760</td><td>Oluwoye (2019)</td><td>38.4 DISPARITIES IN SERVICE UTILIZATION AMONG YOUTH EXPERIENCING FIRST EPISODE PSYCHOSIS...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647071</td><td>Oluwoye (2020)</td><td>Family Experiences Prior to the Initiation of Care for First-Episode Psychosis: A Meta-Synthesis of Qualitative Studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647756</td><td>Oluwoye (2020)</td><td>Developing and implementing a culturally informed FA mily M otivational e ngagement S trategy (FAMES) to increase family engagement in first episode psychosis programs: Mixed methods pilot study protocol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648408</td><td>Oluwoye (2021)</td><td>Barriers and Facilitators That Influence Providers' Ability to Educate, Monitor, and Treat Substance Use in First-Episode Psychosis Programs Using the Theoretical Domains Framework</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647628</td><td>Omachi (2018)</td><td>Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646693</td><td>Omer (2018)</td><td>The importance of clinical observation: A case of subtle tardive dyskinesia with paliperidone palmitate</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644840</td><td>Omori (2009)</td><td>Sulpiride versus other antipsychotics for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645261</td><td>On (2016)</td><td>Relationship between duration of untreated psychosis and neurocognition and social cognition in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647038</td><td>O'Neil (2000)</td><td>First episode psychosis following cyclobenzaprine use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647569</td><td>O'Neill (2018)</td><td>Dysconnectivity of Large-Scale Functional Networks in Early Psychosis: A Meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648303</td><td>O'Neill (2018)</td><td>Cannabidiol induced modulation of mediotemporal activity during a verbal memory task in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648302</td><td>O'Neill (2021)</td><td>Cannabidiol modulation of hippocampal glutamate in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646540</td><td>Ongur (2007)</td><td>Introduction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648653</td><td>Onozato (2020)</td><td>Alterations in methionine to homocysteine ratio in individuals with first-episode psychosis and those with at-risk mental state</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644817</td><td>Onwordi (2020)</td><td>Synaptic marker protein SV2A is reduced in schizophrenia in vivo and unaffected by antipsychotics in rats</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645639</td><td>Onwumere (2019)</td><td>Predictors and moderators of burden of care and emotional distress in first-episode psychosis caregivers: results from the GET UP pragmatic cluster randomised controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633681</td><td>Oo (1983)</td><td>Psychotropic drug prescription in Nigeria</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647001</td><td>Oosthuizen (2001)</td><td>First-episode psychosis: Lessons from 15 yrs of research</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647775</td><td>Oosthuizen (2002)</td><td>Depressive symptoms at baseline predict fewer negative symptoms at follow-up in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646659</td><td>Oosthuizen (2003)</td><td>Incidence of Tardive Dyskinesia in First-Episode Psychosis Patients Treated With Low-Dose Haloperidol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645353</td><td>Oosthuizen (2004)</td><td>A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644920</td><td>Opjordsmoen (2009)</td><td>Stability of medication in early psychosis: A comparison between second-generation and low-dose first-generation antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648782</td><td>Opjordsmoen (2010)</td><td>A 2-year follow-up of involuntary admission's influence upon adherence and outcome in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644677</td><td>Oral (2005)</td><td>Treatment of acute mania</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634013</td><td>Oram (2014)</td><td>Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645849</td><td>Oranje (2013)</td><td>P50 suppression and its neural generators in antipsychotic-Naive first-episode schizophrenia before and after 6 months of quetiapine treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645066</td><td>Oranje (2017)</td><td>Selective attention and mismatch negativity in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646270</td><td>Oresic (2018)</td><td>Metabolism and co-morbidities in psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646460</td><td>Orlando (2014)</td><td>Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646610</td><td>Ortiz (2012)</td><td>Influence of drug treatment with antidepressants and antipsychotics on plasma urea levels</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646774</td><td>Orum (2019)</td><td>Hyponatremia during treatment with the clozapine-amisulpride combination: A suspected association and improvement with dose reduction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648515</td><td>Orus (2016)</td><td>Are depot as effective as oral antipsychotics on first-episode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647520</td><td>Osman (2019)</td><td>Early psychosis workforce development: Core competencies for mental health professionals working in the early psychosis field</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645510</td><td>Osser (2017)</td><td>Prolactin monitoring in first-episode psychotic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648133</td><td>Ostinelli (2019)</td><td>Clozapine for persistent aggressive behaviour or agitation in people with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648478</td><td>O'Sullivan (2015)</td><td>Assessment and treatment of early-stage schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646647</td><td>Ota (2015)</td><td>Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naive patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644587</td><td>Othman (2016)</td><td>Use of queatiapine in treatment of unremitting anxiety: A case report of schizophrenia prodrome</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644692</td><td>O'Toole (2004)</td><td>Treating first episode psychosis - the service users' perspective: A focus group evaluation</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647957</td><td>Ou (2013)</td><td>Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647736</td><td>Ou (2016)</td><td>Differences among first-episode schizophrenia patients, healthy siblings, and controls at the individual level</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647803</td><td>Ou (2018)</td><td>Decreased white matter FA values in the left inferior frontal gyrus is a possible intermediate phenotype of schizophrenia: Evidences from a novel group strategy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648266</td><td>Ouyang (2013)</td><td>A case of recurrent neuroleptic malignant syndrome</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634069</td><td>Overall (1963)</td><td>Comparison of acetophenazine with perphenazine in schizophrenics: Demonstration of differential effects based on computer‚Äêderived diagnostic models</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633860</td><td>Overall (1964)</td><td>Imipramine and Thioridazine in Depressed and Schizophrenic Patients: Are There Specific Antidepressant Drugs?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633950</td><td>Overall (2009)</td><td>Last-observation-carried-forward (LOCF) and tests for difference in mean rates of change in controlled repeated measurements designs with dropouts</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646642</td><td>Owe-Larsson (2011)</td><td>Increased plasma levels of thioredoxin-1 in patients with first episode psychosis and long-term schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634142</td><td>Owens (2012)</td><td>Meet the relatives: a reintroduction to the clinical pharmacology of ‚Äòtypical‚Äô antipsychotics (Part 2)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634148</td><td>Owens (2014)</td><td>A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647601</td><td>Owusu (2020)</td><td>Drug-Drug-Induced Akathisia: Two Case Reports</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645998</td><td>Ozer (2006)</td><td>Obsessive compulsive symptoms associated with quetiapine treatment in a schizophrenic patient: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645290</td><td>Ozgurdal (2008)</td><td>Reduction of auditory event-related P300 amplitude in subjects with at-risk mental state for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648715</td><td>Padder (2006)</td><td>Acute akathisia with suicidal ideation associated with low dose aripiprazole</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645425</td><td>Pagsberg (2017)</td><td>Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647535</td><td>Pagsberg (2018)</td><td>Early non-response to antipsychotic medication in adolescents with first-episode psychosis is a reliable predictor of ultimate non-response and non-remission: results from the 12-week TEA trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647875</td><td>Palaniyappan (2013)</td><td>Cortical folding defects as markers of poor treatment response in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644525</td><td>Palaniyappan (2016)</td><td>Voxel-Based Morphometry for Separation of Schizophrenia From Other Types of Psychosis in First-Episode Psychosis: Diagnostic Test Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646902</td><td>Palaniyappan (2016)</td><td>Globally efficient brain organization and treatment response in psychosis: A connectomic study of gyrification</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644585</td><td>Palhagen (2008)</td><td>Use of selegiline as monotherapy and in combination with levodopa in the management of Parkinson's disease: perspectives from the MONOCOMB study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645908</td><td>Palmier-Claus (2019)</td><td>Oral health in psychosis: An unmet need</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645133</td><td>Pan (2016)</td><td>Role of blonanserin in cannabis-induced psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648712</td><td>Pan (2021)</td><td>Acute conceptual disorganization in untreated first-episode psychosis: a combined magnetic resonance spectroscopy and diffusion imaging study of the cingulum</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645728</td><td>Pandit (2019)</td><td>Phenotypic factors associated with amisulpride-induced weight gain in first-episode psychosis patients (from the OPTiMiSE cohort)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646619</td><td>Pandurangi (2020)</td><td>Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633889</td><td>Panksepp (1982)</td><td>The pleasure in brain substrates of foraging</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648703</td><td>Papadimitriou (2006)</td><td>Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644924</td><td>Pappa (2009)</td><td>Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646193</td><td>Pappa (2009)</td><td>"Movement disorders should be a criterion for schizophrenia": Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644999</td><td>Paquette (2009)</td><td>"The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645712</td><td>Paraschakis (2014)</td><td>Pipamperone augmentation of clozapine and sodium valproate in refractory schizophrenia: A case report</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646684</td><td>Pardo (2011)</td><td>Improvement of cognitive flexibility and cingulate blood flow correlates after atypical antipsychotic treatment in drug-naive patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647594</td><td>Pardo-de-Santayana (2020)</td><td>Duration of active psychosis during early phases of the illness and functional outcome: The PAFIP 10-year follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648717</td><td>Pardo-de-Santayana (2021)</td><td>Active psychosis and pro-inflammatory cytokines in first-episode of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646531</td><td>Pareek (2010)</td><td>Involuntary movements and their correlates in first-episode psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645820</td><td>Parellada (2005)</td><td>Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646589</td><td>Parellada (2017)</td><td>Insular pathology in young people with high-functioning autism and first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645708</td><td>Pariante (2004)</td><td>Pituitary volume in psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646644</td><td>Pariante (2005)</td><td>Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645216</td><td>Pariante (2006)</td><td>Reply: Atypical antipsychotics and pituitary size</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646132</td><td>Parikh (2003)</td><td>Nerve growth factor in never-medicated first-episode psychotic and medicated chronic schizophrenic patients: Possible implications for treatment outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648675</td><td>Park (2014)</td><td>The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646715</td><td>Park (2020)</td><td>Impaired error-processing in patients with first-episode psychosis: An event-related potential study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646714</td><td>Park (2021)</td><td>Impaired error-related processing in patients with first-episode psychosis and subjects at clinical high risk for psychosis: An event-related potential study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634253</td><td>Parry (2021)</td><td>‚ÄúListen to the parents‚Ä¶ Really listen to the child!‚Äù Family Narratives of Supporting Children Hearing Voices</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648374</td><td>Passos (2018)</td><td>Big data analytics and prognosis orientation in bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647002</td><td>Patel (2001)</td><td>First-episode psychosis: Critical management issues during the first two years</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646278</td><td>Patel (2009)</td><td>Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646841</td><td>Patel (2014)</td><td>Health beliefs and carer burden in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644507</td><td>Patel (2017)</td><td>What do register-based studies tell us about migrant mental health? A scoping review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647209</td><td>Pattison (2020)</td><td>Emergence of insight in psychotherapy for early psychosis: A qualitative analysis of a single case study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644495</td><td>Pau (2018)</td><td>Where is the abnormal brain activity in first episode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645935</td><td>Pavlovic (2016)</td><td>Open Dialogue for psychosis or severe mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645959</td><td>Pawelczyk (2015)</td><td>Omega-3 polyunsaturated fatty acids can prevent relapse in first-episode schizophrenia: the results of offer trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645961</td><td>Pawe≈Çczyk (2015)</td><td>Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645386</td><td>Pawe≈Çczyk (2016)</td><td>A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645963</td><td>Pawelczyk (2018)</td><td>Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644777</td><td>Pawe≈Çczyk (2018)</td><td>Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646654</td><td>Pawe≈Çczyk (2019)</td><td>An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645960</td><td>Pawelczyk (2021)</td><td>Omega-3 fatty acids reduce cardiometabolic risk in first-episode schizophrenia patients treated with antipsychotics: findings from the OFFER randomized controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634031</td><td>Pe (1989)</td><td>Time course of antipsychotic effects of neuroleptic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644748</td><td>Peachey (1991)</td><td>Therapeutic skills</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645301</td><td>Pedersen (2008)</td><td>Reduced implicit and explicit sequence learning in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645881</td><td>Pedersen (2010)</td><td>Oxytocin treatment improves social cognition and reduces psychotic symptoms in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648016</td><td>Pedley (2018)</td><td>Collaborative, individualised lifestyle interventions are acceptable to people with first episode psychosis; a qualitative study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645957</td><td>Peet (2008)</td><td>Omega-3 polyunsaturated fatty acids in the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646949</td><td>Peitl (2020)</td><td>Fronto-temporal cerebral blood flow and cognitive functioning in patients with first episode psychoses treated with aripiprazole: Preliminary findings</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647511</td><td>Pelayo-Teran (2010)</td><td>Early response to antipsychotics as a marker of treatment response trajectories in First Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648260</td><td>Pelayo-Ter√°n (2011)</td><td>Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute antipsychotic treatment in first-episode non-affective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644711</td><td>Pelayo-Teran (2014)</td><td>Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644471</td><td>Peleg-Raibstein (2012)</td><td>Withdrawal from amphetamine as an animal model of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646139</td><td>Pelizza (2020)</td><td>Negative symptom dimensions in first episode psychosis: Is there a difference between schizophrenia and non-schizophrenia spectrum disorders?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646140</td><td>Pelizza (2020)</td><td>Negative symptom configuration in first episode Schizophrenia: findings from the "Parma Early Psychosis" program</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634309</td><td>Pelizza (2021)</td><td>Examining disorganization in patients with first episode psychosis: Findings from a 1-year follow-up of the 'Parma early psychosis' program.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634282</td><td>Pemovska (2021)</td><td>Protocol for a process evaluation of a cluster randomised controlled trial to improve psychosocial treatment of patients with psychotic spectrum disorders: the IMPULSE trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647463</td><td>Pen (2011)</td><td>Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647657</td><td>Pena (2012)</td><td>Do the same factors predict outcome in schizophrenia and non-schizophrenia syndromes after first-episode psychosis? A two-year follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648678</td><td>Pencer (2005)</td><td>Adolescent substance use in first episode psychosis: A test of three models</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645325</td><td>Pencer (2008)</td><td>Reasons for using substances in adolescents with and without psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634217</td><td>Penfold (2020)</td><td>Safer use of antipsychotics in youth (SUAY) pragmatic trial protocol</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647178</td><td>Peng (2016)</td><td>Essential brain structural alterations in major depressive disorder: A voxel-wise meta-analysis on first episode, medication-naive patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645449</td><td>Penn (2005)</td><td>Psychosocial treatment for first-episode psychosis: A research update</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645720</td><td>Penn (2011)</td><td>A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647878</td><td>Penn (2012)</td><td>Corrigendum to "A pilot investigation of the Graduated Recovery Intervention Program (GRIP) for first episode psychosis"</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646895</td><td>Penner (2020)</td><td>Glutamate Levels Correlate With Anomalous Brain Functional Networks in First-Episode Psychosis Participants</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645056</td><td>Pepper (2019)</td><td>Self-reported empathy in adults with autism, early psychosis, and social anxiety disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647598</td><td>Peralta (2010)</td><td>DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646333</td><td>Peralta (2011)</td><td>The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633799</td><td>Perenyi (1990)</td><td>Relationship between Tardive Dyskinesia and psychopathology in a group of schizophrenic patients attending a rehabilitation centre</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633754</td><td>Perenyi (1998)</td><td>Negative symptoms, depression, and parkinsonian symptoms in chronic, hospitalised schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646695</td><td>Perestrelo (2016)</td><td>Implications of immunity and inflammation in schizophrenia and related psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647266</td><td>Perez (2003)</td><td>Efficacy and safety of olanzapine, risperidone and haloperidol in acute treatment of patients with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646245</td><td>Perez (2017)</td><td>Mindfulness interventions in early psychosis: a feasibility study to assess neurocognitive and biomarker outcomes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646688</td><td>Perez (2018)</td><td>Improvement in cognitive biases after group psychoeducation and metacognitive training in recent onset psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648766</td><td>Perez-Iglesias (2007)</td><td>A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644514</td><td>Perez-Iglesias (2008)</td><td>Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-na√Øve population</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647465</td><td>Perez-Iglesias (2008)</td><td>Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646900</td><td>Perez-Iglesias (2009)</td><td>Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na√Øve population</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645628</td><td>Perez-Iglesias (2010)</td><td>Predictors of antipsychotic-induced weight gain after the first 3 years of treatment</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647435</td><td>Perez-Iglesias (2010)</td><td>Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646412</td><td>P√©rez-Iglesias (2012)</td><td>Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647846</td><td>Perez-Iglesias (2014)</td><td>Course of weight gain and metabolic abnormalities in first treated episode of psychosis: The first year is a critical period for development of cardiovascular risk factors</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647958</td><td>Perez-Iglesias (2014)</td><td>Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645629</td><td>Perkins (2004)</td><td>Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645630</td><td>Perkins (2006)</td><td>Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645600</td><td>Perkins (2008)</td><td>Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645457</td><td>Perkins (2019)</td><td>The psychosis clinical-high risk syndrome: Ethical issues and practical challenges in the clinical management of a syndrome without a name</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645814</td><td>Perlini (2015)</td><td>Patterns of pragmatic verbal abilities in subjects with first episode psychosis and matched healthy controls</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646024</td><td>Perlini (2018)</td><td>Non literal language comprehension in a large sample of first episode psychosis patients in adulthood</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644502</td><td>Perquin (1998)</td><td>What is the experience with sertindole in clinical practice?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647474</td><td>Perrottelli (2021)</td><td>EEG-Based Measures in At-Risk Mental State and Early Stages of Schizophrenia: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646596</td><td>Perry (2002)</td><td>Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634176</td><td>Perry (2014)</td><td>Early Intervention in the Real World The development and implementation of a pilot CBT for early psychosis service: achievements and challenges</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648471</td><td>Perry (2016)</td><td>The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646452</td><td>Perry (2018)</td><td>Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646708</td><td>Perumaly (2020)</td><td>Impaired left temporal-parietal junction fMRI activity during category fluency in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646782</td><td>Perumaly (2020)</td><td>Hyperactive Left TPJ Activity During Category Fluency in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633519</td><td>Peters (2015)</td><td>The long-term effectiveness of cognitive behavior therapy for psychosis within a routine psychological therapies service.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646681</td><td>Petersen (2005)</td><td>Improving 1-year outcome in first-episode psychosis: OPUS trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645607</td><td>Petersen (2008)</td><td>Predictors of remission and recovery in a first-episode schizophrenia spectrum disorder sample: 2-year follow-up of the OPUS Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633759</td><td>Peterson (1995)</td><td>Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646552</td><td>Petrakis (2017)</td><td>Intervening early with family members during first-episode psychosis: An evaluation of mental health nursing psychoeducation within an inpatient unit</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645186</td><td>Petric (2019)</td><td>Retrospective analysis of the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645836</td><td>Petrikis (2015)</td><td>Parameters of glucose and lipid metabolism at the fasted state in drug-naive first-episode patients with psychosis: Evidence for insulin resistance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647824</td><td>Petrikis (2015)</td><td>Cytokine profile in drug-naive, first episode patients with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645512</td><td>Petrikis (2016)</td><td>Prolactin levels in drug-naive patients with schizophrenia and other psychotic disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648221</td><td>Petrikis (2017)</td><td>Changes in the cytokine profile in first-episode, drug-naive patients with psychosis after short-term antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645017</td><td>Petrikis (2020)</td><td>Sex hormone levels in drug-naive, first-episode patients with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644855</td><td>Petronijevic (2003)</td><td>Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646778</td><td>Petruzzelli (2018)</td><td>Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647534</td><td>Petruzzelli (2018)</td><td>Early onset first episode psychosis: Dimensional structure of symptoms, clinical subtypes and related neurodevelopmental markers</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644579</td><td>Pettersson-Yeo (2013)</td><td>Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646881</td><td>Peuskens (1998)</td><td>Good medical practice in antipsychotic pharmacotherapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647298</td><td>Peuskens (2014)</td><td>The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648230</td><td>Phahladira (2019)</td><td>Changes in insight over the first 24 months of treatment in schizophrenia spectrum disorders</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647780</td><td>Phahladira (2020)</td><td>Depression in schizophrenia spectrum disorders: Longitudinal course and the relationship with other clinical parameters and quality of life</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647853</td><td>Phahladira (2021)</td><td>The course and concomitants of depression in first-episode schizophrenia spectrum disorders: A 24-month longitudinal study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645746</td><td>Pharmacotherapeutic... (2019)</td><td>Pharmacotherapeutic considerations for first-episode psychosis: a summary of the OPTiMiSE trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633569</td><td>Philipp (2000)</td><td>Atypische Neuroleptika ‚Äî Begriffsbestimmung und Datenlage</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647749</td><td>Philipps (2001)</td><td>The development of preventive interventions for early psychosis: early findings and directions for the future</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647748</td><td>Phillips (1999)</td><td>The development of preventive interventions for early psychosis: early findings and directions for the future</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644694</td><td>Phillips (2004)</td><td>Treating body dysmorphic disorder using medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647207</td><td>Phillips (2008)</td><td>Emotion and sensory processing in the risk for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647865</td><td>Phillips (2009)</td><td>Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633675</td><td>Phillipson (1984)</td><td>Effects of chlorpromazine and promazine on the perception of some multi-stable visual figures.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647644</td><td>Picci (2013)</td><td>Does substance use disorder affect clinical expression in first-hospitalization patients with schizophrenia? Analysis of a prospective cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633625</td><td>Pickar (1984)</td><td>Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634185</td><td>Pickar (1987)</td><td>Profiles of the pharmacologic response of positive and negative symptoms in schizophrenia. Comment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634219</td><td>Pierre (2021)</td><td>Diagnostic uncertainty, antipsychotic dosing, and optimal psychosocial interventions: Unanswered questions in first-episode psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634100</td><td>Pietzcker (1984)</td><td>Neuroleptische Langzeitmedikation zur Rezidivprophylaxe schizophrener Erkrankungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633651</td><td>Pietzcker (1986)</td><td>A German Multicenter Study on the Neuroleptic Long-term Therapy of Schizophrenic Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633730</td><td>Pietzcker (1993)</td><td>Intermittent versus maintenance neuroleptic long-term treatment in Schizophrenia‚Äî2-year results of a German multicenter study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633604</td><td>Pietzcker (1998)</td><td>Stellenwert und Grenzen klassischer Neuroleptika in der Akuttherapie schizophrener Erkrankungen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644774</td><td>Pignon (2021)</td><td>Temporal variation in the incidence of treated psychotic disorders in young people</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645869</td><td>Pigoni (2020)</td><td>P.507 Machine learning classification of first-episode psychosis using cortical thickness: a large multicenter magnetic resonance imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646365</td><td>Pigoni (2020)</td><td>Machine learning classification of first-episode psychosis using cortical thickness in a large multicenter MRI study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647661</td><td>Pijnenborg (2015)</td><td>Do antipsychotics affect insight in psychosis differentially? Data from the eufest trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647662</td><td>Pijnenborg (2015)</td><td>Do antipsychotics affect insight in psychosis differentially? Data from the eufest trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647715</td><td>Pijnenborg (2015)</td><td>Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633807</td><td>Pilette (1977)</td><td>What is an adequate therapeutic trial of psychotropic medication</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647078</td><td>Pillay (2018)</td><td>Factors limiting romantic relationship formation for individuals with early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646711</td><td>Pillinger (2017)</td><td>Impaired Glucose Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646712</td><td>Pillinger (2017)</td><td>Impaired glucose homeostasis in first-episode schizophrenia: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646998</td><td>Pillinger (2017)</td><td>First-episode schizophrenia and diabetes risk-In reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648200</td><td>Pillinger (2017)</td><td>Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646517</td><td>Pillinger (2018)</td><td>Is schizophrenia a multi-system disorder? Considering neurological, immune, cardiometabolic, and endocrine alterations in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647144</td><td>Pillinger (2018)</td><td>Evidence of the lipid paradox in psychosis: A meta-analysis of cholesterol and triglyceride levels in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646292</td><td>Pillinger (2019)</td><td>A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646519</td><td>Pillinger (2019)</td><td>"Is psychosis a multisystem disorder? A meta-review of central nervous system, immune, cardiometabolic, and endocrine alterations in first-episode psychosis and perspective on potential models": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634293</td><td>Pillny (2020)</td><td>Update kognitive Verhaltenstherapie bei Psychosen: Standardinterventionen, aktuelle Weiterentwicklungen und ihre Evidenz</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645508</td><td>Pina-Camacho (2020)</td><td>Prominent and persistent autistic traits are associated with early non-remission in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644592</td><td>Pinninti (2005)</td><td>Use of Long-Acting Risperidone: Comment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645868</td><td>Pinto (2020)</td><td>P.509 Centenary Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648380</td><td>Piper (2017)</td><td>Benzoate and Sorbate Salts: A Systematic Review of the Potential Hazards of These Invaluable Preservatives and the Expanding Spectrum of Clinical Uses for Sodium Benzoate</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646534</td><td>Pisanu (2021)</td><td>Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648033</td><td>Piskulic (2012)</td><td>Cognitive remediation in young people at clinical high risk of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645273</td><td>Pittella (1991)</td><td>The relation between involvement of the central nervous system in schistosomiasis mansoni and the clinical forms of the parasitosis. A review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645459</td><td>Pjrek (2005)</td><td>Psychosis as a possible side-effect of treatment with glatiramer acetate</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645679</td><td>Plav√©n-Sigray (2018)</td><td>Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644603</td><td>Plaven-Sigray (2020)</td><td>Updated individual participant data meta-analysis confirms lower levels of the glial marker TSPO in psychosis patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644892</td><td>Plitman (2018)</td><td>Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647132</td><td>Pochiet (2020)</td><td>Examining differences between current cannabis consumption and cognitive functioning of first-episode psychosis patients: A retrospective study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648629</td><td>Poeppl (2014)</td><td>Amygdalohippocampal neuroplastic changes following neuroleptic treatment with quetiapine in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647222</td><td>Polcwiartek (2020)</td><td>Electrocardiogram Characteristics and Their Association With Psychotropic Drugs Among Patients With Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644649</td><td>Polese (2019)</td><td>Treatment-Resistant to Antipsychotics: A Resistance to Everything? Psychotherapy in Treatment-Resistant Schizophrenia and Nonaffective Psychosis: A 25-Year Systematic Review and Exploratory Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647483</td><td>Polillo (2020)</td><td>ED to EPI: protocol for a pragmatic randomised controlled trial of an SMS (text) messaging intervention to improve the transition from the emergency department to early psychosis intervention for young people with psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645251</td><td>Pollak (2021)</td><td>Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647439</td><td>Pollard (2016)</td><td>Effect of early psychosis coordinated specialty care on criminal justice outcomes and prevalence of psychosis among incarcerated transition age youth</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648065</td><td>Pollice (2012)</td><td>Cognitive function and clinical symptoms in first-episode psychosis and chronic schizophrenia before and after the 2009 L'aquila earthquake</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648733</td><td>Ponzoni (2016)</td><td>"Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: Role of serotonin 5HT2-type receptors": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645900</td><td>Poon (2017)</td><td>Outcome of first-episode acute and transient psychotic disorder in Hong Kong Chinese: A 20-year retrospective follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647150</td><td>Pope (2019)</td><td>"Everyone has a role": Perspectives of service users with first-episode psychosis, family caregivers, treatment providers, and policymakers on responsibility for supporting individuals with mental health problems</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646773</td><td>Porter (2006)</td><td>The hypothalamic-pituitary-adrenal axis: a target for intervention in early psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633746</td><td>Post (1975)</td><td>Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633551</td><td>Post (1978)</td><td>Approaches to Brain Amines in Psychiatric Patients: A Reevaluation of Cerebrospinal Fluid Studies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646789</td><td>Post (2020)</td><td>How to prevent the malignant progression of bipolar disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646108</td><td>Potkin (2020)</td><td>The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646109</td><td>Potkin (2020)</td><td>The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645079</td><td>Pouwer (2004)</td><td>Schizophrenia, Syndrome X, and Omega-3 Fatty Acids</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646696</td><td>Powell (2021)</td><td>Implementing Coordinated Specialty Care for First Episode Psychosis: A Review of Barriers and Solutions</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648626</td><td>Power (1998)</td><td>Analysis of the initial treatment phase in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645380</td><td>Power (1999)</td><td>A randomized controlled trial of a suicide preventative cognitive oriented psychotherapy for suicidal young people with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59645362</td><td>Power (2000)</td><td>A randomized controlled trial of suicide prevention therapy for young people with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644843</td><td>Power (2003)</td><td>Suicide prevention in first episode psychosis: the development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646484</td><td>Power (2007)</td><td>The Lambeth Early Onset Crisis Assessment Team Study: general practitioner education and access to an early detection team in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644811</td><td>Power (2020)</td><td>Systematic review and meta-analysis of the effects of cannabis use in adolescence on IQ in longitudinal studies accounting pre-exposure baseline performance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645323</td><td>Poyurovsky (2002)</td><td>Reboxetine but not fluoxetine attenuates olanzapine-induced weight gain in first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645324</td><td>Poyurovsky (2002)</td><td>Reboxetine and attenuation of olanzapine-induced weight gain in first-episode schizophrenia patients. A double-blind placebo-controlled study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645966</td><td>Poyurovsky (2002)</td><td>Olanzapine-induced weight gain in patients with first-episode schizophrenia: A double-blind, placebo-controlled study of fluoxetine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645967</td><td>Poyurovsky (2002)</td><td>Olanzapine-induced weight gain in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648428</td><td>Poyurovsky (2003)</td><td>Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647437</td><td>Poyurovsky (2004)</td><td>The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647459</td><td>Poyurovsky (2005)</td><td>The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648430</td><td>Poyurovsky (2007)</td><td>Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634045</td><td>Pr (1980)</td><td>Predicting outcome of antipsychotic drug treatment from early response.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646044</td><td>Prakash (1982)</td><td>Neurotoxicity with combined administration of lithium and a neuroleptic</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633905</td><td>Prange (1963)</td><td>A double blind clinical trial of chlorpromazine and reserpine in acute mental disturbance.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645839</td><td>Prasad (2004)</td><td>Parahippocampal gyrus in first episode psychotic disorders: A structural magnetic resonance imaging study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647191</td><td>Prasad (2004)</td><td>The entorhinal cortex in first-episode psychotic disorders: A structural magnetic resonance imaging study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646912</td><td>Prasad (2005)</td><td>Genetic polymorphisms of the RGS4 and dorsolateral prefrontal cortex morphometry among first episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645517</td><td>Prasad (2011)</td><td>Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: A longitudinal study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647110</td><td>Prasad (2012)</td><td>Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645608</td><td>Predictors of relapse... (2019)</td><td>Predictors of relapse in first episode psychosis patients in remission</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634104</td><td>Pregelj (2009)</td><td>SODELOVANJE BOLNIKOV S SHIZOFRENIJO PRI ZDRAVLJENJU Z ANTIPSIHOTIKI ADHERENCE TO ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA PATIENTS</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648214</td><td>Premoli (2014)</td><td>Characterization of GABAB-receptor mediated neurotransmission in the human cortex by paired-pulse TMS-EEG</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647758</td><td>Preskorn (2016)</td><td>Determining whether a definitive causal relationship exists between aripiprazole and tardive dyskinesia and/or dystonia in patients with major depressive disorder, part 3: Clinical trial data</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645660</td><td>Preston (2000)</td><td>Predicting community survival in early psychosis and schizophrenia populations after receiving intensive case management</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645552</td><td>Preti (2014)</td><td>Preventing or masking psychosis? Possible unintended consequences of the ultra high-risk strategy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648008</td><td>Preuss (2012)</td><td>Commentary on the study: Impact of depressive symptoms on future alcohol use in patients with co-occurring bipolar disorder and alcohol dependence: A prospective analysis in an 8-week randomized controlled trial of acamprosate (Prisciandaro et al.)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646305</td><td>Preuss (2016)</td><td>[Mental comorbidities of alcohol-related disorders]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645179</td><td>Pribish (2020)</td><td>A Review of Nonanesthetic Uses of Ketamine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648346</td><td>Price (2010)</td><td>Brain pathology in first-episode psychosis: Magnetization transfer imaging provides additional information to MRI measurements of volume loss</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634121</td><td>Priebe (2016)</td><td>Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633657</td><td>Prien (1968)</td><td>High Dose Chlorpromazine Therapy in Chronic Schizophrenia: Report of National Institute of Mental Health‚ÄîPsychopharmacology Research Branch Collaborative Study Group</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645142</td><td>Prikryl (2012)</td><td>Risperidone long-acting injectable in the treatment of the first episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645513</td><td>Prolactin level in patients... (2018)</td><td>Prolactin level in patients with first episode schizophrenia treated for one year with atypical antipsychotics</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644901</td><td>Pruessner (2011)</td><td>Stress and protective factors in individuals at ultra-high risk for psychosis, first episode psychosis and healthy controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646921</td><td>Pu (2020)</td><td>Gender differences in the first-year antipsychotic treatment for chinese first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646612</td><td>Pujol (2020)</td><td>Influence of BDNF and MTHFR polymorphisms on hippocampal volume in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644937</td><td>Puntis (2020)</td><td>Specialised early intervention teams for recent-onset psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644938</td><td>Puntis (2020)</td><td>Specialised early intervention teams (extended time) for recent-onset psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span class='complete'>Tiril Borge</span></td><td></td></tr><tr><td>59646059</td><td>Purdon (2000)</td><td>Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646058</td><td>Purdon (2002)</td><td>" Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol." Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645537</td><td>Purdon (2003)</td><td>Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645538</td><td>Purdon (2011)</td><td>Procedural learning in first episode schizophrenia investigated with functional magnetic resonance imaging</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644926</td><td>Puri (1999)</td><td>Spontaneous dyskinesia in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634129</td><td>Pyle (2016)</td><td>Design and protocol for the Focusing on Clozapine Unresponsive Symptoms (FOCUS) trial: a randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644865</td><td>Pyle (2019)</td><td>Study protocol for a randomised controlled trial of CBT vs antipsychotics vs both in 14-18-year-olds: managing Adolescent first episode Psychosis: a feasibility study (MAPS)</td><td>(I) Included</td><td></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td></tr><tr><td>59645018</td><td>Qi (2020)</td><td>Sex differences in psychotic and non-psychotic major depressive disorder in a Chinese Han population</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647453</td><td>Qi (2021)</td><td>Effect of citalopram on hippocampal volume in first-episode schizophrenia: Structural MRI results from the DECIFER trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648752</td><td>Qi (2021)</td><td>Aberrant Resting-State Functional Connectivity of the Globus Pallidus Subregions in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645697</td><td>Qiao (2016)</td><td>Plasma metabonomics study of first-Episode schizophrenia treated with olanzapine in female patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647589</td><td>Qin (2014)</td><td>Duration of untreated psychosis and clinical outcomes of first-episode schizophrenia: A 4-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645472</td><td>Qiu (2003)</td><td>Psychological status and its influencing factors on patients undergoing electrophysiology studies and radiofrequency catheter ablation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646764</td><td>Qu (2020)</td><td>Identifying Clinically and Functionally Distinct Groups Among Healthy Controls and First Episode Psychosis Patients by Clustering on EEG Patterns</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645180</td><td>Quadrio (2014)</td><td>Review of Models of madness-Psychological, social and biological approaches to schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644705</td><td>Quattrone (2019)</td><td>Transdiagnostic dimensions of psychopathology at first episode psychosis: Findings from the multinational EU-GEI study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646463</td><td>Quattrone (2020)</td><td>Letter to the editor: Is polygenic risk for Parkinson's disease associated with less risk of first episode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647817</td><td>Quattrone (2020)</td><td>Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646705</td><td>Quednow (2008)</td><td>Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633969</td><td>Quitkin (1978)</td><td>Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645398</td><td>Qurashi (2017)</td><td>A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645058</td><td>Raballo (2021)</td><td>The Self in the Spectrum: A Meta-analysis of the Evidence Linking Basic Self-Disorders and Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647481</td><td>Raballo (2021)</td><td>Editorial Perspective: Psychosis risk in adolescence - outcomes, comorbidity, and antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646273</td><td>Rabe-Jablonska (2008)</td><td>The metabolic syndrome and its components in participants of EUFEST</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634024</td><td>Rabiner (1986)</td><td>I: Relapse Rates After 1 Year</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634146</td><td>Rabiner (1986)</td><td>Outcome study of first-episode psychosis. I: Relapse rates after 1 year.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647527</td><td>Rabinovitch (2009)</td><td>Early predictors of nonadherence to antipsychotic therapy in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646603</td><td>Rabinovitch (2013)</td><td>The influence of perceived social support on medication adherence in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645258</td><td>Rabinowitz (2002)</td><td>Relationship between premorbid functioning and symptom severity as assessed at first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648511</td><td>Rabinowitz (2003)</td><td>Are patients enrolled in first episode psychosis drug trials representative of patients treated in routine clinical practice?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645579</td><td>Rabinowitz (2006)</td><td>Premorbid functioning and treatment response in recent-onset schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647762</td><td>Rabinowitz (2014)</td><td>Determinants of antipsychotic response in schizophrenia: Implications for practice and future clinical trials</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645834</td><td>Radley (2020)</td><td>Parenting interventions for people with schizophrenia or related serious mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647153</td><td>Radua (2021)</td><td>Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646175</td><td>Raghava (2021)</td><td>Multimodal assessment of white matter microstructure in antipsychotic-naive schizophrenia patients and confounding effects of recreational drug use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645187</td><td>Ragland (2020)</td><td>Retrieval practice facilitation of family psychoeducation in people with early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647683</td><td>Ragland (2020)</td><td>Disrupted GABAergic facilitation of working memory performance in people with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644596</td><td>Ragonnet (2010)</td><td>Use of clozapine in an adolescent with refractory first-episode psychosis and neutropenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647738</td><td>Rahm (2007)</td><td>Diagnostic stability over 3 years in a total group of first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648719</td><td>Raij (2018)</td><td>Activation of the motivation-related ventral striatum during delusional experience</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648290</td><td>Rais (2010)</td><td>Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648338</td><td>Rais (2012)</td><td>Brain volume reductions in medication-naive patients with schizophrenia in relation to intelligence quotient</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633630</td><td>Raja (1998)</td><td>Managing Antipsychotic-Induced Acute and Tardive Dystonia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648412</td><td>Raja (2010)</td><td>Autistic spectrum disorders and schizophrenia in the adult psychiatric setting: Diagnosis and comorbidty</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646062</td><td>Rajabally (2016)</td><td>Neuropsychiatric Manifestations in Inflammatory Neuropathies: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644762</td><td>Rajapakse (2011)</td><td>Themes of delusions and hallucinations in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633745</td><td>Rajkumar (1989)</td><td>Factors affecting relapse in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647571</td><td>Raket (2020)</td><td>Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645467</td><td>Rakkolainen (2009)</td><td>Psychopharmacological treatment and psychotherapy in schizophrenic psychoses: Part 2: The principles of using and not using neuroleptics in the Finnish need-adapted approach to the treatment of schizophrenic psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633814</td><td>Ram (1992)</td><td>The natural course of schizophrenia: a review of first-admission studies.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647114</td><td>Ramain (2021)</td><td>Exploring the clinical relevance of a dichotomy between affective and non-affective psychosis: Results from a first-episode psychosis cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645603</td><td>Ramirez (2010)</td><td>Predictors of schizophrenia in patients with a first episode of psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646203</td><td>Ramsauer (2018)</td><td>Mothers with acute and chronic postpartum psychoses and impact on the mother-infant interaction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647550</td><td>Rangaswamy (2012)</td><td>Early intervention for first-episode psychosis in India</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647410</td><td>Ranjbar (2013)</td><td>The effect of ranitidine on olanzapine-induced weight gain</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644847</td><td>Rao (2011)</td><td>Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: A case report</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645173</td><td>Rao (2016)</td><td>Reviving life after death: five element acupuncture in refugees with psychological trauma</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633539</td><td>Rappaport (1978)</td><td>Are there schizophrenics for whom drugs may be unnecessary or contraindicated</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646455</td><td>Rascol (2003)</td><td>Limitations of Current Parkinson's Disease Therapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644565</td><td>Rashid (2019)</td><td>Varicose veins, first-episode psychosis, pulmonary rehabilitation, and anonymity online</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633571</td><td>Rasmussen (1970)</td><td>Fluphenazine enanthate in sesame oil, a depot preparation.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646724</td><td>Rasmussen (1999)</td><td>The impact on long-term outcome of early intervention with risperidone or haloperidol in first episode psychosis: characteristics at baseline</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645045</td><td>Rasmussen (2011)</td><td>Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646016</td><td>Rasmussen (2013)</td><td>Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646133</td><td>Rasmussen (2014)</td><td>Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645642</td><td>Rasmussen (2016)</td><td>The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: haloperidol versus olanzapine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645260</td><td>Rasmussen (2017)</td><td>The relationship between early haloperidol response and associated extrapyramidal side effects</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645271</td><td>Rasmussen (2020)</td><td>The relation of basic self-disturbance to self-harm, eating disorder symptomatology and other clinical features: Exploration in an early psychosis sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648096</td><td>Rasskazova (2016)</td><td>Cognitive behavioral therapy for psychosis prevention and treatment in youth</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633676</td><td>Rastogi (1981)</td><td>Effects of short- and long-term neuroleptic treatment on brain serotonin synthesis and turnover: focus on the serotonin hypothesis of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648621</td><td>Ratajczak (2013)</td><td>Animal models of schizophrenia: Developmental preparation in rats</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644897</td><td>Raune (2009)</td><td>Stressful and intrusive life events preceding first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646863</td><td>Raune (2016)</td><td>Group cognitive behaviour therapy combining early intervention with an exclusive focus on single medication-resistant delusional beliefs: A service evaluation</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59646548</td><td>Ravan (2016)</td><td>Interventions for antipsychotic‚Äêinduced amenorrhoea</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647371</td><td>Ravanic (2009)</td><td>Effectiveness of clozapine, haloperidol and chlorpromazine in schizophrenia during a five-year period</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645534</td><td>Raven (2012)</td><td>'Prodromal' diagnosis of psychosis: Ethical problems in research and clinical practice</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646844</td><td>Ray (2017)</td><td>Haloperidol versus risperidone for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646908</td><td>Razali (2005)</td><td>Genomics Revolution in Contemporary Psychiatric Practices</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647934</td><td>Razali (2018)</td><td>Complementing the treatment of a major depressive disorder patient with Ruqyah Shar'iyyah therapy: A Malaysian case study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648111</td><td>Realpe (2020)</td><td>Co-designing a virtual world with young people to deliver social cognition therapy in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646667</td><td>Reay (2010)</td><td>Incidence and diagnostic diversity in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633997</td><td>Rech (1982)</td><td>Neurolepsis: Anhedonia or blunting of emotional reactivity?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645857</td><td>Recio-Barbero (2019)</td><td>P.689 Cognitive enhancers in schizophrenia: A meta-analysis of Alpha-7 nicotinic acetylcholine receptor agonists for cognitive deficits and negative symptoms</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645860</td><td>Recio-Barbero (2020)</td><td>P.566 Paliperidone palmitate long-acting formulations in recent-onset psychosis: a retrospective, non-interventional study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645302</td><td>Reduced heart rate variability... (2018)</td><td>Reduced heart rate variability in a treatment-seeking early psychosis sample</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647127</td><td>Reeve (2021)</td><td>Excessive sleepiness in patients with psychosis: An initial investigation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647305</td><td>Reichenberg (2012)</td><td>The effects of modafinil and cognitive training on cognitive performance</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648737</td><td>Reilly (2005)</td><td>Abnormalities in visually guided saccades suggest corticofugal dysregulation in never-treated schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648674</td><td>Reilly (2006)</td><td>Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648592</td><td>Reilly (2007)</td><td>Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646930</td><td>Reilly (2018)</td><td>Gamma Band Oscillations in the Early Phase of Psychosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644898</td><td>Reininghaus (2016)</td><td>Stress sensitivity, aberrant salience, and threat anticipation in early psychosis: An experience sampling study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647252</td><td>Reininghaus (2019)</td><td>Efficacy of Acceptance and Commitment Therapy in Daily Life (ACT-DL) in early psychosis: study protocol for a multi-centre randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645740</td><td>Remington (1998)</td><td>Pharmacotherapy of first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634153</td><td>Remington (2004)</td><td>The use of pharmacotherapy in the prodrome of schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645336</td><td>Remington (2005)</td><td>Rational pharmacotherapy in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633718</td><td>Remington (2005)</td><td>Augmentation Strategies in Clozapine-Resistant Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634085</td><td>Remington (2005)</td><td>Rational pharmacotherapy in early psychosis* Rational pharmacotherapy in early psychosis*</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648114</td><td>Remington (2013)</td><td>Clozapine's role in the treatment of first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646852</td><td>Remington (2017)</td><td>Guidelines for the Pharmacotherapy of Schizophrenia in Adults</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648624</td><td>Ren (2013)</td><td>Anatomical and functional brain abnormalities in drug-naive first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645811</td><td>Reneerkens (2013)</td><td>The PDE5 inhibitor vardenafil does not affect auditory sensory gating in rats and humans</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647782</td><td>Renwick (2012)</td><td>Depression and quality of life in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647965</td><td>Renwick (2013)</td><td>Comparison of generic and disease-specific measures of quality of life in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645626</td><td>Renwick (2017)</td><td>Predictors of change in social networks, support and satisfaction following a first episode psychosis: A cohort study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646698</td><td>Renwick (2017)</td><td>Implementing an innovative intervention to increase research capacity for enhancing early psychosis care in Indonesia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644922</td><td>Reske (2007)</td><td>Stability of emotional dysfunctions? A long-term fMRI study in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647719</td><td>Reske (2009)</td><td>Differential brain activation during facial emotion discrimination in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645209</td><td>Response letter to the... (2020)</td><td>Response letter to the article by Killackey et al (2019) 'Individual placement and support for vocational recovery in first-episode psychosis: randomised controlled trial'</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644681</td><td>Retsa (2017)</td><td>Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646555</td><td>Retsa (2017)</td><td>Interplay between early sensory processing impairments and glutathione dysregulation in early-phase psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648460</td><td>Reuter (2017)</td><td>Association of anandamide with altered binocular depth inversion illusion in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648571</td><td>Reutfors (2013)</td><td>Antipsychotic prescription filling in patients with schizophrenia or schizoaffective disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645688</td><td>Reynolds (2003)</td><td>Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645768</td><td>Reynolds (2005)</td><td>Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647472</td><td>Reynolds (2006)</td><td>Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647793</td><td>Reynolds (2019)</td><td>Defining disengagement from mental health services for individuals experiencing first episode psychosis: a systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644841</td><td>Rezk (2012)</td><td>Sulpiride dose for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646819</td><td>Rhindress (2017)</td><td>Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648183</td><td>Rho (2015)</td><td>Clinical and functional implications of a history of childhood ADHD in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646004</td><td>Ribeirinho (2020)</td><td>O-01 "Chemsex" : Drug or Sex Addiction?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645792</td><td>Richard (2013)</td><td>Persistence, diagnostic specificity and genetic liability for context-processing deficits in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633795</td><td>Rickels (1966)</td><td>Developments in Psychopharmacology</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644698</td><td>Ricken (2017)</td><td>Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646777</td><td>Riecher-Rossler (2013)</td><td>Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647777</td><td>Riedel (2012)</td><td>Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperido</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646220</td><td>Riedford (2020)</td><td>Moderating perspectives of long acting injectable use of antipsychotics: A literature review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647886</td><td>Riera-Lopez (2020)</td><td>Coping strategies in first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645753</td><td>Riesbeck (2006)</td><td>Pharmacological long term treatment in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633641</td><td>Rifkin (1977)</td><td>Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633687</td><td>Rifkin (1977)</td><td>Fluphenazine decanoate, oral fluphenazine, and placebo in treatment of remitted schizophrenics. II. Rating scale data.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645019</td><td>Rijcken (2005)</td><td>Sex differences in concomitant medication with benzodiazepines or antidepressants in first-break schizophrenic patients treated with antipsychotic medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645662</td><td>Rikandi (2017)</td><td>Precuneus functioning differentiates first-episode psychosis patients during the fantasy movie Alice in Wonderland</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646648</td><td>Rikandi (2018)</td><td>Increased engagement of the fronto-parietal network and decreased engagement of the default-mode-cingulo-opercular-sensorimotor between-network connectivity in first-episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648014</td><td>Rinne (1999)</td><td>Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motoric fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646529</td><td>Ritsner (2010)</td><td>Is a neuroprotective therapy suitable for schizophrenia patients? [References]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646383</td><td>Rizos (2014)</td><td>A longitudinal study of alterations of hippocampal volumes and serum BDNF levels in association to atypical antipsychotics in a sample of first-episode patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633703</td><td>Rj (1961)</td><td>A comparison of fluphenazine, trifluoperazine and a placebo in the context of an active treatment unit.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648606</td><td>Robertson (2019)</td><td>Antidepressants for major depression disorder in older people: a network meta‚Äêanalysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633880</td><td>Robins (1974)</td><td>Megavitamin and Orthomolecular Therapy in Psychiatry</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645597</td><td>Robinson (1999)</td><td>Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645609</td><td>Robinson (1999)</td><td>Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645616</td><td>Robinson (2002)</td><td>Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645747</td><td>Robinson (2005)</td><td>Pharmacological treatments for first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645392</td><td>Robinson (2006)</td><td>Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644864</td><td>Robinson (2010)</td><td>Study protocol: the development of a pilot study employing a randomised controlled design to investigate the feasibility and effects of a peer support program following discharge from a specialist first-episode psychosis treatment centre</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634030</td><td>Robinson (2010)</td><td>First-episode schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646325</td><td>Robinson (2011)</td><td>Medication adherence and relapse in recent-onset psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648241</td><td>Robinson (2013)</td><td>Challenges in assessing antipsychotic response in biomarker studies of first episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645203</td><td>Robinson (2015)</td><td>Response to Saraga</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645394</td><td>Robinson (2015)</td><td>A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645395</td><td>Robinson (2015)</td><td>A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3 month outcomes</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645574</td><td>Robinson (2015)</td><td>Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647953</td><td>Robinson (2016)</td><td>Comparison of omega-3 versus placebo supplementation of risperidone for the treatment of early phase psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645393</td><td>Robinson (2017)</td><td>Randomized comparison of comprehensive versus usual community care for first-episode psychosis: the RAISE-ETP study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645466</td><td>Robinson (2018)</td><td>Psychopharmacological Treatment in the RAISE-ETP Study: outcomes of a Manual and Computer Decision Support System Based Intervention</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645619</td><td>Robinson (2019)</td><td>Predictors of Hospitalization of Individuals With First-Episode Psychosis: data From a 2-Year Follow-Up of the RAISE-ETP</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646436</td><td>Robinson (2020)</td><td>Long term effects of early intervention services for first episode psychosis: outcomes over five years from the recovery after a 1st episode of schizophrenia-early treatment program (raise-ETP)</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648069</td><td>Robles (2011)</td><td>Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633876</td><td>Rodnick (1974)</td><td>Premorbid adjustment and the recovery of mothering function in acute schizophrenic women.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644697</td><td>Rodrigues (2017)</td><td>The traumatic experience of first-episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645456</td><td>Rodriguez-Perez (2017)</td><td>Psychosis in a patient receiving malaria chemoprophylaxis-case report and brief literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648292</td><td>Rodriguez-Sanchez (2010)</td><td>Cannabis use and cognitive functioning in first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648409</td><td>Roffman (2019)</td><td>B vitamin supplements in first-episode psychosis: some neurodevelopmental and physiologic context</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634183</td><td>Rogers (1993)</td><td>Getting the Treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647201</td><td>Rohleder (2012)</td><td>The endocannabinoid system as a pharmacological target for antipsychotic treatment and more?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633775</td><td>R√∂hricht (2010)</td><td>W03-02 - Body psychotherapy in chronic schizophrenia - randomized controlled trials and a naturalistic study on effectiveness of manualised intervention strategies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644785</td><td>Roisum (2020)</td><td>Targeting Cognition and Motivation in Coordinated Specialty Care for Early Psychosis: A Grant Report</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644736</td><td>Roiz-Santianez (2014)</td><td>Three-year longitudinal population-based volumetric MRI study in first-episode schizophrenia spectrum patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646571</td><td>Rojnic (2019)</td><td>Integration of complementary biomarkers in patients with first episode psychosis: Research protocol of a prospective follow up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646915</td><td>Rojnic (2020)</td><td>General functioning in patients with first-episode psychosis after the first 18 months of treatment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646495</td><td>Romeo (2018)</td><td>Kinetics of cytokine levels during antipsychotic treatment in schizophrenia: A meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645024</td><td>Romm (2012)</td><td>Severe social anxiety in early psychosis is associated with poor premorbid functioning, depression, and reduced quality of life</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645707</td><td>Romo-Nava (2013)</td><td>Pituitary volume in schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645389</td><td>Rondeau (2010)</td><td>A randomized controlled evaluation of 'extended specialized early intervention service' vs. 'regular care' for long-term management of early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645388</td><td>Rondeau (2012)</td><td>A randomized controlled evaluation of 'extended specialized early intervention service' vs. 'regular care' for long-term management of early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647660</td><td>Rosebush (1993)</td><td>Do benzodiazepines modify the incidence of neuroleptic-induced dystonia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646079</td><td>Rosebush (1999)</td><td>Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644717</td><td>Rosen (2021)</td><td>Towards clinical application of prediction models for transition to psychosis: A systematic review and external validation study in the PRONIA sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647815</td><td>Rosenbaum (2005)</td><td>The Danish National Schizophrenia Project: prospective, comparative longitudinal treatment study of first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644835</td><td>Rosenbaum (2012)</td><td>Supportive psychodynamic psychotherapy versus treatment as usual for first-episode psychosis: two-year outcome</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646798</td><td>Rosenbaum (2016)</td><td>How can we increase physical activity and exercise among youth experiencing first-episode psychosis? A systematic review of intervention variables</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645739</td><td>Rosenheck (2008)</td><td>Pharmacotherapy of first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647860</td><td>Rosenheck (2016)</td><td>Cost-effectiveness of comprehensive, integrated care for first episode psychosis in the NIMH RAISE Early Treatment Program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644837</td><td>Rosenheck (2017)</td><td>Supported employment and education in comprehensive, integrated care for first episode psychosis: effects on work, school, and disability income</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646657</td><td>Rosenheck (2017)</td><td>Incomes and Outcomes: social Security Disability Benefits in First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647603</td><td>Rosenthal (1959)</td><td>Drug Research Design in Psychiatric Outpatient Setting</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644701</td><td>Roson (2019)</td><td>Transitional discharge interventions for people with serious mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648140</td><td>Ross (2004)</td><td>Clozapine and Typical Antipsychotics</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648512</td><td>Rossberg (2010)</td><td>Are multi family groups appropriate for patients with first episode psychosis? A 5-year naturalistic follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648421</td><td>Rotge (2008)</td><td>Atypical antipsychotics in first-episode psychosis: A review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646343</td><td>Rouleau (2016)</td><td>Managing patients in the early course of schizophrenia: A pragmatic literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646779</td><td>Rousseau (2010)</td><td>Hyperprolactinemia and atypical antipsychotic therapy in a case of fatal thromboembolism</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648127</td><td>Rowntree (2020)</td><td>Clozapine use - has practice changed?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644700</td><td>Roy (2013)</td><td>Transitions to adulthood in first-episode psychosis: A comparative study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634039</td><td>Rs (1986)</td><td>Prevention of Acute Dystonic Reactions in Patients Beginning High-Potency Neuroleptics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645023</td><td>Rubin (2008)</td><td>Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647614</td><td>Rubinstein (2016)</td><td>The double-edged nature of recovery in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648583</td><td>Rubio (2020)</td><td>Antipsychotic exposure and striatal functional connectivity in psychosis relapse: A hypothesis generating study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648366</td><td>Rubio-Abadal (2015)</td><td>Birth weight and obstetric complications determine age at onset in first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647043</td><td>Rudolph (2015)</td><td>Finding the missing-stimulus mismatch negativity (MMN) in early psychosis: Altered MMN to violations of an auditory gestalt</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646188</td><td>Ruggeri (2012)</td><td>A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647053</td><td>Ruggeri (2015)</td><td>Feasibility and Effectiveness of a Multi-Element Psychosocial Intervention for First-Episode Psychosis: results From the Cluster-Randomized Controlled GET UP PIANO Trial in a Catchment Area of 10 Million Inhabitants</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646438</td><td>Ruggeri (2016)</td><td>The long journey from biological markers, environment adversities and treatment effectiveness of early interventions on psychosis - Data from the GET UP project in community services serving a 10 million inhabitant catchment area</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647050</td><td>Ruggeri (2016)</td><td>Feasibility, effectiveness, predictors and moderators of outcome of a multi-element psychosocial intervention for first-episode psychosis in ‚ÄúReal World‚Äù community care. Results from the cluster randomized controlled GET UP PIANO trial in a catchment area of 10 million inhabitants</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59647074</td><td>Ruggeri (2017)</td><td>Family Burden, Emotional Distress and Service Satisfaction in First Episode Psychosis. Data from the GET UP Trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646090</td><td>Ruiz-Veguilla (2008)</td><td>Neurodevelopmental markers in different psychopathological dimensions of first episode psychosis: The ESPIGAS study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647575</td><td>Ruiz-Veguilla (2012)</td><td>The duration of untreated psychosis is associated with social support and temperament</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647450</td><td>Runling (2003)</td><td>Effect of Comprehensive Intervention on Quality of Life and Prognosis of Inpatients with Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648506</td><td>Rus-Calafell (2020)</td><td>Are we there yet?!-a literature review of recent digital technology advances for the treatment of early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61633758</td><td>Ruskin (1991)</td><td>Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633557</td><td>Rw (1974)</td><td>Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647145</td><td>Ryan (2004)</td><td>Evidence of basal pituitary-adrenal overactivity in first episode, drug na√Øve patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647321</td><td>Ryan (2004)</td><td>The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647229</td><td>Ryan (2017)</td><td>The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - CADENCE-BZ: study protocol for a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646514</td><td>Ryan (2019)</td><td>Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644670</td><td>Rybakowski (2012)</td><td>Treatment of depression in first episode of schizophrenia: results from EUFEST</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646946</td><td>Rybakowski (2012)</td><td>"Functional -1149 G/T polymorphism of the prolactin gene in schizophrenia": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647096</td><td>Rybakowski (2014)</td><td>Extrapyramidal symptoms during treatment of first schizophrenia episode: Results from EUFEST</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647656</td><td>Rydkjaer (2020)</td><td>Do young adolescents with first-episode psychosis or ADHD show sensorimotor gating deficits?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648754</td><td>Ryu (2007)</td><td>-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647489</td><td>Ryu (2013)</td><td>Eating-behavior changes associated with antipsychotic medications in patients with schizophrenia as measured by the Drug-Related Eating Behavior Questionnaire</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634247</td><td>S (2021)</td><td>Longitudinal Changes in Functional Connectivity in Antipsychotic-treated and Antipsychotic-naive Patients with First Episode Psychosis</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59647391</td><td>Sabaroedin (2020)</td><td>Effective connectivity of frontostriatal systems in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647392</td><td>Sabaroedin (2021)</td><td>Effective Connectivity of Fronto-Striato-Thalamic Circuitry Across the Psychosis Continuum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634218</td><td>Sabaroedin (2021)</td><td>Effective Connectivity and Dopaminergic Function of Fronto-Striato-Thalamic Circuitry in First-Episode Psychosis, Established Schizophrenia, and Healthy Controls</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646849</td><td>Sacchetti (2000)</td><td>H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644490</td><td>Sacks (2021)</td><td>White Matter Integrity According to the Stage of Mental Disorder in Youth</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647363</td><td>Sadath (2015)</td><td>Effectiveness of group intervention for caregivers of persons with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647647</td><td>Sadath (2017)</td><td>Does group intervention have benefits on expressed emotion and social support in carers of persons with first episode psychosis?</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646662</td><td>Saddichha (2007)</td><td>Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: A six-week prospective study in Indian female patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647419</td><td>Saddichha (2007)</td><td>Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645627</td><td>Saddichha (2008)</td><td>Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646271</td><td>Saddichha (2008)</td><td>Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647183</td><td>Saddichha (2008)</td><td>Erratum to "Metabolic syndrome in first episode schizophrenia-A randomized double-blind controlled, short-term prospective study"</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647744</td><td>Saddichha (2008)</td><td>Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648289</td><td>Safont (2011)</td><td>Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: An in vivo SPECT study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647466</td><td>Sagarwala (2021)</td><td>The effect of antipsychotic medications on white matter integrity in first-episode drug-naive patients with psychosis: A review of DTI studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645239</td><td>Saha (2020)</td><td>Relationship of serum BDNF levels with symptom severity, impulsivity and socio-demographic & clinical variables in first episode mania</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647304</td><td>Sahakian (2012)</td><td>The effects of modafinil and methylphenidate in neuropsychiatric disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647988</td><td>Sahni (2016)</td><td>Comparative study of clozapine versus risperidone in treatment-naive, first-episode schizophrenia: a pilot study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645696</td><td>Sahpolat (2017)</td><td>Plasma nesfatin 1 level in patients with first attack psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645705</td><td>Sahpolat (2020)</td><td>Plasma Apelin, Visfatin and Resistin Levels in Patients with First Episode Psychosis and Chronic Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646828</td><td>Sahpolat (2021)</td><td>Higher prevalence of metabolic syndrome and related factors in patients with first-episode psychosis and schizophrenia: a cross-sectional study in Turkey</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647255</td><td>Sai (2021)</td><td>Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial Data</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646731</td><td>Saija (2012)</td><td>The impact of social cognition training and oxytocin on social functioning in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646821</td><td>Saila (2017)</td><td>Hippocampal subfield volumes in first-episode psychosis: association with glucose metabolism</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644884</td><td>Saiz-Masvidal (2020)</td><td>Structural covariance predictors of clinical improvement at 2-year follow-up in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645287</td><td>Saks (2004)</td><td>Refusing Care: Forced Treatment and the Use of Psychiatric Advance Directives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645854</td><td>Salagre (2020)</td><td>P.831Trajectories of suicidal ideation after a first-episode psychosis: a growth mixture modeling approach</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646922</td><td>Salas-Sender (2020)</td><td>Gender differences in response to metacognitive training in people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644831</td><td>Salazar (2009)</td><td>Switch to ziprazidone treatment is associated with changes in MMN amplitude</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647733</td><td>Salazar (2019)</td><td>Differences by year of publication in duration of untreated psychosis in first episode schizophrenia: Meta-analysis and meta-regression analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647034</td><td>Saleem (2013)</td><td>First episode psychosis patients show impaired cognitive function-A study of a South Asian population in the UK</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645681</td><td>Saleem (2014)</td><td>Positive effects of a novel cognitive remediation computer game (X-Cog) in first episode psychosis: A pilot study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646419</td><td>Salgueiro (2019)</td><td>Long-acting injectable second-generation antipsychotics in first-episode psychosis: a narrative review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648591</td><td>Salimi (2009)</td><td>Antipsychotic drugs for first-episode schizophrenia: A comparative review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645062</td><td>Salisbury (2020)</td><td>Selective Left Hemisphere Auditory Cortex Mismatch Negativity Source Deficit in First Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645889</td><td>Salo (2011)</td><td>Overlapping cognitive patterns in schizophrenia and methamphetamine dependence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633933</td><td>Salvatore (2007)</td><td>Longitudinal research on bipolar disorders.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646336</td><td>Salvatore (2009)</td><td>McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646961</td><td>Samalin (2013)</td><td>French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644971</td><td>Sami (2019)</td><td>Smooth pursuit eye movements indicate biological distinction between cannabis-using and nonusing patients in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648456</td><td>Sami (2020)</td><td>Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647093</td><td>Sami (2021)</td><td>Eye movements in patients in early psychosis with and without a history of cannabis use</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633842</td><td>Sampath (1992)</td><td>Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646151</td><td>San (2006)</td><td>A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645940</td><td>San (2012)</td><td>One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645903</td><td>Sanbrook (2003)</td><td>Origins of early intervention in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647382</td><td>Sanbrook (2003)</td><td>The effectiveness of an early intervention team in the treatment of first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648187</td><td>Sanchez-Gistau (2020)</td><td>Clinical and cognitive correlates of childhood attention-deficit/hyperactivity disorder in first-episode psychosis: A controlled study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644976</td><td>Sanchez-Gutierrez (2018)</td><td>Smoking does not impact social and non-social cognition in patients with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644746</td><td>Sanchez-Gutierrez (2019)</td><td>Think app: a mobile app-based intervention for adolescents with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648291</td><td>Sanchez-Gutierrez (2020)</td><td>Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645976</td><td>Sanger (1997)</td><td>Olanzapine Versus Haloperidol in the Treatment of First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645974</td><td>Sanger (1998)</td><td>Olanzapine versus haloperidol treatment in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645975</td><td>Sanger (1998)</td><td>Olanzapine Versus Haloperidol in the Treatment of Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645973</td><td>Sanger (1999)</td><td>Olanzapine versus haloperidol treatment in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646252</td><td>Sanna (2017)</td><td>Methylphenidate long-term effects on psychiatric outcomes in a Sardinian ADHD population: Preliminary results from the prospective ADDUCE project</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645620</td><td>Santesteban-Echarri (2017)</td><td>Predictors of functional recovery in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645357</td><td>Sanz-Fuentenebro (2013)</td><td>Randomized trial of clozapine vs. Risperidone in treatment-naive first-episode schizophrenia: Results after one year</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647140</td><td>Saraga (2015)</td><td>Evidence-based medicine and clinical expertise</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644953</td><td>Sarandol (2007)</td><td>Sociodemographic, disorder and treatment related characteristics affecting follow-up periods of schizophrenic outpatients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647012</td><td>Sarandol (2015)</td><td>First-episode psychosis is associated with oxidative stress: Effects of short-term antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645027</td><td>Sargant (1949)</td><td>Seven years of experience with modified insulin treatment in neuroses and early psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647119</td><td>Sarkar (1994)</td><td>An exploratory evaluation of ECT in haloperidol-treated DSM-IIIR schizophreniform disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647588</td><td>Sarotar (2008)</td><td>Duration of untreated psychosis and it's effect on the functional outcome in schizophrenia: Preliminary results</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648566</td><td>Sarpal (2015)</td><td>Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646673</td><td>Sarpal (2016)</td><td>In support of neuroimaging biomarkers of treatment response in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648400</td><td>Sarpal (2016)</td><td>Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645262</td><td>Sarpal (2017)</td><td>Relationship between duration of untreated psychosis and intrinsic corticostriatal connectivity in patients with early phase schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647912</td><td>Sarpal (2020)</td><td>Context-specific abnormalities of the central executive network in first-episode psychosis: relationship with cognition</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648584</td><td>Sarpal (2020)</td><td>Antipsychotic efficacy and associated changes in prefrontal neurotransmitter levels: Preliminary results from a 7-tesla neuroimaging study of early phase schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645810</td><td>Sartore (2013)</td><td>Peer support interventions for parents and carers of children with complex needs</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645709</td><td>Saunders (2019)</td><td>Pituitary volume in individuals at elevated risk for psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644532</td><td>Sauras (2017)</td><td>Volumetric and morphological characteristics of the hippocampus are associated with progression to schizophrenia in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645560</td><td>Sauv√© (2019)</td><td>The Prevalence of Negative Symptoms Across the Stages of the Psychosis Continuum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646999</td><td>Saviola (2021)</td><td>"First-episode psychosis: Structural covariance deficits in salience network correlate with symptoms severity"</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646758</td><td>Sawan (2015)</td><td>Iloperidone versus placebo for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td><span >Tiril Borge</span></td><td></td></tr><tr><td>59646054</td><td>Saykin (1994)</td><td>Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634055</td><td>Sc (1982)</td><td>Cholinomimetic-induced co-release of prolactin and beta-endorphin in man.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646091</td><td>Scassellati (2020)</td><td>Neurodevelopmental disorders: Metallomics studies for the identification of potential biomarkers associated to diagnosis and treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647559</td><td>Sch√§fer (2007)</td><td>Early detection of psychotic disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648475</td><td>Schafer (2011)</td><td>Assessment of posttraumatic symptoms in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648745</td><td>Scheffer (2004)</td><td>Abnormal neurological signs at the onset of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647319</td><td>Scheffler (2018)</td><td>Effects of cannabis use on body mass, fasting glucose and lipids during the first 12 months of treatment in schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645232</td><td>Scheffler (2020)</td><td>Relevance of cannabis use as a predictor of clinical outcome in first-episode schizophrenia spectrum disorder patients over 24 months of treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644659</td><td>Schennach (2012)</td><td>Treatment response in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645003</td><td>Schennach (2013)</td><td>Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647776</td><td>Schennach-Wolff (2009)</td><td>Depressive symptoms and their impact on short-term outcome in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645605</td><td>Schennach-Wolff (2011)</td><td>Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646598</td><td>Schennach-Wolff (2011)</td><td>Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646617</td><td>Schiavone (2017)</td><td>Inflammation, stress response, and redox dysregulation biomarkers: Clinical outcomes and pharmacological implications for psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644598</td><td>Schiavone (2018)</td><td>The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634097</td><td>Schied (1990)</td><td>Psychiatric Concepts and Therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645565</td><td>Schimmelmann (2012)</td><td>Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645085</td><td>SCHIZOPHRENIA POLYGENIC... (2019)</td><td>SCHIZOPHRENIA POLYGENIC RISK SCORE PREDICTS ANTIPSYCHOTIC TREATMENT RESPONSE IN PATIENTS WITH FIRST EPISODE PSYCHOSIS</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648498</td><td>Schlachetzki (2008)</td><td>Aripiprazole induced hypersexuality in a 24-year-old female patient with schizoaffective disorder?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644829</td><td>Schlagenhauf (2010)</td><td>Switching schizophrenia patients from typical neuroleptics to aripiprazole: Effects on working memory dependent functional activation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646121</td><td>Schlogelhofer (2018)</td><td>The neurapro study: adherence to study medication</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646746</td><td>Schlogelhofer (2020)</td><td>The impact of antidepressant use on the transition to psychosis rate in the neurapro trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645442</td><td>Schmidinger (2014)</td><td>Pulmonary embolism and aspiration pneumonia after reexposure to clozapine: Pulmonary adverse effects of clozapine</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633776</td><td>Schmidt (1966)</td><td>Persistent dyskinesias following phenothiazine therapy. Report of five cases and a review of the literature.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646232</td><td>Schmidt (2012)</td><td>Mismatch negativity encoding of prediction errors predicts S-ketamine cognitive impairments</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648355</td><td>Schmidt (2013)</td><td>Brain connectivity abnormalities predating the onset of psychosis: Correlation with the effect of medication</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647732</td><td>Schmidt (2014)</td><td>Differences in coping, self-efficacy, and external control beliefs between patients at-risk for psychosis and patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647688</td><td>Schmidt (2018)</td><td>Disorganized gyrification network properties during the transition to psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644906</td><td>Schmied (2010)</td><td>Statement on the debate about second-generation antipsychotics</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644893</td><td>Schmitt (2006)</td><td>Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647597</td><td>Schmitt (2012)</td><td>Dual-isotope SPECT imaging of striatal dopamine: A comparative study between never-treated and haloperidol-treated first-episode schizophrenic patients</td><td>(I) Included</td><td></td><td></td><td></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59648604</td><td>Schneider (2013)</td><td>Antimalarial chemoprophylaxis and the risk of neuropsychiatric disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645685</td><td>Schoeler (2017)</td><td>Poor medication adherence and risk of relapse associated with continued cannabis use in patients with first-episode psychosis: A prospective analysis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647449</td><td>Schoeler (2017)</td><td>Effect of continued cannabis use on medication adherence in the first two years following onset of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647120</td><td>Schoemaker (2009)</td><td>Expert rater assisted score evaluation: a new method to increase efficiency in drug development programs</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633990</td><td>Schoeman (2011)</td><td>A prospective study of cognitive deficits in first episode psychosis, and the response thereof to treatment with Flupenthixol Decanoate</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647730</td><td>Schoer (2019)</td><td>Differences in duration of untreated psychosis for racial and ethnic minority groups with first-episode psychosis: an updated systematic review and meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633972</td><td>Schooler (1967)</td><td>One Year After Discharge: Community Adjustment of Schizophrenic Patients</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633634</td><td>Schooler (1980)</td><td>Prevention of relapse in schizophrenia: An evaluation of fluphenazine decanoate.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646933</td><td>Schooler (1997)</td><td>The FutuRIS study - A prospective long-term evaluation of risperidone versus haloperidol in early psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633639</td><td>Schooler (1997)</td><td>New antipsychotic medications: strategies for evaluation and selected findings</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633513</td><td>Schooler (2003)</td><td>Relapse and rehospitalization: comparing oral and depot antipsychotics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645149</td><td>Schooler (2005)</td><td>Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647268</td><td>Schooler (2007)</td><td>The efficacy and safety of conventional and atypical antipsychotics in first-episode schizophrenia: a review of the literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648061</td><td>Schooler (2016)</td><td>Cognitive functioning in first episode psychosis: comparison of a two-year coordinated specialty care program to community care</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648059</td><td>Schooler (2017)</td><td>Cognitive functioning in first-episode psychosis: -X000B- Comparison of a 2-year coordinated specialty care program to community care</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646435</td><td>Schooler (2019)</td><td>Long term effects of early intervention services for first episode psychosis: outcomes over five years from the recovery after a 1st episode of schizophrenia-early treatment program (RAISE-ETP)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646339</td><td>Schoretsanitis (2021)</td><td>Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647705</td><td>Schottle (2012)</td><td>Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645840</td><td>Schreiner (2015)</td><td>Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647819</td><td>Schroder (2000)</td><td>D2-dopamine receptor upregulation and treatment response under neuroleptic therapy. A procedural study of schizophrenics under first-time treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646630</td><td>Schulte (2012)</td><td>Indications for clozapine</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644470</td><td>Schultz (1995)</td><td>Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645784</td><td>Schultze-Lutter (2012)</td><td>Personality disorders and accentuations in at-risk persons with and without conversion to first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647491</td><td>Schulz (2014)</td><td>Early-stage schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645821</td><td>Schulz (2015)</td><td>Patient-oriented randomisation: a new trial design applied in the Neuroleptic Strategy Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646179</td><td>Schulz (2015)</td><td>A multidisciplinary first-episode psychosis program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645801</td><td>Schwartz (1980)</td><td>Perceptual organization in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648667</td><td>Schwehm (2016)</td><td>Age and sex effects on white matter tracts in psychosis from adolescence through middle adulthood</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647302</td><td>Scoriels (2011)</td><td>Effects of modafinil on emotional processing in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647303</td><td>Scoriels (2012)</td><td>Effects of modafinil on cognitive functions in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645475</td><td>Scott (2017)</td><td>Psychological interventions for early stage bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644770</td><td>Scott (2018)</td><td>Testing for antibodies to N-methyl-D-aspartate receptor and other neuronal cell surface antigens in patients with early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647400</td><td>Scott (2020)</td><td>Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis: a Randomized Clinical Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644949</td><td>Scott (2021)</td><td>Sodium benzoate as an adjunctive treatment in early psychosis: A randomised clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644987</td><td>Scott (2021)</td><td>Sleep disturbances and first onset of major mental disorders in adolescence and early adulthood: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634079</td><td>Scrimali (2002)</td><td>Psychopharmacology, Placebo and Psychotherapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645912</td><td>Secher (2011)</td><td>The Opus-trial: intensive, early, psycho-social intervention versus treatment as usual for first-episode psychosis patients. Results from the 10-year follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645244</td><td>Seemuller (2012)</td><td>The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648661</td><td>Seemuller (2012)</td><td>Akathisia and suicidal ideation in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648470</td><td>Seethaler (2020)</td><td>The association between MMP-9 and choroid plexus volume in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645143</td><td>Segarra (2010)</td><td>Risperidone injectable long-acting treatment vs other oral antipsychotics in first episode psychosis: one year longitudinal study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648043</td><td>Segarra (2011)</td><td>Cognitive performance and smoking in first-episode psychosis: The self-medication hypothesis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644996</td><td>Segarra (2012)</td><td>Similarities in early course among men and women with a first episode of schizophrenia and schizophreniform disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646392</td><td>Segarra (2012)</td><td>Longitudinal changes of insight in first episode psychosis and its relation to clinical symptoms, treatment adherence and global functioning: One-year follow-up from the Eiffel study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645909</td><td>Segarra (2021)</td><td>Oral and Palmitate Paliperidone Long-Acting Injectable Formulations use in Schizophrenia Spectrum Disorders: a retrospective cohort study from the CRUPEP First Episode Psychosis Intervention Program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647300</td><td>Seidman (2016)</td><td>Effects of N-Acetyl-Cysteine on Neurocognition in a double-blind randomized placebo-controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645936</td><td>Seikkula (2003)</td><td>Open Dialogue approach: Treatment principles and preliminary results of a two-year follow-up on first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646988</td><td>Seikkula (2006)</td><td>Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644781</td><td>Selby (2020)</td><td>Technology-enabled collaborative care for youth with early psychosis: a protocol for a feasibility study to improve physical health behaviours</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648407</td><td>Selick (2017)</td><td>Barriers and facilitators to implementing family support and education in Early Psychosis Intervention programmes: A systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647057</td><td>Selick (2021)</td><td>Feasibility and acceptability of a volunteer peer fidelity assessment model in early psychosis intervention programmes in Ontario: Results from a pilot study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645306</td><td>Selvaggi (2020)</td><td>Reduced cortical cerebral blood flow in first episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634149</td><td>Selvapandiyan (2019)</td><td>Status of cognitive behaviour therapy in India: Pitfalls, limitations and future directions‚ÄîA systematic review and critical analysis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644582</td><td>Semenova (2019)</td><td>Use of translational electroencephalo-graphy biomarker in early phase clinical studies for Alzheimer's disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633607</td><td>Semmler (1988)</td><td>Prospektiver 5-Jahres-Verlaufskatalog bei 27 schizophrenen Patienten unter einem teilstation√§ren Behandlungskonzept</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644518</td><td>Sengupta (2005)</td><td>Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647469</td><td>Seppala (2005)</td><td>Effect of Anticholinergics in Preventing Acute Deterioration in Patients Undergoing Abrupt Clozapine Withdrawal</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645078</td><td>Servan-Schreiber (1996)</td><td>Schizophrenic deficits in the processing of context: A test of a theoretical model</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647721</td><td>Setien-Suero (2021)</td><td>Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: a 3-year follow-up comparison</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647880</td><td>Sevy (2001)</td><td>Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648516</td><td>Sevy (2010)</td><td>Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645971</td><td>Sevy (2011)</td><td>Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646469</td><td>Seybolt (2014)</td><td>Less is more</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646674</td><td>Seybolt (2015)</td><td>In response to "Re: Less is more"</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634215</td><td>Sg (2020)</td><td>FebriDx point-of-care test in patients with suspected COVID-19: a systematic review and individual patient data meta-analysis of diagnostic test accuracy studies</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633900</td><td>Shader (1964)</td><td>PHENOBARBITAL AND ATROPINE IN COMBINATION, AN ACTIVE CONTROL SUBSTANCE FOR PHENOTHIAZINE RESEARCH.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646951</td><td>Shafritz (2019)</td><td>Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646516</td><td>Shah (2017)</td><td>Is the clinical high-risk state a valid concept? Retrospective examination in a first-episode psychosis sample</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648005</td><td>Shah (2017)</td><td>Common pattern of gray-matter abnormalities in drug-naive and medicated first-episode schizophrenia: a multimodal meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646577</td><td>Shahrivar (2010)</td><td>Integrated standard program in comparison to the usual treatment in adolescents with first episode psychosis: a randomized clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647249</td><td>Shahrivar (2012)</td><td>The efficacy of an integrated treatment in comparison with treatment as usual in a group of youths with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647250</td><td>Shahrivar (2012)</td><td>The efficacy of an integrated treatment in comparison with treatment as usual in a group of children and adolescents with first-episode psychosis during a two -year follow-up</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648433</td><td>Shahzad (2014)</td><td>Atomoxetine for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646823</td><td>Shakory (2018)</td><td>Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633988</td><td>Shalev (1987)</td><td>Severe akathisia causing neuroleptic failure: an indication for lithium therapy in schizophrenia?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646991</td><td>Shamir (2000)</td><td>First-night effect of melatonin treatment in patients with chronic schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633954</td><td>Shamoo (1996)</td><td>Ethical concerns about relapse studies.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646208</td><td>Shan (2010)</td><td>More evidence to support the role of S2 in P50 studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644800</td><td>Shannon (2020)</td><td>A systematic review of the effectiveness of group-based exercise interventions for individuals with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647276</td><td>Shao (2013)</td><td>Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648257</td><td>Sharma (2006)</td><td>A cautionary note on the use of antidepressants in postpartum depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644851</td><td>Sharma (2010)</td><td>Successful treatment of co-morbid schizophrenia and multiple sclerosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648368</td><td>Sharma (2017)</td><td>Bipolar postpartum depression: An update and recommendations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645462</td><td>Shearer (2018)</td><td>Psychoses: Evidence-based integrated biopsychosocial treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634249</td><td>Sheehan (2019)</td><td>A structured medication review tool to promote psychotropic medication optimisation for adults with intellectual disability: feasibility study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644763</td><td>Sheffield (2020)</td><td>Thalamocortical anatomical connectivity in schizophrenia and psychotic bipolar disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633621</td><td>Sheitman (1997)</td><td>The Evaluation and Treatment of First-episode Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645764</td><td>Sheitman (2001)</td><td>The pharmacologic treatment of first episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633717</td><td>Shen (1999)</td><td>A history of antipsychotic drug development</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646068</td><td>Shen (2021)</td><td>Neuronal signatures of negative and positive schemas towards the self and others in patients with early stage schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633695</td><td>Shepherd (1972)</td><td>The classification of psychotropic drugs.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634266</td><td>Shepherd (2020)</td><td>Supervised treatment in outpatients for schizophrenia plus (STOPS+): protocol for a cluster randomised trial of a community-based intervention to improve treatment adherence and reduce the treatment gap for schizophrenia in Pakistan.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646827</td><td>Shergill (2008)</td><td>Highlights of this issue</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648186</td><td>Sheridan (2019)</td><td>Clinical and cost-effectiveness of contingency management for cannabis use in early psychosis: the CIRCLE randomised clinical trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645016</td><td>Shi (2021)</td><td>Sex-specific Association of Antipsychotic-induced Weight Gain and Treatment Response for Antipsychotic-Naive First Episode Schizophrenia Patients: A Prospective 8-week Longitudinal Study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644903</td><td>Shibib (2009)</td><td>Stimulant induced psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648276</td><td>Shiers (2013)</td><td>"The cardiovascular health of young people with severe mental illness: Addressing an epidemic within an epidemic": Reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648282</td><td>Shiers (2014)</td><td>Cardiometabolic health in young people with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647698</td><td>Shim (2007)</td><td>Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633782</td><td>Shimkunas (1966)</td><td>Abstracting Ability of Schizophrenics Before and During Phenothiazine Therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645874</td><td>Shimomura (2019)</td><td>P.362 Antipsychotic treatment for the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648554</td><td>Shimomura (2020)</td><td>Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648167</td><td>Shin (2021)</td><td>Clinical effectiveness of early treatment with paliperidone palmitate in schizophrenia: A retrospective real-world study in south korea</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644782</td><td>Shivakumar (2019)</td><td>tDCS for schizophrenia: clinical studies from India</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644943</td><td>Shoshina (2015)</td><td>The spatial-frequency characteristics of the visual system in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648401</td><td>Shrivastava (2012)</td><td>Baseline serum prolactin in drug-naive, first-episode schizophrenia and outcome at five years: Is it a predictive factor?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647218</td><td>Shrivastava (2014)</td><td>Electroencephalographic abnormality and clinical response in patients with first-episode schizophrenia treated with clozapine</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633943</td><td>Shtasel (1992)</td><td>Phenomenology and Functioning in First-Episode Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644998</td><td>Shuib (2017)</td><td>The significance of processing speed in metacognitive-based cognitive remediation for first episode psychosis in Malaysia: a pilot randomised trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645931</td><td>Si (2015)</td><td>An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645950</td><td>Si (2017)</td><td>Once-monthly injection of paliperidone palmitate in patients with recently diagnosed and chronic schizophrenia: a post-hoc comparison of efficacy and safety</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634229</td><td>Siafis (2020)</td><td>Antipsychotic drugs v. barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634058</td><td>Sieberns (1988)</td><td>Dosierung von Neuroleptika</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645617</td><td>Sigrunarson (2017)</td><td>Predictors of long term use of psychiatric services of patients with recent-onset schizophrenia: 12 years follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634037</td><td>Silk (2013)</td><td>Development of a Psychotropic PRN Medication Evaluative Tool</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647490</td><td>Silver (2008)</td><td>Early, Nondisabling Parkinson's Disease: weighing the Options for Initial Therapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647281</td><td>Silverstein (2013)</td><td>Effects of short-term inpatient treatment on sensitivity to a size contrast illusion in first-episode psychosis and multiple-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633765</td><td>Silverstone (1990)</td><td>Clinically relevant differences between antipsychotic compounds</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645488</td><td>Sim (2004)</td><td>Psychiatric comorbidity in first episode psychosis: The Early Psychosis Intervention Program (EPIP) experience</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644778</td><td>Sim (2006)</td><td>Telling them apart: Longitudinal outcomes of schizoaffective disorder and schizophrenia within an early psychosis intervention program</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644876</td><td>Simmons (2018)</td><td>A study comparing weight gain from ALKS 3831 to olanzapine in early-illness young adults with schizophreniform, schizophrenia, or bipolar I disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633791</td><td>Simon (1965)</td><td>LONG-TERM FOLLOW-UP STUDY OF SCHIZOPHRENIC PATIENTS.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646914</td><td>Simon (2005)</td><td>General practitioners and schizophrenia: Results from a Swiss survey</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646557</td><td>Simon (2009)</td><td>The international study on general practitioners and early psychosis (IGPS)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646832</td><td>Simon (2010)</td><td>High remission rates from an initial ultra-high risk state for psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644832</td><td>Simon (2012)</td><td>The Swiss Early Psychosis Project SWEPP: A national network</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647555</td><td>Simonsen (2010)</td><td>Early identification of non-remission in first-episode psychosis in a two-year outcome study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645807</td><td>Simonsen (2019)</td><td>Perceived and experienced stigma in first-episode psychosis: A 1-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645286</td><td>Simpson (2001)</td><td>Regional cerebral volume measurements in late-life depression: Relationship to clinical correlates, neuropsychological impairment and response to treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645040</td><td>Simsek (2016)</td><td>Serum IL-4 and IL-10 levels correlate with the symptoms of the drug-naive adolescents with first episode, early onset schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645887</td><td>Simsek (2016)</td><td>Oxidative stress and DNA damage in untreated first-episode psychosis in adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647566</td><td>Sin (2012)</td><td>The E-Sibling Project: development and evaluation of an online multi-component psychoeducational intervention for siblings of people with first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647568</td><td>Sin (2013)</td><td>The E Sibling Project - exploratory randomised controlled trial of an online multi-component psychoeducational intervention for siblings of individuals with first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644505</td><td>Sin (2017)</td><td>What factors influence successful recruitment of siblings of individuals with first episode psychosis to e-health interventions? A qualitative study</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645715</td><td>Singer (2014)</td><td>A pilot study of cognitive behavior therapy for depression in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633766</td><td>Singh (1973)</td><td>Kinetics and dynamics of response to haloperidol in acute schizophrenia: A longitudinal study of the therapeutic process.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633882</td><td>Singh (1973)</td><td>Sleeplessness in acute and chronic schizophrenia ‚Äî Response to haloperidol and anti-Parkinsonism agents</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633734</td><td>Singh (1975)</td><td>A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634052</td><td>Singh (1975)</td><td>Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633574</td><td>Singh (1985)</td><td>Pharmacology of Central Cholinergic Mechanisms and Schizophrenic Disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645736</td><td>Singh (1994)</td><td>Pharmacotherapy of psychiatric syndromes in AIDS</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633654</td><td>Singh (2009)</td><td>Morning pseudoneutropenia during risperidone treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647834</td><td>Singh (2010)</td><td>Cultural diversity in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633912</td><td>Singh (2010)</td><td>Early intervention in psychosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647172</td><td>Singh (2015)</td><td>Ethnicity and pathways to care during first episode psychosis: The role of cultural illness attributions</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647831</td><td>Singh (2020)</td><td>Current and future of Alzheimer's therapy with the best approach</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648337</td><td>Singh (2020)</td><td>Brain-derived neurotrophic factor (BDNF) levels in first-episode schizophrenia and healthy controls: A comparative study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633998</td><td>Sinnamon (1982)</td><td>The reward-effort model: An economic framework for examining the mechanism of neuroleptic action</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648728</td><td>Sint (2018)</td><td>Accounting for group differences in study retention in a randomized trial of specialized treatment for first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646477</td><td>Sint (2021)</td><td>Latent class mediator for multiple indicators of mediation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646646</td><td>Sirota (1999)</td><td>Increased olfactory sensitivity in first episode psychosis and the effect of neuroleptic treatment on olfactory sensitivity in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645337</td><td>Siskind (2021)</td><td>Rates of treatment-resistant schizophrenia from first-episode cohorts: Systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634297</td><td>Sitko (2019)</td><td>Assessing the effectiveness of CBTp across time : a systematic review and meta-analysis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644936</td><td>Skalli (2011)</td><td>Specialised first-episode psychosis services: A systematic review of the literature</td><td>(I) Included</td><td></td><td></td><td><span >Trine Bjerke Johansen</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td></tr><tr><td>59646442</td><td>Sklar (2020)</td><td>Localization of Early-Stage Visual Processing Deficits in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646950</td><td>Sklar (2021)</td><td>Fronto-Parietal Network Function During Cued Visual Search in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645463</td><td>Skosnik (2006)</td><td>Psychophysiological evidence of altered neural synchronization in cannabis use: Relationship to schizotypy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633748</td><td>Slawsky (1986)</td><td>Drug Maintenance Strategies in Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645423</td><td>Small (1997)</td><td>Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645598</td><td>Smart (2019)</td><td>Predictors of treatment resistant schizophrenia: a systematic review of prospective observational studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646200</td><td>Smeerdijk (2015)</td><td>Motivational interviewing and interaction skills training for parents of young adults with recent-onset schizophrenia and co-occurring cannabis use: 15-month follow-up</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648560</td><td>Smelson (2006)</td><td>Antipsychotic Treatment Discontinuation among Individuals with Schizophrenia and Co-occurring Substance Use</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646650</td><td>Smesny (2005)</td><td>Increased Calcium-Independent Phospholipase A2 Activity in First but Not in Multiepisode Chronic Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645727</td><td>Smesny (2011)</td><td>Phospholipase A2 activity in first episode schizophrenia: Associations with symptom severity and outcome at week 12</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648598</td><td>Smesny (2012)</td><td>Antipsychotic drug effects on left prefrontal phospholipid metabolism: A follow-up 31P-2D-CSI study of haloperidol and risperidone in acutely ill chronic schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646588</td><td>Smieskova (2012)</td><td>Insular volume abnormalities associated with different transition probabilities to psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633552</td><td>Smith (2009)</td><td>Writing About Emotional Experiences Reduces beta-Agonist Use in Patients with Asthma-3-Month Follow</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646739</td><td>Smith (2014)</td><td>The impact of insight in a first-episode mania with psychosis population on outcome at 18 months</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645118</td><td>Smith (2016)</td><td>Role of Substance Use and Working Alliance on relapse in treatment for early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646337</td><td>Smith (2019)</td><td>Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647176</td><td>Smith (2019)</td><td>Estimated Staff Time Effort, Costs, and Medicaid Revenues for Coordinated Specialty Care Clinics Serving Clients With First-Episode Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647544</td><td>Smith (2020)</td><td>Early Intervention in Psychosis: Effectiveness and Implementation of a Combined Exercise and Health Behavior Intervention Within Routine Care</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648281</td><td>Smith (2020)</td><td>Cardiometabolic Risk in First Episode Psychosis Patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634234</td><td>Smith (2020)</td><td>Early Intervention in Psychosis: From Science to Services</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646385</td><td>Smucny (2018)</td><td>Longitudinal stability of cognitive control in early psychosis: Nondegenerative deficits across diagnoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646474</td><td>Snitz (2005)</td><td>Lateral and medial hypofrontality in first-episode schizophrenia: Functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633617</td><td>Snyder (1974)</td><td>Drugs, neurotransmitters, and schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633823</td><td>Snyder (1974)</td><td>Antischizophrenic Drugs and Brain Cholinergic Receptors: Affinity for Muscarinic Sites Predicts Extrapyramidal Effects</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644946</td><td>Snyder (2008)</td><td>Spatial working memory and problem solving in schizophrenia: The effect of symptom stabilization with atypical antipsychotic medication</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647245</td><td>So (2006)</td><td>Efficacy of brief intervention for carers of people with first-episode psychosis: A waiting list controlled study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648231</td><td>So (2014)</td><td>Changes in delusions in the early phase of antipsychotic treatment-An experience sampling study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648232</td><td>So (2015)</td><td>Changes in delusional dimensions and emotions over eight weeks of antipsychotic treatment in acute patients</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648509</td><td>Sohler (2004)</td><td>Are there racial differences in the way patients with psychotic disorders are treated at their first hospitalization?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645036</td><td>Solanki (2017)</td><td>Serum levels of neuroactive steroids in first-episode antipsychotic-naive schizophrenic patients and its correlation with aggression: A case-control study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644620</td><td>Soldevila-Matias (2019)</td><td>Unaltered frontal and prefrontal brain response during work memory tasks in patients with a first episode psychosis metaanalysis study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645663</td><td>Soldevila-Mat√≠as (2020)</td><td>Precuneus and insular hypoactivation during cognitive processing in first-episode psychosis: Systematic review and meta-analysis of fMRI studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646229</td><td>Solis-Vivanco (2014)</td><td>Mismatch Negativity reduction in the left cortical regions in first-episode psychosis and in individuals at ultra high-risk for psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648052</td><td>Solis-Vivanco (2020)</td><td>Cognitive impairment in nevertreated schizophrenia spectrum individuals</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633793</td><td>Solomon (1982)</td><td>Attention, dopamine, and schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644666</td><td>Sommer (2012)</td><td>The treatment of hallucinations in schizophrenia spectrum disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648508</td><td>Sommer (2015)</td><td>Are we a step further toward a useful biomarker?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646356</td><td>Sommer (2019)</td><td>Maintenance treatment for patients with a first psychotic episode</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648170</td><td>Sommer (2020)</td><td>The clinical course of schizophrenia in women and men-a nation-wide cohort study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644993</td><td>Sommer (2021)</td><td>Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: a Double-Blind, Randomized Placebo-Controlled Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633721</td><td>Sommers (1985)</td><td>‚ÄúNegative Symptoms‚Äù: Conceptual and Methodological Problems</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646884</td><td>Somogyi (2015)</td><td>Going against the grain: Alternatives to neuroleptic treatment for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647976</td><td>Son (2021)</td><td>Comparison of aripiprazole and risperidone effectiveness in first episode non-affective psychosis: rationale and design of a prospective, randomized, 3-phase, investigator-initiated study (PAFIP-3)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647214</td><td>Song (2013)</td><td>Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645038</td><td>Song (2014)</td><td>Serum levels of BDNF, folate and homocysteine: In relation to hippocampal volume and psychopathology in drug naive, first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647060</td><td>Song (2014)</td><td>Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648225</td><td>Song (2014)</td><td>Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na√Øve, first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648529</td><td>Song (2014)</td><td>APOA-I: A possible novel biomarker for metabolic side effects in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648098</td><td>Sonmez (2014)</td><td>Cognitive behavior therapy in first-episode psychosis with a focus on depression, anxiety, and self-esteem</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648099</td><td>Sonmez (2020)</td><td>Cognitive behavior therapy in early psychosis with a focus on depression and low self-esteem: A randomized controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>61634078</td><td>Soosay (2016)</td><td>Reinvigorating and redesigning early intervention in psychosis services for young people in Auckland</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646700</td><td>Sorensen (2008)</td><td>Implementation of a rational pharmacotherapy intervention for inpatients at a psychiatric department</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646796</td><td>Soroken (2018)</td><td>How do pediatricians rule out underlying organic etiologies among adolescents with the first episode of psychotic symptoms?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634090</td><td>Soubrie (1982)</td><td>Neuroleptic-induced anhedonia: Some psychopharmacological implications</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647077</td><td>Sousa (2019)</td><td>Familial amyloid polyneuropathy-in addition to the organic disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647607</td><td>Soyka (2014)</td><td>Driving ability with alcohol and drug dependence and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644652</td><td>Spangaro (2020)</td><td>Treatment-resistance affects long-term cognitive trajectories in schizophrenia: A longitudinal study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645483</td><td>Spaniel (2015)</td><td>Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647674</td><td>Spark (2021)</td><td>Distinguishing schizophrenia spectrum from non-spectrum disorders among young patients with first episode psychosis and at high clinical risk: The role of basic self-disturbance and neurocognition</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645051</td><td>Spencer (2008)</td><td>Sensory-evoked gamma oscillations in chronic schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646928</td><td>Spencer (2008)</td><td>gamma-Band auditory steady-state responses are impaired in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634113</td><td>Spencer (2018)</td><td>Cognitive Behavioral Therapy for antipsychotic-free schizophrenia spectrum disorders: Does therapy dose influence outcome?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633642</td><td>Spohn (1977)</td><td>Phenothiazine effects on psychological and psychophysiological dysfunction in chronic schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645050</td><td>Spoov (2020)</td><td>Separation of hallucinations from other positive symptoms by prolactin response to 12.5 microg I.V. TRH (mini-TRH test)</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646228</td><td>Spruth (2016)</td><td>A mistaken recurrent depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645183</td><td>Squarcina (2017)</td><td>A review of altered biochemistry in the anterior cingulate cortex of first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646802</td><td>Sridharan (2002)</td><td>"Hospitalisation in first-episode psychosis": Comment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647549</td><td>Srihari (2012)</td><td>Early intervention for psychosis in the U.S. public sector: a pragmatic randomized controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646992</td><td>Srihari (2015)</td><td>First-Episode Services for Psychotic Disorders in the U.S. Public Sector: a Pragmatic Randomized Controlled Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Trine Bjerke Johansen</span></td></tr><tr><td>61633586</td><td>Srivastava (1996)</td><td>Responsivity of Negative Symptoms to Typical Neuroleptic Drugsin Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645506</td><td>Stahl (2004)</td><td>Prophylactic antipsychotics: Do they keep you from catching schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645505</td><td>Stahl (2005)</td><td>Prophylactic antipsychotics: Do they keep you from catching schizophrenia?: Correction</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647772</td><td>Stain (2010)</td><td>The DEPTh randomised controlled trial of cognitive behaviour therapy targeting ultra high risk for psychosis: baseline comparisons for rural and urban youth</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645237</td><td>Stain (2012)</td><td>The relationship of verbal learning and verbal fluency with written story production: Implications for social functioning in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647771</td><td>Stain (2014)</td><td>DEPTh: randomized controlled trial of cognitive behavioral therapy for young people at ultra high risk for psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647487</td><td>Stant (2007)</td><td>Economic consequences of alternative medication strategies in first episode non-affective psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645915</td><td>Starzer (2020)</td><td>Opus 20, 20 year follow-up on the opus trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647512</td><td>Stauffer (2011)</td><td>Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648527</td><td>Steardo (2020)</td><td>Application of Support Vector Machine on fMRI Data as Biomarkers in Schizophrenia Diagnosis: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644979</td><td>Steare (2020)</td><td>Smartphone-delivered self-management for first-episode psychosis: the ARIES feasibility randomised controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634268</td><td>Steel (2020)</td><td>Positive memory training for the treatment of depression in schizophrenia: A randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646440</td><td>Stefanidou (2021)</td><td>Loneliness in early psychosis: a qualitative study exploring the views of mental health practitioners in early intervention services</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645119</td><td>Stefanovic (2016)</td><td>Role of sICAM-1 and sVCAM-1 as biomarkers in early and late stages of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646728</td><td>Steger (2012)</td><td>Impact of symptom resolution on medication adherence in first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644912</td><td>Steggles (2015)</td><td>Stages in the psychological resolution of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648476</td><td>Steiner (2017)</td><td>Assessment of insulin resistance among drug-naive patients with first-episode schizophrenia in the context of hormonal stress axis activation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646899</td><td>Steiner (2019)</td><td>Glucose homeostasis in major depression and schizophrenia: A comparison among drug-naive first-episode patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647924</td><td>Steinert (2005)</td><td>Compulsory admission and treatment in schizophrenia: A study of ethical attitudes in four European countries</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633781</td><td>Stern (1965)</td><td>Electrodermal responsiveness as related to psychiatric diagnosis and prognosis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646993</td><td>Stevens (1999)</td><td>First-episode schizophrenics show normal duration and topography of quasistationary EEG segments as compared to controls, during rest as well as during active tasks</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645289</td><td>Stevens (2013)</td><td>Reduction of crime in first-onset psychosis: a secondary analysis of the OPUS randomized trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648175</td><td>Stevens (2016)</td><td>Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646434</td><td>Stip (2019)</td><td>[Long-acting antipsychotics: The QAAPAPLE algorithm review]</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648533</td><td>Stip (2019)</td><td>Antipsychotiques a Action Prolongee: Revision de l'algorithme QAAPAPLE. [French]</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648532</td><td>Stip (2020)</td><td>"Antipsychotiques a action prolongee: Revision de l'algorithme QAAPAPLE": Corrigendum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645893</td><td>Stockings (2019)</td><td>Outpatient interventions for smoking cessation and reduction for adults with a mental disorder</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644813</td><td>Stogios (2020)</td><td>A Systematic Review and Meta-Analysis of Pharmacological Interventions for Reduction of Weight Gain in People With Schizophrenia: 2019 Update</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647115</td><td>Stogios (2020)</td><td>Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646893</td><td>Stone (2012)</td><td>Glutamate: Gateway to psychosis? [References]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648082</td><td>Stouten (2013)</td><td>Cognitive deficits and ethnicity: A cohort study of early psychosis patients in The Netherlands</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645468</td><td>Stouten (2019)</td><td>Psychopathology, cognition and outcome in Dutch and immigrant first-episode psychosis patients</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645677</td><td>Strakowski (1992)</td><td>Possible affective-state dependence of the Tridimensional Personality Questionnaire in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646488</td><td>Strakowski (1997)</td><td>Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647741</td><td>Strakowski (2003)</td><td>Diagnostic boundaries between bipolar disorder and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645430</td><td>Strakowski (2005)</td><td>Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646315</td><td>Stralin (2019)</td><td>Medication, hospitalizations and mortality in 5 years after first-episode psychosis in a Swedish nation-wide cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647516</td><td>Stralin (2019)</td><td>Early recovery and employment outcome 13 years after first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647031</td><td>Stralin (2021)</td><td>First episode psychosis: Register-based study of comorbid psychiatric disorders and medications before and after</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645283</td><td>Strasser (2004)</td><td>Rehospitalization Rates of Newly Diagnosed Schizophrenic Patients on Atypical Neuroleptic Medication</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647625</td><td>Strassman (1994)</td><td>Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644515</td><td>Strassnig (2007)</td><td>Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633599</td><td>Straube (1984)</td><td>Psychovegetative Ver√§nderung in der Schizophrenie</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633849</td><td>Straube (1989)</td><td>Findings significant with respect to short- and medium-term outcome in schizophrenia--a preliminary report.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634254</td><td>Strelchuk (2020)</td><td>Feasibility study of eye movement desensitisation and reprocessing (EMDR) in people with an at-risk mental state (ARMS) for psychosis: study protocol.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633715</td><td>Stroup (2006)</td><td>Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644595</td><td>Strous (2002)</td><td>Use of dehydro--epiandrosterone in the management of negative symptoms of schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647792</td><td>Strous (2003)</td><td>Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645578</td><td>Strous (2004)</td><td>Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646649</td><td>Strous (2004)</td><td>Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648627</td><td>Strous (2007)</td><td>Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: A randomized, double-blind placebo controlled trail</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644716</td><td>Struye (2016)</td><td>Toxic epidermal necrolysis related to paliperidone palmitate: First case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646791</td><td>Stubbs (2016)</td><td>How much physical activity do people with schizophrenia engage in? A systematic review, comparative meta-analysis and meta-regression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647082</td><td>Sturdevant (2012)</td><td>Factors associated with medication nonadherence in patients with first-episode schizophrenia and treatment strategies using the health belief model</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647696</td><td>Sturup (2016)</td><td>Discontinuation versus maintenance therapy with antipsychotic medication in schizophrenia -Tailor: a randomized controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644792</td><td>Sturup (2017)</td><td>TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645514</td><td>Suarez-Pinilla (2015)</td><td>Progressive structural brain changes and NRG1 gene variants in first-episode nonaffective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645141</td><td>Subotnik (2011)</td><td>Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647390</td><td>Subotnik (2011)</td><td>Effective ness of risperidone long-acting injection in the early phase of schizophrenia: relapse prevention and symptom reduction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647359</td><td>Subotnik (2012)</td><td>Effectiveness of long-acting injectable risperidone after an initial psychotic episode: relapse prevention and symptom reduction</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648188</td><td>Subotnik (2013)</td><td>Clinical advantages of long-acting injectable risperidone after an initial episode of schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646733</td><td>Subotnik (2014)</td><td>The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646420</td><td>Subotnik (2015)</td><td>Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646478</td><td>Suen (2019)</td><td>Late-onset psychosis and very-late-onset-schizophrenia-like-psychosis: an updated systematic review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647813</td><td>Suetani (2014)</td><td>De novo psychosis in a new onset Parkinson disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648487</td><td>Sugerman (2007)</td><td>A. Arthur Sugerman (1929-2007): Obituary</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634131</td><td>Sugg (2018)</td><td>Morita Therapy for depression (Morita Trial): a pilot randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648296</td><td>Sugranyes (2009)</td><td>Cannabis use and age of diagnosis of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644550</td><td>Suh (2020)</td><td>Visual exploration differences during relational memory encoding in early psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646748</td><td>Sukru (2018)</td><td>The impact of a six-month interpersonal group psychotherapy on functionality of patients with schizophrenia in a community mental health center</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646105</td><td>Sumiyoshi (2008)</td><td>Neurocognitive assessment and pharmacotherapy towards prevention of schizophrenia: What can we learn from first episode psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647937</td><td>Sun (2012)</td><td>A comparison study of ziprasidone versus risperidone in the treatment of female first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644632</td><td>Sun (2015)</td><td>Two patterns of white matter abnormalities in medication-naive patients with first-episode schizophrenia revealed by diffusion tensor imaging and cluster analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647669</td><td>Sun (2016)</td><td>Diurnal neurobiological alterations after exposure to clozapine in first-episode schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648746</td><td>Sun (2021)</td><td>Abnormal dynamic functional network connectivity of the mirror neuron system network and the mentalizing network in patients with adolescent-onset, first-episode, drug-naive schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648727</td><td>Sundram (2008)</td><td>Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633728</td><td>Sungur (2011)</td><td>Identifying an optimal treatment for schizophrenia: a 2-year randomized controlled trial comparing integrated care to a high-quality routine treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633669</td><td>Suzuki (1994)</td><td>Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645944</td><td>Suzuki (2004)</td><td>One-year Outcome After Response to ECT in Middle-aged and Elderly Patients With Intractable Catatonic Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645155</td><td>Suzuki (2011)</td><td>Risks of intermittent antipsychotic treatment in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647020</td><td>Svedberg (2001)</td><td>First-episode non-affective psychosis in a total urban population: A 5-year follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644639</td><td>Swadi (2010)</td><td>A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646285</td><td>Sydnor (2020)</td><td>A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647213</td><td>Syed (2020)</td><td>Elevated levels of IL-18 associated with schizophrenia and first episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645185</td><td>Szesko (2003)</td><td>Reversed cerebellar asymmetry in men with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646360</td><td>Szeszko (2012)</td><td>Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644492</td><td>Szeszko (2014)</td><td>White matter changes associated with antipsychotic treatment in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645956</td><td>Szeszko (2018)</td><td>Omega-3 polyunsaturated fatty acids may protect against white matter abnormalities found in early phase psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646386</td><td>Szeszko (2019)</td><td>Longitudinal investigation of the relationship between omega-3 essential fatty acids and social cognition in recent-onset psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647190</td><td>Szkultecka-Debek (2015)</td><td>Epidemiology and treatment guidelines of negative symptoms in schizophrenia in Central and Eastern Europe: A literature review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645164</td><td>Szota (2019)</td><td>The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648130</td><td>Szymanski (1994)</td><td>Clozapine response in treatment-refractory first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647847</td><td>Szymanski (1996)</td><td>Course of treatment response in first-episode and chronic schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648418</td><td>Tahiroglu (2009)</td><td>Atypical symptoms before the first episode in bipolar children and adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646848</td><td>Taiminen (2000)</td><td>Habituation of the blink reflex in first-episode schizophrenia, psychotic depression and non-psychotic depression</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647768</td><td>Tait (2005)</td><td>Design of the Birmingham early detection in untreated psychosis trial (REDIRECT): cluster randomised controlled trial of general practitioner education in detection of first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644808</td><td>Tait (2016)</td><td>A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644827</td><td>Takahashi (2006)</td><td>Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: An open trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644828</td><td>Takahashi (2006)</td><td>Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: An open-label trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645516</td><td>Takahashi (2009)</td><td>Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646975</td><td>Takahashi (2009)</td><td>Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647263</td><td>Takahashi (2009)</td><td>Efficacy and tolerability of aripiprazole in first-episode drug naive patients with schizophrenia: An open-label trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646974</td><td>Takahashi (2010)</td><td>A follow-up MRI study of the superior temporal subregions in schizotypal disorder and first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646976</td><td>Takahashi (2011)</td><td>A follow-up MRI study of the fusiform gyrus and middle and inferior temporal gyri in schizophrenia spectrum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646643</td><td>Takahashi (2013)</td><td>Increased pituitary volume in subjects at risk for psychosis and patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645298</td><td>Takahashi (2019)</td><td>Reduced pineal gland volume across the stages of schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646875</td><td>Takahashi (2020)</td><td>Gray Matter Changes in the Insular Cortex During the Course of the Schizophrenia Spectrum</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646721</td><td>Takase (2017)</td><td>The impacts of dopamine D2 receptor polymorphism and antipsychotic dosage on dopamine supersensitivity psychosis in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648558</td><td>Takeuchi (2012)</td><td>Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647645</td><td>Takeuchi (2019)</td><td>Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645327</td><td>Takeuchi (2020)</td><td>Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648449</td><td>Takiguchi (2017)</td><td>Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647014</td><td>Tan (2001)</td><td>First-episode psychosis in the military: A comparative study of prodromal symptoms</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646322</td><td>Tan (2019)</td><td>Medication adherence in first-episode psychosis patients in Singapore</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648084</td><td>Tan (2020)</td><td>Cognitive clusters in first-episode psychosis and their relationship to symptomatology and developmental scholastic performance</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648055</td><td>Tan (2021)</td><td>Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647081</td><td>Tandberg (2012)</td><td>Factors associated with occupational and academic status in patients with first-episode psychosis with a particular focus on neurocognition</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647995</td><td>Tandon (2009)</td><td>Comparative effectiveness of antipsychotics in the treatment of schizophrenia: guidelines for clinical practice</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645495</td><td>Tang (2014)</td><td>Prospective relationship between duration of untreated psychosis and 13-year clinical outcome: A first-episode psychosis study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645847</td><td>Tang (2020)</td><td>P300 as an index of transition to psychosis and of remission: Data from a clinical high risk for psychosis study and review of literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646866</td><td>Tao (2015)</td><td>Grey matter morphological anomalies in the caudate head in first-episode psychosis patients with delusions of reference</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646586</td><td>Tao (2020)</td><td>Insulin Resistance and Oxidative Stress: In Relation to Cognitive Function and Psychopathology in Drug-Naive, First-Episode Drug-Free Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633927</td><td>Tardy (2014)</td><td>Haloperidol versus low‚Äêpotency first‚Äêgeneration antipsychotic drugs for schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633773</td><td>Targum (1983)</td><td>Neuroendocrine Challenge Studies in Clinical Psychiatry</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647016</td><td>Tarricone (2012)</td><td>First-episode psychosis at the West Bologna Community Mental Health Centre: Results of an 8-year prospective study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645161</td><td>Tarricone (2016)</td><td>Risk of psychosis and internal migration: Results from the Bologna first episode psychosis study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646692</td><td>Tarrier (2000)</td><td>The importance of psychosocial interventions and patient involvement in the treatment of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59648022</td><td>Tarrier (2004)</td><td>Cognitive-behavioural therapy in first-episode and early schizophrenia: 18-month follow-up of a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634157</td><td>Tarsitani (2018)</td><td>The Reality Distortion and Thought Disorganisation Dimensions</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644802</td><td>Tatar (2020)</td><td>A systematic review of technology-based psychotherapeutic interventions for decreasing cannabis use in patients with psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648198</td><td>Tauscher (2001)</td><td>Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645125</td><td>Tauscher-Wisniewski (2002)</td><td>The role of maintenance pharmacotherapy in achieving recovery from a first episode of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645417</td><td>Tauscher-Wisniewski (2002)</td><td>Quetiapine: An effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648258</td><td>Tauscher-Wisniewski (2002)</td><td>Caudate volume changes in first episode psychosis parallel the effects of normal aging: A 5-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644529</td><td>Tauscher-Wisniewski (2005)</td><td>Volumetric MRI measurement of caudate nuclei in antipsychotic-naive patients suffering from a first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633665</td><td>Taylor (2003)</td><td>A prospective follow-up of quality of life, wellbeing, side effects and compliance in the treatment of first episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647130</td><td>Taylor (2012)</td><td>Examining the effectiveness of antipsychotic medication in first-episode psychosis</td><td>(I) Included</td><td></td><td></td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td></tr><tr><td>59648677</td><td>Taylor (2012)</td><td>Advances in the understanding and challenges facing the management of first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645002</td><td>Taylor (2013)</td><td>Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648201</td><td>Taylor (2017)</td><td>Choice of antipsychotic to treat first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648507</td><td>Taylor (2019)</td><td>Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646757</td><td>Taylor (2020)</td><td>iMAgery focused psychological therapy for persecutory delusions in PSychosis (iMAPS): a multiple baseline experimental case series</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645092</td><td>Tchernev (2020)</td><td>Schizophrenia as possible key factor for melanoma development! analysis based on a clinical case!</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644765</td><td>Tctr (2017)</td><td>Thai Health Improvement Profile intervention to prevent obesity in people with early psychosis (HIP-T First)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646628</td><td>Teasdale (2015)</td><td>Individual dietetic consultations in first episode psychosis: a novel intervention to reduce cardiometabolic risk</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646007</td><td>Teasdale (2016)</td><td>Nutrition interventions in people with severe mental illness: Novel strategies for addressing physical health co-morbidity in a high-risk population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647348</td><td>Teasdale (2019)</td><td>The effectiveness of the Keeping the Body in Mind Xtend pilot lifestyle program on dietary intake in first-episode psychosis: two-year outcomes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633606</td><td>Tegeler (1990)</td><td>Wann, wie lange und bei welchen Zustandsbildern ist eine neuroleptische Langzeit-(Depot-)therapie indiziert?</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646426</td><td>Teitelbaum (2019)</td><td>LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN SCHIZOPHRENIA</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633901</td><td>Teja (1975)</td><td>Tranquilizers or Anti-Depressants for Chronic Schizophrenics: A Long Term Study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648544</td><td>Tek (2016)</td><td>Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648545</td><td>Tek (2016)</td><td>Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645559</td><td>Tekin (2016)</td><td>Prevalence of substance use in patients diagnosed with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645770</td><td>Templeman (2004)</td><td>Pharmacogenetics of Antipsychotic Drug Side Effects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647457</td><td>Tenjin (2012)</td><td>Effect of blonanserin on cognitive function in antipsychotic-na√Øve first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645530</td><td>Tenjin (2013)</td><td>Profile of blonanserin for the treatment of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645188</td><td>Tenjin (2017)</td><td>Retraction: 'Effect of blonanserin on cognitive function in antipsychotic-naive first-episode schizophrenia'</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647700</td><td>Teodorescu (2017)</td><td>Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633525</td><td>Terkelsen (1995)</td><td>Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647945</td><td>Tessier (2010)</td><td>A comparison of the metabolic effects of Paliperidone ER vs. oral olanzapine in recently diagnosed and chronic patients with schizophrenia - Results of a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646958</td><td>Tewarie (2016)</td><td>From querulous neurosis to querulous delusion: The psychopathological aspects of persistent dysfunctional complaining. [Dutch]</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645531</td><td>Teyssier (2013)</td><td>Prodromes of schizophrenia: Consensus or confusion?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646282</td><td>Thakore (2004)</td><td>Metabolic disturbance in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646272</td><td>Thakore (2005)</td><td>Metabolic syndrome and schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647427</td><td>THE EFFECT of LOW-FREQUENCY... (2021)</td><td>THE EFFECT of LOW-FREQUENCY REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION ASSISTED DRUG in TREATING FIRST-EPISODE SCHIZOPHRENIA and ITS EFFECTS on SERUM HOMOCYSTEINE, BRAIN DERIVED NEUROTROPHIC FACTOR and COGNITIVE FUNCTION</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646896</td><td>Theberge (2002)</td><td>Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644862</td><td>Theethira (2009)</td><td>Subacute sclerosing panencephalitis presenting as schizophreniform disorder</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648614</td><td>Thepwiwatjit (2018)</td><td>Anti-NMDA-receptor encephalitis of Thai patients: Description of a consecutive series of patients over 10 years and a literature review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648125</td><td>Thien (2018)</td><td>Clozapine use in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647790</td><td>Thien (2019)</td><td>Delays and barriers to the commencement of clozapine in eligible people with a psychotic disorder: A literature review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647717</td><td>Thienel (2012)</td><td>Differential effect of risperidone versus haloperidol on brain activation in firstepisode schizophrenia patients: a multicentre fMRI study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648245</td><td>Thomann (2009)</td><td>Cerebellar substructures and neurological soft signs in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633536</td><td>Thomas (2013)</td><td>Les rechutes : causes et cons√©quences</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647091</td><td>Thomas (2019)</td><td>F131. DEMOGRAPHIC, INTERPERSONAL, NEUROCOGNITIVE, AND ATTITUDINAL PREDICTORS OF SHARED DECISION-MAKING AMONG SERVICE USERS WITH EARLY PSYCHOSIS...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647785</td><td>Thomas (2019)</td><td>Demographic, interpersonal, neurocognitive, and attitudinal predictors of shared decisionmaking among service users with early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648041</td><td>Thomas (2021)</td><td>Cognitive performance in early, treatment-resistant psychosis patients: Could cognitive control play a role in persistent symptoms?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644715</td><td>Thompson (2007)</td><td>Tracking Alzheimer's disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644731</td><td>Thompson (2009)</td><td>Time-lapse mapping of cortical changes in schizophrenia with different treatments</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644786</td><td>Thompson (2011)</td><td>Targeted intervention to improve monitoring of antipsychotic-induced weight gain and metabolic disturbance in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644966</td><td>Thompson (2012)</td><td>Social cognition in clinical "at risk" for psychosis and first episode psychosis populations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645894</td><td>Thompson (2016)</td><td>Outcomes of Maintenance Antipsychotic Treatment versus Discontinuation Strategies Following Remission from First Episode Psychosis: a Systematic Review and Meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633521</td><td>Thompson (2016)</td><td>Views of early psychosis clinicians on discontinuation of antipsychotic medication following symptom remission in first episode psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646358</td><td>Thompson (2018)</td><td>Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647055</td><td>Thompson (2020)</td><td>A Feasibility and Acceptability Trial of Social Cognitive Therapy in Early Psychosis Delivered Through a Virtual World: the VEEP Study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634259</td><td>Thompson (2020)</td><td>Psychosis-spectrum experiences linked to specific psychotherapy readiness domains among psychiatrically hospitalized adolescents.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646576</td><td>Thorup (2005)</td><td>Integrated treatment ameliorates negative symptoms in first episode psychosis--results from the Danish OPUS trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646960</td><td>Thorup (2007)</td><td>Frequency and predictive values of first rank symptoms at baseline among 362 young adult patients with first-episode schizophrenia Results from the Danish OPUS study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646925</td><td>Thorup (2014)</td><td>Gender differences in first-episode psychosis at 5-year follow-up - two different courses of disease? Results from the OPUS study at 5-year follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648759</td><td>Thun (2016)</td><td>The 40-Hz auditory steady-state response in patients with schizophrenia a meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648426</td><td>Tiffin (2009)</td><td>Attitudes and practice in relation to first-episode psychosis: A survey of child and adult psychiatrists</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647375</td><td>Tiihonen (2006)</td><td>Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645687</td><td>Tiihonen (2012)</td><td>Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645158</td><td>Tiihonen (2018)</td><td>Risk of treatment failure: Response to Ghosh and Noble</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645201</td><td>Tiihonen (2018)</td><td>Response to the editorial on antipsychotics and mortality in a nationwide cohort of 29,823 patients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648762</td><td>Tiihonen (2018)</td><td>"20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia": Correction</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648459</td><td>Tiihonen (2019)</td><td>Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645878</td><td>Tiihonen (2020)</td><td>P.186 Molecular pathways underlying schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646216</td><td>Tiihonen (2021)</td><td>Molecular signaling pathways underlying schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647177</td><td>Tindall (2018)</td><td>Essential ingredients of engagement when working alongside people after their first episode of psychosis: A qualitative meta-synthesis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645478</td><td>Tizon (2011)</td><td>A psychological and communitarian approach to treating early psychoses: A service description with some initial findings</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644727</td><td>TMS-EEG signatures of... (2019)</td><td>TMS-EEG signatures of glutamatergic neurotransmission in the human cortex</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648774</td><td>Tocco (2019)</td><td>5.28 LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: REMISSION AND RECOVERY DURING 2 YEARS OF OPEN-LABEL TREATMENT</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>61633930</td><td>Tohen (1992)</td><td>The McLean First-episode Psychosis Project: Six-month Recovery and Recurrence Outcome</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646919</td><td>Tohen (1997)</td><td>Gender Differences in the Response of Olanzapine Versus Haloperidol in the Treatment of First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633614</td><td>Tohen (2000)</td><td>The McLean‚ÄìHarvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644687</td><td>Tollefson (1997)</td><td>Treatment consideration for comorbid mood disorders in schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648453</td><td>Tomasik (2019)</td><td>Association of insulin resistance with schizophrenia polygenic risk score and response to antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647187</td><td>Tomassi (2017)</td><td>Epigenetics and gene expression profile in first-episode psychosis: The role of childhood trauma</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633803</td><td>Tombaugh (1982)</td><td>A discriminating case against anhedonia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646080</td><td>Tomer (1989)</td><td>Neuroleptics reverse attention asymmetries in schizophrenic patients</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647672</td><td>Tomlinson (2014)</td><td>Distress and negative experiences of the caregiving relationship in early psychosis: Does social cognition play a role?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647699</td><td>Tonna (2019)</td><td>Dimensional structure of first episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648564</td><td>Torniainen (2015)</td><td>Antipsychotic treatment and mortality in schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648563</td><td>Torniainen (2016)</td><td>"Antipsychotic treatment and mortality in schizophrenia": Erratum</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648668</td><td>Torrent (2018)</td><td>Affective versus non-affective first episode psychoses: A longitudinal study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634003</td><td>Tourney (1969)</td><td>History of biological psychiatry in America.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648057</td><td>Townsend (2001)</td><td>Cognitive functioning in stabilized first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646931</td><td>Townsend (2004)</td><td>Gains in Speeded Information Processing Following Clozapine Treatment of Schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647158</td><td>Traber-Walker (2019)</td><td>Evaluation of the Combined Treatment Approach "Robin" (Standardized Manual and Smartphone App) for Adolescents at Clinical High Risk for Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644710</td><td>Trampush (2013)</td><td>Trajectory of neurocognition in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645243</td><td>Trampush (2015)</td><td>Relationship of cognition to clinical response in first-episode schizophrenia spectrum disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646267</td><td>Trauelsen (2016)</td><td>Metacognition in first-episode psychosis and its association with positive and negative symptom profiles</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646432</td><td>Tremblay (2018)</td><td>Long-acting aripiprazole in first-episode psychosis: Does one size fit all?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646433</td><td>Tremblay (2019)</td><td>Long-acting aripiprazole in first-episode psychosis: does one size fit all?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648105</td><td>Tripoli (2020)</td><td>Cognition, metacognition and social cognition after a first episode psychosis. preliminary results from a 5-year-follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647753</td><td>Tripp (2017)</td><td>Development and piloting of a cognitive-behavioral selfmanagement program for patients with inflammatory bowel disease: an early stage update</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648102</td><td>Trojano (2018)</td><td>Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646917</td><td>Troudet (2020)</td><td>Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645796</td><td>Trovao (2019)</td><td>Peripheral Biomarkers for First-Episode Psychosis-Opportunities from the Neuroinflammatory Hypothesis of Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646388</td><td>Trzesniak (2012)</td><td>Longitudinal follow-up of cavum septum pellucidum and adhesio interthalamica alterations in first-episode psychosis: A population-based MRI study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648379</td><td>Tsai (2013)</td><td>Benzoate, a d-amino acid oxidase inhibitor, for treatment of early-phase alzheimer's disease: a randomized, double-blind, placebo-controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647636</td><td>Tseng (2017)</td><td>Dopamine transporter availability in drug-naive patients with schizophrenia and later psychotic symptoms severity</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633870</td><td>Tsuang (1971)</td><td>Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646890</td><td>Tsugawa (2019)</td><td>Glutathione levels and activities of glutathione metabolism enzymes in patients with schizophrenia: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646390</td><td>Tsujino (2012)</td><td>Longitudinal effects of perospirone in patients with at-risk mental state</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646594</td><td>Tully (2018)</td><td>Innovative approaches to early identification and treatment: using mobile health technology to improve outcomes in psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633647</td><td>Tune (1981)</td><td>Acute extrapyramidal side effects: Serum levels of neuroleptics and anticholinergics</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644679</td><td>Turcin (2018)</td><td>Treatment of a patient with psychotic disorder undergoing haemodialysis: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645151</td><td>Turk (2017)</td><td>Risperidone (oral forms) for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646983</td><td>Turk (2017)</td><td>Fluphenazine (dose) for people with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648364</td><td>Turk (2017)</td><td>Blonanserin versus risperidone for schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647109</td><td>Turkington (2016)</td><td>Exposure to political violence in Northern Ireland and outcome of first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648142</td><td>Turkmani (2019)</td><td>Clozapine (generic versus branded) for people with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647163</td><td>Turner (2008)</td><td>Evaluating psychosocial interventions in first-episode psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646475</td><td>Tyls (2019)</td><td>Latent Schizencephaly With Psychotic Phenotype or Schizophrenia With Schizencephaly? A Case Report and Review of the Literature</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633515</td><td>U√ßok (2006)</td><td>One year outcome in first episode schizophrenia. Predictors of relapse.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647294</td><td>Ucok (2015)</td><td>Effects of paliperidone extended release on functioning level and symptoms of patients with recent onset schizophrenia: An open-label, single-arm, flexible-dose, 12-months follow-up study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645275</td><td>Ucok (2020)</td><td>Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633839</td><td>Uhlenhuth (1966)</td><td>Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647538</td><td>Undurraga (2014)</td><td>Early medication discontinuation on long-term recovery outcome in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647835</td><td>Upthegrove (2013)</td><td>Cultural and social influences of negative illness appraisals in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647825</td><td>Upthegrove (2014)</td><td>Cytokine function in medication-naive first episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645992</td><td>Urban-Kowalczyk (2019)</td><td>Odor perception and hedonics in chronic schizophrenia and in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648068</td><td>Urben (2012)</td><td>Cognitive efficacy of quetiapine in early-onset first-episode psychosis: A 12-week open label trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648083</td><td>Uren (2017)</td><td>Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644512</td><td>Ursuliak (2015)</td><td>Wellness program for people with early psychosis: Promoting skills and attitudes for recovery</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648190</td><td>Ursuliak (2015)</td><td>Claymation art therapy as adjunctive treatment to promote recovery in early psychosis: a pilot study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646334</td><td>Usher (2019)</td><td>Meals, Mindfulness, & Moving Forward: a feasibility study to a multi-modal lifestyle approach in early psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645144</td><td>Ustohal (2017)</td><td>Risperidone increases the cortical silent period in drug-naive patients with first-episode schizophrenia: A transcranial magnetic stimulation study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645876</td><td>Uygun (2021)</td><td>P.311 Evaluation of serum vitamin B12, folate and ferritin levels in children and adolescents with anxiety disorders</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645582</td><td>Uzenoff (2008)</td><td>A preliminary trial of adherence-coping-education (ACE) therapy for early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648724</td><td>Vaessen (2019)</td><td>Act in daily life in early psychosis: An ecological momentary intervention approach</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646508</td><td>Valderrama (2017)</td><td>Isotretinoin therapy for acne vulgaris and first episode psychosis in an adolescent patient</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646572</td><td>Valencia (2012)</td><td>Integrated treatment to achieve functional recovery for first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633962</td><td>Valenstein (1998)</td><td>Agreement Between Seriously Mentally Ill Veterans and Their Clinicians About Medication Compliance</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644461</td><td>Valentine (2020)</td><td>Young People's Experience of a Long-Term Social Media-Based Intervention for First-Episode Psychosis: qualitative Analysis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648365</td><td>Valentine (2020)</td><td>Blended digital and face-to-face care for first-episode psychosis treatment in young people: qualitative study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645208</td><td>Valevski (2001)</td><td>Response of catatonia to Risperidone: Two case reports</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646185</td><td>Valiente-Gomez (2020)</td><td>A Multicenter Phase II RCT to Compare the Effectiveness of EMDR Versus TAU in Patients With a First-Episode Psychosis and Psychological Trauma: a Protocol Design</td><td>(I) Included</td><td><span >Tiril Borge</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59646597</td><td>V√§lim√§ki (2012)</td><td>Information and communication technology‚Äêbased cognitive remediation for supporting treatment compliance for people with serious mental illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645170</td><td>V√§lim√§ki (2016)</td><td>Risk assessment for aggressive behaviour in schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648649</td><td>Valkonen-Korhonen (2003)</td><td>Altered auditory processing in acutely psychotic never-medicated first-episode patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647223</td><td>Valkonen-Korhonen (2005)</td><td>Electrical brain responses evoked by human faces in acute psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645182</td><td>Valle (2020)</td><td>Review of early intervention programmes in psychosis: Implementation proposal for Peru</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645015</td><td>van Bruggen (2009)</td><td>Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645259</td><td>van de Kerkhof (2015)</td><td>Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645191</td><td>Van Der Gaag (2012)</td><td>The results of a specific CBT intervention in young help-seeking patients with social decline and an ultra-high risk for developing a first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645553</td><td>van der Gaag (2013)</td><td>Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648254</td><td>van der Gaag (2013)</td><td>CBT for those at risk of a first episode psychosis: Evidence-based psychotherapy for people with an 'at risk mental state'</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645866</td><td>Van Der Pluijm (2020)</td><td>P.523 Neuromelanin MRI as biomarker for treatment resistance in first episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647984</td><td>van der Ven (2012)</td><td>Comparing the clinical presentation of first-episode psychosis across different migrant and ethnic minority groups in Montreal, Quebec</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645415</td><td>van der Ven (2020)</td><td>Racial-Ethnic Differences in Service Use Patterns Among Young, Commercially Insured Individuals With Recent-Onset Psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647653</td><td>Van Duin (2018)</td><td>Does cognitive remediation enhance the vocational recovery of young people with first episode psychosis using individual placement and support? Results of the CREW study: a multisite randomized controlled trial in the Netherlands</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644799</td><td>van Haren (2010)</td><td>A systematic review of the effects of antipsychotic drugs on brain volume: Comment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646194</td><td>van Harten (2009)</td><td>Movement disorders should be a criterion for schizophrenia in DSM-V</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633968</td><td>van Hoof (2002)</td><td>The abnormal development of drive and guidance mechanisms in the brain: the pathogenesis of schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633553</td><td>van Meijel (2003)</td><td>Relapse prevention in patients with schizophrenia : A nursing intervention study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647548</td><td>Van Meijel (2006)</td><td>Early intervention has no effect on symptoms in people with first episode, non-affective psychosis, although it may improve overall function and medication adherence</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645996</td><td>van Nimwegen (2008)</td><td>Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647442</td><td>van Nimwegen-Campailla (2010)</td><td>Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634203</td><td>van Praag (1978)</td><td>Neuroleptics I: Development, Therapeutic Effects, Indications</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633678</td><td>Van Putten (1983)</td><td>Plasma levels of thiothixene by radioreceptor assay: clinical usefulness.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634047</td><td>Van Putten (1991)</td><td>Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646471</td><td>van Veelen (2010)</td><td>Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645300</td><td>van Veelen (2011)</td><td>Reduced language lateralization in first-episode medication-naive schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645587</td><td>van Veelen (2011)</td><td>Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647743</td><td>Vancampfort (2016)</td><td>Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648277</td><td>Vancampfort (2017)</td><td>Cardiorespiratory Fitness in Severe Mental Illness: A Systematic Review and Meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646962</td><td>Vanelle (2005)</td><td>French Expert Consensus Guidelines for long-term treatment in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646370</td><td>Vangala (2012)</td><td>Loxapine inhaler for psychosis‚Äêinduced aggression or agitation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645675</td><td>Van't (2020)</td><td>Poster presentation: hamlett: handling antipsychotic medication, a longterm evaluation of targeted treatment a pragmatic single-blind randomised controlled trial of continuation versus discontinuation of psychotic medication</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646306</td><td>Vanurova (2001)</td><td>Menstrual cycle phase and the probability of the recurrence of the illness in female patients with the first episode of schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648141</td><td>Vaquero-Baez (2019)</td><td>Clozapine and desmethylclozapine: Correlation with neutrophils and leucocytes counting in Mexican patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634238</td><td>Varese (2020)</td><td>Eye movement desensitization and reprocessing therapy for psychosis (EMDRp): Protocol of a feasibility randomized controlled trial with early intervention service users</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646734</td><td>Vargas-Caceres (2021)</td><td>The Impact of Psychosis on Sexual Functioning: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646694</td><td>Varley (2009)</td><td>Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645749</td><td>Vasiliu (2019)</td><td>Pharmacological treatment of cannabis use disorder and schizophrenia spectrum disorders dually diagnosed patients - Current state of research</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644654</td><td>Vasiliu (2020)</td><td>Treatment strategies for ultraresistant schizophrenias</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645689</td><td>Vassos (2017)</td><td>Polygenic risk score in a sample of first episode psychosis discriminates schizophrenia from other psychoses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647134</td><td>Vassos (2017)</td><td>An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645647</td><td>Vayisoglu (2016)</td><td>Predictive factors of antipsychotic treatment response in patients with first episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645046</td><td>Vazquez-Bourgon (2010)</td><td>Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646403</td><td>V√°zquez-Bourgon (2018)</td><td>Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-na√Øve patients with a first-episode of non-affective psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647455</td><td>Vazquez-Bourgon (2019)</td><td>Effect of cannabis on weight and metabolism in first-episode non-affective psychosis: Results from a three-year longitudinal study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648297</td><td>Vazquez-Bourgon (2019)</td><td>Cannabis consumption and non-alcoholic fatty liver disease. A three years longitudinal study in first episode non-affective psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648779</td><td>Vazquez-Bourgon (2020)</td><td>A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: a pragmatic clinical trial in first episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644686</td><td>Vazquez-Bourgon (2021)</td><td>Treatment discontinuation impact on long-term (10-year) weight gain and lipid metabolism in first-episode psychosis: Results from the PAFIP-10 cohort</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646310</td><td>Veerman (2017)</td><td>Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648455</td><td>Vehof (2011)</td><td>Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633744</td><td>Veigl (1989)</td><td>The uses and limitations of calmodulin antagonists.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646825</td><td>Velakoulis (2006)</td><td>Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646503</td><td>Velden-Hegelstad (2014)</td><td>JobPrescription: a Scandinavian initiative to optimize work and study engagement or young people with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648103</td><td>Velligan (1995)</td><td>COGNITIVE ADAPTATION TRAINING: COMPENSATORY STRATEGIES IN PSYCHOSOCIAL INTERVENTIONS WITH SCHIZOPHRENIC PATIENTS CONFERENCE ABSTRACT - Vth International Congress on Schizophrenia Research Wormsprings VA, USA 6-12 April 1995</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644702</td><td>Velthorst (2013)</td><td>Transition to first episode psychosis in ultra high risk populations: Does baseline functioning hold the key?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646380</td><td>Venkatasubramanian (2013)</td><td>A longitudinal study of relation between side-effects and clinical improvement in schizophrenia: Is there a neuro-metabolic threshold for second generation antipsychotics?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647084</td><td>Ventriglio (2021)</td><td>Factors Associated to the Onset of Mental Illness Among Hospitalized Migrants to Italy: A Chart Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648037</td><td>Ventura (2019)</td><td>Cognitive remediation can improve negative symptoms and social functioning in first-episode schizophrenia: a randomized controlled trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59648136</td><td>Vera (2012)</td><td>Clozapine as treatment of first choice in first psychotic episodes. What do we know?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647438</td><td>Verdolini (2021)</td><td>The effect of family environment and psychiatric family history on psychosocial functioning in first-episode psychosis at baseline and after 2 years</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644970</td><td>Verdoux (2002)</td><td>Social and clinical consequences of cognitive deficits in early psychosis: A two-year follow-up study of first-admitted patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646462</td><td>Verdoux (2005)</td><td>Letter to the Editors: Impact of visits from pharmaceutical company Representatives on antipsychotic prescription in primary care</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648169</td><td>Verdoux (2019)</td><td>Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648483</td><td>Verhaegh (2007)</td><td>Assertive Community Treatment for patients with a first episode psychosis. Model fidelity and specific adaptations for particular target groups</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645693</td><td>Verma (2005)</td><td>Plasma Risperidone Levels and Clinical Response in Patients With First-episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648666</td><td>Verma (2005)</td><td>Aggression in Asian Patients with First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646277</td><td>Verma (2009)</td><td>Metabolic risk factors in drug-naive patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647396</td><td>Verma (2009)</td><td>Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644821</td><td>Verma (2012)</td><td>Symptomatic and functional remission in patients with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645898</td><td>Vernal (2015)</td><td>Outcome of youth with early-phase schizophrenia-spectrum disorders and psychosis not otherwise specified treated with second-generation antipsychotics: 12 week results from a prospective, naturalistic cohort study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644952</td><td>Veru (2018)</td><td>Socioeconomic deprivation and blood lipid levels in first-episode psychosis: Implications for cardiovascular risk</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644961</td><td>Veru-Lesmes (2018)</td><td>Social determinants of health and preclinical glycemic control in newly diagnosed first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648689</td><td>Veru-Lesmes (2021)</td><td>Adipose tissue dysregulation at the onset of psychosis: Adipokines and social determinants of health</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646375</td><td>Victorsson (2020)</td><td>Lower thalamic dopamine D2-receptor binding in drug-naive patients with psychosis-a replication study using positron emission tomography</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647006</td><td>Vidailhet (2013)</td><td>First-episode psychosis, cognitive difficulties and remediation</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645351</td><td>Vidarsdottir (2018)</td><td>A randomized, controlled trial on integrated cognitive remediation for early psychosis: effectiveness and factors associated with treatment response</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646570</td><td>Vidarsdottir (2019)</td><td>Integrative cognitive remediation for early psychosis: results from a randomized controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648263</td><td>Vidarsdottir (2020)</td><td>Case Report: Successful Implementation of Integrative Cognitive Remediation for Early Psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645279</td><td>Vidgen (2012)</td><td>Relapse prevention for schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646115</td><td>Vieira (2021)</td><td>Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644588</td><td>Vieta (2005)</td><td>The Use of Placebo in Clinical Trials on Bipolar Disorder: A New Approach for an Old Debate</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648166</td><td>Vignaud (2019)</td><td>Clinical Effects of Mindfulness-Based Intervention in Patients With First Episode Psychosis and in Individuals With Ultra-High Risk for Transition to Psychosis: A Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644626</td><td>Vila-Badia (2021)</td><td>Types, prevalence and gender differences of childhood trauma in first-episode psychosis. What is the evidence that childhood trauma is related to symptoms and functional outcomes in first episode psychosis? A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647408</td><td>Vinay (2011)</td><td>Effect of risperidone on metabolic parameters in antipsychotic-naive schizophrenia: A prospective one year follow-up study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647918</td><td>Vinckier (2016)</td><td>Confidence and psychosis: A neuro-computational account of contingency learning disruption by NMDA blockade</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646065</td><td>Vinogradov (2010)</td><td>Neuroplasticity-based cognitive training in early psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646256</td><td>Vishnupriya (2016)</td><td>Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults-a randomized, open labelled, single centered study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646634</td><td>Vogel (2016)</td><td>Increased superior frontal gyrus activation during working memory processing in psychosis: Significant relation to cumulative antipsychotic medication and to negative symptoms</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646265</td><td>Vohs (2018)</td><td>Metacognitive reflection and insight therapy for early psychosis: A preliminary study of a novel integrative psychotherapy</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>61633963</td><td>Volavka (1996)</td><td>Placebo Washout in Trials of Antipsychotic Drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648521</td><td>Volavka (2008)</td><td>Are all antipsychotics equal?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647248</td><td>Volavka (2011)</td><td>Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST)</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647381</td><td>Volavka (2014)</td><td>Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646800</td><td>Volavka (2016)</td><td>Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647380</td><td>Volavka (2016)</td><td>Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644558</td><td>Volavka (2018)</td><td>Very long-term outcome of schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633952</td><td>Volz (2011)</td><td>Psychopharmakotherapie: klinisch-empirische Grundlagen</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647513</td><td>Von Hardenberg (2019)</td><td>Early response to antipsychotic medication in adolescents with first-episode psychosis predictor of ultimate response and remission</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634204</td><td>Von Schenker (1963)</td><td>Phenothiazine und Azaphenothiazine als Heilmittel</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644965</td><td>Voulgaropoulou (2020)</td><td>Social Cognition in Psychosis: Adapting a Behavioral Task for fMRI Purposes</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634050</td><td>W (1983)</td><td>[Indications for long-term neuroleptic medication--standard procedure or individual prognosis-guided intervention? A prospective study of the clinical treatment model].</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633833</td><td>W (1985)</td><td>One-year outcome of schizophrenic patients--the interaction of chronicity and neuroleptic treatment.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645742</td><td>Waddington (2001)</td><td>Pharmacotherapy of cognitive impairment in schizophrenia: Variant approaches</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647161</td><td>Wadell (2016)</td><td>Evaluation and violence risk assessment in early psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648694</td><td>Wadell (2018)</td><td>Addressing Systemic Barriers for the Use of Long-Acting Injectables in Early Psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633976</td><td>Waehrens (1980)</td><td>Antidepressant drugs in anergic schizophrenia: A DOUBLE-BLIND CROSS-OVER STUDY WITH MAPROTILINE AND PLACEBO</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634193</td><td>Wager (1995)</td><td>Psychopharmacology in Clinical Practice</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646037</td><td>Wagner (2013)</td><td>New findings from longitudinal and treatment studies in youth</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644506</td><td>Wainwright (2015)</td><td>What do relatives experience when supporting someone in early psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634228</td><td>Waite (2020)</td><td>Treating sleep problems in young people at ultra-high-risk of psychosis: study protocol for a single-blind parallel group randomised controlled feasibility trial (SleepWell)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647148</td><td>Wakefield (2018)</td><td>The evidence base of acceptance and commitment therapy (ACT) in psychosis: A systematic review</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646879</td><td>Waldheter (2008)</td><td>The Graduated Recovery Intervention Program for first episode psychosis: Treatment development and preliminary data</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647754</td><td>Waldheter (2008)</td><td>Development and initial evaluation of a psychosocial intervention for individuals recovering from a first episode of non-affective psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633699</td><td>Waldrop (1961)</td><td>A comparison of the therapeutic and toxic effects of thioridazine and chlorpromazine in chronic schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633722</td><td>Waller (2014)</td><td>The effects of a brief CBT intervention, delivered by frontline mental health staff, to promote recovery in people with psychosis and comorbid anxiety or depression (the GOALS study): study protocol for a randomized controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646464</td><td>Walloch (2005)</td><td>Letter To The Editor: Electroconvulsive Therapy Administered After Surgical Management of Epilepsy: A Case Report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646350</td><td>Walsh (2005)</td><td>Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645761</td><td>Walter (2001)</td><td>The pharmacologic treatment of the early phase of first-episode psychosis in youths</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646818</td><td>Walter (2012)</td><td>Hippocampal volume in subjects at high risk of psychosis: A longitudinal MRI study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646205</td><td>Walterfang (2008)</td><td>"Morphology of the corpus callosum at different stages of schizophrenia: Cross-sectional study in first-episode and chronic illness": Erratum</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646195</td><td>Walther (2020)</td><td>Movement disorder and sensorimotor abnormalities in schizophrenia and other psychoses - European consensus on assessment and perspectives</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647895</td><td>Wang (2003)</td><td>Controlled study on long-term effect of cognitive behavior intervention on first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span class='complete'>Tiril Borge</span></td></tr><tr><td>59646608</td><td>Wang (2005)</td><td>Influence of earlier rehabilitative interventions on the emotions and the ability of daily living of patients following the first onset of acute stroke</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646609</td><td>Wang (2005)</td><td>Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648063</td><td>Wang (2005)</td><td>Cognitive Function and P300 Potentials in First-Episode Schizophrenia Treated with Quetiapine and Risperidone</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644560</td><td>Wang (2006)</td><td>Verbal memory performance of mildly to moderately depressed outpatient younger adults</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645031</td><td>Wang (2007)</td><td>Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648466</td><td>Wang (2009)</td><td>Association between the influences of cigarette smoking on cognitive functions and smoking behaviors in male patients with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646257</td><td>Wang (2012)</td><td>Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644481</td><td>Wang (2013)</td><td>White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645184</td><td>Wang (2013)</td><td>Reversible skin rash in a bipolar disorder patient on first use of lithium</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645368</td><td>Wang (2013)</td><td>A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648072</td><td>Wang (2013)</td><td>Cognitive effects of atypical antipsychotic drugs in first-episode drug-na√Øve schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647331</td><td>Wang (2014)</td><td>Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647462</td><td>Wang (2014)</td><td>The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646872</td><td>Wang (2017)</td><td>Gray matter morphological anomalies in the cerebellar vermis in first-episode schizophrenia patients with cognitive deficits</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646716</td><td>Wang (2018)</td><td>Impaired binocular depth perception in first-episode drug-naive patients with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647403</td><td>Wang (2019)</td><td>Effect of second-generation antipsychotics on brain network topology in first-episode schizophrenia: A longitudinal rs-fMRI study</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648353</td><td>Wang (2019)</td><td>"brain Connectivity Deviates by Sex and Hemisphere in the First Episode of Schizophrenia" - A Route to the Genetic Basis of Language and Psychosis?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634286</td><td>Wang (2019)</td><td>Cognitive-behavioural therapy for personal recovery of patients with schizophrenia: A systematic review and meta-analysis.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645196</td><td>Wang (2020)</td><td>Resting-state functional hypoconnectivity of amygdala in clinical high risk state and first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646260</td><td>Wang (2020)</td><td>Metformin attenuates liver fat content: Finding from schizophrenia patients with olanzapine-induced weight gain</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646269</td><td>Wang (2020)</td><td>Metabolite abnormalities in psychosis risk: A meta-analysis of proton magnetic resonance spectroscopy studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648397</td><td>Wang (2021)</td><td>Basolateral Amygdala Serotonin 2C Receptor Regulates Emotional Disorder-Related Symptoms Induced by Chronic Methamphetamine Administration</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644678</td><td>Ward (2020)</td><td>The treatment of acute agitation associated with psychosis or mania: investigational drugs in early clinical development, clinical context and potential place in therapy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634291</td><td>Ward (2021)</td><td>Service evaluation of weight gain in patients prescribed antipsychotics within the early intervention service</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647230</td><td>Washida (2013)</td><td>Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648107</td><td>Wastler (2021)</td><td>Cognition and suicide risk among individuals with first-episode psychosis: A 6-month follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644526</td><td>Watson (2012)</td><td>A voxel based morphometry study investigating brain structural changes in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646207</td><td>Watson (2017)</td><td>More haste less speed: A meta-analysis of thinking latencies during planning in people with psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646293</td><td>Watson (2018)</td><td>A meta-analysis of factors associated with quality of life in first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633589</td><td>Watt (1986)</td><td>Prevention of Schizophrenic Disorders</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633511</td><td>Webb (2015)</td><td>Specificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645134</td><td>Wei (2020)</td><td>The role of altered brain structural connectivity in resilience, vulnerability, and disease expression to schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647399</td><td>Weibell (2017)</td><td>The effect of substance use on 10-year outcome in first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647504</td><td>Weibell (2019)</td><td>Early substance use cessation improves cognition-10 years outcome in first-episode psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633618</td><td>Weickert (2003)</td><td>Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633727</td><td>Weickert (2005)</td><td>First- and second-generation antipsychotic medication and cognitive processing in schizophrenia.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633714</td><td>Weickert (2010)</td><td>Relative risk of probabilistic category learning deficits in patients with schizophrenia and their siblings.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634156</td><td>Weickert (2018)</td><td>Probabilistic association learning in schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645292</td><td>Weickert (2019)</td><td>Reduction in peripheral C-reactive protein levels with canakinumab administration is related to reduced positive symptom severity in patients with schizophrenia and inflammation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645293</td><td>Weickert (2019)</td><td>Reduction in Peripheral C-Reactive Protein Levels With Canakinumab Administration is Related to Reduced Positive Symptom Severity in Patients With Schizophrenia and Inflammation</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644614</td><td>Weiden (2007)</td><td>Understanding and treating "first-episode" schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645369</td><td>Weiden (2009)</td><td>A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics fist-episode schizophrenia patients: Initial adherence outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646354</td><td>Weiden (2012)</td><td>Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646422</td><td>Weiden (2012)</td><td>Long-acting injectable medication maintenance treatment of 'first-episode' schizophrenia-a randomized effectiveness study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645113</td><td>Weiden (2019)</td><td>S98. CAN CBT-BASED INTERVENTIONS ADDRESS MEDICATION ADHERENCE IN EARLY PHASES OF SCHIZOPHRENIA? RESULTS FROM A PILOT RCT COMPARING A CBT-BASED VS. PSYCHOEDUCATION-BASED INTERVENTION...2019 Congress of the Schizophrenia International Research Society, 10-14 April 2019, Orlando, Florida</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648315</td><td>Weiden (2019)</td><td>Can cbt-based interventions address medication adherence in early phases of schizophrenia? results from a pilot rct comparing a cbt-based vs. psychoeducation-based intervention</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646468</td><td>Weller (2018)</td><td>Less is more? An Australian RCT comparing dose reduction of anti-psychotic medication to maintenance treatment</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648316</td><td>Weller (2019)</td><td>Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648481</td><td>Welsh (2014)</td><td>Assessing adolescent preference in the treatment of first-episode psychosis and psychosis risk</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646052</td><td>Wessels (2015)</td><td>Neuropsychological functioning as a predictor of treatment response to psychoeducational, cognitive behavioral therapy in people at clinical high risk of first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645595</td><td>Wessels (2017)</td><td>Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634263</td><td>Westermann (2020)</td><td>Internet-based self-help for psychosis: Findings from a randomized controlled trial</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648259</td><td>Westmoreland (1999)</td><td>Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647103</td><td>Westra (2011)</td><td>Extending motivational interviewing to the treatment of major mental health problems: current directions and evidence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648358</td><td>Wetterling (2004)</td><td>Bodyweight in inpatients with schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644804</td><td>Whale (2010)</td><td>Systematic review of randomised interventions for preonset phase psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647682</td><td>Wheeler (2014)</td><td>Disrupted prefrontal interhemispheric structural coupling in schizophrenia related to working memory performance</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644644</td><td>Whicher (2019)</td><td>Trial design for 'liraglutide and the management of overweight and obesity in people with severe mental illness: a pilot study' in southern health NHS foundation trust</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646446</td><td>Whicher (2019)</td><td>Liraglutide and the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first-episode psychosis: protocol for a pilot trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644594</td><td>Whicher (2021)</td><td>The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double-blind, placebo-controlled trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633922</td><td>Whitaker (2004)</td><td>The case against antipsychotic drugs: a 50-year record of doing more harm than good.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633844</td><td>Whitaker (2007)</td><td>Chapter 5.: Reality Check: What Science Has to Tell Us About Psychiatric Drugs and Their Long-Term Effects</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647244</td><td>White (2017)</td><td>Efficacy of cognitive behavior therapy in early psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59646069</td><td>Whitehorn (2002)</td><td>Neuromotor dysfunction in early psychosis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645421</td><td>Whitehorn (2004)</td><td>Quetiapine treatment in early psychosis: no evidence of cataracts</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645491</td><td>Whitehurst (2020)</td><td>Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648104</td><td>Whitson (2021)</td><td>Cognitive ability and metabolic physical health in first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644704</td><td>Whitworth (1999)</td><td>Transient increase of liver enzymes induced by risperidone: Two case reports</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644473</td><td>Wichowicz (2006)</td><td>Wilson's disease associated with delusional disorder</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648494</td><td>Widschwendter (2012)</td><td>Aripiprazole use in early pregnancy: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645588</td><td>Wiegand (2004)</td><td>Prefrontal Cortical Thickness in First-Episode Psychosis: A Magnetic Resonance Imaging Study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646672</td><td>Wiegand (2005)</td><td>An In Vivo MRI Study of Prefrontal Cortical Complexity in First-Episode Psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646351</td><td>Wiegand (2016)</td><td>Major depression treatment in Germany-descriptive analysis of health insurance fund routine data and assessment of guideline-adherence</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633667</td><td>Wilkinson (1975)</td><td>Arsine toxicity aboard the Asiafreighter.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645928</td><td>Williams (2001)</td><td>Optimal dosing with risperidone: Updated recommendations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634046</td><td>Williams (2011)</td><td>A MULTIPLE-CASE STUDY EXPLORING PERSONAL PARADIGM SHIFTS THROUGHOUT THE PSYCHOTIC PROCESS FROM ONSET TO FULL RECOVERY</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648582</td><td>Wils (2017)</td><td>Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647999</td><td>Wilson (2020)</td><td>Comorbidity rates of depression and anxiety in first episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648333</td><td>Wilson (2021)</td><td>Brexanolone and related neurosteroid GABA(A) positive allosteric modulators for postnatal depression</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645439</td><td>Windell (2013)</td><td>A qualitative analysis of influences on recovery following a first episode of psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645826</td><td>Winsper (2013)</td><td>Pathways to violent behavior during first-episode psychosis: A report from the UK National EDEN Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646989</td><td>Winton-Brown (2017)</td><td>Five-fold increased risk of relapse following breaks in antipsychotic treatment of first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>61634186</td><td>Wise (1979)</td><td>Brain endorphin levels increase after long-term chlorpromazine treatment</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633919</td><td>Wise (1982)</td><td>Neuroleptics and operant behavior: The anhedonia hypothesis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634082</td><td>Wise (1982)</td><td>Hypotheses of neuroleptic action: Levels of progress</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633865</td><td>Wisniewski (2009)</td><td>PMH5 PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT: A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634159</td><td>Wistedt (1982)</td><td>A depot neuroleptic withdrawal study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633751</td><td>Witzel (2008)</td><td>Antipsychotic polypharmacy in the emergency treatment of highly aggressive schizophrenic prisoners - a retrospective study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634181</td><td>Wj (1980)</td><td>Anomalous behavioral response to imidazoleacetic acid, a GABA agonist, in animals treated chronically with haloperidol.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61633864</td><td>Wj (1989)</td><td>Attenuation of the behavioral response to quisqualic acid and glutamic acid diethyl ester by chronic haloperidol administration.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648002</td><td>Wobrock (2013)</td><td>Comorbid substance abuse in first-episode schizophrenia: Effects on cognition and psychopathology in the EUFEST study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648139</td><td>Woerner (2003)</td><td>Clozapine as a first treatment for schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634035</td><td>Wohlberg (1973)</td><td>Sustained attention in remitted schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648173</td><td>Wojcik (2010)</td><td>Clinical characteristics of people in randomized clinical trials of first episode schizophrenia spectrum disorders: Attrition versus non-attrition groups</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644633</td><td>Wolf (2020)</td><td>Two Neuroanatomical Subtypes of Schizophrenia Defined by Multi-Site Machine Learning</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646048</td><td>W√∂lwer (2008)</td><td>Neuropsychological impairments predict the clinical course in schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645635</td><td>W√∂lwer (2009)</td><td>Predictors in long-term treatment of first-episode schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645748</td><td>Wong (2000)</td><td>Pharmacological treatment of first episode non affective psychosis: Are typical doses of haloperidol for Caucasians appropriate for Asians?</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647101</td><td>Wong (2010)</td><td>Extent of weight gain in patients with first-episode psychotic disorders after one year of antipsychotic treatment in Hong Kong</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647862</td><td>Wong (2011)</td><td>Cost-effectiveness of an early assessment service for young people with early psychosis in Hong Kong</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648270</td><td>Wong (2019)</td><td>Case management in early psychosis intervention programme: Perspectives of clients and caregivers</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646381</td><td>Wood (2001)</td><td>A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645492</td><td>Wood (2003)</td><td>Proton Magnetic Resonance Spectroscopy in First Episode Psychosis and Ultra High-Risk Individuals</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646966</td><td>Wood (2007)</td><td>Fractionation of verbal memory impairment in schizophrenia and schizophreniform psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646063</td><td>Wood (2010)</td><td>Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: A longitudinal T2 relaxometry pilot study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634120</td><td>Wood (2017)</td><td>A brief cognitive therapy intervention for internalised stigma in acute inpatients who experience psychosis: A feasibility randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646859</td><td>Wood (2021)</td><td>Group teletherapy for first-episode psychosis: Piloting its integration with coordinated specialty care during the COVID-19 pandemic</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644754</td><td>Woodhead (2008)</td><td>Therapeutic group work for young people with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646885</td><td>Woods (2012)</td><td>Glycine treatment of the risk syndrome for psychosis: report of two pilot studies</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648743</td><td>Woodward (2009)</td><td>Abnormal prefrontal cortical activity and connectivity during response selection in first episode psychosis, chronic schizophrenia, and unaffected siblings of individuals with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646326</td><td>Woodward (2020)</td><td>Medial temporal lobe cortical changes in response to exercise interventions in people with early psychosis: A randomized controlled trial</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648663</td><td>Worthington (2020)</td><td>Air pollution and hippocampal atrophy in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646545</td><td>Wright (2004)</td><td>Interventions for psychosis in adolescents</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644623</td><td>Wright (2016)</td><td>The UK STEPWISE Trial, a programme of Structured lifestyle Education for People With SchizophrEnia Schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634140</td><td>Wright (2018)</td><td>The clinical and cost effectiveness of adapted dialectical behaviour therapy (DBT) for bipolar mood instability in primary care (ThrIVe-B programme): a feasibility study.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645057</td><td>Wright (2019)</td><td>Self-defining memories predict engagement in structured activity in first episode psychosis, independent of neurocognition and metacognition</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634267</td><td>Wright (2020)</td><td>Psychological therapy for mood instability within bipolar spectrum disorder: a single-arm feasibility study of a dialectical behaviour therapy-informed approach</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634262</td><td>Wright (2021)</td><td>Psychological Therapy for Mood Instability within Bipolar Spectrum Disorder: A Randomised, Controlled Feasibility Trial of a Dialectical Behaviour Therapy-Informed Approach (the ThrIVe-B Programme)</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>61634075</td><td>Wt (1975)</td><td>The immediate effects of chlorpromazine in newly admitted schizophrenic patients.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647278</td><td>Wu (2006)</td><td>Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645022</td><td>Wu (2007)</td><td>Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646261</td><td>Wu (2008)</td><td>"Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646456</td><td>Wu (2008)</td><td>Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646457</td><td>Wu (2008)</td><td>Lifestyle intervention and metformin for the treatment of antipsychotic-induced weight gain: A randomized controlled trial</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646258</td><td>Wu (2012)</td><td>Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: A double-blind, randomized, placebo-controlled study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647212</td><td>Wu (2012)</td><td>Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647963</td><td>Wu (2013)</td><td>The comparison of glycometabolism parameters and lipid profiles between drug-naive, first-episode schizophrenia patients and healthy controls</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647964</td><td>Wu (2014)</td><td>The comparison of glucose and lipid metabolism parameters in drug-naive, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647640</td><td>Wu (2015)</td><td>Donepezil improved cognitive deficits in a patient with neurosyphilis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648048</td><td>Wu (2016)</td><td>Cognitive impairments in first-episode drug-naive and chronic medicated schizophrenia: MATRICS consensus cognitive battery in a Chinese Han population</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646359</td><td>Wu (2017)</td><td>Magnetic seizure therapy for people with schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644889</td><td>Wu (2018)</td><td>Structural and functional brain abnormalities in drug-naive, first-episode, and chronic patients with schizophrenia: A multimodal MRI study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647289</td><td>Wu (2018)</td><td>Effects of Risperidone and Paliperidone on Brain-Derived Neurotrophic Factor and N400 in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634273</td><td>Wu (2019)</td><td>Real-World Effectiveness and Safety of Antipsychotics in Individuals at Clinical High-Risk for Psychosis: Study Protocol for a Prospective Observational Study (ShangHai at Risk for Psychosis-Phase 2).</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647752</td><td>Wu (2020)</td><td>Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648393</td><td>Wu (2020)</td><td>BDNF serum levels and cognitive improvement in drug-naive first episode patients with schizophrenia: A prospective 12-week longitudinal study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644896</td><td>Wulff (2015)</td><td>Striatal D2/3 binding potential values in drug-naive first-episode schizophrenia patients correlate with treatment outcome</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645274</td><td>Wulff (2020)</td><td>The relation between dopamine D2 receptor blockade and the brain reward system: A longitudinal study of first-episode schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645899</td><td>Wunderink (2005)</td><td>Outcome of Two Medication Strategies in First-Onset Schizophrenia: the Mesifos RCT</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645643</td><td>Wunderink (2007)</td><td>Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646854</td><td>Wunderink (2007)</td><td>Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648158</td><td>Wunderink (2009)</td><td>Clinical recovery in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645313</td><td>Wunderink (2013)</td><td>Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645314</td><td>Wunderink (2013)</td><td>Recovery in remitted first episode psychosis at 7 years of follow-up of early guided discontinuation or maintenance treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647537</td><td>Wunderink (2014)</td><td>"Early medication discontinuation on long-term recovery outcome in first-episode psychosis": Reply</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644480</td><td>Wunderink (2018)</td><td>Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645779</td><td>Wunderink (2019)</td><td>Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59645213</td><td>Wunderink (2020)</td><td>Reprint of: Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646135</td><td>Wunderink (2020)</td><td>Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645843</td><td>Wustmann (2010)</td><td>Palinacousis as discontinuation symptom after antipsychotic treatment in a patient with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633914</td><td>Wyatt (1991)</td><td>Neuroleptics and the Natural Course of Schizophrenia</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646995</td><td>Wyatt (1998)</td><td>First-episode schizophrenia: Early intervention and medication discontinuation in the context of course and treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648194</td><td>Wykes (2018)</td><td>The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): protocol for a randomised controlled trial</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59648363</td><td>Xavier (2020)</td><td>Blood gene expression changes after risperidone treatment in an antipsychotic-naive cohort of first episode of psychosis patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645089</td><td>Xi (2020)</td><td>Schizophrenia patients and their healthy siblings share decreased prefronto-thalamic connectivity but not increased sensorimotor-thalamic connectivity</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646012</td><td>Xia (2008)</td><td>Novel mechanisms of drug treatment in psychiatry</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645451</td><td>Xiao (2012)</td><td>Psychosocial processes influencing weight management among persons newly prescribed atypical antipsychotic medications</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648648</td><td>Xiao (2015)</td><td>Altered cortical thickness related to clinical severity but not the untreated disease duration in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645916</td><td>Xiao (2021)</td><td>Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648645</td><td>Xiu (2008)</td><td>Altered interleukin-3 serum levels in drug-naive and neuroleptic-treated schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646561</td><td>Xiu (2018)</td><td>Interleukin-3, symptoms and cognitive deficits in first-episode drug-naive and chronic medicated schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645198</td><td>Yadav (2021)</td><td>Resting state quantitative electroencephalogram gamma power spectra in patients with first episode psychosis: An observational study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634165</td><td>Yager (2017)</td><td>Impact of a Structured Treatment Program for First-Episode Psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644967</td><td>Yamada (2019)</td><td>Social Cognition Deficits as a Target of Early Intervention for Psychoses: A Systematic Review</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644743</td><td>Yamamoto (2008)</td><td>Three cases of schizophrenia for which olanzapine was effective after early acute phase</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633567</td><td>Yamazawa (2002)</td><td>DUP in first‚Äêepisode schizophrenia and its early prognosis in Japan</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648062</td><td>Yang (2000)</td><td>Cognitive function in first episode schizophrenics</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647415</td><td>Yang (2002)</td><td>Effect of pharmacotherapy on the cognitive functions in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647287</td><td>Yang (2010)</td><td>Effects of risperidone on auditory gating potential P50 in acute medication-free patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647247</td><td>Yang (2011)</td><td>Efficacy of atypical antipsychotics on memory function in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648351</td><td>Yang (2015)</td><td>Brain differences in first-episode schizophrenia treated with quetiapine: A deformation-based morphometric study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648642</td><td>Yang (2016)</td><td>Altered serum levels of interleukin-3 in first-episode drug-naive and chronic medicated schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648492</td><td>Yang (2017)</td><td>Aripiprazole versus ziprasidone for schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644776</td><td>Yang (2019)</td><td>Temporal dynamic changes of intrinsic brain activity in schizophrenia with cigarette smoking</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646302</td><td>Yang (2020)</td><td>A Meta-Analysis of Abnormal Glucose Metabolism in First-Episode Drug-Naive Schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648676</td><td>Yang (2020)</td><td>Advancing study of cognitive impairments for antipsychotic-naive psychosis comparing high-income versus low- and middle-income countries with a focus on urban China: Systematic review of cognition and study methodology</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645773</td><td>Yang (2021)</td><td>Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647458</td><td>Yang (2021)</td><td>Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648350</td><td>Yang (2021)</td><td>Brain dysfunction of methamphetamine-associated psychosis in resting state: Approaching schizophrenia and critical role of right superior temporal deficit</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646811</td><td>Yao (2010)</td><td>Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naive patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648646</td><td>Yao (2010)</td><td>Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647802</td><td>Yao (2014)</td><td>The default mode network is disrupted in Parkinson's disease with visual hallucinations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646363</td><td>Yassin (2020)</td><td>Machine-learning classification using neuroimaging data in schizophrenia, autism, ultra-high risk and first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648163</td><td>Yasuda (2013)</td><td>Clinical features of late-onset schizophrenia in Japan: Comparison with early-onset cases</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648189</td><td>Yazbek (2014)</td><td>The clinic of apathy in schizophrenia: A critical review of the issue</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644982</td><td>Yazihan (2020)</td><td>Sleep, sleep spindles, and cognitive functions in drug-naive patients with first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634182</td><td>Yd (1975)</td><td>Pimozide and the social behavior of schizophrenics.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59648641</td><td>Ye (2018)</td><td>Altered serum levels of vascular endothelial growth factor in first-episode drug-naive and chronic medicated schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645848</td><td>Yee (1998)</td><td>P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645025</td><td>Yee (2011)</td><td>Severe non-lethal violence during psychotic illness</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644590</td><td>Yeisen (2016)</td><td>Use of medication algorithms in first episode psychosis: A naturalistic observational study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647123</td><td>Yeisen (2017)</td><td>Experiences of antipsychotic use in patients with early psychosis: A two-year follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648240</td><td>Yen (2020)</td><td>Challenges in differentiating between obsession and delusion in schizophrenic patients: A case report</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648730</td><td>Yeo (2017)</td><td>Acceptance rate of long-acting injection after short information: A survey in patients with first- and multiple-episode psychoses and their caregivers</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634290</td><td>Yi (2019)</td><td>History and Future of Antipsychotic Drugs</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644628</td><td>Yin (2021)</td><td>The type 2 diabetes mellitus susceptibility gene CDKAL1 polymorphism is associated with depressive symptom in first-episode drug-naive schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644519</td><td>Yoon (2008)</td><td>Weight gain and first-generation antipsychotics: Experience from a developing country</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648467</td><td>Yoshida (2020)</td><td>Association between the -2548G/A polymorphism of the leptin gene and antipsychotic-induced weight gain: Analysis of the CATIE sample and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645699</td><td>Yoshimura (2003)</td><td>Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648503</td><td>Yoshimura (2012)</td><td>Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645606</td><td>Yoshimura (2019)</td><td>Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646666</td><td>Yoshimura (2019)</td><td>Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: Secondary analysis of an observational study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648657</td><td>Yoshimura (2019)</td><td>Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647297</td><td>Yoshimuta (2016)</td><td>The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633587</td><td>Young (1995)</td><td>Aspects of drug use in schizophrenia, cardiac surgery and palliative care</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59644578</td><td>Young (2016)</td><td>Using machine learning to predict outcomes in psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646019</td><td>Yow (2017)</td><td>Non‚Äêclozapine antipsychotic combinations for treatment‚Äêresistant schizophrenia</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648651</td><td>Yu (2015)</td><td>Alterations of miR-132 are novel diagnostic biomarkers in peripheral blood of schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647407</td><td>Yu (2020)</td><td>[Effect of risperidone on prepulse inhibition of the startle reflex and P50 deficit in patients with first-episode and chronic schizophrenia]</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646362</td><td>Yu (2021)</td><td>Macrophage migration inhibitory factor as a potential novel biomarker for cognitive function in patients with first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647346</td><td>Yuan (2014)</td><td>Effectiveness of three atypical antipsychotic-initiated treatments in chinese first-episode schizophrenia: an open randomized clinical trial</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648229</td><td>Yuan (2018)</td><td>Changes in metabolism and microbiota after 24-week risperidone treatment in drug naive, normal weight patients with first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646620</td><td>Yuan (2019)</td><td>Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648749</td><td>Yuksel (2021)</td><td>Abnormal Brain Bioenergetics in First-Episode Psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646771</td><td>Yung (2007)</td><td>Identification and treatment of the prodromal phase of psychotic disorders: Perspectives from the PACE clinic</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645379</td><td>Yung (2012)</td><td>Randomized controlled trial of antipsychotic and cognitive therapy in young people at ultra-high risk of psychosis</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td><span >Tiril Borge</span></td></tr><tr><td>59646075</td><td>Zabala (2006)</td><td>Neurological soft signs in adolescents with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648045</td><td>Zabala (2009)</td><td>Cognitive performance and cigarette smoking in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646051</td><td>Zabala (2010)</td><td>Neuropsychological functioning in early-onset first-episode psychosis: Comparison of diagnostic subgroups</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647343</td><td>Zalsman (2003)</td><td>Effectiveness, Safety, and Tolerability of Risperidone in Adolescents with Schizophrenia: An Open-Label Study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647608</td><td>Zalsman (2003)</td><td>DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: A pilot pharmacogenetic study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645614</td><td>Zambrano (2021)</td><td>Predictors of Persistent Symptoms in People in Coordinated Specialty Care Services for Early Psychosis in New York State</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645644</td><td>Zandi (2011)</td><td>Predictive validity of a culturally informed diagnosis of schizophrenia: A 30 month follow-up study with first episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644930</td><td>Zanelli (2010)</td><td>Specific and generalized neuropsychological deficits: A comparison of patients with various first-episode psychosis presentations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644482</td><td>Zanetti (2008)</td><td>"White-matter hyperintensities in first-episode psychosis": Erratum</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644483</td><td>Zanetti (2008)</td><td>White-matter hyperintensities in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648597</td><td>Zarate (2000)</td><td>Antipsychotic drug treatment in first-episode mania: A 6-month longitudinal study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645101</td><td>Zare (2018)</td><td>Saffron (adjunct) for people with schizophrenia who have antipsychotic‚Äêinduced metabolic syndrome</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644904</td><td>Zaske (2019)</td><td>Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647349</td><td>Zaytseva (2010)</td><td>Effectiveness of the integrated long-term program of management of patients after first psychotic episode in 5-year follow-up</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646098</td><td>Zaytseva (2011)</td><td>Neurocognitive functioning in drug-naive patients with first episode of psychosis before and after treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633785</td><td>Zemlan (1984)</td><td>Mood-incongruent versus mood-congruent psychosis: Differential antipsychotic response to Lithium therapy</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647104</td><td>Zeng (2003)</td><td>An extended two-year follow up of psychological education on insight recovery and drug therapy compliance and recurrence in schizophrenic patients</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648738</td><td>Zeng (2016)</td><td>Abnormal white matter microstructure in drug-naive first episode schizophrenia patients before and after eight weeks of antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645583</td><td>Zeng (2020)</td><td>A preliminary study on schizophrenia of distinct antipsychotic response based on diffusion tensor imaging. [Chinese]</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645571</td><td>Zeng (2021)</td><td>Pretreatment abnormalities in white matter integrity predict one-year clinical outcome in first episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646985</td><td>Zesiewicz (2017)</td><td>A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645440</td><td>Zhai (2017)</td><td>QTc interval lengthening in first-episode schizophrenia (FES) patients in the earliest stages of antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648280</td><td>Zhai (2017)</td><td>Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645399</td><td>Zhang (1994)</td><td>Randomised-control trial of family intervention for 78 first-episode male schizophrenic patients: An 18-month study in Suzhou, Jiangsu</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647062</td><td>Zhang (1999)</td><td>Family psychotherapy and remission of symptoms of schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647434</td><td>Zhang (2005)</td><td>Effect of health education for parents in preventing the recurrence of schizophrenia in their children after first episode</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646011</td><td>Zhang (2009)</td><td>The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646636</td><td>Zhang (2010)</td><td>Increased serum S100B in never-medicated and medicated schizophrenic patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646924</td><td>Zhang (2012)</td><td>Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647220</td><td>Zhang (2012)</td><td>Electroconvulsive therapy improves antipsychotic and somnographic responses in adolescents with first-episode psychosis-A case-control study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647272</td><td>Zhang (2012)</td><td>EfÔ¨Åcacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648474</td><td>Zhang (2012)</td><td>Association analysis of ZNF804A (zinc finger protein 804A) rs1344706 with therapeutic response to atypical antipsychotics in first-episode Chinese patients with schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646562</td><td>Zhang (2013)</td><td>Interleukin 18 and cognitive impairment in first episode and drug naive schizophrenia versus healthy controls</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647265</td><td>Zhang (2013)</td><td>The efficacy and safety of ropinirole prolonged release tablets as adjunctive therapy in Chinese subjects with advanced Parkinson's disease: a multicenter, double-blind, randomized, placebo-controlled study</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647267</td><td>Zhang (2013)</td><td>Efficacy and safety of individual second-generation vs. first generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645499</td><td>Zhang (2014)</td><td>Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645604</td><td>Zhang (2014)</td><td>Predictors of response to second generation antipsychotics in drug naive patients with schizophrenia: A 1 year follow-up study in Shanghai</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647863</td><td>Zhang (2014)</td><td>Cost-effectiveness analysis of psychosocial intervention for early stage schizophrenia in China: a randomized, one-year study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647684</td><td>Zhang (2015)</td><td>Disrupted brain anatomical connectivity in medication-naive patients with first-episode schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648461</td><td>Zhang (2015)</td><td>Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first-episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648462</td><td>Zhang (2015)</td><td>Association of a schizophrenia risk variant at the DRD2 locus with antipsychotic treatment response in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645084</td><td>Zhang (2016)</td><td>Schizophrenia polygenic risk score predicts antipsychotic treatment response in patients with first episode psychosis</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645774</td><td>Zhang (2016)</td><td>Pharmacogenetic associations of antipsychotic drug-related weight gain: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646927</td><td>Zhang (2016)</td><td>Gender and Racial Disparities in Cases of Autoenucleation</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634167</td><td>Zhang (2016)</td><td>The Benefits of Antipsychotic Drugs: Symptom Control and Improved Quality of Life</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645083</td><td>Zhang (2017)</td><td>Schizophrenia risk variant at DRD2 locus predicts antipsychotic treatment response in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645086</td><td>Zhang (2017)</td><td>Schizophrenia polygenic risk score predicts antipsychotic efficacy in first episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645087</td><td>Zhang (2019)</td><td>"Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis": Correction</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646297</td><td>Zhang (2019)</td><td>Meta-analysis of cognitive function in Chinese first-episode schizophrenia: MATRICS Consensus Cognitive Battery (MCCB) profile of impairment</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td></tr><tr><td>59646036</td><td>Zhang (2020)</td><td>A new sex-specific underlying mechanism for female schizophrenia: accelerated skewed X chromosome inactivation</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646281</td><td>Zhang (2020)</td><td>Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: a Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644496</td><td>Zhang (2021)</td><td>When to initiate antipsychotic treatment for psychotic symptoms: At the premorbid phase or first episode of psychosis?</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647414</td><td>Zhang (2021)</td><td>The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645925</td><td>Zhang-Wong (1999)</td><td>Optimal haloperidol dosage in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645999</td><td>Zhao (2002)</td><td>The observation on the outcome of psychological guidance on schizophrenia in EEG and ECG examination</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647264</td><td>Zhao (2012)</td><td>Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: An 8-week, open-label, multicenter trial</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648647</td><td>Zhao (2018)</td><td>Altered effective connectivity in the default network of the brains of first-episode, drug-naive schizophrenia patients with auditory verbal hallucinations</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647685</td><td>Zheng (2016)</td><td>Disrupted amplitude of low-frequency fluctuations in antipsychotic-naive adolescents with early-onset schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648685</td><td>Zheng (2017)</td><td>Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648686</td><td>Zheng (2019)</td><td>Adjunctive aripiprazole for antipsychotic-related hyperprolactinaemia in patients with first-episode schizophrenia: a meta-analysis</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646945</td><td>Zhong (2016)</td><td>Functional alterations of fronto-limbic circuit and default mode network systems in first-episode, drug-naive patients with major depressive disorder: A meta-analysis of resting-state fMRI data</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648064</td><td>Zhou (2013)</td><td>Cognitive function and factors associated with remission in first episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645641</td><td>Zhou (2014)</td><td>Predictive value of prospective memory for remission in first-episode schizophrenia</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645497</td><td>Zhou (2019)</td><td>Prospective memory in schizophrenia: A meta-analysis of comparative studies</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648184</td><td>Zhu (2002)</td><td>Clinical and experimental observation of He-Ne laser intravascular irradiation for schizophrenia</td><td>(I) Included</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646787</td><td>Zhu (2017)</td><td>How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Trine Bjerke Johansen</span></td><td></td></tr><tr><td>59648590</td><td>Zhu (2017)</td><td>Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647599</td><td>Zhu (2020)</td><td>Drug-naive first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61633628</td><td>Zhuang (2014)</td><td>Effect of cognitive behavioural interventions on the quality of life in Chinese heroin-dependent individuals in detoxification: a randomised controlled trial.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59647701</td><td>Zhuo (2016)</td><td>Diffusion tensor MR imaging evaluation of callosal abnormalities in Schizophrenia: A meta-analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647726</td><td>Zhuo (2020)</td><td>Differences in functional connectivity density among subtypes of schizophrenic auditory hallucination</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648007</td><td>Zhuo (2020)</td><td>Common and distinct global functional connectivity density alterations in drug-naive patients with first-episode major depressive disorder with and without auditory verbal hallucination</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648603</td><td>Zhuo (2020)</td><td>Antipsychotic agents deteriorate brain and retinal function in schizophrenia patients with combined auditory and visual hallucinations: A pilot study and secondary follow-up study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648457</td><td>Ziauddeen (2016)</td><td>Association of birth weight and the development of antipsychotic induced adiposity in individuals with treatment resistant schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648177</td><td>Zimbron (2013)</td><td>Clinical and sociodemographic comparison of people at high-risk for psychosis and with first-episode psychosis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645666</td><td>Zimbron (2014)</td><td>Pre-morbid fertility in psychosis: Findings from the AESOP first episode study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648436</td><td>Zincir (2014)</td><td>Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: A controlled study</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648435</td><td>Zincir (2015)</td><td>Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: Author's reply</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645970</td><td>Zink (2007)</td><td>Olanzapine-associated bilateral eyelid edema</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646192</td><td>Zipursky (1998)</td><td>MRI correlates of treatment response in first episode psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645924</td><td>Zipursky (2002)</td><td>Optimal pharmacologic management of the first episode of schizophrenia</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644656</td><td>Zipursky (2005)</td><td>Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647851</td><td>Zipursky (2005)</td><td>Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol</td><td>(I) Included</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59646166</td><td>Zipursky (2013)</td><td>The myth of schizophrenia as a progressive brain disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59645160</td><td>Zipursky (2014)</td><td>Risk of symptom recurrence with medication discontinuation in first-episode psychosis: A systematic review</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59646677</td><td>Zipursky (2018)</td><td>Improving outcomes in schizophrenia by preventing early relapses</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td><span class='complete'>Tiril Borge</span></td><td></td><td></td></tr><tr><td>59644464</td><td>Zipursky (2020)</td><td>You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td><span >Tiril Borge</span></td><td></td><td></td></tr><tr><td>59647908</td><td>Zisman-Ilani (2018)</td><td>Continue, adjust, or stop antipsychotic medication: Developing and user testing an encounter decision aid for people with first-episode and long-term psychosis</td><td>(E) Excluded</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span><br /><span >Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647162</td><td>Zisman-Ilani (2021)</td><td>Evaluating the feasibility of a decision aid to promote shared decision making among young adults with first-episode psychosis: protocol for a pilot study</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634196</td><td>Zito (1988)</td><td>Pharmacoepidemiologic methods for identifying and quantifying behavioral effects of neuropharmacological agents.</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645189</td><td>Zito (2020)</td><td>Rethinking the risks and benefits of long-term maintenance in schizophrenia</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648446</td><td>Zivkovic (2013)</td><td>The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648519</td><td>Zohar (2004)</td><td>Are All Atypical Antipsychotics Equal for the Treatment of Cognition and Affect in Schizophrenia?</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647680</td><td>Zong (2019)</td><td>A dissociation in effects of risperidone monotherapy on functional and anatomical connectivity within the default mode network</td><td>(E) Excluded</td><td><span class='complete'>Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr><tr><td>59645011</td><td>Zourkova (2005)</td><td>Sexual function in male patients treated with antipsychotics</td><td>(E) Excluded</td><td><span >Trine Bjerke Johansen</span><br /><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59648305</td><td>Zuardi (2009)</td><td>Cannabidiol for the treatment of psychosis in Parkinson's disease</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59644885</td><td>Zugman (2015)</td><td>Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>59647137</td><td>Zun (2018)</td><td>Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy</td><td>(E) Excluded</td><td><span >Patricia Sofia Jacobsen Jardim</span><br /><span class='complete'>Tiril Borge</span></td><td></td><td></td><td></td></tr><tr><td>61634073</td><td>ÈÉ≠ÊôìÂ≥∞ (2010)</td><td>Effect of Antipsychotic Medication Alone vs Combined With Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia A Randomized, 1-Year Study</td><td>(I) Included</td><td><span class='complete'>Patricia Sofia Jacobsen Jardim</span></td><td></td><td></td><td></td></tr></table></body></html>